id sid tid token lemma pos admet-338 1 1 manuscript manuscript PROPN admet-338 1 2 doi doi PROPN admet-338 1 3 : : PUNCT admet-338 1 4 10.5599 10.5599 NUM admet-338 1 5 / / SYM admet-338 1 6 admet.4.4.338 admet.4.4.338 NUM admet-338 1 7 335 335 NUM admet-338 1 8 admet admet X admet-338 1 9 & & CCONJ admet-338 1 10 dmpk dmpk PROPN admet-338 1 11 4(4 4(4 NUM admet-338 1 12 ) ) PUNCT admet-338 1 13 ( ( PUNCT admet-338 1 14 2016 2016 NUM admet-338 1 15 ) ) PUNCT admet-338 1 16 335 335 NUM admet-338 1 17 - - SYM admet-338 1 18 360 360 NUM admet-338 1 19 ; ; PUNCT admet-338 1 20 doi doi NOUN admet-338 1 21 : : PUNCT admet-338 1 22 10.5599 10.5599 NUM admet-338 1 23 / / SYM admet-338 1 24 admet.4.4.338 admet.4.4.338 VERB admet-338 1 25 open open ADJ admet-338 1 26 access access NOUN admet-338 1 27 : : PUNCT admet-338 1 28 issn issn PROPN admet-338 1 29 : : PUNCT admet-338 1 30 1848 1848 NUM admet-338 1 31 - - SYM admet-338 1 32 7718 7718 NUM admet-338 1 33 http://www.pub.iapchem.org/ojs/index.php/admet/index http://www.pub.iapchem.org/ojs/index.php/admet/index NOUN admet-338 1 34 original original ADJ admet-338 1 35 scientific scientific ADJ admet-338 1 36 paper paper NOUN admet-338 1 37 investigation investigation NOUN admet-338 1 38 of of ADP admet-338 1 39 biopharmaceutical biopharmaceutical ADJ admet-338 1 40 and and CCONJ admet-338 1 41 physicochemical physicochemical ADJ admet-338 1 42 drug drug NOUN admet-338 1 43 properties property NOUN admet-338 1 44 suitable suitable ADJ admet-338 1 45 for for ADP admet-338 1 46 orally orally ADV admet-338 1 47 disintegrating disintegrate VERB admet-338 1 48 tablets tablet NOUN admet-338 1 49 asami asami PROPN admet-338 1 50 ono ono PROPN admet-338 1 51 * * PROPN admet-338 1 52 , , PUNCT admet-338 1 53 takumi takumi PROPN admet-338 1 54 tomono1 tomono1 PROPN admet-338 1 55 , , PUNCT admet-338 1 56 takuo takuo PROPN admet-338 1 57 ogihara1 ogihara1 PROPN admet-338 1 58 , , PUNCT admet-338 1 59 katsuhide katsuhide NOUN admet-338 1 60 terada2,a terada2,a PROPN admet-338 1 61 , , PUNCT admet-338 1 62 and and CCONJ admet-338 1 63 kiyohiko kiyohiko PROPN admet-338 1 64 sugano2 sugano2 PROPN admet-338 1 65 asahi asahi PROPN admet-338 1 66 kasei kasei PROPN admet-338 1 67 pharma pharma PROPN admet-338 1 68 , , PUNCT admet-338 1 69 632 632 NUM admet-338 1 70 - - SYM admet-338 1 71 1 1 NUM admet-338 1 72 mifuku mifuku NOUN admet-338 1 73 , , PUNCT admet-338 1 74 izunokuni izunokuni PROPN admet-338 1 75 , , PUNCT admet-338 1 76 shizuoka shizuoka PROPN admet-338 1 77 410 410 NUM admet-338 1 78 - - SYM admet-338 1 79 2321 2321 NUM admet-338 1 80 , , PUNCT admet-338 1 81 japan japan PROPN admet-338 1 82 . . PUNCT admet-338 2 1 1 1 NUM admet-338 2 2 laboratory laboratory NOUN admet-338 2 3 of of ADP admet-338 2 4 clinical clinical ADJ admet-338 2 5 pharmacokinetics pharmacokinetic NOUN admet-338 2 6 , , PUNCT admet-338 2 7 graduate graduate NOUN admet-338 2 8 school school NOUN admet-338 2 9 of of ADP admet-338 2 10 pharmaceutical pharmaceutical NOUN admet-338 2 11 sciences science NOUN admet-338 2 12 , , PUNCT admet-338 2 13 takasaki takasaki ADJ admet-338 2 14 university university NOUN admet-338 2 15 of of ADP admet-338 2 16 health health NOUN admet-338 2 17 and and CCONJ admet-338 2 18 welfare welfare NOUN admet-338 2 19 , , PUNCT admet-338 2 20 60 60 NUM admet-338 2 21 nakaorui nakaorui NOUN admet-338 2 22 takasaki takasaki ADJ admet-338 2 23 , , PUNCT admet-338 2 24 gunma gunma PROPN admet-338 2 25 370 370 NUM admet-338 2 26 - - SYM admet-338 2 27 0033 0033 NUM admet-338 2 28 , , PUNCT admet-338 2 29 japan japan PROPN admet-338 2 30 . . PUNCT admet-338 3 1 2 2 NUM admet-338 3 2 department department NOUN admet-338 3 3 of of ADP admet-338 3 4 pharmaceutics pharmaceutic NOUN admet-338 3 5 , , PUNCT admet-338 3 6 faculty faculty NOUN admet-338 3 7 of of ADP admet-338 3 8 pharmaceutical pharmaceutical NOUN admet-338 3 9 sciences science NOUN admet-338 3 10 , , PUNCT admet-338 3 11 toho toho NOUN admet-338 3 12 university university NOUN admet-338 3 13 , , PUNCT admet-338 3 14 2 2 NUM admet-338 3 15 - - SYM admet-338 3 16 2 2 NUM admet-338 3 17 - - SYM admet-338 3 18 1 1 NUM admet-338 3 19 miyama miyama NOUN admet-338 3 20 , , PUNCT admet-338 3 21 funabashi funabashi PROPN admet-338 3 22 , , PUNCT admet-338 3 23 chiba chiba PROPN admet-338 3 24 274 274 NUM admet-338 3 25 - - SYM admet-338 3 26 8510 8510 NUM admet-338 3 27 , , PUNCT admet-338 3 28 japan japan PROPN admet-338 3 29 . . PUNCT admet-338 4 1 a a DET admet-338 4 2 present present ADJ admet-338 4 3 address address NOUN admet-338 4 4 : : PUNCT admet-338 4 5 laboratory laboratory NOUN admet-338 4 6 of of ADP admet-338 4 7 molecular molecular ADJ admet-338 4 8 pharmaceutics pharmaceutic NOUN admet-338 4 9 and and CCONJ admet-338 4 10 technology technology NOUN admet-338 4 11 , , PUNCT admet-338 4 12 faculty faculty NOUN admet-338 4 13 of of ADP admet-338 4 14 pharmacy pharmacy NOUN admet-338 4 15 , , PUNCT admet-338 4 16 takasaki takasaki ADJ admet-338 4 17 university university NOUN admet-338 4 18 of of ADP admet-338 4 19 health health NOUN admet-338 4 20 and and CCONJ admet-338 4 21 welfare welfare NOUN admet-338 4 22 , , PUNCT admet-338 4 23 60 60 NUM admet-338 4 24 nakaorui nakaorui NOUN admet-338 4 25 takasaki takasaki ADJ admet-338 4 26 , , PUNCT admet-338 4 27 gunma gunma PROPN admet-338 4 28 370 370 NUM admet-338 4 29 - - SYM admet-338 4 30 0033 0033 NUM admet-338 4 31 , , PUNCT admet-338 4 32 japan japan PROPN admet-338 4 33 . . PUNCT admet-338 5 1 * * PUNCT admet-338 5 2 corresponding correspond VERB admet-338 5 3 author author NOUN admet-338 5 4 : : PUNCT admet-338 5 5 e e NOUN admet-338 5 6 - - NOUN admet-338 5 7 mail mail NOUN admet-338 5 8 : : PUNCT admet-338 5 9 ono.ar@om.asahi-kasei.co.jp ono.ar@om.asahi-kasei.co.jp NUM admet-338 5 10 ; ; PUNCT admet-338 5 11 tel tel PROPN admet-338 5 12 . . PROPN admet-338 5 13 : : PUNCT admet-338 6 1 +81 +81 NUM admet-338 6 2 - - PUNCT admet-338 6 3 558 558 NUM admet-338 6 4 - - PUNCT admet-338 6 5 76 76 NUM admet-338 6 6 - - PUNCT admet-338 6 7 7061 7061 NUM admet-338 6 8 ; ; PUNCT admet-338 6 9 fax fax NOUN admet-338 6 10 : : PUNCT admet-338 6 11 +81 +81 ADJ admet-338 6 12 - - PUNCT admet-338 6 13 558 558 NUM admet-338 6 14 - - PUNCT admet-338 6 15 76 76 NUM admet-338 6 16 - - PUNCT admet-338 6 17 7137 7137 NUM admet-338 6 18 received receive VERB admet-338 6 19 : : PUNCT admet-338 6 20 september september PROPN admet-338 6 21 14 14 NUM admet-338 6 22 , , PUNCT admet-338 6 23 2016 2016 NUM admet-338 6 24 ; ; PUNCT admet-338 6 25 revised revise VERB admet-338 6 26 : : PUNCT admet-338 6 27 november november PROPN admet-338 6 28 18 18 NUM admet-338 6 29 , , PUNCT admet-338 6 30 2016 2016 NUM admet-338 6 31 ; ; PUNCT admet-338 6 32 published publish VERB admet-338 6 33 : : PUNCT admet-338 6 34 december december PROPN admet-338 6 35 26 26 NUM admet-338 6 36 , , PUNCT admet-338 6 37 2016 2016 NUM admet-338 6 38 abstract abstract NOUN admet-338 6 39 the the DET admet-338 6 40 purpose purpose NOUN admet-338 6 41 of of ADP admet-338 6 42 this this DET admet-338 6 43 study study NOUN admet-338 6 44 was be AUX admet-338 6 45 to to PART admet-338 6 46 evaluate evaluate VERB admet-338 6 47 the the DET admet-338 6 48 biopharmaceutical biopharmaceutical ADJ admet-338 6 49 and and CCONJ admet-338 6 50 physicochemical physicochemical ADJ admet-338 6 51 drug drug NOUN admet-338 6 52 properties property NOUN admet-338 6 53 suitable suitable ADJ admet-338 6 54 for for ADP admet-338 6 55 orally orally ADV admet-338 6 56 disintegrating disintegrate VERB admet-338 6 57 tablets tablet NOUN admet-338 6 58 ( ( PUNCT admet-338 6 59 odts odts ADJ admet-338 6 60 ) ) PUNCT admet-338 6 61 . . PUNCT admet-338 7 1 the the DET admet-338 7 2 molecular molecular ADJ admet-338 7 3 weight weight NOUN admet-338 7 4 ( ( PUNCT admet-338 7 5 mw mw NOUN admet-338 7 6 ) ) PUNCT admet-338 7 7 , , PUNCT admet-338 7 8 polar polar ADJ admet-338 7 9 surface surface NOUN admet-338 7 10 area area NOUN admet-338 7 11 ( ( PUNCT admet-338 7 12 psa psa NOUN admet-338 7 13 ) ) PUNCT admet-338 7 14 , , PUNCT admet-338 7 15 hydrogen hydrogen NOUN admet-338 7 16 bond bond NOUN admet-338 7 17 donor donor NOUN admet-338 7 18 ( ( PUNCT admet-338 7 19 hbd hbd NOUN admet-338 7 20 ) ) PUNCT admet-338 7 21 and and CCONJ admet-338 7 22 acceptor acceptor NOUN admet-338 7 23 ( ( PUNCT admet-338 7 24 hba hba NOUN admet-338 7 25 ) ) PUNCT admet-338 7 26 numbers number NOUN admet-338 7 27 , , PUNCT admet-338 7 28 net net ADJ admet-338 7 29 charge charge NOUN admet-338 7 30 at at ADP admet-338 7 31 ph ph PROPN admet-338 7 32 7.4 7.4 NUM admet-338 7 33 , , PUNCT admet-338 7 34 log log NOUN admet-338 7 35 d6.5 d6.5 PROPN admet-338 7 36 , , PUNCT admet-338 7 37 the the DET admet-338 7 38 highest high ADJ admet-338 7 39 dose dose NOUN admet-338 7 40 strength strength NOUN admet-338 7 41 , , PUNCT admet-338 7 42 solubility solubility NOUN admet-338 7 43 in in ADP admet-338 7 44 water water NOUN admet-338 7 45 , , PUNCT admet-338 7 46 dose dose NOUN admet-338 7 47 number number NOUN admet-338 7 48 , , PUNCT admet-338 7 49 and and CCONJ admet-338 7 50 elimination elimination NOUN admet-338 7 51 t1/2 t1/2 NOUN admet-338 7 52 of of ADP admet-338 7 53 57 57 NUM admet-338 7 54 odt odt ADJ admet-338 7 55 drugs drug NOUN admet-338 7 56 and and CCONJ admet-338 7 57 113 113 NUM admet-338 7 58 drugs drug NOUN admet-338 7 59 of of ADP admet-338 7 60 immediate immediate ADJ admet-338 7 61 - - PUNCT admet-338 7 62 release release NOUN admet-338 7 63 ( ( PUNCT admet-338 7 64 ir ir NOUN admet-338 7 65 ) ) PUNCT admet-338 7 66 formulations formulation NOUN admet-338 7 67 were be AUX admet-338 7 68 compared compare VERB admet-338 7 69 . . PUNCT admet-338 8 1 these these DET admet-338 8 2 drugs drug NOUN admet-338 8 3 were be AUX admet-338 8 4 classified classify VERB admet-338 8 5 according accord VERB admet-338 8 6 to to ADP admet-338 8 7 the the DET admet-338 8 8 biopharmaceutical biopharmaceutical ADJ admet-338 8 9 classification classification NOUN admet-338 8 10 system system NOUN admet-338 8 11 ( ( PUNCT admet-338 8 12 bcs bcs NOUN admet-338 8 13 ) ) PUNCT admet-338 8 14 . . PUNCT admet-338 9 1 a a DET admet-338 9 2 lower low ADJ admet-338 9 3 dose dose NOUN admet-338 9 4 strength strength NOUN admet-338 9 5 and and CCONJ admet-338 9 6 a a DET admet-338 9 7 longer long ADJ admet-338 9 8 elimination elimination NOUN admet-338 9 9 t1/2 t1/2 NOUN admet-338 9 10 have have AUX admet-338 9 11 been be AUX admet-338 9 12 observed observe VERB admet-338 9 13 as as ADP admet-338 9 14 characteristic characteristic ADJ admet-338 9 15 properties property NOUN admet-338 9 16 of of ADP admet-338 9 17 odts odts NOUN admet-338 9 18 . . PUNCT admet-338 10 1 the the DET admet-338 10 2 proportion proportion NOUN admet-338 10 3 of of ADP admet-338 10 4 basic basic ADJ admet-338 10 5 drugs drug NOUN admet-338 10 6 was be AUX admet-338 10 7 higher high ADJ admet-338 10 8 in in ADP admet-338 10 9 the the DET admet-338 10 10 odts odts NOUN admet-338 10 11 than than ADP admet-338 10 12 in in ADP admet-338 10 13 the the DET admet-338 10 14 ir ir PROPN admet-338 10 15 formulations formulation NOUN admet-338 10 16 . . PUNCT admet-338 11 1 a a DET admet-338 11 2 significant significant ADJ admet-338 11 3 difference difference NOUN admet-338 11 4 was be AUX admet-338 11 5 not not PART admet-338 11 6 observed observe VERB admet-338 11 7 between between ADP admet-338 11 8 the the DET admet-338 11 9 odt odt NOUN admet-338 11 10 and and CCONJ admet-338 11 11 the the DET admet-338 11 12 ir ir PROPN admet-338 11 13 formulation formulation NOUN admet-338 11 14 for for ADP admet-338 11 15 mw mw PROPN admet-338 11 16 , , PUNCT admet-338 11 17 psa psa NOUN admet-338 11 18 , , PUNCT admet-338 11 19 hbd hbd NOUN admet-338 11 20 , , PUNCT admet-338 11 21 hba hba PROPN admet-338 11 22 , , PUNCT admet-338 11 23 log log PROPN admet-338 11 24 d6.5 d6.5 PROPN admet-338 11 25 , , PUNCT admet-338 11 26 solubility solubility NOUN admet-338 11 27 in in ADP admet-338 11 28 water water NOUN admet-338 11 29 , , PUNCT admet-338 11 30 and and CCONJ admet-338 11 31 dose dose NOUN admet-338 11 32 number number NOUN admet-338 11 33 . . PUNCT admet-338 12 1 the the DET admet-338 12 2 distributions distribution NOUN admet-338 12 3 of of ADP admet-338 12 4 the the DET admet-338 12 5 odts odts NOUN admet-338 12 6 and and CCONJ admet-338 12 7 ir ir PROPN admet-338 12 8 formulations formulation NOUN admet-338 12 9 among among ADP admet-338 12 10 each each DET admet-338 12 11 bcs bcs NOUN admet-338 12 12 class class NOUN admet-338 12 13 were be AUX admet-338 12 14 similar similar ADJ admet-338 12 15 , , PUNCT admet-338 12 16 suggesting suggest VERB admet-338 12 17 that that SCONJ admet-338 12 18 an an DET admet-338 12 19 odt odt NOUN admet-338 12 20 can can AUX admet-338 12 21 be be AUX admet-338 12 22 developed develop VERB admet-338 12 23 regardless regardless ADV admet-338 12 24 of of ADP admet-338 12 25 the the DET admet-338 12 26 bcs bcs NOUN admet-338 12 27 class class NOUN admet-338 12 28 of of ADP admet-338 12 29 a a DET admet-338 12 30 drug drug NOUN admet-338 12 31 . . PUNCT admet-338 13 1 keywords keyword NOUN admet-338 13 2 orally orally ADV admet-338 13 3 disintegrating disintegrate VERB admet-338 13 4 tablet tablet NOUN admet-338 13 5 ( ( PUNCT admet-338 13 6 odt odt PROPN admet-338 13 7 ) ) PUNCT admet-338 13 8 ; ; PUNCT admet-338 13 9 bioequivalence bioequivalence NOUN admet-338 13 10 ; ; PUNCT admet-338 13 11 biopharmaceutics biopharmaceutics NOUN admet-338 13 12 classification classification NOUN admet-338 13 13 system system NOUN admet-338 13 14 ( ( PUNCT admet-338 13 15 bcs bcs NOUN admet-338 13 16 ) ) PUNCT admet-338 13 17 . . PUNCT admet-338 14 1 introduction introduction NOUN admet-338 14 2 an an DET admet-338 14 3 orally orally ADV admet-338 14 4 disintegrating disintegrate VERB admet-338 14 5 tablet tablet NOUN admet-338 14 6 ( ( PUNCT admet-338 14 7 odt odt NOUN admet-338 14 8 ) ) PUNCT admet-338 14 9 improves improve VERB admet-338 14 10 patient patient ADJ admet-338 14 11 compliance compliance NOUN admet-338 14 12 because because SCONJ admet-338 14 13 it it PRON admet-338 14 14 can can AUX admet-338 14 15 be be AUX admet-338 14 16 taken take VERB admet-338 14 17 without without ADP admet-338 14 18 water water NOUN admet-338 14 19 , , PUNCT admet-338 14 20 does do AUX admet-338 14 21 not not PART admet-338 14 22 cause cause VERB admet-338 14 23 dysphagia dysphagia NOUN admet-338 14 24 , , PUNCT admet-338 14 25 and and CCONJ admet-338 14 26 can can AUX admet-338 14 27 prevent prevent VERB admet-338 14 28 patients patient NOUN admet-338 14 29 from from ADP admet-338 14 30 spitting spit VERB admet-338 14 31 out out ADP admet-338 14 32 their their PRON admet-338 14 33 medication medication NOUN admet-338 14 34 [ [ X admet-338 14 35 1,2 1,2 NUM admet-338 14 36 ] ] PUNCT admet-338 14 37 . . PUNCT admet-338 15 1 many many ADJ admet-338 15 2 pharmaceutical pharmaceutical ADJ admet-338 15 3 companies company NOUN admet-338 15 4 are be AUX admet-338 15 5 working work VERB admet-338 15 6 on on ADP admet-338 15 7 the the DET admet-338 15 8 development development NOUN admet-338 15 9 of of ADP admet-338 15 10 odts odts NOUN admet-338 15 11 . . PUNCT admet-338 16 1 an an DET admet-338 16 2 odt odt NOUN admet-338 16 3 should should AUX admet-338 16 4 be be AUX admet-338 16 5 bioequivalent bioequivalent NOUN admet-338 16 6 to to ADP admet-338 16 7 a a DET admet-338 16 8 corresponding corresponding ADJ admet-338 16 9 standard standard ADJ admet-338 16 10 formulation formulation NOUN admet-338 16 11 , , PUNCT admet-338 16 12 e.g. e.g. ADV admet-338 16 13 an an DET admet-338 16 14 immediate immediate ADJ admet-338 16 15 - - PUNCT admet-338 16 16 release release NOUN admet-338 16 17 ( ( PUNCT admet-338 16 18 ir ir NOUN admet-338 16 19 ) ) PUNCT admet-338 16 20 formulation formulation NOUN admet-338 16 21 . . PUNCT admet-338 17 1 an an DET admet-338 17 2 odt odt NOUN admet-338 17 3 disintegrates disintegrate VERB admet-338 17 4 and and CCONJ admet-338 17 5 dissolves dissolve VERB admet-338 17 6 rapidly rapidly ADV admet-338 17 7 in in ADP admet-338 17 8 the the DET admet-338 17 9 oral oral ADJ admet-338 17 10 cavity cavity NOUN admet-338 17 11 within within ADP admet-338 17 12 30 30 NUM admet-338 17 13 seconds second NOUN admet-338 17 14 . . PUNCT admet-338 18 1 therefore therefore ADV admet-338 18 2 , , PUNCT admet-338 18 3 the the DET admet-338 18 4 dissolution dissolution NOUN admet-338 18 5 rate rate NOUN admet-338 18 6 may may AUX admet-338 18 7 differ differ VERB admet-338 18 8 significantly significantly ADV admet-338 18 9 between between ADP admet-338 18 10 odts odts NOUN admet-338 18 11 and and CCONJ admet-338 18 12 ir ir PROPN admet-338 18 13 formulations formulation NOUN admet-338 18 14 . . PUNCT admet-338 19 1 when when SCONJ admet-338 19 2 the the DET admet-338 19 3 dissolution dissolution NOUN admet-338 19 4 rates rate NOUN admet-338 19 5 are be AUX admet-338 19 6 different different ADJ admet-338 19 7 between between ADP admet-338 19 8 the the DET admet-338 19 9 odt odt NOUN admet-338 19 10 and and CCONJ admet-338 19 11 the the DET admet-338 19 12 ir ir PROPN admet-338 19 13 formulation formulation NOUN admet-338 19 14 , , PUNCT admet-338 19 15 the the DET admet-338 19 16 risk risk NOUN admet-338 19 17 to to PART admet-338 19 18 fail fail VERB admet-338 19 19 in in ADP admet-338 19 20 a a DET admet-338 19 21 bioequivalence bioequivalence NOUN admet-338 19 22 ( ( PUNCT admet-338 19 23 be be AUX admet-338 19 24 ) ) PUNCT admet-338 19 25 study study NOUN admet-338 19 26 is be AUX admet-338 19 27 high high ADJ admet-338 19 28 . . PUNCT admet-338 20 1 therefore therefore ADV admet-338 20 2 , , PUNCT admet-338 20 3 during during ADP admet-338 20 4 the the DET admet-338 20 5 development development NOUN admet-338 20 6 of of ADP admet-338 20 7 an an DET admet-338 20 8 odt odt NOUN admet-338 20 9 , , PUNCT admet-338 20 10 it it PRON admet-338 20 11 is be AUX admet-338 20 12 important important ADJ admet-338 20 13 to to PART admet-338 20 14 assess assess VERB admet-338 20 15 the the DET admet-338 20 16 risk risk NOUN admet-338 20 17 of of ADP admet-338 20 18 failing fail VERB admet-338 20 19 in in ADP admet-338 20 20 a a DET admet-338 20 21 clinical clinical ADJ admet-338 20 22 be be NOUN admet-338 20 23 study study NOUN admet-338 20 24 . . PUNCT admet-338 21 1 it it PRON admet-338 21 2 is be AUX admet-338 21 3 preferable preferable ADJ admet-338 21 4 to to PART admet-338 21 5 reduce reduce VERB admet-338 21 6 the the DET admet-338 21 7 risk risk NOUN admet-338 21 8 of of ADP admet-338 21 9 failing fail VERB admet-338 21 10 a a DET admet-338 21 11 clinical clinical ADJ admet-338 21 12 be be NOUN admet-338 21 13 study study NOUN admet-338 21 14 because because SCONJ admet-338 21 15 such such ADJ admet-338 21 16 studies study NOUN admet-338 21 17 are be AUX admet-338 21 18 expensive expensive ADJ admet-338 21 19 , , PUNCT admet-338 21 20 time time NOUN admet-338 21 21 consuming consuming NOUN admet-338 21 22 , , PUNCT admet-338 21 23 and and CCONJ admet-338 21 24 a a DET admet-338 21 25 burden burden NOUN admet-338 21 26 to to ADP admet-338 21 27 healthy healthy ADJ admet-338 21 28 http://www.pub.iapchem.org/ojs/index.php/admet/index http://www.pub.iapchem.org/ojs/index.php/admet/index NOUN admet-338 21 29 mailto:ono.ar@om.asahi-kasei.co.jp mailto:ono.ar@om.asahi-kasei.co.jp PROPN admet-338 22 1 asami asami PROPN admet-338 22 2 ono ono PROPN admet-338 22 3 et et PROPN admet-338 22 4 al al PROPN admet-338 22 5 . . PROPN admet-338 22 6 admet admet PROPN admet-338 22 7 & & CCONJ admet-338 22 8 dmpk dmpk PROPN admet-338 22 9 4(4 4(4 NUM admet-338 22 10 ) ) PUNCT admet-338 22 11 ( ( PUNCT admet-338 22 12 2016 2016 NUM admet-338 22 13 ) ) PUNCT admet-338 22 14 335 335 NUM admet-338 22 15 - - SYM admet-338 22 16 360 360 NUM admet-338 22 17 336 336 NUM admet-338 22 18 volunteers volunteer NOUN admet-338 22 19 . . PUNCT admet-338 23 1 however however ADV admet-338 23 2 , , PUNCT admet-338 23 3 there there PRON admet-338 23 4 has have AUX admet-338 23 5 been be AUX admet-338 23 6 no no DET admet-338 23 7 research research NOUN admet-338 23 8 investigating investigate VERB admet-338 23 9 the the DET admet-338 23 10 biopharmaceutical biopharmaceutical ADJ admet-338 23 11 properties property NOUN admet-338 23 12 of of ADP admet-338 23 13 drugs drug NOUN admet-338 23 14 suitable suitable ADJ admet-338 23 15 to to PART admet-338 23 16 be be AUX admet-338 23 17 an an DET admet-338 23 18 odt odt NOUN admet-338 23 19 . . PUNCT admet-338 24 1 in in ADP admet-338 24 2 the the DET admet-338 24 3 present present ADJ admet-338 24 4 study study NOUN admet-338 24 5 , , PUNCT admet-338 24 6 several several ADJ admet-338 24 7 physicochemical physicochemical ADJ admet-338 24 8 and and CCONJ admet-338 24 9 biopharmaceutical biopharmaceutical NOUN admet-338 24 10 properties property NOUN admet-338 24 11 were be AUX admet-338 24 12 selected select VERB admet-338 24 13 and and CCONJ admet-338 24 14 a a DET admet-338 24 15 survey survey NOUN admet-338 24 16 was be AUX admet-338 24 17 performed perform VERB admet-338 24 18 to to PART admet-338 24 19 compare compare VERB admet-338 24 20 the the DET admet-338 24 21 properties property NOUN admet-338 24 22 between between ADP admet-338 24 23 the the DET admet-338 24 24 two two NUM admet-338 24 25 types type NOUN admet-338 24 26 of of ADP admet-338 24 27 oral oral ADJ admet-338 24 28 dose dose NOUN admet-338 24 29 formulations formulation NOUN admet-338 24 30 . . PUNCT admet-338 25 1 methods method NOUN admet-338 25 2 drug drug NOUN admet-338 25 3 list list NOUN admet-338 25 4 the the DET admet-338 25 5 physicochemical physicochemical ADJ admet-338 25 6 and and CCONJ admet-338 25 7 biopharmaceutical biopharmaceutical NOUN admet-338 25 8 properties property NOUN admet-338 25 9 of of ADP admet-338 25 10 drugs drug NOUN admet-338 25 11 marketed market VERB admet-338 25 12 as as ADP admet-338 25 13 odts odts NOUN admet-338 25 14 and and CCONJ admet-338 25 15 ir ir PROPN admet-338 25 16 formulations formulation NOUN admet-338 25 17 were be AUX admet-338 25 18 compared compare VERB admet-338 25 19 in in ADP admet-338 25 20 this this DET admet-338 25 21 study study NOUN admet-338 25 22 . . PUNCT admet-338 26 1 currently currently ADV admet-338 26 2 , , PUNCT admet-338 26 3 the the DET admet-338 26 4 number number NOUN admet-338 26 5 of of ADP admet-338 26 6 drugs drug NOUN admet-338 26 7 developed develop VERB admet-338 26 8 as as ADP admet-338 26 9 odt odt NOUN admet-338 26 10 is be AUX admet-338 26 11 largest large ADJ admet-338 26 12 in in ADP admet-338 26 13 japan japan PROPN admet-338 26 14 . . PUNCT admet-338 27 1 in in ADP admet-338 27 2 addition addition NOUN admet-338 27 3 , , PUNCT admet-338 27 4 all all DET admet-338 27 5 the the DET admet-338 27 6 odt odt NOUN admet-338 27 7 formulations formulation NOUN admet-338 27 8 approved approve VERB admet-338 27 9 in in ADP admet-338 27 10 japan japan PROPN admet-338 27 11 were be AUX admet-338 27 12 proved prove VERB admet-338 27 13 to to PART admet-338 27 14 be be AUX admet-338 27 15 bioequivalent bioequivalent NOUN admet-338 27 16 to to ADP admet-338 27 17 the the DET admet-338 27 18 ir ir PROPN admet-338 27 19 formulation formulation NOUN admet-338 27 20 with with ADP admet-338 27 21 and and CCONJ admet-338 27 22 without without ADP admet-338 27 23 water water NOUN admet-338 27 24 intake intake NOUN admet-338 27 25 . . PUNCT admet-338 28 1 therefore therefore ADV admet-338 28 2 , , PUNCT admet-338 28 3 the the DET admet-338 28 4 odt odt NOUN admet-338 28 5 formulations formulation NOUN admet-338 28 6 in in ADP admet-338 28 7 japanese japanese ADJ admet-338 28 8 market market NOUN admet-338 28 9 were be AUX admet-338 28 10 selected select VERB admet-338 28 11 in in ADP admet-338 28 12 this this DET admet-338 28 13 study study NOUN admet-338 28 14 . . PUNCT admet-338 29 1 the the DET admet-338 29 2 list list NOUN admet-338 29 3 of of ADP admet-338 29 4 the the DET admet-338 29 5 odt odt ADJ admet-338 29 6 drugs drug NOUN admet-338 29 7 was be AUX admet-338 29 8 obtained obtain VERB admet-338 29 9 from from ADP admet-338 29 10 the the DET admet-338 29 11 pharmaceuticals pharmaceutical NOUN admet-338 29 12 and and CCONJ admet-338 29 13 medicinal medicinal ADJ admet-338 29 14 devices device NOUN admet-338 29 15 agency agency NOUN admet-338 29 16 website website NOUN admet-338 29 17 ( ( PUNCT admet-338 29 18 http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html PROPN admet-338 29 19 ) ) PUNCT admet-338 29 20 ( ( PUNCT admet-338 29 21 supplement supplement NOUN admet-338 29 22 table table NOUN admet-338 29 23 1 1 NUM admet-338 29 24 ) ) PUNCT admet-338 29 25 . . PUNCT admet-338 30 1 the the DET admet-338 30 2 list list NOUN admet-338 30 3 of of ADP admet-338 30 4 the the DET admet-338 30 5 ir ir PROPN admet-338 30 6 formulations formulation NOUN admet-338 30 7 were be AUX admet-338 30 8 selected select VERB admet-338 30 9 from from ADP admet-338 30 10 the the DET admet-338 30 11 top top ADJ admet-338 30 12 200 200 NUM admet-338 30 13 pharmaceutical pharmaceutical ADJ admet-338 30 14 products product NOUN admet-338 30 15 in in ADP admet-338 30 16 japan japan PROPN admet-338 30 17 ( ( PUNCT admet-338 30 18 supplement supplement NOUN admet-338 30 19 table table NOUN admet-338 30 20 2 2 NUM admet-338 30 21 ) ) PUNCT admet-338 31 1 [ [ X admet-338 31 2 3 3 NUM admet-338 31 3 ] ] PUNCT admet-338 31 4 . . PUNCT admet-338 32 1 finally finally ADV admet-338 32 2 , , PUNCT admet-338 32 3 57 57 NUM admet-338 32 4 compounds compound NOUN admet-338 32 5 for for ADP admet-338 32 6 the the DET admet-338 32 7 odt odt NOUN admet-338 32 8 and and CCONJ admet-338 32 9 113 113 NUM admet-338 32 10 compounds compound NOUN admet-338 32 11 for for ADP admet-338 32 12 the the DET admet-338 32 13 ir ir PROPN admet-338 32 14 formulation formulation NOUN admet-338 32 15 were be AUX admet-338 32 16 selected select VERB admet-338 32 17 and and CCONJ admet-338 32 18 analysed analyse VERB admet-338 32 19 . . PUNCT admet-338 33 1 the the DET admet-338 33 2 25 25 NUM admet-338 33 3 compounds compound NOUN admet-338 33 4 were be AUX admet-338 33 5 overlapping overlap VERB admet-338 33 6 between between ADP admet-338 33 7 the the DET admet-338 33 8 lists list NOUN admet-338 33 9 of of ADP admet-338 33 10 the the DET admet-338 33 11 odts odts NOUN admet-338 33 12 and and CCONJ admet-338 33 13 ir ir PROPN admet-338 33 14 formulations formulation NOUN admet-338 33 15 . . PUNCT admet-338 34 1 biopharmaceutical biopharmaceutical ADJ admet-338 34 2 drug drug NOUN admet-338 34 3 properties property NOUN admet-338 34 4 the the DET admet-338 34 5 physicochemical physicochemical ADJ admet-338 34 6 and and CCONJ admet-338 34 7 biopharmaceutical biopharmaceutical NOUN admet-338 34 8 properties property NOUN admet-338 34 9 of of ADP admet-338 34 10 drugs drug NOUN admet-338 34 11 related relate VERB admet-338 34 12 to to ADP admet-338 34 13 the the DET admet-338 34 14 formulation formulation NOUN admet-338 34 15 design design NOUN admet-338 34 16 and and CCONJ admet-338 34 17 oral oral ADJ admet-338 34 18 bioavailability bioavailability NOUN admet-338 34 19 were be AUX admet-338 34 20 selected select VERB admet-338 34 21 [ [ PUNCT admet-338 34 22 4,5 4,5 NUM admet-338 34 23 ] ] PUNCT admet-338 34 24 . . PUNCT admet-338 35 1 the the DET admet-338 35 2 molecular molecular ADJ admet-338 35 3 weight weight NOUN admet-338 35 4 ( ( PUNCT admet-338 35 5 mw mw NOUN admet-338 35 6 ) ) PUNCT admet-338 35 7 , , PUNCT admet-338 35 8 polar polar ADJ admet-338 35 9 surface surface NOUN admet-338 35 10 area area NOUN admet-338 35 11 ( ( PUNCT admet-338 35 12 psa psa NOUN admet-338 35 13 ) ) PUNCT admet-338 35 14 , , PUNCT admet-338 35 15 hydrogen hydrogen NOUN admet-338 35 16 bond bond NOUN admet-338 35 17 donor donor NOUN admet-338 35 18 ( ( PUNCT admet-338 35 19 hbd hbd NOUN admet-338 35 20 ) ) PUNCT admet-338 35 21 and and CCONJ admet-338 35 22 acceptor acceptor NOUN admet-338 35 23 ( ( PUNCT admet-338 35 24 hba hba NOUN admet-338 35 25 ) ) PUNCT admet-338 35 26 numbers number NOUN admet-338 35 27 , , PUNCT admet-338 35 28 dissociation dissociation NOUN admet-338 35 29 constants constant NOUN admet-338 35 30 ( ( PUNCT admet-338 35 31 pka pka NOUN admet-338 35 32 ) ) PUNCT admet-338 35 33 , , PUNCT admet-338 35 34 and and CCONJ admet-338 35 35 n n CCONJ admet-338 35 36 - - PUNCT admet-338 35 37 octanol octanol NOUN admet-338 35 38 / / SYM admet-338 35 39 water water NOUN admet-338 35 40 distribution distribution NOUN admet-338 35 41 coefficients coefficient NOUN admet-338 35 42 at at ADP admet-338 35 43 ph6.5 ph6.5 NOUN admet-338 35 44 ( ( PUNCT admet-338 35 45 log log PROPN admet-338 35 46 d6.5 d6.5 PROPN admet-338 35 47 ) ) PUNCT admet-338 35 48 were be AUX admet-338 35 49 calculated calculate VERB admet-338 35 50 using use VERB admet-338 35 51 acd acd NOUN admet-338 35 52 percepta percepta NOUN admet-338 35 53 ( ( PUNCT admet-338 35 54 acd acd NOUN admet-338 35 55 / / SYM admet-338 35 56 labs lab NOUN admet-338 35 57 software software VERB admet-338 35 58 v v ADP admet-338 35 59 14.0.0 14.0.0 NUM admet-338 35 60 ( ( PUNCT admet-338 35 61 http://www.acdlabs.com/products/percepta/predictors.php http://www.acdlabs.com/products/percepta/predictors.php NOUN admet-338 35 62 ) ) PUNCT admet-338 35 63 ) ) PUNCT admet-338 35 64 . . PUNCT admet-338 36 1 the the DET admet-338 36 2 calculated calculate VERB admet-338 36 3 pka pka PROPN admet-338 36 4 and and CCONJ admet-338 36 5 log log NOUN admet-338 36 6 d d ADP admet-338 36 7 were be AUX admet-338 36 8 used use VERB admet-338 36 9 for for ADP admet-338 36 10 all all DET admet-338 36 11 drugs drug NOUN admet-338 36 12 , , PUNCT admet-338 36 13 as as SCONJ admet-338 36 14 the the DET admet-338 36 15 experimental experimental ADJ admet-338 36 16 values value NOUN admet-338 36 17 were be AUX admet-338 36 18 not not PART admet-338 36 19 available available ADJ admet-338 36 20 for for ADP admet-338 36 21 some some DET admet-338 36 22 drugs drug NOUN admet-338 36 23 . . PUNCT admet-338 37 1 net net ADJ admet-338 37 2 charge charge NOUN admet-338 37 3 ( ( PUNCT admet-338 37 4 nc nc NOUN admet-338 37 5 ) ) PUNCT admet-338 37 6 at at ADP admet-338 37 7 ph ph PROPN admet-338 37 8 7.4 7.4 NUM admet-338 37 9 was be AUX admet-338 37 10 represented represent VERB admet-338 37 11 as as ADP admet-338 37 12 the the DET admet-338 37 13 weighted weighted ADJ admet-338 37 14 sum sum NOUN admet-338 37 15 of of ADP admet-338 37 16 the the DET admet-338 37 17 charge charge NOUN admet-338 37 18 of of ADP admet-338 37 19 each each DET admet-338 37 20 species specie NOUN admet-338 37 21 . . PUNCT admet-338 38 1 nc nc PROPN admet-338 38 2 = = NOUN admet-338 38 3 ( ( PUNCT admet-338 38 4 Β±0 Β±0 NOUN admet-338 38 5 ) ) PUNCT admet-338 39 1 βˆ™ βˆ™ PROPN admet-338 39 2 𝑓0 𝑓0 PROPN admet-338 39 3 + + CCONJ admet-338 39 4 ( ( PUNCT admet-338 39 5 +1 +1 INTJ admet-338 39 6 ) ) PUNCT admet-338 39 7 βˆ™ βˆ™ PROPN admet-338 39 8 𝑓+ 𝑓+ VERB admet-338 39 9 + + CCONJ admet-338 39 10 ( ( PUNCT admet-338 39 11 βˆ’1 βˆ’1 NOUN admet-338 39 12 ) ) PUNCT admet-338 39 13 βˆ™ βˆ™ PROPN admet-338 39 14 π‘“βˆ’ π‘“βˆ’ X admet-338 39 15 + + CCONJ admet-338 39 16 ( ( PUNCT admet-338 39 17 +2 +2 ADJ admet-338 39 18 ) ) PUNCT admet-338 39 19 βˆ™ βˆ™ NOUN admet-338 39 20 𝑓++ 𝑓++ NOUN admet-338 39 21 + + CCONJ admet-338 39 22 β‹― β‹― VERB admet-338 39 23 ( ( PUNCT admet-338 39 24 1 1 NUM admet-338 39 25 ) ) PUNCT admet-338 39 26 ( ( PUNCT admet-338 39 27 𝑓0 𝑓0 PROPN admet-338 39 28 + + CCONJ admet-338 39 29 𝑓+ 𝑓+ X admet-338 39 30 + + X admet-338 39 31 π‘“βˆ’ π‘“βˆ’ PROPN admet-338 39 32 + + PUNCT admet-338 39 33 𝑓++ 𝑓++ NOUN admet-338 39 34 + + X admet-338 39 35 β‹― β‹― NOUN admet-338 39 36 = = SYM admet-338 39 37 1 1 NUM admet-338 39 38 ) ) PUNCT admet-338 39 39 where where SCONJ admet-338 39 40 f0 f0 PROPN admet-338 39 41 is be AUX admet-338 39 42 the the DET admet-338 39 43 fraction fraction NOUN admet-338 39 44 of of ADP admet-338 39 45 the the DET admet-338 39 46 undissociated undissociated ADJ admet-338 39 47 species specie NOUN admet-338 39 48 , , PUNCT admet-338 39 49 f+ f+ PROPN admet-338 39 50 is be AUX admet-338 39 51 that that PRON admet-338 39 52 of of ADP admet-338 39 53 +1 +1 PROPN admet-338 39 54 charged charge VERB admet-338 39 55 species specie NOUN admet-338 39 56 , , PUNCT admet-338 39 57 etc etc X admet-338 39 58 . . X admet-338 40 1 each each DET admet-338 40 2 fraction fraction NOUN admet-338 40 3 was be AUX admet-338 40 4 calculated calculate VERB admet-338 40 5 by by ADP admet-338 40 6 the the DET admet-338 40 7 pka pka PROPN admet-338 40 8 and and CCONJ admet-338 40 9 the the DET admet-338 40 10 ph ph NOUN admet-338 40 11 ( ( PUNCT admet-338 40 12 set set VERB admet-338 40 13 to to PART admet-338 40 14 be be AUX admet-338 40 15 7.4 7.4 NUM admet-338 40 16 in in ADP admet-338 40 17 this this DET admet-338 40 18 study study NOUN admet-338 40 19 ) ) PUNCT admet-338 40 20 using use VERB admet-338 40 21 the the DET admet-338 40 22 henderson henderson PROPN admet-338 40 23 - - PUNCT admet-338 40 24 hasselbalch hasselbalch PROPN admet-338 40 25 equation equation NOUN admet-338 40 26 [ [ X admet-338 40 27 6 6 NUM admet-338 40 28 ] ] PUNCT admet-338 40 29 . . PUNCT admet-338 41 1 the the DET admet-338 41 2 nc nc PROPN admet-338 41 3 equations equation NOUN admet-338 41 4 for for ADP admet-338 41 5 acids acid NOUN admet-338 41 6 and and CCONJ admet-338 41 7 bases basis NOUN admet-338 41 8 containing contain VERB admet-338 41 9 up up ADP admet-338 41 10 to to PART admet-338 41 11 three three NUM admet-338 41 12 ionization ionization NOUN admet-338 41 13 centers center NOUN admet-338 41 14 are be AUX admet-338 41 15 summarized summarize VERB admet-338 41 16 in in ADP admet-338 41 17 supplement supplement NOUN admet-338 41 18 table table NOUN admet-338 41 19 3 3 NUM admet-338 41 20 . . PUNCT admet-338 41 21 when when SCONJ admet-338 41 22 a a DET admet-338 41 23 drug drug NOUN admet-338 41 24 was be AUX admet-338 41 25 more more ADJ admet-338 41 26 than than ADP admet-338 41 27 50 50 NUM admet-338 41 28 % % NOUN admet-338 41 29 dissociated dissociate VERB admet-338 41 30 at at ADP admet-338 41 31 ph ph PROPN admet-338 41 32 7.4 7.4 NUM admet-338 41 33 , , PUNCT admet-338 41 34 it it PRON admet-338 41 35 was be AUX admet-338 41 36 classified classify VERB admet-338 41 37 as as ADP admet-338 41 38 an an DET admet-338 41 39 acid acid NOUN admet-338 41 40 ( ( PUNCT admet-338 41 41 nc nc PROPN admet-338 41 42 < < X admet-338 41 43 -0.5 -0.5 PROPN admet-338 41 44 ) ) PUNCT admet-338 41 45 or or CCONJ admet-338 41 46 as as ADP admet-338 41 47 a a DET admet-338 41 48 base base NOUN admet-338 41 49 ( ( PUNCT admet-338 41 50 nc nc X admet-338 41 51 > > X admet-338 41 52 0.5 0.5 NUM admet-338 41 53 ) ) PUNCT admet-338 41 54 . . PUNCT admet-338 42 1 log log PROPN admet-338 42 2 d d PROPN admet-338 42 3 was be AUX admet-338 42 4 calculated calculate VERB admet-338 42 5 at at ADP admet-338 42 6 ph ph PROPN admet-338 42 7 6.5 6.5 NUM admet-338 42 8 to to PART admet-338 42 9 estimate estimate VERB admet-338 42 10 the the DET admet-338 42 11 permeability permeability NOUN admet-338 42 12 , , PUNCT admet-338 42 13 whereas whereas SCONJ admet-338 42 14 nc nc PROPN admet-338 42 15 was be AUX admet-338 42 16 calculated calculate VERB admet-338 42 17 at at ADP admet-338 42 18 ph ph PROPN admet-338 42 19 7.4 7.4 NUM admet-338 42 20 to to PART admet-338 42 21 discuss discuss VERB admet-338 42 22 the the DET admet-338 42 23 pharmacokinetics pharmacokinetic NOUN admet-338 42 24 after after ADP admet-338 42 25 the the DET admet-338 42 26 absorption absorption NOUN admet-338 42 27 . . PUNCT admet-338 43 1 the the DET admet-338 43 2 solubility solubility NOUN admet-338 43 3 in in ADP admet-338 43 4 water water NOUN admet-338 43 5 , , PUNCT admet-338 43 6 the the DET admet-338 43 7 highest high ADJ admet-338 43 8 dose dose NOUN admet-338 43 9 strength strength NOUN admet-338 43 10 , , PUNCT admet-338 43 11 and and CCONJ admet-338 43 12 the the DET admet-338 43 13 elimination elimination NOUN admet-338 43 14 t1/2 t1/2 NOUN admet-338 43 15 were be AUX admet-338 43 16 obtained obtain VERB admet-338 43 17 from from ADP admet-338 43 18 the the DET admet-338 43 19 prescription prescription NOUN admet-338 43 20 information information NOUN admet-338 43 21 . . PUNCT admet-338 44 1 when when SCONJ admet-338 44 2 a a DET admet-338 44 3 reliable reliable ADJ admet-338 44 4 solubility solubility NOUN admet-338 44 5 figure figure NOUN admet-338 44 6 was be AUX admet-338 44 7 unavailable unavailable ADJ admet-338 44 8 , , PUNCT admet-338 44 9 a a DET admet-338 44 10 solubility solubility NOUN admet-338 44 11 value value NOUN admet-338 44 12 was be AUX admet-338 44 13 assigned assign VERB admet-338 44 14 based base VERB admet-338 44 15 on on ADP admet-338 44 16 the the DET admet-338 44 17 solubility solubility NOUN admet-338 44 18 category category NOUN admet-338 44 19 defined define VERB admet-338 44 20 by by ADP admet-338 44 21 the the DET admet-338 44 22 japanese japanese ADJ admet-338 44 23 pharmacopeia pharmacopeia NOUN admet-338 44 24 ( ( PUNCT admet-338 44 25 supplement supplement NOUN admet-338 44 26 table table NOUN admet-338 44 27 4 4 NUM admet-338 44 28 ) ) PUNCT admet-338 44 29 . . PUNCT admet-338 45 1 provisional provisional ADJ admet-338 45 2 classification classification NOUN admet-338 45 3 according accord VERB admet-338 45 4 to to ADP admet-338 45 5 the the DET admet-338 45 6 biopharmaceutical biopharmaceutical ADJ admet-338 45 7 classification classification NOUN admet-338 45 8 system system NOUN admet-338 45 9 according accord VERB admet-338 45 10 to to ADP admet-338 45 11 the the DET admet-338 45 12 biopharmaceutical biopharmaceutical ADJ admet-338 45 13 classification classification NOUN admet-338 45 14 system system NOUN admet-338 45 15 ( ( PUNCT admet-338 45 16 bcs bcs NOUN admet-338 45 17 ) ) PUNCT admet-338 45 18 , , PUNCT admet-338 45 19 drugs drug NOUN admet-338 45 20 can can AUX admet-338 45 21 be be AUX admet-338 45 22 categorized categorize VERB admet-338 45 23 into into ADP admet-338 45 24 the the DET admet-338 45 25 four four NUM admet-338 45 26 classes class NOUN admet-338 45 27 , , PUNCT admet-338 45 28 i.e. i.e. X admet-338 45 29 high high ADJ admet-338 45 30 solubility solubility NOUN admet-338 45 31 / / SYM admet-338 45 32 high high ADJ admet-338 45 33 permeability permeability NOUN admet-338 45 34 ( ( PUNCT admet-338 45 35 class class NOUN admet-338 45 36 i i PROPN admet-338 45 37 ) ) PUNCT admet-338 45 38 , , PUNCT admet-338 45 39 low low ADJ admet-338 45 40 solubility solubility NOUN admet-338 45 41 / / SYM admet-338 45 42 high high ADJ admet-338 45 43 permeability permeability NOUN admet-338 45 44 ( ( PUNCT admet-338 45 45 class class NOUN admet-338 45 46 ii ii PROPN admet-338 45 47 ) ) PUNCT admet-338 45 48 , , PUNCT admet-338 45 49 high high ADJ admet-338 45 50 solubility solubility NOUN admet-338 45 51 / / SYM admet-338 45 52 low low ADJ admet-338 45 53 permeability permeability NOUN admet-338 45 54 ( ( PUNCT admet-338 45 55 class class NOUN admet-338 45 56 iii iii NOUN admet-338 45 57 ) ) PUNCT admet-338 45 58 , , PUNCT admet-338 45 59 and and CCONJ admet-338 45 60 low low ADJ admet-338 45 61 solubility solubility NOUN admet-338 45 62 / / SYM admet-338 45 63 low low ADJ admet-338 45 64 permeability permeability NOUN admet-338 45 65 ( ( PUNCT admet-338 45 66 class class NOUN admet-338 45 67 iv iv NUM admet-338 45 68 ) ) PUNCT admet-338 45 69 . . PUNCT admet-338 46 1 moreover moreover ADV admet-338 46 2 , , PUNCT admet-338 46 3 bcs bcs NOUN admet-338 46 4 class class NOUN admet-338 46 5 ii ii NOUN admet-338 46 6 drugs drug NOUN admet-338 46 7 can can AUX admet-338 46 8 be be AUX admet-338 46 9 sub sub ADJ admet-338 46 10 - - ADJ admet-338 46 11 classified classified ADJ admet-338 46 12 into into ADP admet-338 46 13 acid acid PROPN admet-338 46 14 ( ( PUNCT admet-338 46 15 class class NOUN admet-338 46 16 iia iia NOUN admet-338 46 17 ) ) PUNCT admet-338 46 18 , , PUNCT admet-338 46 19 base base NOUN admet-338 46 20 ( ( PUNCT admet-338 46 21 class class NOUN admet-338 46 22 iib iib PROPN admet-338 46 23 ) ) PUNCT admet-338 46 24 , , PUNCT admet-338 46 25 and and CCONJ admet-338 46 26 undissociated undissociated ADJ admet-338 46 27 drugs drug NOUN admet-338 46 28 ( ( PUNCT admet-338 46 29 class class NOUN admet-338 46 30 iic iic PROPN admet-338 46 31 ) ) PUNCT admet-338 47 1 [ [ X admet-338 47 2 7 7 NUM admet-338 47 3 ] ] PUNCT admet-338 47 4 . . PUNCT admet-338 48 1 admet admet PROPN admet-338 48 2 & & CCONJ admet-338 48 3 dmpk dmpk PROPN admet-338 48 4 4(4 4(4 NUM admet-338 48 5 ) ) PUNCT admet-338 48 6 ( ( PUNCT admet-338 48 7 2016 2016 NUM admet-338 48 8 ) ) PUNCT admet-338 48 9 335 335 NUM admet-338 48 10 - - SYM admet-338 48 11 360 360 NUM admet-338 48 12 biopharmaceutical biopharmaceutical NOUN admet-338 48 13 and and CCONJ admet-338 48 14 physchem physchem NOUN admet-338 48 15 properties property NOUN admet-338 48 16 for for ADP admet-338 48 17 odt odt ADJ admet-338 48 18 doi doi NOUN admet-338 48 19 : : PUNCT admet-338 48 20 10.5599 10.5599 NUM admet-338 48 21 / / SYM admet-338 48 22 admet.4.4.331 admet.4.4.331 PROPN admet-338 48 23 337 337 NUM admet-338 48 24 337 337 NUM admet-338 48 25 in in ADP admet-338 48 26 the the DET admet-338 48 27 previous previous ADJ admet-338 48 28 studies study NOUN admet-338 48 29 , , PUNCT admet-338 48 30 solubility solubility NOUN admet-338 48 31 in in ADP admet-338 48 32 water water NOUN admet-338 48 33 and and CCONJ admet-338 48 34 calculated calculate VERB admet-338 48 35 log log NOUN admet-338 48 36 d6.5 d6.5 PROPN admet-338 48 37 were be AUX admet-338 48 38 used use VERB admet-338 48 39 as as ADP admet-338 48 40 the the DET admet-338 48 41 surrogates surrogate NOUN admet-338 48 42 of of ADP admet-338 48 43 solubility solubility NOUN admet-338 48 44 and and CCONJ admet-338 48 45 permeability permeability NOUN admet-338 48 46 data datum NOUN admet-338 48 47 to to PART admet-338 48 48 provide provide VERB admet-338 48 49 provisional provisional ADJ admet-338 48 50 bcs bcs NOUN admet-338 48 51 class class NOUN admet-338 49 1 [ [ X admet-338 49 2 3,8 3,8 NUM admet-338 49 3 ] ] PUNCT admet-338 49 4 . . PUNCT admet-338 50 1 the the DET admet-338 50 2 same same ADJ admet-338 50 3 approach approach NOUN admet-338 50 4 was be AUX admet-338 50 5 taken take VERB admet-338 50 6 in in ADP admet-338 50 7 this this DET admet-338 50 8 study study NOUN admet-338 50 9 . . PUNCT admet-338 51 1 according accord VERB admet-338 51 2 to to ADP admet-338 51 3 the the DET admet-338 51 4 official official ADJ admet-338 51 5 bcs bcs NOUN admet-338 51 6 guidance guidance NOUN admet-338 51 7 , , PUNCT admet-338 51 8 the the DET admet-338 51 9 equilibrium equilibrium NOUN admet-338 51 10 solubility solubility NOUN admet-338 51 11 of of ADP admet-338 51 12 a a DET admet-338 51 13 drug drug NOUN admet-338 51 14 at at ADP admet-338 51 15 the the DET admet-338 51 16 physiological physiological ADJ admet-338 51 17 gastrointestinal gastrointestinal ADJ admet-338 51 18 ph ph ADJ admet-338 51 19 range range NOUN admet-338 51 20 ( ( PUNCT admet-338 51 21 namely namely ADV admet-338 51 22 , , PUNCT admet-338 51 23 ph ph ADJ admet-338 51 24 1.2 1.2 NUM admet-338 51 25 to to ADP admet-338 51 26 ph ph VERB admet-338 51 27 6.8 6.8 NUM admet-338 51 28 or or CCONJ admet-338 51 29 7.4 7.4 NUM admet-338 51 30 ) ) PUNCT admet-338 51 31 is be AUX admet-338 51 32 required require VERB admet-338 51 33 . . PUNCT admet-338 52 1 however however ADV admet-338 52 2 , , PUNCT admet-338 52 3 the the DET admet-338 52 4 ph ph NOUN admet-338 52 5 solubility solubility NOUN admet-338 52 6 profile profile NOUN admet-338 52 7 data datum NOUN admet-338 52 8 were be AUX admet-338 52 9 not not PART admet-338 52 10 available available ADJ admet-338 52 11 for for ADP admet-338 52 12 many many ADJ admet-338 52 13 drugs drug NOUN admet-338 52 14 . . PUNCT admet-338 53 1 therefore therefore ADV admet-338 53 2 , , PUNCT admet-338 53 3 solubility solubility NOUN admet-338 53 4 in in ADP admet-338 53 5 water water NOUN admet-338 53 6 reported report VERB admet-338 53 7 in in ADP admet-338 53 8 the the DET admet-338 53 9 prescription prescription NOUN admet-338 53 10 information information NOUN admet-338 53 11 was be AUX admet-338 53 12 used use VERB admet-338 53 13 in in ADP admet-338 53 14 this this DET admet-338 53 15 study study NOUN admet-338 53 16 . . PUNCT admet-338 54 1 the the DET admet-338 54 2 dose dose NOUN admet-338 54 3 number number NOUN admet-338 54 4 ( ( PUNCT admet-338 54 5 do do AUX admet-338 54 6 ) ) PUNCT admet-338 54 7 is be AUX admet-338 54 8 a a DET admet-338 54 9 dimensionless dimensionless NOUN admet-338 54 10 number number NOUN admet-338 54 11 expressed express VERB admet-338 54 12 by by ADP admet-338 54 13 the the DET admet-338 54 14 ratio ratio NOUN admet-338 54 15 of of ADP admet-338 54 16 the the DET admet-338 54 17 dose dose NOUN admet-338 54 18 and and CCONJ admet-338 54 19 the the DET admet-338 54 20 maximum maximum ADJ admet-338 54 21 dissolved dissolve VERB admet-338 54 22 amount amount NOUN admet-338 54 23 in in ADP admet-338 54 24 the the DET admet-338 54 25 intestine intestine NOUN admet-338 54 26 . . PUNCT admet-338 55 1 do do AUX admet-338 55 2 was be AUX admet-338 55 3 calculated calculate VERB admet-338 55 4 by by ADP admet-338 55 5 using use VERB admet-338 55 6 eq eq ADP admet-338 55 7 . . PROPN admet-338 55 8 2 2 NUM admet-338 56 1 [ [ SYM admet-338 56 2 5 5 NUM admet-338 56 3 ] ] PUNCT admet-338 56 4 : : PUNCT admet-338 56 5 π·π‘œ π·π‘œ NOUN admet-338 56 6 = = SYM admet-338 56 7 𝑀 𝑀 PROPN admet-338 56 8 𝑆 𝑆 PROPN admet-338 56 9 Γ— Γ— PROPN admet-338 56 10 𝑉 𝑉 PROPN admet-338 56 11 ( ( PUNCT admet-338 56 12 2 2 NUM admet-338 56 13 ) ) PUNCT admet-338 56 14 where where SCONJ admet-338 56 15 s s NOUN admet-338 56 16 is be AUX admet-338 56 17 the the DET admet-338 56 18 solubility solubility NOUN admet-338 56 19 of of ADP admet-338 56 20 a a DET admet-338 56 21 drug drug NOUN admet-338 56 22 in in ADP admet-338 56 23 water water NOUN admet-338 56 24 , , PUNCT admet-338 56 25 v v NOUN admet-338 56 26 is be AUX admet-338 56 27 the the DET admet-338 56 28 intestinal intestinal ADJ admet-338 56 29 fluid fluid NOUN admet-338 56 30 volume volume NOUN admet-338 56 31 ( ( PUNCT admet-338 56 32 set set VERB admet-338 56 33 to to PART admet-338 56 34 be be AUX admet-338 56 35 250 250 NUM admet-338 56 36 ml ml NOUN admet-338 56 37 in in ADP admet-338 56 38 this this DET admet-338 56 39 study study NOUN admet-338 56 40 ) ) PUNCT admet-338 56 41 , , PUNCT admet-338 56 42 and and CCONJ admet-338 56 43 m m PROPN admet-338 56 44 is be AUX admet-338 56 45 the the DET admet-338 56 46 highest high ADJ admet-338 56 47 dose dose NOUN admet-338 56 48 strength strength NOUN admet-338 56 49 . . PUNCT admet-338 57 1 drugs drug NOUN admet-338 57 2 were be AUX admet-338 57 3 defined define VERB admet-338 57 4 as as ADP admet-338 57 5 highly highly ADV admet-338 57 6 soluble soluble ADJ admet-338 57 7 when when SCONJ admet-338 57 8 the the DET admet-338 57 9 do do NOUN admet-338 57 10 was be AUX admet-338 57 11 ≀ ≀ NUM admet-338 57 12 1 1 NUM admet-338 57 13 . . PUNCT admet-338 58 1 according accord VERB admet-338 58 2 to to ADP admet-338 58 3 the the DET admet-338 58 4 official official ADJ admet-338 58 5 bcs bcs NOUN admet-338 58 6 guidance guidance NOUN admet-338 58 7 , , PUNCT admet-338 58 8 to to PART admet-338 58 9 classify classify VERB admet-338 58 10 the the DET admet-338 58 11 permeability permeability NOUN admet-338 58 12 category category NOUN admet-338 58 13 , , PUNCT admet-338 58 14 the the DET admet-338 58 15 fraction fraction NOUN admet-338 58 16 of of ADP admet-338 58 17 a a DET admet-338 58 18 dose dose NOUN admet-338 58 19 absorbed absorb VERB admet-338 58 20 ( ( PUNCT admet-338 58 21 fa% fa% NOUN admet-338 58 22 ) ) PUNCT admet-338 58 23 in in ADP admet-338 58 24 humans human NOUN admet-338 58 25 or or CCONJ admet-338 58 26 caco-2 caco-2 NUM admet-338 58 27 permeability permeability NOUN admet-338 58 28 data datum NOUN admet-338 58 29 is be AUX admet-338 58 30 required require VERB admet-338 58 31 . . PUNCT admet-338 59 1 however however ADV admet-338 59 2 , , PUNCT admet-338 59 3 due due ADP admet-338 59 4 to to ADP admet-338 59 5 the the DET admet-338 59 6 limited limited ADJ admet-338 59 7 availability availability NOUN admet-338 59 8 of of ADP admet-338 59 9 these these DET admet-338 59 10 data datum NOUN admet-338 59 11 , , PUNCT admet-338 59 12 the the DET admet-338 59 13 permeability permeability NOUN admet-338 59 14 was be AUX admet-338 59 15 classified classify VERB admet-338 59 16 based base VERB admet-338 59 17 on on ADP admet-338 59 18 the the DET admet-338 59 19 calculated calculate VERB admet-338 59 20 log log NOUN admet-338 59 21 d6.5 d6.5 VERB admet-338 59 22 in in ADP admet-338 59 23 this this DET admet-338 59 24 study study NOUN admet-338 59 25 . . PUNCT admet-338 60 1 the the DET admet-338 60 2 log log NOUN admet-338 60 3 d6.5 d6.5 NOUN admet-338 60 4 value value NOUN admet-338 60 5 of of ADP admet-338 60 6 metoprolol metoprolol NOUN admet-338 60 7 was be AUX admet-338 60 8 chosen choose VERB admet-338 60 9 as as ADP admet-338 60 10 the the DET admet-338 60 11 criteria criterion NOUN admet-338 60 12 for for ADP admet-338 60 13 high high ADJ admet-338 60 14 permeability permeability NOUN admet-338 60 15 [ [ X admet-338 60 16 fa% fa% NOUN admet-338 60 17 in in ADP admet-338 60 18 human human NOUN admet-338 60 19 , , PUNCT admet-338 60 20 95 95 NUM admet-338 60 21 % % NOUN admet-338 61 1 [ [ X admet-338 61 2 9 9 NUM admet-338 61 3 ] ] PUNCT admet-338 61 4 ; ; PUNCT admet-338 61 5 human human ADJ admet-338 61 6 effective effective ADJ admet-338 61 7 permeability permeability NOUN admet-338 61 8 , , PUNCT admet-338 61 9 1.26 1.26 NUM admet-338 61 10 Γ— Γ— NOUN admet-338 61 11 10 10 NUM admet-338 61 12 - - SYM admet-338 61 13 4 4 NUM admet-338 61 14 cm cm NOUN admet-338 61 15 / / SYM admet-338 61 16 s s PART admet-338 62 1 [ [ X admet-338 62 2 9 9 NUM admet-338 62 3 ] ] PUNCT admet-338 62 4 ; ; PUNCT admet-338 62 5 log log PROPN admet-338 62 6 d6.5 d6.5 PROPN admet-338 62 7 , , PUNCT admet-338 62 8 -0.92 -0.92 ADP admet-338 62 9 ( ( PUNCT admet-338 62 10 acd acd NOUN admet-338 62 11 percepta percepta NOUN admet-338 62 12 ) ) PUNCT admet-338 62 13 ] ] PUNCT admet-338 62 14 . . PUNCT admet-338 63 1 statistical statistical ADJ admet-338 63 2 analysis analysis NOUN admet-338 63 3 a a DET admet-338 63 4 student student NOUN admet-338 63 5 ’s ’s PART admet-338 63 6 t t PROPN admet-338 63 7 - - PUNCT admet-338 63 8 test test NOUN admet-338 63 9 was be AUX admet-338 63 10 used use VERB admet-338 63 11 to to PART admet-338 63 12 evaluate evaluate VERB admet-338 63 13 the the DET admet-338 63 14 significance significance NOUN admet-338 63 15 of of ADP admet-338 63 16 difference difference NOUN admet-338 63 17 between between ADP admet-338 63 18 the the DET admet-338 63 19 odts odts NOUN admet-338 63 20 and and CCONJ admet-338 63 21 ir ir PROPN admet-338 63 22 formulations formulation NOUN admet-338 63 23 in in ADP admet-338 63 24 mw mw NOUN admet-338 63 25 , , PUNCT admet-338 63 26 psa psa VERB admet-338 63 27 , , PUNCT admet-338 63 28 hbd hbd NOUN admet-338 63 29 , , PUNCT admet-338 63 30 hba hba PROPN admet-338 63 31 , , PUNCT admet-338 63 32 nc nc PROPN admet-338 63 33 at at ADP admet-338 63 34 ph ph PROPN admet-338 63 35 7.4 7.4 NUM admet-338 63 36 , , PUNCT admet-338 63 37 log log NOUN admet-338 63 38 d6.5 d6.5 PROPN admet-338 63 39 , , PUNCT admet-338 63 40 the the DET admet-338 63 41 highest high ADJ admet-338 63 42 dose dose NOUN admet-338 63 43 strength strength NOUN admet-338 63 44 , , PUNCT admet-338 63 45 solubility solubility NOUN admet-338 63 46 in in ADP admet-338 63 47 water water NOUN admet-338 63 48 , , PUNCT admet-338 63 49 do do VERB admet-338 63 50 , , PUNCT admet-338 63 51 and and CCONJ admet-338 63 52 elimination elimination NOUN admet-338 63 53 t1/2 t1/2 NOUN admet-338 63 54 . . PUNCT admet-338 64 1 one one NUM admet-338 64 2 - - PUNCT admet-338 64 3 way way NOUN admet-338 64 4 analysis analysis NOUN admet-338 64 5 of of ADP admet-338 64 6 variance variance NOUN admet-338 64 7 was be AUX admet-338 64 8 used use VERB admet-338 64 9 to to PART admet-338 64 10 evaluate evaluate VERB admet-338 64 11 the the DET admet-338 64 12 significance significance NOUN admet-338 64 13 of of ADP admet-338 64 14 difference difference NOUN admet-338 64 15 between between ADP admet-338 64 16 acids acid NOUN admet-338 64 17 , , PUNCT admet-338 64 18 bases basis NOUN admet-338 64 19 , , PUNCT admet-338 64 20 and and CCONJ admet-338 64 21 undissociated undissociated ADJ admet-338 64 22 drugs drug NOUN admet-338 64 23 in in ADP admet-338 64 24 elimination elimination NOUN admet-338 64 25 t1/2 t1/2 NOUN admet-338 64 26 for for ADP admet-338 64 27 the the DET admet-338 64 28 odts odts NOUN admet-338 64 29 and and CCONJ admet-338 64 30 ir ir PROPN admet-338 64 31 formulations formulation NOUN admet-338 64 32 , , PUNCT admet-338 64 33 respectively respectively ADV admet-338 64 34 . . PUNCT admet-338 65 1 a a DET admet-338 65 2 minimum minimum ADJ admet-338 65 3 p p NOUN admet-338 65 4 value value NOUN admet-338 65 5 of of ADP admet-338 65 6 0.05 0.05 NUM admet-338 65 7 was be AUX admet-338 65 8 used use VERB admet-338 65 9 as as ADP admet-338 65 10 the the DET admet-338 65 11 significance significance NOUN admet-338 65 12 level level NOUN admet-338 65 13 for for ADP admet-338 65 14 all all DET admet-338 65 15 tests test NOUN admet-338 65 16 . . PUNCT admet-338 66 1 microsoft microsoft PROPN admet-338 66 2 excel excel VERB admet-338 66 3 2010 2010 NUM admet-338 66 4 ( ( PUNCT admet-338 66 5 microsoft microsoft PROPN admet-338 66 6 ) ) PUNCT admet-338 66 7 was be AUX admet-338 66 8 used use VERB admet-338 66 9 for for ADP admet-338 66 10 statistical statistical ADJ admet-338 66 11 analysis analysis NOUN admet-338 66 12 . . PUNCT admet-338 67 1 results result NOUN admet-338 67 2 mw mw X admet-338 67 3 of of ADP admet-338 67 4 free free ADJ admet-338 67 5 form form NOUN admet-338 67 6 , , PUNCT admet-338 67 7 psa psa NOUN admet-338 67 8 , , PUNCT admet-338 67 9 hbd hbd NOUN admet-338 67 10 , , PUNCT admet-338 67 11 hba hba PROPN admet-338 67 12 , , PUNCT admet-338 67 13 nc nc PROPN admet-338 67 14 at at ADP admet-338 67 15 ph ph PROPN admet-338 67 16 7.4 7.4 NUM admet-338 67 17 , , PUNCT admet-338 67 18 log log NOUN admet-338 67 19 d6.5 d6.5 PROPN admet-338 67 20 , , PUNCT admet-338 67 21 the the DET admet-338 67 22 highest high ADJ admet-338 67 23 dose dose NOUN admet-338 67 24 strength strength NOUN admet-338 67 25 , , PUNCT admet-338 67 26 solubility solubility NOUN admet-338 67 27 in in ADP admet-338 67 28 water water NOUN admet-338 67 29 , , PUNCT admet-338 67 30 do do VERB admet-338 67 31 , , PUNCT admet-338 67 32 and and CCONJ admet-338 67 33 elimination elimination NOUN admet-338 67 34 t1/2 t1/2 NOUN admet-338 67 35 are be AUX admet-338 67 36 shown show VERB admet-338 67 37 in in ADP admet-338 67 38 table table NOUN admet-338 67 39 1 1 NUM admet-338 67 40 . . PUNCT admet-338 68 1 some some PRON admet-338 68 2 calculated calculate VERB admet-338 68 3 pka pka PROPN admet-338 68 4 and and CCONJ admet-338 68 5 log log VERB admet-338 68 6 d6.5 d6.5 PROPN admet-338 68 7 might might AUX admet-338 68 8 have have VERB admet-338 68 9 a a DET admet-338 68 10 margin margin NOUN admet-338 68 11 of of ADP admet-338 68 12 error error NOUN admet-338 68 13 about about ADP admet-338 68 14 1 1 NUM admet-338 68 15 log log NOUN admet-338 68 16 unit unit NOUN admet-338 68 17 ( ( PUNCT admet-338 68 18 e.g. e.g. ADV admet-338 68 19 pkas pkas NOUN admet-338 68 20 of of ADP admet-338 68 21 cetirizine cetirizine NOUN admet-338 68 22 ( ( PUNCT admet-338 68 23 6.7 6.7 NUM admet-338 68 24 ( ( PUNCT admet-338 68 25 b b NOUN admet-338 68 26 ) ) PUNCT admet-338 68 27 ; ; PUNCT admet-338 68 28 7.7 7.7 NUM admet-338 68 29 ( ( PUNCT admet-338 68 30 b b NOUN admet-338 68 31 ) ) PUNCT admet-338 69 1 [ [ X admet-338 69 2 10 10 NUM admet-338 69 3 ] ] NUM admet-338 69 4 ) ) PUNCT admet-338 69 5 , , PUNCT admet-338 69 6 domperidone domperidone NOUN admet-338 69 7 ( ( PUNCT admet-338 69 8 9.0 9.0 NUM admet-338 69 9 ( ( PUNCT admet-338 69 10 b b NOUN admet-338 69 11 ) ) PUNCT admet-338 69 12 ; ; PUNCT admet-338 69 13 7.1 7.1 NUM admet-338 69 14 ( ( PUNCT admet-338 69 15 b b NOUN admet-338 69 16 ) ) PUNCT admet-338 70 1 [ [ X admet-338 70 2 10 10 NUM admet-338 70 3 ] ] NUM admet-338 70 4 ) ) PUNCT admet-338 70 5 , , PUNCT admet-338 70 6 glimepiride glimepiride NOUN admet-338 70 7 ( ( PUNCT admet-338 70 8 5.1 5.1 NUM admet-338 70 9 ( ( PUNCT admet-338 70 10 a a NOUN admet-338 70 11 ) ) PUNCT admet-338 70 12 ; ; PUNCT admet-338 70 13 6.2 6.2 NUM admet-338 70 14 ( ( PUNCT admet-338 70 15 a a NOUN admet-338 70 16 ) ) PUNCT admet-338 71 1 [ [ X admet-338 71 2 11 11 NUM admet-338 71 3 ] ] NUM admet-338 71 4 ) ) PUNCT admet-338 71 5 , , PUNCT admet-338 71 6 log log VERB admet-338 71 7 d6.5 d6.5 PROPN admet-338 71 8 of of ADP admet-338 71 9 famotidine famotidine NOUN admet-338 71 10 ( ( PUNCT admet-338 71 11 -2.14 -2.14 NOUN admet-338 71 12 ; ; PUNCT admet-338 72 1 -1.3 -1.3 PROPN admet-338 73 1 [ [ X admet-338 73 2 11 11 NUM admet-338 73 3 ] ] NUM admet-338 73 4 ) ) PUNCT admet-338 73 5 , , PUNCT admet-338 73 6 glimepiride glimepiride NOUN admet-338 73 7 ( ( PUNCT admet-338 73 8 1.51 1.51 NUM admet-338 73 9 ; ; PUNCT admet-338 73 10 3.0 3.0 NUM admet-338 74 1 [ [ X admet-338 74 2 11 11 NUM admet-338 74 3 ] ] SYM admet-338 74 4 ) ) PUNCT admet-338 74 5 ( ( PUNCT admet-338 74 6 calculated calculate VERB admet-338 74 7 values value NOUN admet-338 74 8 ; ; PUNCT admet-338 74 9 experimental experimental ADJ admet-338 74 10 values value NOUN admet-338 74 11 ) ) PUNCT admet-338 74 12 . . PUNCT admet-338 75 1 nc nc PROPN admet-338 75 2 at at ADP admet-338 75 3 ph ph PROPN admet-338 75 4 7.4 7.4 NUM admet-338 75 5 was be AUX admet-338 75 6 significantly significantly ADV admet-338 75 7 higher high ADJ admet-338 75 8 in in ADP admet-338 75 9 the the DET admet-338 75 10 odt odt NOUN admet-338 75 11 than than ADP admet-338 75 12 that that PRON admet-338 75 13 for for ADP admet-338 75 14 the the DET admet-338 75 15 ir ir PROPN admet-338 75 16 formulation formulation NOUN admet-338 75 17 ( ( PUNCT admet-338 75 18 p p NOUN admet-338 75 19 = = NOUN admet-338 75 20 0.02 0.02 NUM admet-338 75 21 ) ) PUNCT admet-338 75 22 ( ( PUNCT admet-338 75 23 figure figure NOUN admet-338 75 24 1e 1e NUM admet-338 75 25 ) ) PUNCT admet-338 75 26 . . PUNCT admet-338 76 1 the the DET admet-338 76 2 percentages percentage NOUN admet-338 76 3 of of ADP admet-338 76 4 acid acid NOUN admet-338 76 5 , , PUNCT admet-338 76 6 base base NOUN admet-338 76 7 , , PUNCT admet-338 76 8 and and CCONJ admet-338 76 9 undissociated undissociated ADJ admet-338 76 10 drugs drug NOUN admet-338 76 11 for for ADP admet-338 76 12 the the DET admet-338 76 13 odts odts NOUN admet-338 76 14 were be AUX admet-338 76 15 13 13 NUM admet-338 76 16 , , PUNCT admet-338 76 17 41 41 NUM admet-338 76 18 and and CCONJ admet-338 76 19 45 45 NUM admet-338 76 20 % % NOUN admet-338 76 21 , , PUNCT admet-338 76 22 respectively respectively ADV admet-338 76 23 ( ( PUNCT admet-338 76 24 2 2 NUM admet-338 76 25 % % NOUN admet-338 76 26 unclassifiable unclassifiable ADJ admet-338 76 27 ) ) PUNCT admet-338 76 28 . . PUNCT admet-338 77 1 the the DET admet-338 77 2 corresponding corresponding ADJ admet-338 77 3 percentages percentage NOUN admet-338 77 4 in in ADP admet-338 77 5 the the DET admet-338 77 6 ir ir PROPN admet-338 77 7 formulations formulation NOUN admet-338 77 8 were be AUX admet-338 77 9 30 30 NUM admet-338 77 10 , , PUNCT admet-338 77 11 30 30 NUM admet-338 77 12 and and CCONJ admet-338 77 13 38 38 NUM admet-338 77 14 % % NOUN admet-338 77 15 , , PUNCT admet-338 77 16 respectively respectively ADV admet-338 77 17 ( ( PUNCT admet-338 77 18 2 2 NUM admet-338 77 19 % % NOUN admet-338 77 20 unclassifiable unclassifiable ADJ admet-338 77 21 ) ) PUNCT admet-338 77 22 . . PUNCT admet-338 78 1 the the DET admet-338 78 2 highest high ADJ admet-338 78 3 dose dose NOUN admet-338 78 4 strength strength NOUN admet-338 78 5 of of ADP admet-338 78 6 the the DET admet-338 78 7 odts odts NOUN admet-338 78 8 was be AUX admet-338 78 9 significantly significantly ADV admet-338 78 10 lower low ADJ admet-338 78 11 than than ADP admet-338 78 12 that that PRON admet-338 78 13 of of ADP admet-338 78 14 the the DET admet-338 78 15 ir ir PROPN admet-338 78 16 formulations formulation NOUN admet-338 78 17 ( ( PUNCT admet-338 78 18 p p X admet-338 78 19 = = NOUN admet-338 78 20 0.01 0.01 NUM admet-338 78 21 ) ) PUNCT admet-338 78 22 ( ( PUNCT admet-338 78 23 figure figure NOUN admet-338 78 24 1 1 NUM admet-338 78 25 g g NOUN admet-338 78 26 ) ) PUNCT admet-338 78 27 . . PUNCT admet-338 79 1 the the DET admet-338 79 2 medians median NOUN admet-338 79 3 of of ADP admet-338 79 4 the the DET admet-338 79 5 highest high ADJ admet-338 79 6 dose dose NOUN admet-338 79 7 strength strength NOUN admet-338 79 8 in in ADP admet-338 79 9 the the DET admet-338 79 10 odts odts NOUN admet-338 79 11 and and CCONJ admet-338 79 12 ir ir PROPN admet-338 79 13 formulations formulation NOUN admet-338 79 14 were be AUX admet-338 79 15 10 10 NUM admet-338 79 16 mg mg ADJ admet-338 79 17 and and CCONJ admet-338 79 18 30 30 NUM admet-338 79 19 mg mg PROPN admet-338 79 20 , , PUNCT admet-338 79 21 respectively respectively ADV admet-338 79 22 . . PUNCT admet-338 80 1 the the DET admet-338 80 2 maximum maximum ADJ admet-338 80 3 values value NOUN admet-338 80 4 of of ADP admet-338 80 5 the the DET admet-338 80 6 highest high ADJ admet-338 80 7 dose dose NOUN admet-338 80 8 strength strength NOUN admet-338 80 9 in in ADP admet-338 80 10 the the DET admet-338 80 11 odts odts NOUN admet-338 80 12 and and CCONJ admet-338 80 13 ir ir PROPN admet-338 80 14 formulations formulation NOUN admet-338 80 15 were be AUX admet-338 80 16 200 200 NUM admet-338 80 17 mg mg NOUN admet-338 80 18 and and CCONJ admet-338 80 19 900 900 NUM admet-338 80 20 mg mg NOUN admet-338 80 21 , , PUNCT admet-338 80 22 respectively respectively ADV admet-338 80 23 ( ( PUNCT admet-338 80 24 table table NOUN admet-338 80 25 2 2 NUM admet-338 80 26 ) ) PUNCT admet-338 80 27 . . PUNCT admet-338 81 1 the the DET admet-338 81 2 elimination elimination NOUN admet-338 81 3 t1/2 t1/2 NOUN admet-338 81 4 of of ADP admet-338 81 5 the the DET admet-338 81 6 odts odts NOUN admet-338 81 7 tended tend VERB admet-338 81 8 to to PART admet-338 81 9 be be AUX admet-338 81 10 longer long ADJ admet-338 81 11 than than ADP admet-338 81 12 that that PRON admet-338 81 13 of of ADP admet-338 81 14 the the DET admet-338 81 15 ir ir PROPN admet-338 81 16 formulations formulation NOUN admet-338 81 17 ( ( PUNCT admet-338 81 18 p p NOUN admet-338 81 19 = = NOUN admet-338 81 20 0.07 0.07 NUM admet-338 81 21 ) ) PUNCT admet-338 81 22 ( ( PUNCT admet-338 81 23 figure figure NOUN admet-338 81 24 1j 1j NUM admet-338 81 25 ) ) PUNCT admet-338 81 26 . . PUNCT admet-338 82 1 the the DET admet-338 82 2 medians median NOUN admet-338 82 3 of of ADP admet-338 82 4 t1/2 t1/2 NOUN admet-338 82 5 in in ADP admet-338 82 6 the the DET admet-338 82 7 odts odts NOUN admet-338 82 8 and and CCONJ admet-338 82 9 ir ir PROPN admet-338 82 10 formulations formulation NOUN admet-338 82 11 were be AUX admet-338 82 12 6.7 6.7 NUM admet-338 82 13 h h NOUN admet-338 82 14 , , PUNCT admet-338 82 15 and and CCONJ admet-338 82 16 3.3 3.3 NUM admet-338 82 17 h h NOUN admet-338 82 18 , , PUNCT admet-338 82 19 respectively respectively ADV admet-338 82 20 ( ( PUNCT admet-338 82 21 table table NOUN admet-338 82 22 2 2 NUM admet-338 82 23 ) ) PUNCT admet-338 82 24 . . PUNCT admet-338 83 1 a a DET admet-338 83 2 significant significant ADJ admet-338 83 3 difference difference NOUN admet-338 83 4 was be AUX admet-338 83 5 not not PART admet-338 83 6 observed observe VERB admet-338 83 7 between between ADP admet-338 83 8 the the DET admet-338 83 9 odts odts NOUN admet-338 83 10 and and CCONJ admet-338 83 11 the the DET admet-338 83 12 ir ir PROPN admet-338 83 13 formulations formulation NOUN admet-338 83 14 for for ADP admet-338 83 15 mw mw NOUN admet-338 83 16 , , PUNCT admet-338 83 17 psa psa NOUN admet-338 83 18 , , PUNCT admet-338 83 19 hbd hbd NOUN admet-338 83 20 , , PUNCT admet-338 83 21 hba hba PROPN admet-338 83 22 , , PUNCT admet-338 83 23 log log PROPN admet-338 83 24 d6.5 d6.5 PROPN admet-338 83 25 , , PUNCT admet-338 83 26 solubility solubility NOUN admet-338 83 27 in in ADP admet-338 83 28 water water NOUN admet-338 83 29 , , PUNCT admet-338 83 30 and and CCONJ admet-338 83 31 do do AUX admet-338 83 32 ( ( PUNCT admet-338 83 33 figure figure VERB admet-338 83 34 1a 1a NOUN admet-338 83 35 , , PUNCT admet-338 83 36 b b X admet-338 83 37 , , PUNCT admet-338 83 38 c c NOUN admet-338 83 39 , , PUNCT admet-338 83 40 d d NOUN admet-338 83 41 , , PUNCT admet-338 83 42 f f X admet-338 83 43 , , PUNCT admet-338 83 44 h h NOUN admet-338 83 45 , , PUNCT admet-338 83 46 i i PROPN admet-338 83 47 ) ) PUNCT admet-338 83 48 . . PUNCT admet-338 84 1 the the DET admet-338 84 2 distribution distribution NOUN admet-338 84 3 of of ADP admet-338 84 4 the the DET admet-338 84 5 odts odts NOUN admet-338 84 6 and and CCONJ admet-338 84 7 ir ir PROPN admet-338 84 8 formulations formulation NOUN admet-338 84 9 among among ADP admet-338 84 10 each each DET admet-338 84 11 bcs bcs NOUN admet-338 84 12 class class NOUN admet-338 84 13 were be AUX admet-338 84 14 similar similar ADJ admet-338 84 15 ( ( PUNCT admet-338 84 16 figure figure NOUN admet-338 84 17 2 2 NUM admet-338 84 18 ) ) PUNCT admet-338 84 19 . . PUNCT admet-338 85 1 the the DET admet-338 85 2 percentages percentage NOUN admet-338 85 3 of of ADP admet-338 85 4 bcs bcs NOUN admet-338 85 5 class class NOUN admet-338 85 6 i i PROPN admet-338 85 7 , , PUNCT admet-338 85 8 class class PROPN admet-338 85 9 ii ii PROPN admet-338 85 10 , , PUNCT admet-338 85 11 class class NOUN admet-338 85 12 iii iii PROPN admet-338 85 13 , , PUNCT admet-338 85 14 and and CCONJ admet-338 85 15 class class NOUN admet-338 85 16 iv iv NUM admet-338 85 17 for for ADP admet-338 85 18 the the DET admet-338 85 19 odt odt NOUN admet-338 85 20 were be AUX admet-338 85 21 52 52 NUM admet-338 85 22 , , PUNCT admet-338 85 23 29 29 NUM admet-338 85 24 , , PUNCT admet-338 85 25 20 20 NUM admet-338 85 26 and and CCONJ admet-338 85 27 0 0 NUM admet-338 85 28 % % NOUN admet-338 85 29 , , PUNCT admet-338 85 30 respectively respectively ADV admet-338 85 31 asami asami PROPN admet-338 85 32 ono ono PROPN admet-338 85 33 et et PROPN admet-338 85 34 al al PROPN admet-338 85 35 . . PROPN admet-338 85 36 admet admet PROPN admet-338 85 37 & & CCONJ admet-338 85 38 dmpk dmpk PROPN admet-338 85 39 4(4 4(4 NUM admet-338 85 40 ) ) PUNCT admet-338 85 41 ( ( PUNCT admet-338 85 42 2016 2016 NUM admet-338 85 43 ) ) PUNCT admet-338 85 44 335 335 NUM admet-338 85 45 - - SYM admet-338 85 46 360 360 NUM admet-338 85 47 338 338 NUM admet-338 85 48 ( ( PUNCT admet-338 85 49 2 2 NUM admet-338 85 50 % % NOUN admet-338 85 51 unclassifiable unclassifiable ADJ admet-338 85 52 ) ) PUNCT admet-338 85 53 . . PUNCT admet-338 86 1 the the DET admet-338 86 2 corresponding corresponding ADJ admet-338 86 3 percentages percentage NOUN admet-338 86 4 for for ADP admet-338 86 5 the the DET admet-338 86 6 ir ir PROPN admet-338 86 7 formulation formulation NOUN admet-338 86 8 were be AUX admet-338 86 9 48 48 NUM admet-338 86 10 , , PUNCT admet-338 86 11 30 30 NUM admet-338 86 12 , , PUNCT admet-338 86 13 16 16 NUM admet-338 86 14 and and CCONJ admet-338 86 15 4 4 NUM admet-338 86 16 % % NOUN admet-338 86 17 , , PUNCT admet-338 86 18 respectively respectively ADV admet-338 86 19 ( ( PUNCT admet-338 86 20 2 2 NUM admet-338 86 21 % % NOUN admet-338 86 22 unclassifiable unclassifiable ADJ admet-338 86 23 ) ) PUNCT admet-338 86 24 . . PUNCT admet-338 87 1 the the DET admet-338 87 2 distribution distribution NOUN admet-338 87 3 of of ADP admet-338 87 4 bcs bcs PROPN admet-338 87 5 ii ii PROPN admet-338 87 6 subclass subclass NOUN admet-338 87 7 was be AUX admet-338 87 8 also also ADV admet-338 87 9 similar similar ADJ admet-338 87 10 ( ( PUNCT admet-338 87 11 figure figure NOUN admet-338 87 12 2 2 NUM admet-338 87 13 ) ) PUNCT admet-338 87 14 . . PUNCT admet-338 88 1 the the DET admet-338 88 2 percentages percentage NOUN admet-338 88 3 of of ADP admet-338 88 4 bcs bcs NOUN admet-338 88 5 class class NOUN admet-338 88 6 iia iia NOUN admet-338 88 7 , , PUNCT admet-338 88 8 class class NOUN admet-338 88 9 iib iib NOUN admet-338 88 10 , , PUNCT admet-338 88 11 and and CCONJ admet-338 88 12 class class PROPN admet-338 88 13 iic iic PROPN admet-338 88 14 for for ADP admet-338 88 15 the the DET admet-338 88 16 odt odt NOUN admet-338 88 17 were be AUX admet-338 88 18 7 7 NUM admet-338 88 19 , , PUNCT admet-338 88 20 12 12 NUM admet-338 88 21 and and CCONJ admet-338 88 22 9 9 NUM admet-338 88 23 % % NOUN admet-338 88 24 , , PUNCT admet-338 88 25 respectively respectively ADV admet-338 88 26 , , PUNCT admet-338 88 27 whereas whereas SCONJ admet-338 88 28 the the DET admet-338 88 29 corresponding corresponding ADJ admet-338 88 30 percentages percentage NOUN admet-338 88 31 for for ADP admet-338 88 32 the the DET admet-338 88 33 ir ir PROPN admet-338 88 34 formulation formulation NOUN admet-338 88 35 were be AUX admet-338 88 36 10 10 NUM admet-338 88 37 , , PUNCT admet-338 88 38 10 10 NUM admet-338 88 39 and and CCONJ admet-338 88 40 11 11 NUM admet-338 88 41 % % NOUN admet-338 88 42 , , PUNCT admet-338 88 43 respectively respectively ADV admet-338 88 44 . . PUNCT admet-338 89 1 figure figure NOUN admet-338 89 2 1 1 NUM admet-338 89 3 . . PUNCT admet-338 89 4 box box NOUN admet-338 89 5 and and CCONJ admet-338 89 6 whisker whisker NOUN admet-338 89 7 plots plot NOUN admet-338 89 8 of of ADP admet-338 89 9 biopharmaceutical biopharmaceutical ADJ admet-338 89 10 properties property NOUN admet-338 89 11 of of ADP admet-338 89 12 odt odt NOUN admet-338 89 13 and and CCONJ admet-338 89 14 ir ir PROPN admet-338 89 15 formulation formulation NOUN admet-338 89 16 drugs drug NOUN admet-338 89 17 ; ; PUNCT admet-338 89 18 the the DET admet-338 89 19 bottom bottom NOUN admet-338 89 20 and and CCONJ admet-338 89 21 top top NOUN admet-338 89 22 of of ADP admet-338 89 23 the the DET admet-338 89 24 box box NOUN admet-338 89 25 are be AUX admet-338 89 26 the the DET admet-338 89 27 first first ADJ admet-338 89 28 and and CCONJ admet-338 89 29 third third ADJ admet-338 89 30 quartiles quartile NOUN admet-338 89 31 , , PUNCT admet-338 89 32 the the DET admet-338 89 33 band band NOUN admet-338 89 34 inside inside ADP admet-338 89 35 the the DET admet-338 89 36 box box NOUN admet-338 89 37 is be AUX admet-338 89 38 the the DET admet-338 89 39 median median NOUN admet-338 89 40 , , PUNCT admet-338 89 41 and and CCONJ admet-338 89 42 the the DET admet-338 89 43 ends end NOUN admet-338 89 44 of of ADP admet-338 89 45 the the DET admet-338 89 46 whiskers whisker NOUN admet-338 89 47 are be AUX admet-338 89 48 the the DET admet-338 89 49 minimum minimum NOUN admet-338 89 50 and and CCONJ admet-338 89 51 maximum maximum ADJ admet-338 89 52 . . PUNCT admet-338 90 1 ( ( PUNCT admet-338 90 2 a a X admet-338 90 3 ) ) PUNCT admet-338 90 4 mw mw NOUN admet-338 90 5 of of ADP admet-338 90 6 free free ADJ admet-338 90 7 form form NOUN admet-338 90 8 . . PUNCT admet-338 91 1 ( ( PUNCT admet-338 91 2 b b X admet-338 91 3 ) ) PUNCT admet-338 91 4 polar polar ADJ admet-338 91 5 surface surface NOUN admet-338 91 6 area area NOUN admet-338 91 7 . . PUNCT admet-338 92 1 ( ( PUNCT admet-338 92 2 c c X admet-338 92 3 ) ) PUNCT admet-338 92 4 hydrogen hydrogen NOUN admet-338 92 5 bond bond NOUN admet-338 92 6 donor donor NOUN admet-338 92 7 number number NOUN admet-338 92 8 . . PUNCT admet-338 93 1 ( ( PUNCT admet-338 93 2 d d X admet-338 93 3 ) ) PUNCT admet-338 93 4 hydrogen hydrogen NOUN admet-338 93 5 bond bond NOUN admet-338 93 6 acceptor acceptor NOUN admet-338 93 7 number number NOUN admet-338 93 8 . . PUNCT admet-338 94 1 ( ( PUNCT admet-338 94 2 e e NOUN admet-338 94 3 ) ) PUNCT admet-338 94 4 net net ADJ admet-338 94 5 charge charge NOUN admet-338 94 6 at at ADP admet-338 94 7 ph ph PROPN admet-338 94 8 7.4 7.4 NUM admet-338 94 9 . . PUNCT admet-338 95 1 ( ( PUNCT admet-338 95 2 f f X admet-338 95 3 ) ) PUNCT admet-338 95 4 log log NOUN admet-338 95 5 d6.5 d6.5 PROPN admet-338 95 6 . . PUNCT admet-338 96 1 ( ( PUNCT admet-338 96 2 g g NOUN admet-338 96 3 ) ) PUNCT admet-338 96 4 the the DET admet-338 96 5 highest high ADJ admet-338 96 6 dose dose NOUN admet-338 96 7 strength strength NOUN admet-338 96 8 . . PUNCT admet-338 97 1 ( ( PUNCT admet-338 97 2 h h NOUN admet-338 97 3 ) ) PUNCT admet-338 97 4 solubility solubility NOUN admet-338 97 5 in in ADP admet-338 97 6 water water NOUN admet-338 97 7 . . PUNCT admet-338 98 1 ( ( PUNCT admet-338 98 2 i i NOUN admet-338 98 3 ) ) PUNCT admet-338 98 4 dose dose NOUN admet-338 98 5 number number NOUN admet-338 98 6 . . PUNCT admet-338 99 1 ( ( PUNCT admet-338 99 2 j j NOUN admet-338 99 3 ) ) PUNCT admet-338 99 4 elimination elimination NOUN admet-338 99 5 t1/2 t1/2 NOUN admet-338 99 6 . . PUNCT admet-338 100 1 * * PUNCT admet-338 100 2 p p X admet-338 100 3 < < X admet-338 100 4 0.05 0.05 NUM admet-338 100 5 . . PUNCT admet-338 100 6 0 0 NUM admet-338 101 1 200 200 NUM admet-338 101 2 400 400 NUM admet-338 101 3 600 600 NUM admet-338 101 4 800 800 NUM admet-338 101 5 1000 1000 NUM admet-338 101 6 1200 1200 NUM admet-338 101 7 1400 1400 NUM admet-338 101 8 1600 1600 NUM admet-338 101 9 odt odt X admet-338 101 10 ir ir PROPN admet-338 101 11 formulation formulation PROPN admet-338 101 12 m m PROPN admet-338 101 13 w w NOUN admet-338 101 14 o o NOUN admet-338 102 1 f f NOUN admet-338 102 2 fr fr INTJ admet-338 102 3 ee ee INTJ admet-338 102 4 f f PROPN admet-338 102 5 o o PROPN admet-338 102 6 rm rm PROPN admet-338 102 7 0 0 NUM admet-338 102 8 100 100 NUM admet-338 102 9 200 200 NUM admet-338 102 10 300 300 NUM admet-338 102 11 400 400 NUM admet-338 102 12 500 500 NUM admet-338 102 13 600 600 NUM admet-338 102 14 odt odt X admet-338 102 15 ir ir PROPN admet-338 102 16 formulation formulation PROPN admet-338 102 17 p p PROPN admet-338 102 18 sa sa PROPN admet-338 102 19 0 0 NUM admet-338 102 20 5 5 NUM admet-338 102 21 10 10 NUM admet-338 102 22 15 15 NUM admet-338 102 23 20 20 NUM admet-338 102 24 odt odt X admet-338 102 25 ir ir PROPN admet-338 102 26 formulation formulation PROPN admet-338 102 27 h h NOUN admet-338 102 28 b b PROPN admet-338 103 1 d d NOUN admet-338 103 2 -4 -4 INTJ admet-338 103 3 -3 -3 INTJ admet-338 103 4 -2 -2 INTJ admet-338 103 5 -1 -1 SYM admet-338 103 6 0 0 NUM admet-338 103 7 1 1 NUM admet-338 103 8 2 2 NUM admet-338 103 9 3 3 NUM admet-338 103 10 odt odt X admet-338 103 11 ir ir PROPN admet-338 103 12 formulation formulation NOUN admet-338 103 13 n n PROPN admet-338 103 14 c c PROPN admet-338 103 15 a a DET admet-338 103 16 t t NOUN admet-338 103 17 p p NOUN admet-338 103 18 h h NOUN admet-338 103 19 7 7 NUM admet-338 103 20 .4 .4 NUM admet-338 103 21 -10 -10 PUNCT admet-338 104 1 -5 -5 PUNCT admet-338 104 2 0 0 NUM admet-338 104 3 5 5 NUM admet-338 104 4 10 10 NUM admet-338 104 5 15 15 NUM admet-338 104 6 odt odt X admet-338 104 7 ir ir PROPN admet-338 104 8 formulation formulation NOUN admet-338 104 9 lo lo PROPN admet-338 104 10 g g PROPN admet-338 104 11 d d PROPN admet-338 104 12 6 6 NUM admet-338 104 13 .5 .5 NUM admet-338 104 14 0.001 0.001 NUM admet-338 104 15 0.01 0.01 NUM admet-338 104 16 0.1 0.1 NUM admet-338 104 17 1 1 NUM admet-338 104 18 10 10 NUM admet-338 104 19 100 100 NUM admet-338 104 20 1000 1000 NUM admet-338 104 21 odt odt X admet-338 104 22 ir ir PROPN admet-338 104 23 formulation formulation NOUN admet-338 105 1 d d X admet-338 105 2 o o X admet-338 105 3 se se X admet-338 105 4 ( ( PUNCT admet-338 105 5 m m PROPN admet-338 105 6 g g NOUN admet-338 105 7 ) ) PUNCT admet-338 105 8 0.001 0.001 NUM admet-338 105 9 0.01 0.01 NUM admet-338 105 10 0.1 0.1 NUM admet-338 105 11 1 1 NUM admet-338 105 12 10 10 NUM admet-338 105 13 100 100 NUM admet-338 105 14 1000 1000 NUM admet-338 105 15 10000 10000 NUM admet-338 105 16 odt odt X admet-338 105 17 ir ir PROPN admet-338 105 18 formulation formulation NOUN admet-338 106 1 so so ADV admet-338 106 2 lu lu PROPN admet-338 106 3 b b PROPN admet-338 106 4 ili ili PROPN admet-338 106 5 ty ty INTJ admet-338 106 6 ( ( PUNCT admet-338 106 7 m m VERB admet-338 106 8 g g NOUN admet-338 106 9 /m /m PROPN admet-338 106 10 l l NOUN admet-338 106 11 ) ) PUNCT admet-338 107 1 -8 -8 NOUN admet-338 108 1 -6 -6 INTJ admet-338 108 2 -4 -4 INTJ admet-338 109 1 -2 -2 NOUN admet-338 109 2 0 0 NUM admet-338 109 3 2 2 NUM admet-338 109 4 odt odt X admet-338 109 5 ir ir PROPN admet-338 109 6 formulation formulation NOUN admet-338 110 1 lo lo PROPN admet-338 110 2 g g PROPN admet-338 111 1 d d PROPN admet-338 111 2 o o NOUN admet-338 111 3 0 0 NUM admet-338 111 4 20 20 NUM admet-338 111 5 40 40 NUM admet-338 111 6 60 60 NUM admet-338 111 7 80 80 NUM admet-338 111 8 100 100 NUM admet-338 111 9 120 120 NUM admet-338 111 10 140 140 NUM admet-338 111 11 odt odt X admet-338 111 12 ir ir PROPN admet-338 111 13 formulation formulation NOUN admet-338 111 14 t t PROPN admet-338 111 15 1 1 NUM admet-338 111 16 /2 /2 NUM admet-338 111 17 ( ( PUNCT admet-338 111 18 h h NOUN admet-338 111 19 ) ) PUNCT admet-338 112 1 * * PUNCT admet-338 113 1 * * PUNCT admet-338 113 2 ( ( PUNCT admet-338 113 3 a a NOUN admet-338 113 4 ) ) PUNCT admet-338 113 5 ( ( PUNCT admet-338 113 6 b b X admet-338 113 7 ) ) PUNCT admet-338 113 8 ( ( PUNCT admet-338 113 9 c c X admet-338 113 10 ) ) PUNCT admet-338 113 11 ( ( PUNCT admet-338 113 12 e e NOUN admet-338 113 13 ) ) PUNCT admet-338 113 14 ( ( PUNCT admet-338 113 15 f f X admet-338 113 16 ) ) PUNCT admet-338 113 17 ( ( PUNCT admet-338 113 18 g g NOUN admet-338 113 19 ) ) PUNCT admet-338 113 20 ( ( PUNCT admet-338 113 21 h h NOUN admet-338 113 22 ) ) PUNCT admet-338 113 23 ( ( PUNCT admet-338 113 24 i i NOUN admet-338 113 25 ) ) PUNCT admet-338 113 26 ( ( PUNCT admet-338 113 27 j j NOUN admet-338 113 28 ) ) PUNCT admet-338 113 29 0 0 NUM admet-338 114 1 5 5 NUM admet-338 114 2 10 10 NUM admet-338 114 3 15 15 NUM admet-338 114 4 20 20 NUM admet-338 114 5 25 25 NUM admet-338 114 6 30 30 NUM admet-338 114 7 odt odt X admet-338 114 8 ir ir PROPN admet-338 114 9 formulation formulation PROPN admet-338 114 10 h h PROPN admet-338 114 11 b b PROPN admet-338 114 12 a a DET admet-338 114 13 ( ( PUNCT admet-338 114 14 d d NOUN admet-338 114 15 ) ) PUNCT admet-338 114 16 admet admet PROPN admet-338 114 17 & & CCONJ admet-338 114 18 dmpk dmpk PROPN admet-338 114 19 4(4 4(4 NUM admet-338 114 20 ) ) PUNCT admet-338 114 21 ( ( PUNCT admet-338 114 22 2016 2016 NUM admet-338 114 23 ) ) PUNCT admet-338 114 24 335 335 NUM admet-338 114 25 - - SYM admet-338 114 26 360 360 NUM admet-338 114 27 biopharmaceutical biopharmaceutical NOUN admet-338 114 28 and and CCONJ admet-338 114 29 physchem physchem NOUN admet-338 114 30 properties property NOUN admet-338 114 31 for for ADP admet-338 114 32 odt odt ADJ admet-338 114 33 doi doi NOUN admet-338 114 34 : : PUNCT admet-338 114 35 10.5599 10.5599 NUM admet-338 114 36 / / SYM admet-338 114 37 admet.4.4.338 admet.4.4.338 VERB admet-338 114 38 339 339 NUM admet-338 114 39 table table NOUN admet-338 114 40 1 1 NUM admet-338 114 41 . . PUNCT admet-338 114 42 mw mw X admet-338 114 43 of of ADP admet-338 114 44 free free ADJ admet-338 114 45 form form NOUN admet-338 114 46 , , PUNCT admet-338 114 47 psa psa NOUN admet-338 114 48 , , PUNCT admet-338 114 49 hbd hbd NOUN admet-338 114 50 , , PUNCT admet-338 114 51 hba hba PROPN admet-338 114 52 , , PUNCT admet-338 114 53 nc nc PROPN admet-338 114 54 at at ADP admet-338 114 55 ph ph PROPN admet-338 114 56 7.4 7.4 NUM admet-338 114 57 , , PUNCT admet-338 114 58 log log NOUN admet-338 114 59 d6.5 d6.5 PROPN admet-338 114 60 , , PUNCT admet-338 114 61 the the DET admet-338 114 62 highest high ADJ admet-338 114 63 dose dose NOUN admet-338 114 64 strength strength NOUN admet-338 114 65 , , PUNCT admet-338 114 66 solubility solubility NOUN admet-338 114 67 in in ADP admet-338 114 68 water water NOUN admet-338 114 69 , , PUNCT admet-338 114 70 do do AUX admet-338 114 71 , , PUNCT admet-338 114 72 elimination elimination NOUN admet-338 114 73 t1/2 t1/2 NOUN admet-338 114 74 , , PUNCT admet-338 114 75 and and CCONJ admet-338 114 76 bcs bcs NOUN admet-338 114 77 class class NOUN admet-338 114 78 of of ADP admet-338 114 79 drugs drug NOUN admet-338 114 80 used use VERB admet-338 114 81 in in ADP admet-338 114 82 this this DET admet-338 114 83 study study NOUN admet-338 114 84 . . PUNCT admet-338 115 1 drug drug NOUN admet-338 115 2 mw mw PROPN admet-338 115 3 ( ( PUNCT admet-338 115 4 free free ADJ admet-338 115 5 form form NOUN admet-338 115 6 ) ) PUNCT admet-338 115 7 psa psa VERB admet-338 115 8 b b PROPN admet-338 115 9 hbd hbd PROPN admet-338 115 10 b b PROPN admet-338 115 11 hba hba PROPN admet-338 115 12 b b PROPN admet-338 115 13 nc nc PROPN admet-338 115 14 a a DET admet-338 115 15 ph ph PROPN admet-338 115 16 7.4 7.4 NUM admet-338 115 17 pka pka PROPN admet-338 115 18 b b PROPN admet-338 115 19 log log NOUN admet-338 115 20 d6.5 d6.5 PROPN admet-338 115 21 b b X admet-338 115 22 highest high ADJ admet-338 115 23 dose dose NOUN admet-338 115 24 strength strength NOUN admet-338 115 25 ( ( PUNCT admet-338 115 26 mg mg PROPN admet-338 115 27 ) ) PUNCT admet-338 115 28 c c NOUN admet-338 115 29 solubility solubility NOUN admet-338 115 30 in in ADP admet-338 115 31 water water NOUN admet-338 115 32 ( ( PUNCT admet-338 115 33 mg mg PROPN admet-338 115 34 / / SYM admet-338 115 35 ml ml NOUN admet-338 115 36 ) ) PUNCT admet-338 116 1 c c NOUN admet-338 116 2 do do AUX admet-338 116 3 t1/2 t1/2 VERB admet-338 116 4 ( ( PUNCT admet-338 116 5 h h NOUN admet-338 116 6 ) ) PUNCT admet-338 116 7 c c NOUN admet-338 116 8 bcs bcs NOUN admet-338 116 9 class class NOUN admet-338 116 10 acarbose acarbose PROPN admet-338 117 1 d d PROPN admet-338 117 2 , , PUNCT admet-338 117 3 e e PROPN admet-338 117 4 646 646 NUM admet-338 117 5 321 321 NUM admet-338 117 6 14 14 NUM admet-338 117 7 19 19 NUM admet-338 117 8 0.0 0.0 NUM admet-338 117 9 – – PUNCT admet-338 117 10 -4.88 -4.88 NUM admet-338 117 11 100 100 NUM admet-338 117 12 1429 1429 NUM admet-338 117 13 0.00028 0.00028 NUM admet-338 117 14 3.2 3.2 NUM admet-338 117 15 3 3 NUM admet-338 117 16 acetaminophen acetaminophen NOUN admet-338 117 17 151 151 NUM admet-338 117 18 49 49 NUM admet-338 117 19 2 2 NUM admet-338 117 20 3 3 NUM admet-338 117 21 0.0 0.0 NUM admet-338 117 22 – – PUNCT admet-338 117 23 0.40 0.40 NUM admet-338 117 24 500 500 NUM admet-338 117 25 10 10 NUM admet-338 117 26 0.2 0.2 NUM admet-338 117 27 2.9 2.9 NUM admet-338 117 28 1 1 NUM admet-338 117 29 acetylsalicylic acetylsalicylic NOUN admet-338 117 30 acid acid NOUN admet-338 117 31 180 180 NUM admet-338 117 32 64 64 NUM admet-338 117 33 1 1 NUM admet-338 117 34 4 4 NUM admet-338 117 35 -1.0 -1.0 PROPN admet-338 117 36 3.5 3.5 NUM admet-338 117 37 ( ( PUNCT admet-338 117 38 a a NOUN admet-338 117 39 ) ) PUNCT admet-338 117 40 -1.39 -1.39 NUM admet-338 117 41 100 100 NUM admet-338 117 42 3.33 3.33 NUM admet-338 117 43 0.12 0.12 NUM admet-338 117 44 0.4 0.4 NUM admet-338 117 45 3 3 NUM admet-338 117 46 acyclovir acyclovir PROPN admet-338 117 47 225 225 NUM admet-338 117 48 115 115 NUM admet-338 117 49 4 4 NUM admet-338 117 50 8 8 NUM admet-338 117 51 0.0 0.0 NUM admet-338 117 52 – – PUNCT admet-338 117 53 -1.23 -1.23 NUM admet-338 117 54 400 400 NUM admet-338 117 55 1 1 NUM admet-338 117 56 1.6 1.6 NUM admet-338 117 57 2.4 2.4 NUM admet-338 117 58 4 4 NUM admet-338 117 59 alendronate alendronate NOUN admet-338 117 60 sodium sodium NOUN admet-338 117 61 hydrate hydrate NOUN admet-338 117 62 249 249 NUM admet-338 117 63 181 181 NUM admet-338 117 64 7 7 NUM admet-338 117 65 8 8 NUM admet-338 117 66 -2.0 -2.0 X admet-338 117 67 1.7 1.7 NUM admet-338 117 68 ( ( PUNCT admet-338 117 69 a a NOUN admet-338 117 70 ) ) PUNCT admet-338 117 71 , , PUNCT admet-338 117 72 2.7 2.7 NUM admet-338 117 73 ( ( PUNCT admet-338 117 74 a a NOUN admet-338 117 75 ) ) PUNCT admet-338 117 76 , , PUNCT admet-338 117 77 6.1 6.1 NUM admet-338 117 78 ( ( PUNCT admet-338 117 79 a a NOUN admet-338 117 80 ) ) PUNCT admet-338 117 81 , , PUNCT admet-338 117 82 10.3 10.3 NUM admet-338 117 83 ( ( PUNCT admet-338 117 84 b b NOUN admet-338 117 85 ) ) PUNCT admet-338 117 86 -8.44 -8.44 PUNCT admet-338 117 87 35 35 NUM admet-338 117 88 25.6 25.6 NUM admet-338 117 89 0.00546 0.00546 NUM admet-338 117 90 1.5 1.5 NUM admet-338 117 91 3 3 NUM admet-338 117 92 alfacalcidol alfacalcidol VERB admet-338 117 93 401 401 NUM admet-338 117 94 40 40 NUM admet-338 117 95 2 2 NUM admet-338 117 96 2 2 NUM admet-338 117 97 0.0 0.0 NUM admet-338 117 98 – – PUNCT admet-338 117 99 7.58 7.58 NUM admet-338 117 100 0.03 0.03 NUM admet-338 117 101 0.01 0.01 NUM admet-338 117 102 0.0012 0.0012 NUM admet-338 117 103 17.6 17.6 NUM admet-338 117 104 1 1 NUM admet-338 117 105 allopurinol allopurinol NOUN admet-338 117 106 136 136 NUM admet-338 117 107 66 66 NUM admet-338 117 108 2 2 NUM admet-338 117 109 5 5 NUM admet-338 117 110 0.0 0.0 NUM admet-338 117 111 – – PUNCT admet-338 117 112 -0.70 -0.70 NUM admet-338 117 113 100 100 NUM admet-338 117 114 0.1 0.1 NUM admet-338 117 115 4 4 NUM admet-338 117 116 1.6 1.6 NUM admet-338 117 117 2 2 NUM admet-338 117 118 ambroxol ambroxol NOUN admet-338 117 119 hydrochloride hydrochloride NOUN admet-338 117 120 378 378 NUM admet-338 117 121 58 58 NUM admet-338 117 122 4 4 NUM admet-338 117 123 3 3 NUM admet-338 117 124 1.0 1.0 NUM admet-338 117 125 8.7 8.7 NUM admet-338 117 126 ( ( PUNCT admet-338 117 127 b b NOUN admet-338 117 128 ) ) PUNCT admet-338 117 129 0.48 0.48 NUM admet-338 117 130 45 45 NUM admet-338 117 131 26.8 26.8 NUM admet-338 117 132 0.00672 0.00672 NUM admet-338 117 133 11.2 11.2 NUM admet-338 117 134 1 1 NUM admet-338 117 135 amlodipine amlodipine NOUN admet-338 117 136 besylate besylate VERB admet-338 117 137 409 409 NUM admet-338 117 138 100 100 NUM admet-338 117 139 3 3 NUM admet-338 117 140 7 7 NUM admet-338 117 141 1.0 1.0 NUM admet-338 117 142 9.0 9.0 NUM admet-338 117 143 ( ( PUNCT admet-338 117 144 b b NOUN admet-338 117 145 ) ) PUNCT admet-338 117 146 1.09 1.09 NUM admet-338 117 147 10 10 NUM admet-338 117 148 2.22 2.22 NUM admet-338 117 149 0.018 0.018 NUM admet-338 117 150 36.2 36.2 NUM admet-338 117 151 1 1 NUM admet-338 117 152 aripiprazole aripiprazole NOUN admet-338 117 153 448 448 NUM admet-338 117 154 45 45 NUM admet-338 117 155 1 1 NUM admet-338 117 156 5 5 NUM admet-338 117 157 0.6 0.6 NUM admet-338 117 158 7.7 7.7 NUM admet-338 117 159 ( ( PUNCT admet-338 117 160 b b NOUN admet-338 117 161 ) ) PUNCT admet-338 117 162 4.42 4.42 NUM admet-338 117 163 24 24 NUM admet-338 117 164 0.01 0.01 NUM admet-338 117 165 9.6 9.6 NUM admet-338 117 166 59.6 59.6 NUM admet-338 117 167 2 2 NUM admet-338 117 168 atenolol atenolol NOUN admet-338 117 169 266 266 NUM admet-338 117 170 85 85 NUM admet-338 117 171 4 4 NUM admet-338 117 172 5 5 NUM admet-338 117 173 1.0 1.0 NUM admet-338 117 174 9.4 9.4 NUM admet-338 117 175 ( ( PUNCT admet-338 117 176 b b NOUN admet-338 117 177 ) ) PUNCT admet-338 117 178 -2.53 -2.53 NOUN admet-338 117 179 50 50 NUM admet-338 117 180 1 1 NUM admet-338 117 181 0.2 0.2 NUM admet-338 117 182 10.8 10.8 NUM admet-338 117 183 3 3 NUM admet-338 117 184 atorvastatin atorvastatin NOUN admet-338 117 185 calcium calcium NOUN admet-338 118 1 559 559 NUM admet-338 118 2 112 112 NUM admet-338 118 3 4 4 NUM admet-338 118 4 7 7 NUM admet-338 118 5 -1.0 -1.0 PROPN admet-338 118 6 4.3 4.3 NUM admet-338 118 7 ( ( PUNCT admet-338 118 8 a a NOUN admet-338 118 9 ) ) PUNCT admet-338 118 10 2.06 2.06 NUM admet-338 118 11 10 10 NUM admet-338 118 12 0.145 0.145 NUM admet-338 118 13 0.276 0.276 NUM admet-338 118 14 10.8 10.8 NUM admet-338 118 15 1 1 NUM admet-338 118 16 azithromycin azithromycin NOUN admet-338 118 17 hydrate hydrate NOUN admet-338 118 18 749 749 NUM admet-338 118 19 180 180 NUM admet-338 118 20 5 5 NUM admet-338 118 21 14 14 NUM admet-338 118 22 1.8 1.8 NUM admet-338 118 23 8.2 8.2 NUM admet-338 118 24 ( ( PUNCT admet-338 118 25 b b NOUN admet-338 118 26 ) ) PUNCT admet-338 118 27 , , PUNCT admet-338 118 28 8.6 8.6 NUM admet-338 118 29 ( ( PUNCT admet-338 118 30 b b NOUN admet-338 118 31 ) ) PUNCT admet-338 118 32 -0.19 -0.19 NOUN admet-338 118 33 600 600 NUM admet-338 118 34 0.01 0.01 NUM admet-338 118 35 240 240 NUM admet-338 118 36 61.9 61.9 NUM admet-338 118 37 2 2 NUM admet-338 118 38 azulene azulene NOUN admet-338 118 39 sulfonate sulfonate NOUN admet-338 118 40 sodium sodium NOUN admet-338 118 41 hydrate hydrate NOUN admet-338 118 42 278 278 NUM admet-338 118 43 63 63 NUM admet-338 118 44 1 1 NUM admet-338 118 45 3 3 NUM admet-338 118 46 -1.0 -1.0 PROPN admet-338 118 47 1.7 1.7 NUM admet-338 118 48 ( ( PUNCT admet-338 118 49 a a NOUN admet-338 118 50 ) ) PUNCT admet-338 118 51 -2.03 -2.03 NUM admet-338 118 52 2 2 NUM admet-338 118 53 10 10 NUM admet-338 118 54 0.0008 0.0008 NUM admet-338 118 55 2.45 2.45 NUM admet-338 118 56 3 3 NUM admet-338 118 57 benidipine benidipine NOUN admet-338 118 58 hydrochloride hydrochloride NOUN admet-338 118 59 506 506 NUM admet-338 118 60 114 114 NUM admet-338 118 61 1 1 NUM admet-338 118 62 9 9 NUM admet-338 118 63 0.8 0.8 NUM admet-338 118 64 8.0 8.0 NUM admet-338 118 65 ( ( PUNCT admet-338 118 66 b b NOUN admet-338 118 67 ) ) PUNCT admet-338 118 68 3.54 3.54 NUM admet-338 118 69 8 8 NUM admet-338 118 70 0.01 0.01 NUM admet-338 118 71 3.2 3.2 NUM admet-338 118 72 1.0 1.0 NUM admet-338 118 73 2 2 NUM admet-338 118 74 bepotastine bepotastine NOUN admet-338 118 75 besylate besylate VERB admet-338 118 76 389 389 NUM admet-338 118 77 63 63 NUM admet-338 118 78 1 1 NUM admet-338 118 79 5 5 NUM admet-338 118 80 0.0 0.0 NUM admet-338 118 81 4.4 4.4 NUM admet-338 118 82 ( ( PUNCT admet-338 118 83 a a NOUN admet-338 118 84 ) ) PUNCT admet-338 118 85 , , PUNCT admet-338 118 86 8.9 8.9 NUM admet-338 118 87 ( ( PUNCT admet-338 118 88 b b NOUN admet-338 118 89 ) ) PUNCT admet-338 118 90 0.86 0.86 NUM admet-338 118 91 10 10 NUM admet-338 118 92 23.3 23.3 NUM admet-338 118 93 0.00172 0.00172 NUM admet-338 118 94 2.5 2.5 NUM admet-338 118 95 1 1 NUM admet-338 118 96 beraprost beraprost NOUN admet-338 118 97 sodium sodium NOUN admet-338 118 98 398 398 NUM admet-338 118 99 87 87 NUM admet-338 118 100 3 3 NUM admet-338 118 101 5 5 NUM admet-338 118 102 -1.0 -1.0 PROPN admet-338 118 103 4.8 4.8 NUM admet-338 118 104 ( ( PUNCT admet-338 118 105 a a NOUN admet-338 118 106 ) ) PUNCT admet-338 118 107 1.42 1.42 NUM admet-338 118 108 0.04 0.04 NUM admet-338 118 109 833 833 NUM admet-338 118 110 1.92 1.92 NUM admet-338 118 111 Γ— Γ— NOUN admet-338 118 112 10 10 NUM admet-338 118 113 -7 -7 NOUN admet-338 118 114 1.1 1.1 NUM admet-338 118 115 1 1 NUM admet-338 118 116 bicalutamide bicalutamide VERB admet-338 118 117 430 430 NUM admet-338 118 118 116 116 NUM admet-338 118 119 2 2 NUM admet-338 118 120 6 6 NUM admet-338 118 121 0.0 0.0 NUM admet-338 118 122 – – PUNCT admet-338 118 123 2.53 2.53 NUM admet-338 118 124 80 80 NUM admet-338 118 125 0.01 0.01 NUM admet-338 118 126 32 32 NUM admet-338 118 127 4.9 4.9 NUM admet-338 118 128 2 2 NUM admet-338 118 129 bisoprolol bisoprolol NOUN admet-338 118 130 fumarate fumarate NOUN admet-338 118 131 325 325 NUM admet-338 118 132 60 60 NUM admet-338 118 133 2 2 NUM admet-338 118 134 5 5 NUM admet-338 118 135 1.0 1.0 NUM admet-338 118 136 9.4 9.4 NUM admet-338 118 137 ( ( PUNCT admet-338 118 138 b b NOUN admet-338 118 139 ) ) PUNCT admet-338 118 140 -0.55 -0.55 NOUN admet-338 118 141 5 5 NUM admet-338 118 142 1250 1250 NUM admet-338 118 143 1.6 1.6 NUM admet-338 118 144 Γ— Γ— NOUN admet-338 118 145 10 10 NUM admet-338 118 146 -5 -5 NUM admet-338 118 147 8.6 8.6 NUM admet-338 118 148 1 1 NUM admet-338 118 149 brotizolam brotizolam NOUN admet-338 118 150 394 394 NUM admet-338 118 151 71 71 NUM admet-338 118 152 0 0 NUM admet-338 118 153 4 4 NUM admet-338 118 154 0.0 0.0 NUM admet-338 118 155 – – PUNCT admet-338 118 156 2.80 2.80 NUM admet-338 118 157 0.25 0.25 NUM admet-338 118 158 0.01 0.01 NUM admet-338 118 159 0.1 0.1 NUM admet-338 118 160 7 7 NUM admet-338 118 161 1 1 NUM admet-338 118 162 cabergoline cabergoline NOUN admet-338 118 163 452 452 NUM admet-338 118 164 72 72 NUM admet-338 118 165 2 2 NUM admet-338 118 166 7 7 NUM admet-338 118 167 1.0 1.0 NUM admet-338 118 168 9.4 9.4 NUM admet-338 118 169 ( ( PUNCT admet-338 118 170 b b NOUN admet-338 118 171 ) ) PUNCT admet-338 118 172 0.40 0.40 NUM admet-338 118 173 1 1 NUM admet-338 118 174 0.01 0.01 NUM admet-338 118 175 0.4 0.4 NUM admet-338 118 176 43 43 NUM admet-338 118 177 1 1 NUM admet-338 118 178 camostat camostat NOUN admet-338 118 179 mesylate mesylate VERB admet-338 118 180 398 398 NUM admet-338 118 181 137 137 NUM admet-338 118 182 4 4 NUM admet-338 118 183 9 9 NUM admet-338 118 184 1.0 1.0 NUM admet-338 118 185 9.1 9.1 NUM admet-338 118 186 ( ( PUNCT admet-338 118 187 b b NOUN admet-338 118 188 ) ) PUNCT admet-338 118 189 -0.53 -0.53 NOUN admet-338 118 190 100 100 NUM admet-338 118 191 45 45 NUM admet-338 118 192 . . PUNCT admet-338 118 193 5 5 NUM admet-338 118 194 0.0088 0.0088 NUM admet-338 118 195 1.7 1.7 NUM admet-338 118 196 1 1 NUM admet-338 118 197 candesartan candesartan NOUN admet-338 118 198 cilexetil cilexetil ADP admet-338 118 199 440 440 NUM admet-338 118 200 119 119 NUM admet-338 118 201 2 2 NUM admet-338 118 202 9 9 NUM admet-338 118 203 -2.0 -2.0 NOUN admet-338 118 204 2.1 2.1 NUM admet-338 118 205 ( ( PUNCT admet-338 118 206 a a NOUN admet-338 118 207 ) ) PUNCT admet-338 118 208 , , PUNCT admet-338 118 209 4.2 4.2 NUM admet-338 118 210 ( ( PUNCT admet-338 118 211 a a X admet-338 118 212 ) ) PUNCT admet-338 118 213 0.29 0.29 NUM admet-338 118 214 12 12 NUM admet-338 118 215 0.01 0.01 NUM admet-338 118 216 4.8 4.8 NUM admet-338 118 217 2.2 2.2 NUM admet-338 118 218 2 2 NUM admet-338 118 219 asami asami PROPN admet-338 118 220 ono ono PROPN admet-338 118 221 et et PROPN admet-338 118 222 al al PROPN admet-338 118 223 . . PROPN admet-338 118 224 admet admet PROPN admet-338 118 225 & & CCONJ admet-338 118 226 dmpk dmpk PROPN admet-338 118 227 4(4 4(4 NUM admet-338 118 228 ) ) PUNCT admet-338 118 229 ( ( PUNCT admet-338 118 230 2016 2016 NUM admet-338 118 231 ) ) PUNCT admet-338 118 232 335 335 NUM admet-338 118 233 - - SYM admet-338 118 234 360 360 NUM admet-338 118 235 340 340 NUM admet-338 118 236 table table NOUN admet-338 118 237 1 1 NUM admet-338 118 238 . . PUNCT admet-338 119 1 ( ( PUNCT admet-338 119 2 continued continue VERB admet-338 119 3 ) ) PUNCT admet-338 119 4 drug drug NOUN admet-338 119 5 mw mw X admet-338 119 6 ( ( PUNCT admet-338 119 7 free free ADJ admet-338 119 8 form form NOUN admet-338 119 9 ) ) PUNCT admet-338 119 10 psa psa VERB admet-338 119 11 b b PROPN admet-338 119 12 hbd hbd PROPN admet-338 119 13 b b PROPN admet-338 119 14 hba hba PROPN admet-338 119 15 b b PROPN admet-338 119 16 nc nc PROPN admet-338 119 17 a a DET admet-338 119 18 ph ph PROPN admet-338 119 19 7.4 7.4 NUM admet-338 119 20 pka pka PROPN admet-338 119 21 b b PROPN admet-338 119 22 log log NOUN admet-338 119 23 d6.5 d6.5 PROPN admet-338 119 24 b b X admet-338 119 25 highest high ADJ admet-338 119 26 dose dose NOUN admet-338 119 27 strength strength NOUN admet-338 119 28 ( ( PUNCT admet-338 119 29 mg mg PROPN admet-338 119 30 ) ) PUNCT admet-338 119 31 c c NOUN admet-338 119 32 solubility solubility NOUN admet-338 119 33 in in ADP admet-338 119 34 water water NOUN admet-338 119 35 ( ( PUNCT admet-338 119 36 mg mg PROPN admet-338 119 37 / / SYM admet-338 119 38 ml ml NOUN admet-338 119 39 ) ) PUNCT admet-338 120 1 c c NOUN admet-338 120 2 do do AUX admet-338 120 3 t1/2 t1/2 VERB admet-338 120 4 ( ( PUNCT admet-338 120 5 h h NOUN admet-338 120 6 ) ) PUNCT admet-338 120 7 c c NOUN admet-338 120 8 bcs bcs NOUN admet-338 120 9 class class NOUN admet-338 120 10 carvedilol carvedilol NOUN admet-338 120 11 406 406 NUM admet-338 120 12 76 76 NUM admet-338 120 13 3 3 NUM admet-338 120 14 6 6 NUM admet-338 120 15 0.9 0.9 NUM admet-338 120 16 8.2 8.2 NUM admet-338 120 17 ( ( PUNCT admet-338 120 18 b b NOUN admet-338 120 19 ) ) PUNCT admet-338 120 20 2.20 2.20 NUM admet-338 120 21 20 20 NUM admet-338 120 22 0.01 0.01 NUM admet-338 120 23 8 8 NUM admet-338 120 24 7.7 7.7 NUM admet-338 120 25 2 2 NUM admet-338 120 26 cefcapene cefcapene NOUN admet-338 120 27 pivoxil pivoxil NOUN admet-338 120 28 hydrochloride hydrochloride NOUN admet-338 120 29 594 594 NUM admet-338 120 30 257 257 NUM admet-338 120 31 3 3 NUM admet-338 120 32 16 16 NUM admet-338 120 33 0.0 0.0 NUM admet-338 120 34 5.9 5.9 NUM admet-338 120 35 ( ( PUNCT admet-338 120 36 a a NOUN admet-338 120 37 ) ) PUNCT admet-338 120 38 , , PUNCT admet-338 120 39 9.0 9.0 NUM admet-338 120 40 ( ( PUNCT admet-338 120 41 b b NOUN admet-338 120 42 ) ) PUNCT admet-338 120 43 -1.59 -1.59 NOUN admet-338 120 44 100 100 NUM admet-338 120 45 1.88 1.88 NUM admet-338 120 46 0.213 0.213 NUM admet-338 120 47 1.1 1.1 NUM admet-338 120 48 3 3 NUM admet-338 120 49 cefdinir cefdinir NOUN admet-338 120 50 395 395 NUM admet-338 120 51 212 212 NUM admet-338 120 52 5 5 NUM admet-338 120 53 10 10 NUM admet-338 120 54 -1.0 -1.0 PROPN admet-338 120 55 2.8 2.8 NUM admet-338 120 56 ( ( PUNCT admet-338 120 57 a a NOUN admet-338 120 58 ) ) PUNCT admet-338 120 59 -3.92 -3.92 PUNCT admet-338 120 60 100 100 NUM admet-338 120 61 0.381 0.381 NUM admet-338 120 62 1.05 1.05 NUM admet-338 120 63 1.6 1.6 NUM admet-338 120 64 4 4 NUM admet-338 120 65 cefditoren cefditoren NOUN admet-338 120 66 pivoxil pivoxil NOUN admet-338 120 67 621 621 NUM admet-338 120 68 257 257 NUM admet-338 120 69 3 3 NUM admet-338 120 70 13 13 NUM admet-338 120 71 -0.2 -0.2 NOUN admet-338 120 72 8.1 8.1 NUM admet-338 120 73 ( ( PUNCT admet-338 120 74 a a X admet-338 120 75 ) ) PUNCT admet-338 120 76 2.45 2.45 NUM admet-338 120 77 100 100 NUM admet-338 120 78 0.01 0.01 NUM admet-338 120 79 40 40 NUM admet-338 120 80 1.1 1.1 NUM admet-338 120 81 2 2 NUM admet-338 120 82 cefotiam cefotiam NOUN admet-338 120 83 hexetil hexetil PROPN admet-338 120 84 hydrochloride hydrochloride NOUN admet-338 120 85 696 696 NUM admet-338 120 86 276 276 NUM admet-338 120 87 3 3 NUM admet-338 120 88 16 16 NUM admet-338 120 89 0.8 0.8 NUM admet-338 120 90 8.0 8.0 NUM admet-338 120 91 ( ( PUNCT admet-338 120 92 b b NOUN admet-338 120 93 ) ) PUNCT admet-338 120 94 -0.14 -0.14 NOUN admet-338 120 95 200 200 NUM admet-338 120 96 1000 1000 NUM admet-338 120 97 0.0008 0.0008 NUM admet-338 120 98 0.8 0.8 NUM admet-338 120 99 1 1 NUM admet-338 120 100 cetirizine cetirizine NOUN admet-338 120 101 hydrochloride hydrochloride NOUN admet-338 120 102 389 389 NUM admet-338 120 103 53 53 NUM admet-338 120 104 1 1 NUM admet-338 120 105 5 5 NUM admet-338 120 106 -0.8 -0.8 NUM admet-338 120 107 3.5 3.5 NUM admet-338 120 108 ( ( PUNCT admet-338 120 109 a a NOUN admet-338 120 110 ) ) PUNCT admet-338 120 111 , , PUNCT admet-338 120 112 6.7 6.7 NUM admet-338 120 113 ( ( PUNCT admet-338 120 114 b b NOUN admet-338 120 115 ) ) PUNCT admet-338 120 116 -0.09 -0.09 NUM admet-338 120 117 10 10 NUM admet-338 120 118 1000 1000 NUM admet-338 120 119 4.0 4.0 NUM admet-338 120 120 Γ— Γ— NOUN admet-338 120 121 10 10 NUM admet-338 120 122 -5 -5 NUM admet-338 120 123 7.5 7.5 NUM admet-338 120 124 1 1 NUM admet-338 120 125 cilostazol cilostazol ADJ admet-338 120 126 369 369 NUM admet-338 120 127 82 82 NUM admet-338 120 128 1 1 NUM admet-338 120 129 7 7 NUM admet-338 120 130 0.0 0.0 NUM admet-338 120 131 – – PUNCT admet-338 120 132 3.01 3.01 NUM admet-338 120 133 100 100 NUM admet-338 120 134 0.01 0.01 NUM admet-338 120 135 40 40 NUM admet-338 120 136 10.1 10.1 NUM admet-338 120 137 2 2 NUM admet-338 120 138 clarithromycin clarithromycin NOUN admet-338 120 139 748 748 NUM admet-338 120 140 183 183 NUM admet-338 120 141 4 4 NUM admet-338 120 142 14 14 NUM admet-338 120 143 0.9 0.9 NUM admet-338 120 144 8.2 8.2 NUM admet-338 120 145 ( ( PUNCT admet-338 120 146 b b NOUN admet-338 120 147 ) ) PUNCT admet-338 120 148 1.56 1.56 NUM admet-338 120 149 200 200 NUM admet-338 120 150 0.01 0.01 NUM admet-338 120 151 80 80 NUM admet-338 120 152 4.4 4.4 NUM admet-338 120 153 2 2 NUM admet-338 120 154 cyclosporin cyclosporin NOUN admet-338 120 155 a a DET admet-338 120 156 1203 1203 NUM admet-338 120 157 279 279 NUM admet-338 120 158 5 5 NUM admet-338 120 159 23 23 NUM admet-338 120 160 0.0 0.0 NUM admet-338 120 161 – – PUNCT admet-338 120 162 1.80 1.80 NUM admet-338 120 163 50 50 NUM admet-338 120 164 3.38 3.38 NUM admet-338 120 165 0.0592 0.0592 NUM admet-338 120 166 1.6 1.6 NUM admet-338 120 167 1 1 NUM admet-338 120 168 desmopressin desmopressin NOUN admet-338 120 169 acetate acetate NOUN admet-338 120 170 hydrate hydrate NOUN admet-338 120 171 1069 1069 NUM admet-338 120 172 486 486 NUM admet-338 120 173 18 18 NUM admet-338 120 174 26 26 NUM admet-338 120 175 0.0 0.0 NUM admet-338 120 176 – – PUNCT admet-338 120 177 -7.34 -7.34 NUM admet-338 120 178 0.24 0.24 NUM admet-338 120 179 33 33 NUM admet-338 120 180 2.9 2.9 NUM admet-338 120 181 Γ— Γ— NOUN admet-338 120 182 10 10 NUM admet-338 120 183 -5 -5 NUM admet-338 120 184 2 2 NUM admet-338 120 185 3 3 NUM admet-338 120 186 diclofenac diclofenac NOUN admet-338 120 187 sodium sodium NOUN admet-338 120 188 296 296 NUM admet-338 120 189 49 49 NUM admet-338 120 190 2 2 NUM admet-338 120 191 3 3 NUM admet-338 120 192 -1.0 -1.0 PROPN admet-338 120 193 4.2 4.2 NUM admet-338 120 194 ( ( PUNCT admet-338 120 195 a a X admet-338 120 196 ) ) PUNCT admet-338 120 197 2.17 2.17 NUM admet-338 120 198 25 25 NUM admet-338 120 199 17.2 17.2 NUM admet-338 120 200 0.0058 0.0058 NUM admet-338 120 201 1.2 1.2 NUM admet-338 120 202 1 1 NUM admet-338 120 203 dienogest dienog ADJ admet-338 120 204 311 311 NUM admet-338 120 205 61 61 NUM admet-338 120 206 1 1 NUM admet-338 120 207 3 3 NUM admet-338 120 208 0.0 0.0 NUM admet-338 120 209 – – PUNCT admet-338 120 210 2.64 2.64 NUM admet-338 120 211 1 1 NUM admet-338 120 212 0.01 0.01 NUM admet-338 120 213 0.4 0.4 NUM admet-338 120 214 8.0 8.0 NUM admet-338 120 215 1 1 NUM admet-338 120 216 domperidone domperidone NOUN admet-338 120 217 426 426 NUM admet-338 120 218 68 68 NUM admet-338 120 219 2 2 NUM admet-338 120 220 7 7 NUM admet-338 120 221 1.0 1.0 NUM admet-338 120 222 9.0 9.0 NUM admet-338 120 223 ( ( PUNCT admet-338 120 224 b b NOUN admet-338 120 225 ) ) PUNCT admet-338 120 226 2.26 2.26 NUM admet-338 120 227 10 10 NUM admet-338 120 228 0.01 0.01 NUM admet-338 120 229 4 4 NUM admet-338 120 230 0.9 0.9 NUM admet-338 120 231 2 2 NUM admet-338 120 232 donepezil donepezil NOUN admet-338 120 233 hydrochloride hydrochloride NOUN admet-338 120 234 379 379 NUM admet-338 120 235 39 39 NUM admet-338 120 236 0 0 NUM admet-338 120 237 4 4 NUM admet-338 120 238 1.0 1.0 NUM admet-338 120 239 8.8 8.8 NUM admet-338 120 240 ( ( PUNCT admet-338 120 241 b b NOUN admet-338 120 242 ) ) PUNCT admet-338 120 243 1.97 1.97 NUM admet-338 120 244 10 10 NUM admet-338 120 245 10 10 NUM admet-338 120 246 0.004 0.004 NUM admet-338 120 247 70.7 70.7 NUM admet-338 120 248 1 1 NUM admet-338 120 249 doxazosin doxazosin NOUN admet-338 120 250 mesylate mesylate NOUN admet-338 120 251 451 451 NUM admet-338 120 252 112 112 NUM admet-338 121 1 2 2 NUM admet-338 121 2 10 10 NUM admet-338 121 3 0.1 0.1 NUM admet-338 121 4 6.5 6.5 NUM admet-338 121 5 ( ( PUNCT admet-338 121 6 b b NOUN admet-338 121 7 ) ) PUNCT admet-338 121 8 1.20 1.20 NUM admet-338 121 9 4 4 NUM admet-338 121 10 1 1 NUM admet-338 121 11 0.016 0.016 NUM admet-338 121 12 11.8 11.8 NUM admet-338 121 13 1 1 NUM admet-338 121 14 doxifluridine doxifluridine NOUN admet-338 121 15 246 246 NUM admet-338 121 16 99 99 NUM admet-338 121 17 3 3 NUM admet-338 121 18 7 7 NUM admet-338 121 19 -0.4 -0.4 NUM admet-338 121 20 7.6 7.6 NUM admet-338 121 21 ( ( PUNCT admet-338 121 22 a a NOUN admet-338 121 23 ) ) PUNCT admet-338 121 24 -1.13 -1.13 NOUN admet-338 121 25 200 200 NUM admet-338 121 26 33 33 NUM admet-338 121 27 0.0242 0.0242 NUM admet-338 121 28 0.8 0.8 NUM admet-338 121 29 f f NOUN admet-338 121 30 3 3 NUM admet-338 121 31 droxidopa droxidopa VERB admet-338 121 32 213 213 NUM admet-338 121 33 124 124 NUM admet-338 121 34 6 6 NUM admet-338 121 35 6 6 NUM admet-338 121 36 -0.1 -0.1 NOUN admet-338 121 37 2.1 2.1 NUM admet-338 121 38 ( ( PUNCT admet-338 121 39 a a NOUN admet-338 121 40 ) ) PUNCT admet-338 121 41 , , PUNCT admet-338 121 42 8.3 8.3 NUM admet-338 121 43 ( ( PUNCT admet-338 121 44 b b NOUN admet-338 121 45 ) ) PUNCT admet-338 121 46 -3.57 -3.57 VERB admet-338 121 47 200 200 NUM admet-338 121 48 2.4 2.4 NUM admet-338 121 49 0.333 0.333 NUM admet-338 121 50 2 2 NUM admet-338 121 51 3 3 NUM admet-338 121 52 ebastine ebastine NOUN admet-338 121 53 470 470 NUM admet-338 121 54 30 30 NUM admet-338 121 55 0 0 NUM admet-338 121 56 3 3 NUM admet-338 121 57 0.9 0.9 NUM admet-338 121 58 8.2 8.2 NUM admet-338 121 59 ( ( PUNCT admet-338 121 60 b b NOUN admet-338 121 61 ) ) PUNCT admet-338 121 62 5.49 5.49 NUM admet-338 121 63 10 10 NUM admet-338 121 64 0.01 0.01 NUM admet-338 121 65 4 4 NUM admet-338 121 66 17.6 17.6 NUM admet-338 121 67 2 2 NUM admet-338 121 68 enalapril enalapril NOUN admet-338 121 69 maleate maleate NOUN admet-338 121 70 376 376 NUM admet-338 121 71 96 96 NUM admet-338 121 72 2 2 NUM admet-338 121 73 7 7 NUM admet-338 121 74 -1.0 -1.0 PROPN admet-338 121 75 3.1 3.1 NUM admet-338 121 76 ( ( PUNCT admet-338 121 77 a a NOUN admet-338 121 78 ) ) PUNCT admet-338 121 79 -1.06 -1.06 NUM admet-338 121 80 10 10 NUM admet-338 121 81 21 21 NUM admet-338 121 82 0.00191 0.00191 NUM admet-338 121 83 6.1 6.1 NUM admet-338 121 84 3 3 NUM admet-338 121 85 epalrestat epalrestat NOUN admet-338 121 86 319 319 NUM admet-338 121 87 115 115 NUM admet-338 121 88 1 1 NUM admet-338 121 89 4 4 NUM admet-338 121 90 -1.0 -1.0 PROPN admet-338 121 91 3.6 3.6 NUM admet-338 121 92 ( ( PUNCT admet-338 121 93 a a PRON admet-338 121 94 ) ) PUNCT admet-338 121 95 -1.04 -1.04 NOUN admet-338 121 96 50 50 NUM admet-338 121 97 0.009 0.009 NUM admet-338 121 98 22.2 22.2 NUM admet-338 121 99 1.8 1.8 NUM admet-338 121 100 4 4 NUM admet-338 121 101 eperisone eperisone NOUN admet-338 121 102 hydrochloride hydrochloride NOUN admet-338 121 103 259 259 NUM admet-338 121 104 20 20 NUM admet-338 121 105 0 0 NUM admet-338 121 106 2 2 NUM admet-338 121 107 0.9 0.9 NUM admet-338 121 108 8.5 8.5 NUM admet-338 121 109 ( ( PUNCT admet-338 121 110 b b NOUN admet-338 121 111 ) ) PUNCT admet-338 121 112 2.02 2.02 NUM admet-338 121 113 50 50 NUM admet-338 121 114 200 200 NUM admet-338 121 115 0.001 0.001 NUM admet-338 121 116 1.6 1.6 NUM admet-338 121 117 1 1 NUM admet-338 121 118 epinastine epinastine VERB admet-338 121 119 hydrochloride hydrochloride NOUN admet-338 121 120 249 249 NUM admet-338 121 121 42 42 NUM admet-338 121 122 2 2 NUM admet-338 121 123 3 3 NUM admet-338 121 124 1.0 1.0 NUM admet-338 121 125 12.0 12.0 NUM admet-338 121 126 ( ( PUNCT admet-338 121 127 b b NOUN admet-338 121 128 ) ) PUNCT admet-338 121 129 0.77 0.77 NUM admet-338 121 130 20 20 NUM admet-338 121 131 133 133 NUM admet-338 121 132 0.0006 0.0006 NUM admet-338 121 133 9.2 9.2 NUM admet-338 121 134 1 1 NUM admet-338 121 135 ethyl ethyl NOUN admet-338 121 136 icosapentate icosapentate ADJ admet-338 121 137 331 331 NUM admet-338 121 138 26 26 NUM admet-338 121 139 0 0 NUM admet-338 121 140 2 2 NUM admet-338 121 141 0.0 0.0 NUM admet-338 121 142 – – PUNCT admet-338 121 143 6.65 6.65 NUM admet-338 121 144 900 900 NUM admet-338 121 145 0.01 0.01 NUM admet-338 121 146 360 360 NUM admet-338 121 147 58.9 58.9 NUM admet-338 121 148 2 2 NUM admet-338 121 149 etizolam etizolam NOUN admet-338 121 150 343 343 NUM admet-338 121 151 71 71 NUM admet-338 121 152 0 0 NUM admet-338 121 153 4 4 NUM admet-338 121 154 0.0 0.0 NUM admet-338 121 155 – – PUNCT admet-338 121 156 2.87 2.87 NUM admet-338 121 157 1 1 NUM admet-338 121 158 0.01 0.01 NUM admet-338 121 159 0.4 0.4 NUM admet-338 121 160 6.3 6.3 NUM admet-338 121 161 1 1 NUM admet-338 121 162 admet admet X admet-338 121 163 & & CCONJ admet-338 121 164 dmpk dmpk PROPN admet-338 121 165 4(4 4(4 NUM admet-338 121 166 ) ) PUNCT admet-338 121 167 ( ( PUNCT admet-338 121 168 2016 2016 NUM admet-338 121 169 ) ) PUNCT admet-338 121 170 335 335 NUM admet-338 121 171 - - SYM admet-338 121 172 360 360 NUM admet-338 121 173 biopharmaceutical biopharmaceutical NOUN admet-338 121 174 and and CCONJ admet-338 121 175 physchem physchem NOUN admet-338 121 176 properties property NOUN admet-338 121 177 for for ADP admet-338 121 178 odt odt ADJ admet-338 121 179 doi doi NOUN admet-338 121 180 : : PUNCT admet-338 121 181 10.5599 10.5599 NUM admet-338 121 182 / / SYM admet-338 121 183 admet.4.4.331 admet.4.4.331 PROPN admet-338 121 184 341 341 NUM admet-338 121 185 table table NOUN admet-338 121 186 1 1 NUM admet-338 121 187 . . PUNCT admet-338 122 1 ( ( PUNCT admet-338 122 2 continued continue VERB admet-338 122 3 ) ) PUNCT admet-338 122 4 drug drug NOUN admet-338 122 5 mw mw X admet-338 122 6 ( ( PUNCT admet-338 122 7 free free ADJ admet-338 122 8 form form NOUN admet-338 122 9 ) ) PUNCT admet-338 122 10 psa psa VERB admet-338 122 11 b b PROPN admet-338 122 12 hbd hbd PROPN admet-338 122 13 b b PROPN admet-338 122 14 hba hba PROPN admet-338 122 15 b b PROPN admet-338 122 16 nc nc PROPN admet-338 122 17 a a DET admet-338 122 18 ph ph PROPN admet-338 122 19 7.4 7.4 NUM admet-338 122 20 pka pka PROPN admet-338 122 21 b b PROPN admet-338 122 22 log log NOUN admet-338 122 23 d6.5 d6.5 PROPN admet-338 122 24 b b X admet-338 122 25 highest high ADJ admet-338 122 26 dose dose NOUN admet-338 122 27 strength strength NOUN admet-338 122 28 ( ( PUNCT admet-338 122 29 mg mg PROPN admet-338 122 30 ) ) PUNCT admet-338 122 31 c c NOUN admet-338 122 32 solubility solubility NOUN admet-338 122 33 in in ADP admet-338 122 34 water water NOUN admet-338 122 35 ( ( PUNCT admet-338 122 36 mg mg PROPN admet-338 122 37 / / SYM admet-338 122 38 ml ml NOUN admet-338 122 39 ) ) PUNCT admet-338 123 1 c c NOUN admet-338 123 2 do do AUX admet-338 123 3 t1/2 t1/2 VERB admet-338 123 4 ( ( PUNCT admet-338 123 5 h h NOUN admet-338 123 6 ) ) PUNCT admet-338 123 7 c c NOUN admet-338 123 8 bcs bcs NOUN admet-338 123 9 class class NOUN admet-338 123 10 famotidine famotidine NOUN admet-338 123 11 337 337 NUM admet-338 123 12 238 238 NUM admet-338 123 13 8 8 NUM admet-338 123 14 9 9 NUM admet-338 123 15 0.8 0.8 NUM admet-338 123 16 7.9 7.9 NUM admet-338 123 17 ( ( PUNCT admet-338 123 18 b b NOUN admet-338 123 19 ) ) PUNCT admet-338 123 20 -2.14 -2.14 NOUN admet-338 123 21 20 20 NUM admet-338 123 22 0.741 0.741 NUM admet-338 123 23 0.108 0.108 NUM admet-338 123 24 3.1 3.1 NUM admet-338 123 25 3 3 NUM admet-338 123 26 fexofenadine fexofenadine NOUN admet-338 123 27 hydrochloride hydrochloride NOUN admet-338 123 28 502 502 NUM admet-338 123 29 81 81 NUM admet-338 123 30 3 3 NUM admet-338 123 31 5 5 NUM admet-338 123 32 0.0 0.0 NUM admet-338 123 33 4.4 4.4 NUM admet-338 123 34 ( ( PUNCT admet-338 123 35 a a NOUN admet-338 123 36 ) ) PUNCT admet-338 123 37 , , PUNCT admet-338 123 38 9.4 9.4 NUM admet-338 123 39 ( ( PUNCT admet-338 123 40 b b NOUN admet-338 123 41 ) ) PUNCT admet-338 123 42 2.43 2.43 NUM admet-338 123 43 60 60 NUM admet-338 123 44 1.43 1.43 NUM admet-338 123 45 0.168 0.168 NUM admet-338 123 46 19 19 NUM admet-338 123 47 1 1 NUM admet-338 123 48 fluconazole fluconazole NOUN admet-338 123 49 306 306 NUM admet-338 123 50 82 82 NUM admet-338 123 51 1 1 NUM admet-338 123 52 7 7 NUM admet-338 123 53 0.0 0.0 NUM admet-338 123 54 – – PUNCT admet-338 123 55 0.70 0.70 NUM admet-338 123 56 400 400 NUM admet-338 123 57 1 1 NUM admet-338 123 58 1.6 1.6 NUM admet-338 123 59 30 30 NUM admet-338 123 60 2 2 NUM admet-338 123 61 flurbiprofen flurbiprofen NOUN admet-338 123 62 244 244 NUM admet-338 123 63 37 37 NUM admet-338 123 64 1 1 NUM admet-338 123 65 2 2 NUM admet-338 123 66 -1.0 -1.0 PROPN admet-338 123 67 4.1 4.1 NUM admet-338 123 68 ( ( PUNCT admet-338 123 69 a a NOUN admet-338 123 70 ) ) PUNCT admet-338 123 71 1.48 1.48 NUM admet-338 123 72 40 40 NUM admet-338 123 73 0.01 0.01 NUM admet-338 123 74 16 16 NUM admet-338 123 75 2.7 2.7 NUM admet-338 123 76 2 2 NUM admet-338 123 77 fluvastatin fluvastatin NOUN admet-338 123 78 sodium sodium NOUN admet-338 123 79 411 411 NUM admet-338 123 80 83 83 NUM admet-338 123 81 3 3 NUM admet-338 123 82 5 5 NUM admet-338 123 83 -1.0 -1.0 PROPN admet-338 123 84 4.3 4.3 NUM admet-338 123 85 ( ( PUNCT admet-338 123 86 a a NOUN admet-338 123 87 ) ) PUNCT admet-338 123 88 1.33 1.33 NUM admet-338 123 89 30 30 NUM admet-338 123 90 82.0 82.0 NUM admet-338 123 91 0.00146 0.00146 NUM admet-338 123 92 1.3 1.3 NUM admet-338 123 93 1 1 NUM admet-338 123 94 fluvoxamine fluvoxamine NOUN admet-338 123 95 maleate maleate NOUN admet-338 123 96 318 318 NUM admet-338 123 97 57 57 NUM admet-338 123 98 2 2 NUM admet-338 123 99 4 4 NUM admet-338 123 100 1.0 1.0 NUM admet-338 123 101 9.4 9.4 NUM admet-338 123 102 ( ( PUNCT admet-338 123 103 b b NOUN admet-338 123 104 ) ) PUNCT admet-338 123 105 0.36 0.36 NUM admet-338 123 106 75 75 NUM admet-338 123 107 14 14 NUM admet-338 123 108 0.0214 0.0214 NUM admet-338 123 109 14.1 14.1 NUM admet-338 123 110 1 1 NUM admet-338 123 111 fursultiamine fursultiamine NOUN admet-338 123 112 399 399 NUM admet-338 123 113 152 152 NUM admet-338 123 114 3 3 NUM admet-338 123 115 7 7 NUM admet-338 123 116 0.0 0.0 NUM admet-338 123 117 – – PUNCT admet-338 123 118 2.05 2.05 NUM admet-338 123 119 50 50 NUM admet-338 123 120 200 200 NUM admet-338 123 121 0.001 0.001 NUM admet-338 123 122 14.7 14.7 NUM admet-338 123 123 1 1 NUM admet-338 123 124 galantamine galantamine NOUN admet-338 123 125 hydrobromide hydrobromide NOUN admet-338 123 126 287 287 NUM admet-338 123 127 42 42 NUM admet-338 123 128 1 1 NUM admet-338 123 129 4 4 NUM admet-338 123 130 0.8 0.8 NUM admet-338 123 131 7.9 7.9 NUM admet-338 123 132 ( ( PUNCT admet-338 123 133 b b NOUN admet-338 123 134 ) ) PUNCT admet-338 123 135 0.12 0.12 NUM admet-338 123 136 12 12 NUM admet-338 123 137 33 33 NUM admet-338 123 138 0.00145 0.00145 NUM admet-338 123 139 6.8 6.8 NUM admet-338 123 140 1 1 NUM admet-338 123 141 gefitinib gefitinib NOUN admet-338 123 142 447 447 NUM admet-338 123 143 69 69 NUM admet-338 123 144 1 1 NUM admet-338 123 145 7 7 NUM admet-338 123 146 0.3 0.3 NUM admet-338 123 147 7.0 7.0 NUM admet-338 123 148 ( ( PUNCT admet-338 123 149 b b NOUN admet-338 123 150 ) ) PUNCT admet-338 123 151 3.07 3.07 NUM admet-338 123 152 250 250 NUM admet-338 123 153 0.01 0.01 NUM admet-338 123 154 100 100 NUM admet-338 123 155 30.1 30.1 NUM admet-338 123 156 2 2 NUM admet-338 123 157 gimeracil gimeracil NOUN admet-338 123 158 146 146 NUM admet-338 123 159 53 53 NUM admet-338 123 160 2 2 NUM admet-338 123 161 3 3 NUM admet-338 123 162 0.1 0.1 NUM admet-338 123 163 6.5 6.5 NUM admet-338 123 164 ( ( PUNCT admet-338 123 165 a a NOUN admet-338 123 166 ) ) PUNCT admet-338 123 167 , , PUNCT admet-338 123 168 12.6 12.6 NUM admet-338 123 169 ( ( PUNCT admet-338 123 170 b b NOUN admet-338 123 171 ) ) PUNCT admet-338 123 172 -2.58 -2.58 VERB admet-338 123 173 7.25 7.25 NUM admet-338 123 174 1.74 1.74 NUM admet-338 123 175 0.0167 0.0167 NUM admet-338 123 176 3 3 NUM admet-338 123 177 3 3 NUM admet-338 123 178 glimepiride glimepiride NOUN admet-338 123 179 491 491 NUM admet-338 123 180 133 133 NUM admet-338 123 181 3 3 NUM admet-338 123 182 9 9 NUM admet-338 123 183 -1.0 -1.0 PROPN admet-338 123 184 5.1 5.1 NUM admet-338 123 185 ( ( PUNCT admet-338 123 186 a a NOUN admet-338 123 187 ) ) PUNCT admet-338 123 188 1.51 1.51 NUM admet-338 123 189 3 3 NUM admet-338 123 190 0.01 0.01 NUM admet-338 123 191 1.2 1.2 NUM admet-338 123 192 5.8 5.8 NUM admet-338 123 193 2 2 NUM admet-338 123 194 granisetron granisetron ADJ admet-338 123 195 hydrochloride hydrochloride NOUN admet-338 123 196 312 312 NUM admet-338 123 197 50 50 NUM admet-338 123 198 1 1 NUM admet-338 123 199 5 5 NUM admet-338 123 200 1.0 1.0 NUM admet-338 123 201 10.5 10.5 NUM admet-338 123 202 ( ( PUNCT admet-338 123 203 b b NOUN admet-338 123 204 ) ) PUNCT admet-338 123 205 -0.95 -0.95 NOUN admet-338 123 206 2 2 NUM admet-338 123 207 588 588 NUM admet-338 123 208 1.36 1.36 NUM admet-338 123 209 Γ— Γ— NOUN admet-338 123 210 10 10 NUM admet-338 123 211 -5 -5 NOUN admet-338 123 212 5.3 5.3 NUM admet-338 123 213 3 3 NUM admet-338 123 214 hydrochlorothiazide hydrochlorothiazide NOUN admet-338 123 215 298 298 NUM admet-338 123 216 135 135 NUM admet-338 123 217 4 4 NUM admet-338 123 218 7 7 NUM admet-338 123 219 0.0 0.0 NUM admet-338 123 220 – – PUNCT admet-338 123 221 0.01 0.01 NUM admet-338 123 222 12.5 12.5 NUM admet-338 123 223 0.1 0.1 NUM admet-338 123 224 0.5 0.5 NUM admet-338 123 225 9.1 9.1 NUM admet-338 123 226 1 1 NUM admet-338 123 227 imatinib imatinib NOUN admet-338 123 228 mesylate mesylate VERB admet-338 123 229 494 494 NUM admet-338 123 230 86 86 NUM admet-338 123 231 2 2 NUM admet-338 123 232 8 8 NUM admet-338 123 233 0.6 0.6 NUM admet-338 123 234 7.6 7.6 NUM admet-338 123 235 ( ( PUNCT admet-338 123 236 b b NOUN admet-338 123 237 ) ) PUNCT admet-338 123 238 2.00 2.00 NUM admet-338 123 239 200 200 NUM admet-338 123 240 1300 1300 NUM admet-338 123 241 0.000615 0.000615 NUM admet-338 123 242 15.9 15.9 NUM admet-338 123 243 1 1 NUM admet-338 123 244 imidafenacin imidafenacin NOUN admet-338 123 245 319 319 NUM admet-338 123 246 61 61 NUM admet-338 123 247 2 2 NUM admet-338 123 248 4 4 NUM admet-338 123 249 0.6 0.6 NUM admet-338 123 250 7.6 7.6 NUM admet-338 123 251 ( ( PUNCT admet-338 123 252 b b NOUN admet-338 123 253 ) ) PUNCT admet-338 123 254 1.68 1.68 NUM admet-338 123 255 0.1 0.1 NUM admet-338 123 256 0.01 0.01 NUM admet-338 123 257 0.04 0.04 NUM admet-338 123 258 3.1 3.1 NUM admet-338 123 259 1 1 NUM admet-338 123 260 imidapril imidapril NOUN admet-338 123 261 hydrochloride hydrochloride NOUN admet-338 123 262 405 405 NUM admet-338 123 263 116 116 NUM admet-338 123 264 2 2 NUM admet-338 123 265 9 9 NUM admet-338 123 266 -1.0 -1.0 PROPN admet-338 123 267 2.4 2.4 NUM admet-338 123 268 ( ( PUNCT admet-338 123 269 a a X admet-338 123 270 ) ) PUNCT admet-338 123 271 -2.51 -2.51 NOUN admet-338 123 272 10 10 NUM admet-338 123 273 49.3 49.3 NUM admet-338 123 274 0.000812 0.000812 NUM admet-338 123 275 1.7 1.7 NUM admet-338 123 276 3 3 NUM admet-338 123 277 irsogladine irsogladine NOUN admet-338 123 278 maleate maleate NOUN admet-338 124 1 359 359 NUM admet-338 124 2 96 96 NUM admet-338 124 3 1 1 NUM admet-338 124 4 6 6 NUM admet-338 124 5 0.0 0.0 NUM admet-338 124 6 – – PUNCT admet-338 124 7 1.81 1.81 NUM admet-338 124 8 4 4 NUM admet-338 124 9 0.01 0.01 NUM admet-338 124 10 1.6 1.6 NUM admet-338 124 11 128 128 NUM admet-338 124 12 2 2 NUM admet-338 124 13 itraconazole itraconazole NOUN admet-338 124 14 706 706 NUM admet-338 124 15 101 101 NUM admet-338 124 16 0 0 NUM admet-338 124 17 12 12 NUM admet-338 124 18 0.1 0.1 NUM admet-338 124 19 6.5 6.5 NUM admet-338 124 20 ( ( PUNCT admet-338 124 21 b b NOUN admet-338 124 22 ) ) PUNCT admet-338 124 23 4.67 4.67 NUM admet-338 124 24 200 200 NUM admet-338 124 25 0.01 0.01 NUM admet-338 124 26 80 80 NUM admet-338 124 27 27.9 27.9 NUM admet-338 124 28 2 2 NUM admet-338 124 29 ketoprofen ketoprofen NOUN admet-338 124 30 254 254 NUM admet-338 124 31 54 54 NUM admet-338 124 32 1 1 NUM admet-338 124 33 3 3 NUM admet-338 124 34 -1.0 -1.0 PROPN admet-338 124 35 4.2 4.2 NUM admet-338 124 36 ( ( PUNCT admet-338 124 37 a a PROPN admet-338 124 38 ) ) PUNCT admet-338 124 39 0.87 0.87 NUM admet-338 124 40 75 75 NUM admet-338 124 41 0.01 0.01 NUM admet-338 124 42 30 30 NUM admet-338 124 43 1.6 1.6 NUM admet-338 124 44 2 2 NUM admet-338 124 45 ketotifen ketotifen NOUN admet-338 124 46 fumarate fumarate NOUN admet-338 124 47 309 309 NUM admet-338 124 48 49 49 NUM admet-338 124 49 0 0 NUM admet-338 124 50 2 2 NUM admet-338 124 51 1.0 1.0 NUM admet-338 124 52 8.8 8.8 NUM admet-338 124 53 ( ( PUNCT admet-338 124 54 b b NOUN admet-338 124 55 ) ) PUNCT admet-338 124 56 1.79 1.79 NUM admet-338 124 57 1 1 NUM admet-338 124 58 1 1 NUM admet-338 124 59 0.004 0.004 NUM admet-338 124 60 6.7 6.7 NUM admet-338 124 61 1 1 NUM admet-338 124 62 l l NOUN admet-338 124 63 - - PUNCT admet-338 124 64 carbocysteine carbocysteine NOUN admet-338 124 65 179 179 NUM admet-338 124 66 126 126 NUM admet-338 124 67 4 4 NUM admet-338 124 68 5 5 NUM admet-338 124 69 -1.0 -1.0 PROPN admet-338 124 70 2.1 2.1 NUM admet-338 124 71 ( ( PUNCT admet-338 124 72 a a NOUN admet-338 124 73 ) ) PUNCT admet-338 124 74 , , PUNCT admet-338 124 75 3.8 3.8 NUM admet-338 124 76 ( ( PUNCT admet-338 124 77 a a NOUN admet-338 124 78 ) ) PUNCT admet-338 124 79 , , PUNCT admet-338 124 80 8.8 8.8 NUM admet-338 124 81 ( ( PUNCT admet-338 124 82 b b NOUN admet-338 124 83 ) ) PUNCT admet-338 124 84 -3.80 -3.80 NOUN admet-338 124 85 500 500 NUM admet-338 124 86 0.1 0.1 NUM admet-338 124 87 20 20 NUM admet-338 124 88 1.6 1.6 NUM admet-338 124 89 4 4 NUM admet-338 124 90 lafutidine lafutidine VERB admet-338 124 91 432 432 NUM admet-338 124 92 104 104 NUM admet-338 124 93 1 1 NUM admet-338 124 94 7 7 NUM admet-338 124 95 0.4 0.4 NUM admet-338 124 96 7.2 7.2 NUM admet-338 124 97 ( ( PUNCT admet-338 124 98 b b NOUN admet-338 124 99 ) ) PUNCT admet-338 124 100 0.56 0.56 NUM admet-338 124 101 10 10 NUM admet-338 124 102 0.01 0.01 NUM admet-338 124 103 4 4 NUM admet-338 124 104 1.6 1.6 NUM admet-338 124 105 2 2 NUM admet-338 124 106 lansoprazole lansoprazole NOUN admet-338 124 107 369 369 NUM admet-338 124 108 87 87 NUM admet-338 124 109 1 1 NUM admet-338 124 110 5 5 NUM admet-338 124 111 0.0 0.0 NUM admet-338 124 112 – – PUNCT admet-338 124 113 2.40 2.40 NUM admet-338 124 114 30 30 NUM admet-338 124 115 0.0323 0.0323 NUM admet-338 124 116 3.72 3.72 NUM admet-338 124 117 1.4 1.4 NUM admet-338 124 118 2 2 NUM admet-338 125 1 asami asami PROPN admet-338 125 2 ono ono PROPN admet-338 125 3 et et PROPN admet-338 125 4 al al PROPN admet-338 125 5 . . PROPN admet-338 125 6 admet admet PROPN admet-338 125 7 & & CCONJ admet-338 125 8 dmpk dmpk PROPN admet-338 125 9 4(4 4(4 NUM admet-338 125 10 ) ) PUNCT admet-338 125 11 ( ( PUNCT admet-338 125 12 2016 2016 NUM admet-338 125 13 ) ) PUNCT admet-338 125 14 335 335 NUM admet-338 125 15 - - SYM admet-338 125 16 360 360 NUM admet-338 125 17 342 342 NUM admet-338 125 18 table table NOUN admet-338 125 19 1 1 NUM admet-338 125 20 . . PUNCT admet-338 126 1 ( ( PUNCT admet-338 126 2 continued continue VERB admet-338 126 3 ) ) PUNCT admet-338 126 4 drug drug NOUN admet-338 126 5 mw mw X admet-338 126 6 ( ( PUNCT admet-338 126 7 free free ADJ admet-338 126 8 form form NOUN admet-338 126 9 ) ) PUNCT admet-338 126 10 psa psa VERB admet-338 126 11 b b PROPN admet-338 126 12 hbd hbd PROPN admet-338 126 13 b b PROPN admet-338 126 14 hba hba PROPN admet-338 126 15 b b PROPN admet-338 126 16 nc nc PROPN admet-338 126 17 a a DET admet-338 126 18 ph ph PROPN admet-338 126 19 7.4 7.4 NUM admet-338 126 20 pka pka PROPN admet-338 126 21 b b PROPN admet-338 126 22 log log NOUN admet-338 126 23 d6.5 d6.5 PROPN admet-338 126 24 b b X admet-338 126 25 highest high ADJ admet-338 126 26 dose dose NOUN admet-338 126 27 strength strength NOUN admet-338 126 28 ( ( PUNCT admet-338 126 29 mg mg PROPN admet-338 126 30 ) ) PUNCT admet-338 126 31 c c NOUN admet-338 126 32 solubility solubility NOUN admet-338 126 33 in in ADP admet-338 126 34 water water NOUN admet-338 126 35 ( ( PUNCT admet-338 126 36 mg mg PROPN admet-338 126 37 / / SYM admet-338 126 38 ml ml NOUN admet-338 126 39 ) ) PUNCT admet-338 127 1 c c NOUN admet-338 127 2 do do AUX admet-338 127 3 t1/2 t1/2 VERB admet-338 127 4 ( ( PUNCT admet-338 127 5 h h NOUN admet-338 127 6 ) ) PUNCT admet-338 127 7 c c NOUN admet-338 127 8 bcs bcs NOUN admet-338 127 9 class class NOUN admet-338 127 10 levofloxacin levofloxacin PROPN admet-338 127 11 361 361 NUM admet-338 127 12 73 73 NUM admet-338 127 13 1 1 NUM admet-338 127 14 7 7 NUM admet-338 127 15 -0.5 -0.5 NUM admet-338 127 16 5.2 5.2 NUM admet-338 127 17 ( ( PUNCT admet-338 127 18 a a NOUN admet-338 127 19 ) ) PUNCT admet-338 127 20 , , PUNCT admet-338 127 21 7.4 7.4 NUM admet-338 127 22 ( ( PUNCT admet-338 127 23 b b NOUN admet-338 127 24 ) ) PUNCT admet-338 127 25 -1.76 -1.76 NUM admet-338 127 26 500 500 NUM admet-338 127 27 16 16 NUM admet-338 127 28 . . PUNCT admet-338 127 29 7 7 NUM admet-338 127 30 0.12 0.12 NUM admet-338 127 31 7.9 7.9 NUM admet-338 127 32 3 3 NUM admet-338 127 33 limaprost limaprost NOUN admet-338 127 34 alfadex alfadex NOUN admet-338 127 35 366 366 NUM admet-338 127 36 95 95 NUM admet-338 127 37 3 3 NUM admet-338 127 38 5 5 NUM admet-338 127 39 -1.0 -1.0 PROPN admet-338 127 40 4.6 4.6 NUM admet-338 127 41 ( ( PUNCT admet-338 127 42 a a NOUN admet-338 127 43 ) ) PUNCT admet-338 127 44 0.85 0.85 NUM admet-338 127 45 0.005 0.005 NUM admet-338 127 46 370 370 NUM admet-338 127 47 5.4 5.4 NUM admet-338 127 48 Γ— Γ— NOUN admet-338 127 49 10 10 NUM admet-338 127 50 -8 -8 NUM admet-338 127 51 0.5 0.5 NUM admet-338 127 52 1 1 NUM admet-338 127 53 loratadine loratadine NOUN admet-338 127 54 383 383 NUM admet-338 127 55 42 42 NUM admet-338 127 56 0 0 NUM admet-338 127 57 4 4 NUM admet-338 127 58 0.0 0.0 NUM admet-338 127 59 – – PUNCT admet-338 127 60 5.32 5.32 NUM admet-338 127 61 10 10 NUM admet-338 127 62 0.00303 0.00303 NUM admet-338 127 63 13.2 13.2 NUM admet-338 127 64 20.1 20.1 NUM admet-338 127 65 2 2 NUM admet-338 127 66 losartan losartan ADJ admet-338 127 67 potassium potassium VERB admet-338 127 68 423 423 NUM admet-338 127 69 93 93 NUM admet-338 127 70 2 2 NUM admet-338 127 71 7 7 NUM admet-338 127 72 -1.0 -1.0 PROPN admet-338 127 73 4.2 4.2 NUM admet-338 127 74 ( ( PUNCT admet-338 127 75 a a NOUN admet-338 127 76 ) ) PUNCT admet-338 127 77 1.77 1.77 NUM admet-338 127 78 100 100 NUM admet-338 127 79 1000 1000 NUM admet-338 127 80 0.0004 0.0004 NUM admet-338 127 81 1.8 1.8 NUM admet-338 127 82 1 1 NUM admet-338 127 83 loxoprofen loxoprofen VERB admet-338 127 84 sodium sodium NOUN admet-338 127 85 hydrate hydrate NOUN admet-338 127 86 246 246 NUM admet-338 127 87 54 54 NUM admet-338 127 88 1 1 NUM admet-338 127 89 3 3 NUM admet-338 127 90 -1.0 -1.0 PROPN admet-338 127 91 4.4 4.4 NUM admet-338 127 92 ( ( PUNCT admet-338 127 93 a a PROPN admet-338 127 94 ) ) PUNCT admet-338 127 95 0.37 0.37 NUM admet-338 127 96 60 60 NUM admet-338 127 97 1000 1000 NUM admet-338 127 98 0.00024 0.00024 NUM admet-338 127 99 1.2 1.2 NUM admet-338 127 100 1 1 NUM admet-338 127 101 manidipine manidipine NOUN admet-338 127 102 hydrochloride hydrochloride NOUN admet-338 127 103 611 611 NUM admet-338 127 104 117 117 NUM admet-338 127 105 1 1 NUM admet-338 127 106 10 10 NUM admet-338 127 107 0.1 0.1 NUM admet-338 127 108 6.1 6.1 NUM admet-338 127 109 ( ( PUNCT admet-338 127 110 b b NOUN admet-338 127 111 ) ) PUNCT admet-338 127 112 5.29 5.29 NUM admet-338 127 113 20 20 NUM admet-338 127 114 3.88 3.88 NUM admet-338 127 115 0.0206 0.0206 NUM admet-338 127 116 1.5 1.5 NUM admet-338 127 117 1 1 NUM admet-338 127 118 mecobalamin mecobalamin NOUN admet-338 127 119 1344 1344 NUM admet-338 127 120 nd nd PRON admet-338 127 121 nd nd NOUN admet-338 127 122 nd nd PROPN admet-338 127 123 – – PUNCT admet-338 127 124 nd nd ADV admet-338 127 125 nd nd ADV admet-338 127 126 0.5 0.5 NUM admet-338 127 127 12.5 12.5 NUM admet-338 127 128 0.00016 0.00016 NUM admet-338 127 129 12.5 12.5 NUM admet-338 127 130 uc uc INTJ admet-338 127 131 meloxicam meloxicam NOUN admet-338 127 132 351 351 NUM admet-338 127 133 136 136 NUM admet-338 127 134 2 2 NUM admet-338 127 135 7 7 NUM admet-338 127 136 -1.0 -1.0 PROPN admet-338 127 137 4.5 4.5 NUM admet-338 127 138 ( ( PUNCT admet-338 127 139 a a NOUN admet-338 127 140 ) ) PUNCT admet-338 127 141 0.29 0.29 NUM admet-338 127 142 10 10 NUM admet-338 127 143 0.01 0.01 NUM admet-338 127 144 4 4 NUM admet-338 127 145 27.6 27.6 NUM admet-338 127 146 2 2 NUM admet-338 127 147 memantine memantine NOUN admet-338 127 148 hydrochloride hydrochloride NOUN admet-338 127 149 179 179 NUM admet-338 127 150 26 26 NUM admet-338 127 151 2 2 NUM admet-338 127 152 1 1 NUM admet-338 127 153 1.0 1.0 NUM admet-338 127 154 10.8 10.8 NUM admet-338 127 155 ( ( PUNCT admet-338 127 156 b b NOUN admet-338 127 157 ) ) PUNCT admet-338 127 158 0.40 0.40 NUM admet-338 127 159 20 20 NUM admet-338 127 160 33 33 NUM admet-338 127 161 0.00242 0.00242 NUM admet-338 127 162 53.6 53.6 NUM admet-338 127 163 1 1 NUM admet-338 127 164 menatetrenone menatetrenone NOUN admet-338 127 165 445 445 NUM admet-338 127 166 34 34 NUM admet-338 127 167 0 0 NUM admet-338 127 168 2 2 NUM admet-338 127 169 0.0 0.0 NUM admet-338 127 170 – – PUNCT admet-338 127 171 9.55 9.55 NUM admet-338 127 172 15 15 NUM admet-338 127 173 0.01 0.01 NUM admet-338 127 174 6 6 NUM admet-338 127 175 3.9 3.9 NUM admet-338 127 176 2 2 NUM admet-338 127 177 mesalazine mesalazine NOUN admet-338 127 178 153 153 NUM admet-338 127 179 84 84 NUM admet-338 127 180 4 4 NUM admet-338 127 181 4 4 NUM admet-338 127 182 -1.0 -1.0 PROPN admet-338 127 183 1.9 1.9 NUM admet-338 127 184 ( ( PUNCT admet-338 127 185 a a NOUN admet-338 127 186 ) ) PUNCT admet-338 127 187 -1.85 -1.85 NUM admet-338 127 188 500 500 NUM admet-338 127 189 1 1 NUM admet-338 127 190 2 2 NUM admet-338 127 191 6.4 6.4 NUM admet-338 127 192 4 4 NUM admet-338 127 193 methylmethionine methylmethionine PROPN admet-338 127 194 sulfonium sulfonium NOUN admet-338 127 195 chloride chloride PROPN admet-338 127 196 164 164 NUM admet-338 127 197 nd nd NOUN admet-338 127 198 nd nd PRON admet-338 127 199 nd nd PROPN admet-338 127 200 – – PUNCT admet-338 127 201 nd nd ADV admet-338 127 202 nd nd ADV admet-338 127 203 25 25 NUM admet-338 127 204 1000 1000 NUM admet-338 127 205 0.0001 0.0001 NUM admet-338 127 206 3.2 3.2 NUM admet-338 127 207 uc uc NOUN admet-338 127 208 mexiletine mexiletine NOUN admet-338 127 209 hydrochloride hydrochloride NOUN admet-338 127 210 179 179 NUM admet-338 127 211 35 35 NUM admet-338 127 212 2 2 NUM admet-338 127 213 2 2 NUM admet-338 127 214 0.9 0.9 NUM admet-338 127 215 8.6 8.6 NUM admet-338 127 216 ( ( PUNCT admet-338 127 217 b b NOUN admet-338 127 218 ) ) PUNCT admet-338 127 219 0.39 0.39 NUM admet-338 127 220 100 100 NUM admet-338 127 221 833 833 NUM admet-338 127 222 0.00048 0.00048 NUM admet-338 127 223 9.4 9.4 NUM admet-338 127 224 1 1 NUM admet-338 127 225 midodrine midodrine ADJ admet-338 127 226 hydrochloride hydrochloride NOUN admet-338 127 227 254 254 NUM admet-338 127 228 94 94 NUM admet-338 127 229 4 4 NUM admet-338 127 230 6 6 NUM admet-338 127 231 0.7 0.7 NUM admet-338 127 232 7.8 7.8 NUM admet-338 127 233 ( ( PUNCT admet-338 127 234 b b NOUN admet-338 127 235 ) ) PUNCT admet-338 127 236 -1.24 -1.24 NOUN admet-338 127 237 2 2 NUM admet-338 127 238 138 138 NUM admet-338 127 239 5.80 5.80 NUM admet-338 127 240 Γ— Γ— NOUN admet-338 127 241 10 10 NUM admet-338 127 242 -5 -5 NUM admet-338 127 243 2.4 2.4 NUM admet-338 127 244 3 3 NUM admet-338 127 245 miglitol miglitol NOUN admet-338 127 246 207 207 NUM admet-338 127 247 104 104 NUM admet-338 127 248 5 5 NUM admet-338 128 1 6 6 NUM admet-338 128 2 0.1 0.1 NUM admet-338 128 3 6.5 6.5 NUM admet-338 128 4 ( ( PUNCT admet-338 128 5 b b NOUN admet-338 128 6 ) ) PUNCT admet-338 128 7 -2.27 -2.27 PROPN admet-338 128 8 75 75 NUM admet-338 128 9 791 791 NUM admet-338 128 10 0.000379 0.000379 NUM admet-338 128 11 2.0 2.0 NUM admet-338 128 12 3 3 NUM admet-338 128 13 montelukast montelukast NOUN admet-338 128 14 sodium sodium NOUN admet-338 129 1 586 586 NUM admet-338 129 2 96 96 NUM admet-338 129 3 2 2 NUM admet-338 129 4 4 4 NUM admet-338 129 5 -1.0 -1.0 PROPN admet-338 129 6 4.8 4.8 NUM admet-338 129 7 ( ( PUNCT admet-338 129 8 a a X admet-338 129 9 ) ) PUNCT admet-338 129 10 5.82 5.82 NUM admet-338 129 11 10 10 NUM admet-338 129 12 200 200 NUM admet-338 129 13 0.0002 0.0002 NUM admet-338 129 14 4.3 4.3 NUM admet-338 129 15 1 1 NUM admet-338 129 16 mosapride mosapride ADJ admet-338 129 17 citrate citrate NOUN admet-338 129 18 hydrate hydrate NOUN admet-338 129 19 422 422 NUM admet-338 129 20 77 77 NUM admet-338 129 21 3 3 NUM admet-338 129 22 6 6 NUM admet-338 129 23 0.1 0.1 NUM admet-338 129 24 6.2 6.2 NUM admet-338 129 25 ( ( PUNCT admet-338 129 26 b b NOUN admet-338 129 27 ) ) PUNCT admet-338 129 28 2.89 2.89 NUM admet-338 129 29 5 5 NUM admet-338 129 30 0.01 0.01 NUM admet-338 129 31 2 2 NUM admet-338 129 32 2 2 NUM admet-338 129 33 2 2 NUM admet-338 129 34 naftopizil naftopizil NOUN admet-338 129 35 393 393 NUM admet-338 129 36 45 45 NUM admet-338 129 37 1 1 NUM admet-338 129 38 5 5 NUM admet-338 129 39 0.2 0.2 NUM admet-338 129 40 6.9 6.9 NUM admet-338 129 41 ( ( PUNCT admet-338 129 42 b b NOUN admet-338 129 43 ) ) PUNCT admet-338 129 44 3.65 3.65 NUM admet-338 129 45 75 75 NUM admet-338 129 46 0.01 0.01 NUM admet-338 129 47 30 30 NUM admet-338 129 48 11.2 11.2 NUM admet-338 129 49 2 2 NUM admet-338 129 50 nicardipine nicardipine NOUN admet-338 129 51 hydrochloride hydrochloride NOUN admet-338 129 52 480 480 NUM admet-338 129 53 114 114 NUM admet-338 129 54 1 1 NUM admet-338 129 55 9 9 NUM admet-338 129 56 0.4 0.4 NUM admet-338 129 57 7.3 7.3 NUM admet-338 129 58 ( ( PUNCT admet-338 129 59 b b NOUN admet-338 129 60 ) ) PUNCT admet-338 129 61 3.94 3.94 NUM admet-338 129 62 20 20 NUM admet-338 129 63 6 6 NUM admet-338 129 64 0.0133 0.0133 NUM admet-338 129 65 1.5 1.5 NUM admet-338 129 66 1 1 NUM admet-338 129 67 nicergoline nicergoline NOUN admet-338 129 68 484 484 NUM admet-338 129 69 57 57 NUM admet-338 129 70 0 0 NUM admet-338 129 71 6 6 NUM admet-338 129 72 0.1 0.1 NUM admet-338 129 73 6.3 6.3 NUM admet-338 129 74 ( ( PUNCT admet-338 129 75 b b NOUN admet-338 129 76 ) ) PUNCT admet-338 129 77 4.29 4.29 NUM admet-338 129 78 5 5 NUM admet-338 129 79 0.01 0.01 NUM admet-338 129 80 2 2 NUM admet-338 129 81 3.3 3.3 NUM admet-338 129 82 2 2 NUM admet-338 129 83 nicorandil nicorandil NOUN admet-338 129 84 211 211 NUM admet-338 129 85 97 97 NUM admet-338 129 86 1 1 NUM admet-338 129 87 7 7 NUM admet-338 129 88 0.0 0.0 NUM admet-338 129 89 – – PUNCT admet-338 129 90 0.93 0.93 NUM admet-338 129 91 5 5 NUM admet-338 129 92 10 10 NUM admet-338 129 93 0.002 0.002 NUM admet-338 129 94 0.8 0.8 NUM admet-338 129 95 1 1 NUM admet-338 129 96 nifedipine nifedipine NOUN admet-338 129 97 346 346 NUM admet-338 129 98 110 110 NUM admet-338 129 99 1 1 NUM admet-338 129 100 8 8 NUM admet-338 129 101 0.0 0.0 NUM admet-338 129 102 – – PUNCT admet-338 129 103 3.45 3.45 NUM admet-338 129 104 10 10 NUM admet-338 129 105 0.01 0.01 NUM admet-338 129 106 4 4 NUM admet-338 129 107 1.0 1.0 NUM admet-338 129 108 2 2 NUM admet-338 129 109 nilvadipine nilvadipine NOUN admet-338 129 110 385 385 NUM admet-338 129 111 134 134 NUM admet-338 129 112 1 1 NUM admet-338 129 113 9 9 NUM admet-338 129 114 0.0 0.0 NUM admet-338 129 115 – – PUNCT admet-338 129 116 3.23 3.23 NUM admet-338 129 117 4 4 NUM admet-338 129 118 0.01 0.01 NUM admet-338 129 119 1.6 1.6 NUM admet-338 129 120 10.7 10.7 NUM admet-338 129 121 2 2 NUM admet-338 129 122 nizatidine nizatidine NOUN admet-338 129 123 331 331 NUM admet-338 129 124 140 140 NUM admet-338 129 125 2 2 NUM admet-338 129 126 7 7 NUM admet-338 129 127 0.5 0.5 NUM admet-338 129 128 7.3 7.3 NUM admet-338 129 129 ( ( PUNCT admet-338 129 130 b b NOUN admet-338 129 131 ) ) PUNCT admet-338 129 132 -0.61 -0.61 NOUN admet-338 129 133 150 150 NUM admet-338 129 134 17.3 17.3 NUM admet-338 129 135 0.0347 0.0347 NUM admet-338 129 136 1.7 1.7 NUM admet-338 129 137 1 1 NUM admet-338 129 138 admet admet X admet-338 129 139 & & CCONJ admet-338 129 140 dmpk dmpk PROPN admet-338 129 141 4(4 4(4 NUM admet-338 129 142 ) ) PUNCT admet-338 129 143 ( ( PUNCT admet-338 129 144 2016 2016 NUM admet-338 129 145 ) ) PUNCT admet-338 129 146 335 335 NUM admet-338 129 147 - - SYM admet-338 129 148 360 360 NUM admet-338 129 149 biopharmaceutical biopharmaceutical NOUN admet-338 129 150 and and CCONJ admet-338 129 151 physchem physchem NOUN admet-338 129 152 properties property NOUN admet-338 129 153 for for ADP admet-338 129 154 odt odt ADJ admet-338 129 155 doi doi NOUN admet-338 129 156 : : PUNCT admet-338 129 157 10.5599 10.5599 NUM admet-338 129 158 / / SYM admet-338 129 159 admet.4.4.331 admet.4.4.331 PROPN admet-338 129 160 343 343 NUM admet-338 129 161 table table NOUN admet-338 129 162 1 1 NUM admet-338 129 163 . . PUNCT admet-338 129 164 ( ( PUNCT admet-338 129 165 continued continue VERB admet-338 129 166 ) ) PUNCT admet-338 129 167 drug drug NOUN admet-338 129 168 mw mw X admet-338 129 169 ( ( PUNCT admet-338 129 170 free free ADJ admet-338 129 171 form form NOUN admet-338 129 172 ) ) PUNCT admet-338 129 173 psa psa VERB admet-338 129 174 b b PROPN admet-338 129 175 hbd hbd PROPN admet-338 129 176 b b PROPN admet-338 129 177 hba hba PROPN admet-338 129 178 b b PROPN admet-338 129 179 nc nc PROPN admet-338 129 180 a a DET admet-338 129 181 ph ph PROPN admet-338 129 182 7.4 7.4 NUM admet-338 129 183 pka pka PROPN admet-338 129 184 b b PROPN admet-338 129 185 log log NOUN admet-338 129 186 d6.5 d6.5 PROPN admet-338 129 187 b b X admet-338 129 188 highest high ADJ admet-338 129 189 dose dose NOUN admet-338 129 190 strength strength NOUN admet-338 129 191 ( ( PUNCT admet-338 129 192 mg mg PROPN admet-338 129 193 ) ) PUNCT admet-338 129 194 c c NOUN admet-338 129 195 solubility solubility NOUN admet-338 129 196 in in ADP admet-338 129 197 water water NOUN admet-338 129 198 ( ( PUNCT admet-338 129 199 mg mg PROPN admet-338 129 200 / / SYM admet-338 129 201 ml ml NOUN admet-338 129 202 ) ) PUNCT admet-338 130 1 c c NOUN admet-338 130 2 do do AUX admet-338 130 3 t1/2 t1/2 VERB admet-338 130 4 ( ( PUNCT admet-338 130 5 h h NOUN admet-338 130 6 ) ) PUNCT admet-338 130 7 c c NOUN admet-338 130 8 bcs bcs NOUN admet-338 130 9 class class NOUN admet-338 130 10 olanzapine olanzapine NOUN admet-338 131 1 312 312 NUM admet-338 131 2 56 56 NUM admet-338 131 3 1 1 NUM admet-338 131 4 4 4 NUM admet-338 131 5 1.0 1.0 NUM admet-338 131 6 10.4 10.4 NUM admet-338 131 7 ( ( PUNCT admet-338 131 8 b b NOUN admet-338 131 9 ) ) PUNCT admet-338 131 10 -0.35 -0.35 NOUN admet-338 131 11 10 10 NUM admet-338 131 12 0.01 0.01 NUM admet-338 131 13 4 4 NUM admet-338 131 14 30.6 30.6 NUM admet-338 131 15 2 2 NUM admet-338 131 16 olopatadine olopatadine NOUN admet-338 131 17 hydrochloride hydrochloride NOUN admet-338 131 18 337 337 NUM admet-338 131 19 50 50 NUM admet-338 131 20 1 1 NUM admet-338 131 21 4 4 NUM admet-338 131 22 0.0 0.0 NUM admet-338 131 23 4.3 4.3 NUM admet-338 131 24 ( ( PUNCT admet-338 131 25 a a NOUN admet-338 131 26 ) ) PUNCT admet-338 131 27 , , PUNCT admet-338 131 28 9.2 9.2 NUM admet-338 131 29 ( ( PUNCT admet-338 131 30 b b NOUN admet-338 131 31 ) ) PUNCT admet-338 131 32 1.54 1.54 NUM admet-338 131 33 5 5 NUM admet-338 131 34 10 10 NUM admet-338 131 35 0.002 0.002 NUM admet-338 131 36 0.8 0.8 NUM admet-338 131 37 1 1 NUM admet-338 131 38 ondansetron ondansetron NOUN admet-338 131 39 293 293 NUM admet-338 131 40 40 40 NUM admet-338 131 41 0 0 NUM admet-338 131 42 4 4 NUM admet-338 131 43 0.6 0.6 NUM admet-338 131 44 7.5 7.5 NUM admet-338 131 45 ( ( PUNCT admet-338 131 46 b b NOUN admet-338 131 47 ) ) PUNCT admet-338 131 48 1.76 1.76 NUM admet-338 131 49 4 4 NUM admet-338 131 50 0.01 0.01 NUM admet-338 131 51 1.6 1.6 NUM admet-338 131 52 4.5 4.5 NUM admet-338 131 53 2 2 NUM admet-338 131 54 oseltamivir oseltamivir NOUN admet-338 131 55 phosphate phosphate VERB admet-338 131 56 312 312 NUM admet-338 131 57 91 91 NUM admet-338 131 58 3 3 NUM admet-338 131 59 6 6 NUM admet-338 131 60 1.0 1.0 NUM admet-338 131 61 8.8 8.8 NUM admet-338 131 62 ( ( PUNCT admet-338 131 63 b b NOUN admet-338 131 64 ) ) PUNCT admet-338 131 65 -0.19 -0.19 NOUN admet-338 131 66 75 75 NUM admet-338 131 67 521 521 NUM admet-338 131 68 0.000576 0.000576 NUM admet-338 131 69 7 7 NUM admet-338 131 70 1 1 NUM admet-338 131 71 oteracil oteracil NOUN admet-338 131 72 potassium potassium NOUN admet-338 131 73 157 157 NUM admet-338 131 74 108 108 NUM admet-338 131 75 3 3 NUM admet-338 131 76 7 7 NUM admet-338 131 77 -1.0 -1.0 PROPN admet-338 131 78 -3.1 -3.1 PROPN admet-338 131 79 ( ( PUNCT admet-338 131 80 a a NOUN admet-338 131 81 ) ) PUNCT admet-338 131 82 -5.54 -5.54 PROPN admet-338 131 83 24.5 24.5 NUM admet-338 131 84 7.42 7.42 NUM admet-338 131 85 0.0132 0.0132 NUM admet-338 131 86 3 3 NUM admet-338 131 87 3 3 NUM admet-338 131 88 paroxetine paroxetine NOUN admet-338 131 89 hydrochloride hydrochloride NOUN admet-338 131 90 hydrate hydrate NOUN admet-338 131 91 329 329 NUM admet-338 131 92 40 40 NUM admet-338 131 93 1 1 NUM admet-338 131 94 4 4 NUM admet-338 131 95 1.0 1.0 NUM admet-338 131 96 9.7 9.7 NUM admet-338 131 97 ( ( PUNCT admet-338 131 98 b b NOUN admet-338 131 99 ) ) PUNCT admet-338 131 100 0.84 0.84 NUM admet-338 131 101 20 20 NUM admet-338 131 102 2 2 NUM admet-338 131 103 0.04 0.04 NUM admet-338 131 104 13.6 13.6 NUM admet-338 131 105 1 1 NUM admet-338 131 106 pergolide pergolide NOUN admet-338 131 107 mesylate mesylate NOUN admet-338 131 108 314 314 NUM admet-338 131 109 44 44 NUM admet-338 131 110 1 1 NUM admet-338 131 111 2 2 NUM admet-338 131 112 0.8 0.8 NUM admet-338 131 113 8.0 8.0 NUM admet-338 131 114 ( ( PUNCT admet-338 131 115 b b NOUN admet-338 131 116 ) ) PUNCT admet-338 131 117 2.39 2.39 NUM admet-338 131 118 0.25 0.25 NUM admet-338 131 119 5 5 NUM admet-338 131 120 0.0002 0.0002 NUM admet-338 131 121 8.8 8.8 NUM admet-338 131 122 1 1 NUM admet-338 131 123 perindopril perindopril ADJ admet-338 131 124 erbumine erbumine NOUN admet-338 131 125 368 368 NUM admet-338 131 126 96 96 NUM admet-338 131 127 2 2 NUM admet-338 131 128 7 7 NUM admet-338 131 129 -1.0 -1.0 PROPN admet-338 131 130 3.2 3.2 NUM admet-338 131 131 ( ( PUNCT admet-338 131 132 a a NOUN admet-338 131 133 ) ) PUNCT admet-338 131 134 0.07 0.07 NUM admet-338 131 135 4 4 NUM admet-338 131 136 500 500 NUM admet-338 131 137 3.2 3.2 NUM admet-338 131 138 Γ— Γ— NOUN admet-338 131 139 10 10 NUM admet-338 131 140 -5 -5 NUM admet-338 131 141 0.8 0.8 NUM admet-338 131 142 1 1 NUM admet-338 131 143 pilsicainide pilsicainide NOUN admet-338 131 144 hydrochloride hydrochloride NOUN admet-338 131 145 hydrate hydrate NOUN admet-338 131 146 272 272 NUM admet-338 131 147 32 32 NUM admet-338 131 148 1 1 NUM admet-338 131 149 3 3 NUM admet-338 131 150 1.0 1.0 NUM admet-338 131 151 10.4 10.4 NUM admet-338 131 152 ( ( PUNCT admet-338 131 153 b b NOUN admet-338 131 154 ) ) PUNCT admet-338 131 155 -0.12 -0.12 NUM admet-338 131 156 50 50 NUM admet-338 131 157 100 100 NUM admet-338 131 158 0.002 0.002 NUM admet-338 131 159 4.4 4.4 NUM admet-338 131 160 1 1 NUM admet-338 131 161 pioglitazone pioglitazone NOUN admet-338 131 162 hydrochloride hydrochloride NOUN admet-338 131 163 356 356 NUM admet-338 131 164 94 94 NUM admet-338 131 165 1 1 NUM admet-338 131 166 5 5 NUM admet-338 131 167 -0.9 -0.9 NOUN admet-338 131 168 6.3 6.3 NUM admet-338 131 169 ( ( PUNCT admet-338 131 170 a a X admet-338 131 171 ) ) PUNCT admet-338 131 172 2.16 2.16 NUM admet-338 131 173 30 30 NUM admet-338 131 174 0.01 0.01 NUM admet-338 131 175 12 12 NUM admet-338 131 176 6.7 6.7 NUM admet-338 131 177 2 2 NUM admet-338 131 178 pitavastatin pitavastatin NOUN admet-338 131 179 calcium calcium NOUN admet-338 131 180 421 421 NUM admet-338 131 181 91 91 NUM admet-338 131 182 3 3 NUM admet-338 131 183 5 5 NUM admet-338 131 184 -1.0 -1.0 PROPN admet-338 131 185 4.2 4.2 NUM admet-338 131 186 ( ( PUNCT admet-338 131 187 a a NOUN admet-338 131 188 ) ) PUNCT admet-338 131 189 1.17 1.17 NUM admet-338 131 190 4 4 NUM admet-338 131 191 0.1 0.1 NUM admet-338 131 192 0.16 0.16 NUM admet-338 131 193 9.3 9.3 NUM admet-338 131 194 1 1 NUM admet-338 131 195 polaprezinc polaprezinc NOUN admet-338 131 196 nd nd INTJ admet-338 131 197 nd nd INTJ admet-338 131 198 nd nd NOUN admet-338 131 199 nd nd PROPN admet-338 131 200 – – PUNCT admet-338 131 201 nd nd ADV admet-338 131 202 nd nd ADV admet-338 131 203 75 75 NUM admet-338 131 204 0.01 0.01 NUM admet-338 131 205 30 30 NUM admet-338 131 206 2.2 2.2 NUM admet-338 131 207 uc uc NOUN admet-338 131 208 pramipexole pramipexole NOUN admet-338 131 209 hydrochloride hydrochloride NOUN admet-338 131 210 hydrate hydrate NOUN admet-338 131 211 211 211 NUM admet-338 131 212 79 79 NUM admet-338 131 213 3 3 NUM admet-338 131 214 3 3 NUM admet-338 131 215 1.0 1.0 NUM admet-338 131 216 9.5(b 9.5(b NUM admet-338 131 217 ) ) PUNCT admet-338 131 218 -1.03 -1.03 NUM admet-338 131 219 0.5 0.5 NUM admet-338 131 220 1000 1000 NUM admet-338 131 221 2.0 2.0 NUM admet-338 131 222 Γ— Γ— NOUN admet-338 131 223 10 10 NUM admet-338 132 1 -6 -6 NOUN admet-338 132 2 8.4 8.4 NUM admet-338 132 3 3 3 NUM admet-338 132 4 pranlukast pranlukast NOUN admet-338 132 5 hydrate hydrate NOUN admet-338 132 6 482 482 NUM admet-338 132 7 119 119 NUM admet-338 132 8 2 2 NUM admet-338 132 9 9 9 NUM admet-338 132 10 -1.0 -1.0 PROPN admet-338 132 11 5.3 5.3 NUM admet-338 132 12 ( ( PUNCT admet-338 132 13 a a PROPN admet-338 132 14 ) ) PUNCT admet-338 132 15 2.74 2.74 NUM admet-338 132 16 112.5 112.5 NUM admet-338 132 17 0.0012 0.0012 NUM admet-338 132 18 375 375 NUM admet-338 132 19 1.2 1.2 NUM admet-338 132 20 2 2 NUM admet-338 132 21 pravastatin pravastatin NOUN admet-338 132 22 sodium sodium NOUN admet-338 132 23 hydrate hydrate NOUN admet-338 132 24 425 425 NUM admet-338 132 25 124 124 NUM admet-338 132 26 4 4 NUM admet-338 132 27 7 7 NUM admet-338 132 28 -1.0 -1.0 PROPN admet-338 132 29 4.3 4.3 NUM admet-338 132 30 ( ( PUNCT admet-338 132 31 a a NOUN admet-338 132 32 ) ) PUNCT admet-338 132 33 0.06 0.06 NUM admet-338 132 34 10 10 NUM admet-338 132 35 100 100 NUM admet-338 132 36 0.0004 0.0004 NUM admet-338 132 37 2.7 2.7 NUM admet-338 132 38 1 1 NUM admet-338 132 39 procaterol procaterol NOUN admet-338 132 40 hydrochloride hydrochloride NOUN admet-338 132 41 290 290 NUM admet-338 132 42 82 82 NUM admet-338 132 43 4 4 NUM admet-338 132 44 5 5 NUM admet-338 132 45 1.0 1.0 NUM admet-338 132 46 9.4 9.4 NUM admet-338 132 47 ( ( PUNCT admet-338 132 48 b b NOUN admet-338 132 49 ) ) PUNCT admet-338 132 50 -1.47 -1.47 NUM admet-338 132 51 0.05 0.05 NUM admet-338 132 52 50 50 NUM admet-338 132 53 4.0 4.0 NUM admet-338 132 54 Γ— Γ— NOUN admet-338 132 55 10 10 NUM admet-338 132 56 -6 -6 NOUN admet-338 132 57 3.8 3.8 NUM admet-338 132 58 3 3 NUM admet-338 132 59 propiverine propiverine ADJ admet-338 132 60 hydrochloride hydrochloride NOUN admet-338 132 61 367 367 NUM admet-338 132 62 39 39 NUM admet-338 132 63 0 0 NUM admet-338 132 64 4 4 NUM admet-338 132 65 0.7 0.7 NUM admet-338 132 66 7.8 7.8 NUM admet-338 132 67 ( ( PUNCT admet-338 132 68 b b NOUN admet-338 132 69 ) ) PUNCT admet-338 132 70 4.10 4.10 NUM admet-338 132 71 20 20 NUM admet-338 132 72 124 124 NUM admet-338 132 73 0.000645 0.000645 NUM admet-338 132 74 10.7 10.7 NUM admet-338 132 75 1 1 NUM admet-338 132 76 quetiapine quetiapine NOUN admet-338 132 77 fumarate fumarate NOUN admet-338 132 78 384 384 NUM admet-338 132 79 74 74 NUM admet-338 132 80 1 1 NUM admet-338 132 81 5 5 NUM admet-338 132 82 0.2 0.2 NUM admet-338 132 83 6.7 6.7 NUM admet-338 132 84 ( ( PUNCT admet-338 132 85 b b NOUN admet-338 132 86 ) ) PUNCT admet-338 132 87 1.92 1.92 NUM admet-338 132 88 200 200 NUM admet-338 132 89 3.38 3.38 NUM admet-338 132 90 0.2364 0.2364 NUM admet-338 132 91 3.5 3.5 NUM admet-338 132 92 1 1 NUM admet-338 132 93 ramosetron ramosetron NOUN admet-338 132 94 hydrochloride hydrochloride NOUN admet-338 132 95 279 279 NUM admet-338 132 96 51 51 NUM admet-338 132 97 1 1 NUM admet-338 132 98 4 4 NUM admet-338 132 99 0.4 0.4 NUM admet-338 132 100 7.3 7.3 NUM admet-338 132 101 ( ( PUNCT admet-338 132 102 b b NOUN admet-338 132 103 ) ) PUNCT admet-338 132 104 1.80 1.80 NUM admet-338 132 105 0.005 0.005 NUM admet-338 132 106 575 575 NUM admet-338 132 107 3.48 3.48 NUM admet-338 132 108 Γ— Γ— NOUN admet-338 132 109 10 10 NUM admet-338 132 110 -8 -8 NUM admet-338 132 111 7 7 NUM admet-338 132 112 1 1 NUM admet-338 132 113 ranitidine ranitidine NOUN admet-338 132 114 hydrochloride hydrochloride NOUN admet-338 132 115 314 314 NUM admet-338 132 116 112 112 NUM admet-338 132 117 2 2 NUM admet-338 132 118 7 7 NUM admet-338 132 119 0.9 0.9 NUM admet-338 132 120 8.4 8.4 NUM admet-338 132 121 ( ( PUNCT admet-338 132 122 b b NOUN admet-338 132 123 ) ) PUNCT admet-338 132 124 -1.47 -1.47 NUM admet-338 132 125 150 150 NUM admet-338 132 126 1429 1429 NUM admet-338 132 127 0.00042 0.00042 NUM admet-338 132 128 2.7 2.7 NUM admet-338 132 129 3 3 NUM admet-338 132 130 rebamipide rebamipide NOUN admet-338 132 131 371 371 NUM admet-338 132 132 96 96 NUM admet-338 132 133 3 3 NUM admet-338 132 134 6 6 NUM admet-338 132 135 -1.0 -1.0 PROPN admet-338 132 136 3.4 3.4 NUM admet-338 132 137 ( ( PUNCT admet-338 132 138 a a NOUN admet-338 132 139 ) ) PUNCT admet-338 132 140 -0.75 -0.75 NUM admet-338 132 141 100 100 NUM admet-338 132 142 0.006 0.006 NUM admet-338 132 143 66.7 66.7 NUM admet-338 132 144 1.9 1.9 NUM admet-338 132 145 2 2 NUM admet-338 132 146 risedronate risedronate NOUN admet-338 132 147 sodium sodium NOUN admet-338 132 148 hydrate hydrate NOUN admet-338 132 149 283 283 NUM admet-338 132 150 168 168 NUM admet-338 132 151 5 5 NUM admet-338 132 152 8 8 NUM admet-338 132 153 -3.0 -3.0 SYM admet-338 132 154 1.4 1.4 NUM admet-338 133 1 ( ( PUNCT admet-338 133 2 a a NOUN admet-338 133 3 ) ) PUNCT admet-338 133 4 , , PUNCT admet-338 133 5 2.4 2.4 NUM admet-338 133 6 ( ( PUNCT admet-338 133 7 a a NOUN admet-338 133 8 ) ) PUNCT admet-338 133 9 , , PUNCT admet-338 133 10 6.0 6.0 NUM admet-338 133 11 ( ( PUNCT admet-338 133 12 a a NOUN admet-338 133 13 ) ) PUNCT admet-338 133 14 -8.38 -8.38 NOUN admet-338 133 15 75 75 NUM admet-338 133 16 33 33 NUM admet-338 133 17 0.00909 0.00909 NUM admet-338 133 18 1.5 1.5 NUM admet-338 133 19 3 3 NUM admet-338 133 20 risperidone risperidone NOUN admet-338 133 21 410 410 NUM admet-338 133 22 62 62 NUM admet-338 133 23 0 0 NUM admet-338 133 24 6 6 NUM admet-338 133 25 0.8 0.8 NUM admet-338 133 26 8.1 8.1 NUM admet-338 133 27 ( ( PUNCT admet-338 133 28 b b NOUN admet-338 133 29 ) ) PUNCT admet-338 133 30 0.99 0.99 NUM admet-338 133 31 2 2 NUM admet-338 133 32 0.01 0.01 NUM admet-338 133 33 0.8 0.8 NUM admet-338 133 34 0.3 0.3 NUM admet-338 133 35 1 1 NUM admet-338 133 36 asami asami PROPN admet-338 133 37 ono ono PROPN admet-338 133 38 et et PROPN admet-338 133 39 al al PROPN admet-338 133 40 . . PROPN admet-338 133 41 admet admet PROPN admet-338 133 42 & & CCONJ admet-338 133 43 dmpk dmpk PROPN admet-338 133 44 4(4 4(4 NUM admet-338 133 45 ) ) PUNCT admet-338 133 46 ( ( PUNCT admet-338 133 47 2016 2016 NUM admet-338 133 48 ) ) PUNCT admet-338 133 49 335 335 NUM admet-338 133 50 - - SYM admet-338 133 51 360 360 NUM admet-338 133 52 344 344 NUM admet-338 133 53 table table NOUN admet-338 133 54 1 1 NUM admet-338 133 55 . . PUNCT admet-338 134 1 ( ( PUNCT admet-338 134 2 continued continue VERB admet-338 134 3 ) ) PUNCT admet-338 134 4 drug drug NOUN admet-338 134 5 mw mw X admet-338 134 6 ( ( PUNCT admet-338 134 7 free free ADJ admet-338 134 8 form form NOUN admet-338 134 9 ) ) PUNCT admet-338 134 10 psa psa VERB admet-338 134 11 b b PROPN admet-338 134 12 hbd hbd PROPN admet-338 134 13 b b PROPN admet-338 134 14 hba hba PROPN admet-338 134 15 b b PROPN admet-338 134 16 nc nc PROPN admet-338 134 17 a a DET admet-338 134 18 ph ph PROPN admet-338 134 19 7.4 7.4 NUM admet-338 134 20 pka pka PROPN admet-338 134 21 b b PROPN admet-338 134 22 log log NOUN admet-338 134 23 d6.5 d6.5 PROPN admet-338 134 24 b b X admet-338 134 25 highest high ADJ admet-338 134 26 dose dose NOUN admet-338 134 27 strength strength NOUN admet-338 134 28 ( ( PUNCT admet-338 134 29 mg mg PROPN admet-338 134 30 ) ) PUNCT admet-338 134 31 c c NOUN admet-338 134 32 solubility solubility NOUN admet-338 134 33 in in ADP admet-338 134 34 water water NOUN admet-338 134 35 ( ( PUNCT admet-338 134 36 mg mg PROPN admet-338 134 37 / / SYM admet-338 134 38 ml ml NOUN admet-338 134 39 ) ) PUNCT admet-338 135 1 c c NOUN admet-338 135 2 do do AUX admet-338 135 3 t1/2 t1/2 VERB admet-338 135 4 ( ( PUNCT admet-338 135 5 h h NOUN admet-338 135 6 ) ) PUNCT admet-338 135 7 c c PROPN admet-338 135 8 bcs bcs NOUN admet-338 135 9 class class PROPN admet-338 135 10 rizatriptan rizatriptan PROPN admet-338 135 11 benzoate benzoate NOUN admet-338 135 12 269 269 NUM admet-338 135 13 50 50 NUM admet-338 135 14 1 1 NUM admet-338 135 15 5 5 NUM admet-338 135 16 1.0 1.0 NUM admet-338 135 17 9.5 9.5 NUM admet-338 135 18 ( ( PUNCT admet-338 135 19 b b NOUN admet-338 135 20 ) ) PUNCT admet-338 135 21 -0.70 -0.70 NOUN admet-338 135 22 10 10 NUM admet-338 135 23 34 34 NUM admet-338 135 24 0.00118 0.00118 NUM admet-338 135 25 1.7 1.7 NUM admet-338 135 26 1 1 NUM admet-338 135 27 sarpogrelate sarpogrelate NOUN admet-338 135 28 hydrochloride hydrochloride NOUN admet-338 135 29 430 430 NUM admet-338 135 30 85 85 NUM admet-338 135 31 1 1 NUM admet-338 135 32 7 7 NUM admet-338 135 33 -0.2 -0.2 NUM admet-338 135 34 4.3 4.3 NUM admet-338 135 35 ( ( PUNCT admet-338 135 36 a a NOUN admet-338 135 37 ) ) PUNCT admet-338 135 38 , , PUNCT admet-338 135 39 8.1 8.1 NUM admet-338 135 40 ( ( PUNCT admet-338 135 41 b b NOUN admet-338 135 42 ) ) PUNCT admet-338 135 43 1.37 1.37 NUM admet-338 135 44 100 100 NUM admet-338 135 45 1 1 NUM admet-338 135 46 0.4 0.4 NUM admet-338 135 47 0.8 0.8 NUM admet-338 135 48 1 1 NUM admet-338 135 49 selegiline selegiline ADJ admet-338 135 50 hydrochloride hydrochloride NOUN admet-338 135 51 187 187 NUM admet-338 135 52 3 3 NUM admet-338 135 53 0 0 NUM admet-338 135 54 1 1 NUM admet-338 135 55 0.6 0.6 NUM admet-338 135 56 7.5 7.5 NUM admet-338 135 57 ( ( PUNCT admet-338 135 58 b b NOUN admet-338 135 59 ) ) PUNCT admet-338 135 60 1.81 1.81 NUM admet-338 135 61 2.5 2.5 NUM admet-338 135 62 1667 1667 NUM admet-338 135 63 6.0 6.0 NUM admet-338 135 64 Γ— Γ— NOUN admet-338 135 65 10 10 NUM admet-338 135 66 -6 -6 NOUN admet-338 135 67 5.3 5.3 NUM admet-338 135 68 1 1 NUM admet-338 135 69 sertraline sertraline NOUN admet-338 135 70 hydrochloride hydrochloride NOUN admet-338 135 71 306 306 NUM admet-338 135 72 12 12 NUM admet-338 135 73 1 1 NUM admet-338 135 74 1 1 NUM admet-338 135 75 1.0 1.0 NUM admet-338 135 76 9.5 9.5 NUM admet-338 135 77 ( ( PUNCT admet-338 135 78 b b NOUN admet-338 135 79 ) ) PUNCT admet-338 135 80 2.45 2.45 NUM admet-338 135 81 100 100 NUM admet-338 135 82 2.70 2.70 NUM admet-338 135 83 0.148 0.148 NUM admet-338 135 84 25.1 25.1 NUM admet-338 135 85 1 1 NUM admet-338 135 86 sildenafil sildenafil NOUN admet-338 135 87 citrate citrate NOUN admet-338 135 88 475 475 NUM admet-338 135 89 118 118 NUM admet-338 135 90 1 1 NUM admet-338 135 91 10 10 NUM admet-338 135 92 0.0 0.0 NUM admet-338 135 93 – – PUNCT admet-338 135 94 1.85 1.85 NUM admet-338 135 95 50 50 NUM admet-338 135 96 1 1 NUM admet-338 135 97 0.2 0.2 NUM admet-338 135 98 1.6 1.6 NUM admet-338 135 99 1 1 NUM admet-338 135 100 simvastatin simvastatin NOUN admet-338 135 101 419 419 NUM admet-338 135 102 73 73 NUM admet-338 135 103 1 1 NUM admet-338 135 104 5 5 NUM admet-338 135 105 0.0 0.0 NUM admet-338 135 106 – – PUNCT admet-338 135 107 4.60 4.60 NUM admet-338 135 108 20 20 NUM admet-338 135 109 0.01 0.01 NUM admet-338 135 110 8 8 NUM admet-338 135 111 2.3 2.3 NUM admet-338 135 112 2 2 NUM admet-338 135 113 solifenacin solifenacin NOUN admet-338 135 114 succinate succinate NOUN admet-338 135 115 362 362 NUM admet-338 135 116 171 171 NUM admet-338 135 117 5 5 NUM admet-338 135 118 12 12 NUM admet-338 135 119 1.0 1.0 NUM admet-338 135 120 9.0 9.0 NUM admet-338 135 121 ( ( PUNCT admet-338 135 122 b b NOUN admet-338 135 123 ) ) PUNCT admet-338 135 124 1.36 1.36 NUM admet-338 135 125 5 5 NUM admet-338 135 126 610 610 NUM admet-338 135 127 3.28 3.28 NUM admet-338 135 128 Γ— Γ— NOUN admet-338 135 129 10 10 NUM admet-338 135 130 -5 -5 NUM admet-338 135 131 46.5 46.5 NUM admet-338 135 132 1 1 NUM admet-338 135 133 sultamicillin sultamicillin NOUN admet-338 135 134 tosilate tosilate NOUN admet-338 135 135 595 595 NUM admet-338 135 136 216 216 NUM admet-338 135 137 3 3 NUM admet-338 135 138 13 13 NUM admet-338 135 139 0.2 0.2 NUM admet-338 135 140 6.8 6.8 NUM admet-338 135 141 ( ( PUNCT admet-338 135 142 b b NOUN admet-338 135 143 ) ) PUNCT admet-338 135 144 -0.46 -0.46 NUM admet-338 135 145 375 375 NUM admet-338 135 146 0.1 0.1 NUM admet-338 135 147 15 15 NUM admet-338 135 148 1.0 1.0 NUM admet-338 135 149 2 2 NUM admet-338 135 150 tacrolimus tacrolimus NOUN admet-338 135 151 hydrate hydrate NOUN admet-338 135 152 804 804 NUM admet-338 135 153 178 178 NUM admet-338 135 154 3 3 NUM admet-338 135 155 13 13 NUM admet-338 135 156 0.0 0.0 NUM admet-338 135 157 – – PUNCT admet-338 135 158 4.10 4.10 NUM admet-338 135 159 5 5 NUM admet-338 135 160 0.01 0.01 NUM admet-338 135 161 2 2 NUM admet-338 135 162 32.0 32.0 NUM admet-338 135 163 2 2 NUM admet-338 135 164 taltirelin taltirelin NOUN admet-338 135 165 hydrate hydrate NOUN admet-338 135 166 405 405 NUM admet-338 135 167 171 171 NUM admet-338 135 168 5 5 NUM admet-338 135 169 12 12 NUM admet-338 135 170 0.2 0.2 NUM admet-338 135 171 6.7 6.7 NUM admet-338 135 172 ( ( PUNCT admet-338 135 173 b b NOUN admet-338 135 174 ) ) PUNCT admet-338 135 175 -2.73 -2.73 NUM admet-338 135 176 5 5 NUM admet-338 135 177 208 208 NUM admet-338 135 178 9.6 9.6 NUM admet-338 135 179 Γ— Γ— NOUN admet-338 135 180 10 10 NUM admet-338 135 181 -5 -5 NUM admet-338 135 182 2 2 NUM admet-338 135 183 3 3 NUM admet-338 135 184 tamoxifen tamoxifen NOUN admet-338 135 185 citrate citrate NOUN admet-338 135 186 372 372 NUM admet-338 135 187 12 12 NUM admet-338 135 188 0 0 NUM admet-338 135 189 2 2 NUM admet-338 135 190 1.0 1.0 NUM admet-338 135 191 8.7 8.7 NUM admet-338 135 192 ( ( PUNCT admet-338 135 193 b b NOUN admet-338 135 194 ) ) PUNCT admet-338 135 195 4.68 4.68 NUM admet-338 135 196 20 20 NUM admet-338 135 197 0.09 0.09 NUM admet-338 135 198 0.889 0.889 NUM admet-338 135 199 27.2 27.2 NUM admet-338 135 200 1 1 NUM admet-338 135 201 tamsulosin tamsulosin NOUN admet-338 135 202 hydrochloride hydrochloride NOUN admet-338 135 203 409 409 NUM admet-338 135 204 108 108 NUM admet-338 135 205 3 3 NUM admet-338 135 206 7 7 NUM admet-338 135 207 1.0 1.0 NUM admet-338 135 208 8.8 8.8 NUM admet-338 135 209 ( ( PUNCT admet-338 135 210 b b NOUN admet-338 135 211 ) ) PUNCT admet-338 135 212 -0.06 -0.06 PROPN admet-338 135 213 0.2 0.2 NUM admet-338 135 214 11.8 11.8 NUM admet-338 135 215 6.76 6.76 NUM admet-338 135 216 Γ— Γ— NOUN admet-338 135 217 10 10 NUM admet-338 135 218 -5 -5 NUM admet-338 135 219 11.7 11.7 NUM admet-338 135 220 1 1 NUM admet-338 135 221 tegafur tegafur NOUN admet-338 135 222 200 200 NUM admet-338 135 223 59 59 NUM admet-338 135 224 1 1 NUM admet-338 135 225 5 5 NUM admet-338 135 226 -0.4 -0.4 NUM admet-338 135 227 7.6 7.6 NUM admet-338 135 228 ( ( PUNCT admet-338 135 229 a a NOUN admet-338 135 230 ) ) PUNCT admet-338 135 231 -0.43 -0.43 NUM admet-338 135 232 25 25 NUM admet-338 135 233 16.8 16.8 NUM admet-338 135 234 0.00595 0.00595 NUM admet-338 135 235 1.9 1.9 NUM admet-338 135 236 1 1 NUM admet-338 135 237 temocapril temocapril NOUN admet-338 135 238 hydrochloride hydrochloride NOUN admet-338 135 239 477 477 NUM admet-338 135 240 149 149 NUM admet-338 135 241 2 2 NUM admet-338 135 242 7 7 NUM admet-338 135 243 -1.0 -1.0 PROPN admet-338 135 244 3.7 3.7 NUM admet-338 135 245 ( ( PUNCT admet-338 135 246 a a PROPN admet-338 135 247 ) ) PUNCT admet-338 135 248 0.62 0.62 NUM admet-338 135 249 4 4 NUM admet-338 135 250 0.719 0.719 NUM admet-338 135 251 0.0223 0.0223 NUM admet-338 135 252 0.2 0.2 NUM admet-338 135 253 1 1 NUM admet-338 135 254 teprenone teprenone NOUN admet-338 135 255 331 331 NUM admet-338 135 256 17 17 NUM admet-338 135 257 0 0 NUM admet-338 135 258 1 1 NUM admet-338 135 259 0.0 0.0 NUM admet-338 135 260 – – PUNCT admet-338 135 261 7.40 7.40 NUM admet-338 135 262 50 50 NUM admet-338 135 263 8.32 8.32 NUM admet-338 135 264 0.0240 0.0240 NUM admet-338 135 265 1.8 1.8 NUM admet-338 135 266 1 1 NUM admet-338 135 267 terbinafine terbinafine NOUN admet-338 135 268 hydrochloride hydrochloride VERB admet-338 135 269 291 291 NUM admet-338 135 270 3 3 NUM admet-338 135 271 0 0 NUM admet-338 135 272 1 1 NUM admet-338 135 273 0.2 0.2 NUM admet-338 135 274 6.9 6.9 NUM admet-338 135 275 ( ( PUNCT admet-338 135 276 b b NOUN admet-338 135 277 ) ) PUNCT admet-338 135 278 5.45 5.45 NUM admet-338 135 279 125 125 NUM admet-338 135 280 5.07 5.07 NUM admet-338 135 281 0.0987 0.0987 NUM admet-338 135 282 6.2 6.2 NUM admet-338 135 283 1 1 NUM admet-338 135 284 ticlopidine ticlopidine NOUN admet-338 135 285 hydrochloride hydrochloride NOUN admet-338 135 286 264 264 NUM admet-338 135 287 31 31 NUM admet-338 135 288 0 0 NUM admet-338 135 289 1 1 NUM admet-338 135 290 0.3 0.3 NUM admet-338 135 291 7.1 7.1 NUM admet-338 135 292 ( ( PUNCT admet-338 135 293 b b NOUN admet-338 135 294 ) ) PUNCT admet-338 135 295 3.41 3.41 NUM admet-338 135 296 100 100 NUM admet-338 135 297 58.8 58.8 NUM admet-338 135 298 0.0068 0.0068 NUM admet-338 135 299 1.6 1.6 NUM admet-338 135 300 1 1 NUM admet-338 135 301 tocopherol tocopherol NOUN admet-338 135 302 nicotinate nicotinate NOUN admet-338 135 303 536 536 NUM admet-338 135 304 48 48 NUM admet-338 135 305 0 0 NUM admet-338 135 306 4 4 NUM admet-338 135 307 0.0 0.0 NUM admet-338 135 308 – – PUNCT admet-338 135 309 11.14 11.14 NUM admet-338 135 310 200 200 NUM admet-338 135 311 0.01 0.01 NUM admet-338 135 312 80 80 NUM admet-338 135 313 4.3 4.3 NUM admet-338 135 314 2 2 NUM admet-338 135 315 tramadol tramadol NOUN admet-338 135 316 hydrochloride hydrochloride NOUN admet-338 135 317 263 263 NUM admet-338 135 318 33 33 NUM admet-338 135 319 1 1 NUM admet-338 135 320 3 3 NUM admet-338 135 321 1.0 1.0 NUM admet-338 135 322 9.6 9.6 NUM admet-338 135 323 ( ( PUNCT admet-338 135 324 b b NOUN admet-338 135 325 ) ) PUNCT admet-338 135 326 -0.18 -0.18 NOUN admet-338 135 327 50 50 NUM admet-338 135 328 100 100 NUM admet-338 135 329 0.002 0.002 NUM admet-338 135 330 5.7 5.7 NUM admet-338 135 331 1 1 NUM admet-338 135 332 tulobuterol tulobuterol NOUN admet-338 135 333 hydrochloride hydrochloride NOUN admet-338 135 334 228 228 NUM admet-338 135 335 32 32 NUM admet-338 135 336 2 2 NUM admet-338 135 337 2 2 NUM admet-338 135 338 1.0 1.0 NUM admet-338 135 339 9.6 9.6 NUM admet-338 135 340 ( ( PUNCT admet-338 135 341 b b NOUN admet-338 135 342 ) ) PUNCT admet-338 135 343 -0.17 -0.17 NOUN admet-338 135 344 1 1 NUM admet-338 135 345 714 714 NUM admet-338 135 346 5.6 5.6 NUM admet-338 135 347 Γ— Γ— NOUN admet-338 135 348 10 10 NUM admet-338 135 349 -6 -6 NOUN admet-338 135 350 3.2 3.2 NUM admet-338 135 351 1 1 NUM admet-338 135 352 ursodeoxycholic ursodeoxycholic NOUN admet-338 135 353 acid acid NOUN admet-338 135 354 393 393 NUM admet-338 135 355 78 78 NUM admet-338 135 356 3 3 NUM admet-338 135 357 4 4 NUM admet-338 135 358 -1.0 -1.0 PROPN admet-338 135 359 4.8 4.8 NUM admet-338 135 360 ( ( PUNCT admet-338 135 361 a a X admet-338 135 362 ) ) PUNCT admet-338 135 363 2.01 2.01 NUM admet-338 135 364 100 100 NUM admet-338 135 365 0.01 0.01 NUM admet-338 135 366 40 40 NUM admet-338 135 367 1.1 1.1 NUM admet-338 135 368 2 2 NUM admet-338 135 369 valacyclovir valacyclovir NOUN admet-338 135 370 hydrochloride hydrochloride VERB admet-338 135 371 324 324 NUM admet-338 135 372 147 147 NUM admet-338 135 373 5 5 NUM admet-338 135 374 10 10 NUM admet-338 135 375 0.7 0.7 NUM admet-338 135 376 7.8 7.8 NUM admet-338 135 377 ( ( PUNCT admet-338 135 378 b b NOUN admet-338 135 379 ) ) PUNCT admet-338 135 380 -1.78 -1.78 ADP admet-338 135 381 500 500 NUM admet-338 135 382 100 100 NUM admet-338 135 383 0.02 0.02 NUM admet-338 135 384 3.0 3.0 NUM admet-338 135 385 3 3 NUM admet-338 135 386 valproate valproate ADJ admet-338 135 387 sodium sodium NOUN admet-338 135 388 144 144 NUM admet-338 135 389 37 37 NUM admet-338 135 390 1 1 NUM admet-338 135 391 2 2 NUM admet-338 135 392 -1.0 -1.0 PROPN admet-338 135 393 4.8 4.8 NUM admet-338 135 394 ( ( PUNCT admet-338 135 395 a a NOUN admet-338 135 396 ) ) PUNCT admet-338 135 397 0.97 0.97 NUM admet-338 135 398 200 200 NUM admet-338 135 399 1000 1000 NUM admet-338 135 400 0.0008 0.0008 NUM admet-338 135 401 9.5 9.5 NUM admet-338 135 402 1 1 NUM admet-338 135 403 valsartan valsartan VERB admet-338 135 404 436 436 NUM admet-338 135 405 112 112 NUM admet-338 135 406 2 2 NUM admet-338 135 407 8 8 NUM admet-338 135 408 -2.0 -2.0 X admet-338 135 409 3.6 3.6 NUM admet-338 135 410 ( ( PUNCT admet-338 135 411 a a NOUN admet-338 135 412 ) ) PUNCT admet-338 135 413 , , PUNCT admet-338 135 414 4.2 4.2 NUM admet-338 135 415 ( ( PUNCT admet-338 135 416 a a NOUN admet-338 135 417 ) ) PUNCT admet-338 135 418 -0.71 -0.71 NOUN admet-338 135 419 160 160 NUM admet-338 135 420 0.17 0.17 NUM admet-338 135 421 3.76 3.76 NUM admet-338 135 422 7.7 7.7 NUM admet-338 135 423 2 2 NUM admet-338 135 424 admet admet NOUN admet-338 135 425 & & CCONJ admet-338 135 426 dmpk dmpk PROPN admet-338 135 427 4(4 4(4 NUM admet-338 135 428 ) ) PUNCT admet-338 135 429 ( ( PUNCT admet-338 135 430 2016 2016 NUM admet-338 135 431 ) ) PUNCT admet-338 135 432 335 335 NUM admet-338 135 433 - - SYM admet-338 135 434 360 360 NUM admet-338 135 435 biopharmaceutical biopharmaceutical NOUN admet-338 135 436 and and CCONJ admet-338 135 437 physchem physchem NOUN admet-338 135 438 properties property NOUN admet-338 135 439 for for ADP admet-338 135 440 odt odt ADJ admet-338 135 441 doi doi NOUN admet-338 135 442 : : PUNCT admet-338 135 443 10.5599 10.5599 NUM admet-338 135 444 / / SYM admet-338 135 445 admet.4.4.331 admet.4.4.331 PROPN admet-338 135 446 345 345 NUM admet-338 135 447 table table NOUN admet-338 135 448 1 1 NUM admet-338 135 449 . . PUNCT admet-338 136 1 ( ( PUNCT admet-338 136 2 continued continue VERB admet-338 136 3 ) ) PUNCT admet-338 136 4 drug drug NOUN admet-338 136 5 mw mw X admet-338 136 6 ( ( PUNCT admet-338 136 7 free free ADJ admet-338 136 8 form form NOUN admet-338 136 9 ) ) PUNCT admet-338 136 10 psa psa VERB admet-338 136 11 b b PROPN admet-338 136 12 hbd hbd PROPN admet-338 136 13 b b PROPN admet-338 136 14 hba hba PROPN admet-338 136 15 b b PROPN admet-338 136 16 nc nc PROPN admet-338 136 17 a a DET admet-338 136 18 ph ph PROPN admet-338 136 19 7.4 7.4 NUM admet-338 136 20 pka pka PROPN admet-338 136 21 b b PROPN admet-338 136 22 log log NOUN admet-338 136 23 d6.5 d6.5 PROPN admet-338 136 24 b b X admet-338 136 25 highest high ADJ admet-338 136 26 dose dose NOUN admet-338 136 27 strength strength NOUN admet-338 136 28 ( ( PUNCT admet-338 136 29 mg mg PROPN admet-338 136 30 ) ) PUNCT admet-338 136 31 c c NOUN admet-338 136 32 solubility solubility NOUN admet-338 136 33 in in ADP admet-338 136 34 water water NOUN admet-338 136 35 ( ( PUNCT admet-338 136 36 mg mg PROPN admet-338 136 37 / / SYM admet-338 136 38 ml ml NOUN admet-338 136 39 ) ) PUNCT admet-338 137 1 c c AUX admet-338 137 2 do do AUX admet-338 137 3 t1/2 t1/2 VERB admet-338 137 4 ( ( PUNCT admet-338 137 5 h h NOUN admet-338 137 6 ) ) PUNCT admet-338 137 7 c c NOUN admet-338 137 8 bcs bcs NOUN admet-338 137 9 class class NOUN admet-338 137 10 voglibose voglibose NOUN admet-338 137 11 267 267 NUM admet-338 137 12 154 154 NUM admet-338 137 13 8 8 NUM admet-338 137 14 8 8 NUM admet-338 137 15 0.2 0.2 NUM admet-338 137 16 6.8 6.8 NUM admet-338 137 17 ( ( PUNCT admet-338 137 18 b b NOUN admet-338 137 19 ) ) PUNCT admet-338 137 20 -3.57 -3.57 VERB admet-338 137 21 0.3 0.3 NUM admet-338 137 22 1000 1000 NUM admet-338 137 23 1.2 1.2 NUM admet-338 137 24 Γ— Γ— NOUN admet-338 137 25 10 10 NUM admet-338 137 26 -6 -6 NOUN admet-338 137 27 5.3 5.3 NUM admet-338 137 28 3 3 NUM admet-338 137 29 zolmitriptan zolmitriptan PROPN admet-338 137 30 287 287 NUM admet-338 137 31 57 57 NUM admet-338 137 32 2 2 NUM admet-338 137 33 5 5 NUM admet-338 137 34 1.0 1.0 NUM admet-338 137 35 9.5 9.5 NUM admet-338 137 36 ( ( PUNCT admet-338 137 37 b b NOUN admet-338 137 38 ) ) PUNCT admet-338 137 39 -0.29 -0.29 NOUN admet-338 137 40 2.5 2.5 NUM admet-338 137 41 0.1 0.1 NUM admet-338 137 42 0.1 0.1 NUM admet-338 137 43 2.9 2.9 NUM admet-338 137 44 1 1 NUM admet-338 137 45 zolpidem zolpidem NOUN admet-338 137 46 tartrate tartrate NOUN admet-338 137 47 307 307 NUM admet-338 137 48 38 38 NUM admet-338 137 49 0 0 NUM admet-338 137 50 4 4 NUM admet-338 137 51 0.2 0.2 NUM admet-338 137 52 6.8 6.8 NUM admet-338 137 53 ( ( PUNCT admet-338 137 54 b b NOUN admet-338 137 55 ) ) PUNCT admet-338 137 56 2.78 2.78 NUM admet-338 137 57 10 10 NUM admet-338 137 58 8.9 8.9 NUM admet-338 137 59 0.00449 0.00449 NUM admet-338 137 60 1.9 1.9 NUM admet-338 137 61 1 1 NUM admet-338 137 62 zonizamide zonizamide ADP admet-338 137 63 212 212 NUM admet-338 137 64 95 95 NUM admet-338 137 65 2 2 NUM admet-338 137 66 5 5 NUM admet-338 137 67 0.0 0.0 NUM admet-338 137 68 – – PUNCT admet-338 137 69 0.45 0.45 NUM admet-338 137 70 25 25 NUM admet-338 137 71 0.270 0.270 NUM admet-338 137 72 0.37 0.37 NUM admet-338 137 73 119.1 119.1 NUM admet-338 137 74 1 1 NUM admet-338 137 75 nd nd NOUN admet-338 137 76 = = NOUN admet-338 137 77 no no DET admet-338 137 78 data data NOUN admet-338 137 79 . . PUNCT admet-338 138 1 uc uc ADJ admet-338 138 2 = = PUNCT admet-338 138 3 unclassifiable unclassifiable ADJ admet-338 138 4 . . PUNCT admet-338 139 1 a a DET admet-338 139 2 net net ADJ admet-338 139 3 charge charge NOUN admet-338 139 4 at at ADP admet-338 139 5 ph ph PROPN admet-338 139 6 7.4 7.4 NUM admet-338 139 7 calculated calculate VERB admet-338 139 8 by by ADP admet-338 139 9 eq eq PROPN admet-338 139 10 . . PROPN admet-338 139 11 1 1 NUM admet-338 139 12 . . X admet-338 139 13 b b NUM admet-338 139 14 calculated calculate VERB admet-338 139 15 value value NOUN admet-338 139 16 ( ( PUNCT admet-338 139 17 acd acd NOUN admet-338 139 18 / / SYM admet-338 139 19 labs labs PROPN admet-338 139 20 software software VERB admet-338 139 21 v v ADP admet-338 139 22 14.0.0 14.0.0 NUM admet-338 139 23 ) ) PUNCT admet-338 139 24 . . PUNCT admet-338 140 1 c c PROPN admet-338 140 2 data datum NOUN admet-338 140 3 from from ADP admet-338 140 4 prescription prescription NOUN admet-338 140 5 information information NOUN admet-338 140 6 ( ( PUNCT admet-338 140 7 supplement supplement NOUN admet-338 140 8 tables table NOUN admet-338 140 9 1 1 NUM admet-338 140 10 and and CCONJ admet-338 140 11 2 2 NUM admet-338 140 12 ) ) PUNCT admet-338 140 13 otherwise otherwise ADV admet-338 140 14 noted note VERB admet-338 140 15 . . PUNCT admet-338 141 1 d d X admet-338 141 2 underscored underscore VERB admet-338 141 3 drugs drug NOUN admet-338 141 4 correspond correspond VERB admet-338 141 5 to to PART admet-338 141 6 odts odts VERB admet-338 141 7 . . PUNCT admet-338 142 1 e e VERB admet-338 142 2 drugs drug NOUN admet-338 142 3 in in ADP admet-338 142 4 italics italic NOUN admet-338 142 5 correspond correspond VERB admet-338 142 6 to to ADP admet-338 142 7 ir ir PROPN admet-338 142 8 formulations formulation NOUN admet-338 142 9 . . PUNCT admet-338 143 1 f f PROPN admet-338 143 2 reference reference NOUN admet-338 143 3 [ [ X admet-338 143 4 12 12 NUM admet-338 143 5 ] ] X admet-338 143 6 admet admet PROPN admet-338 143 7 & & CCONJ admet-338 143 8 dmpk dmpk PROPN admet-338 143 9 4(4 4(4 NUM admet-338 143 10 ) ) PUNCT admet-338 143 11 ( ( PUNCT admet-338 143 12 2016 2016 NUM admet-338 143 13 ) ) PUNCT admet-338 143 14 335 335 NUM admet-338 143 15 - - SYM admet-338 143 16 360 360 NUM admet-338 143 17 biopharmaceutical biopharmaceutical NOUN admet-338 143 18 and and CCONJ admet-338 143 19 physchem physchem NOUN admet-338 143 20 properties property NOUN admet-338 143 21 for for ADP admet-338 143 22 odt odt ADJ admet-338 143 23 doi doi NOUN admet-338 143 24 : : PUNCT admet-338 143 25 10.5599 10.5599 NUM admet-338 143 26 / / SYM admet-338 143 27 admet.4.4.338 admet.4.4.338 VERB admet-338 143 28 346 346 NUM admet-338 143 29 table table NOUN admet-338 143 30 2 2 NUM admet-338 143 31 . . PUNCT admet-338 144 1 minimum minimum ADJ admet-338 144 2 , , PUNCT admet-338 144 3 maximum maximum ADJ admet-338 144 4 , , PUNCT admet-338 144 5 and and CCONJ admet-338 144 6 median median NOUN admet-338 144 7 of of ADP admet-338 144 8 biopharmaceutical biopharmaceutical ADJ admet-338 144 9 properties property NOUN admet-338 144 10 of of ADP admet-338 144 11 odt odt NOUN admet-338 144 12 and and CCONJ admet-338 144 13 ir ir PROPN admet-338 144 14 formulation formulation NOUN admet-338 144 15 drugs drug NOUN admet-338 144 16 . . PUNCT admet-338 145 1 biopharmaceutical biopharmaceutical ADJ admet-338 145 2 properties property NOUN admet-338 145 3 odt odt VERB admet-338 145 4 ir ir PROPN admet-338 145 5 formulation formulation NOUN admet-338 145 6 mw mw NOUN admet-338 145 7 of of ADP admet-338 145 8 free free ADJ admet-338 145 9 form form NOUN admet-338 145 10 n n CCONJ admet-338 145 11 56 56 NUM admet-338 145 12 113 113 NUM admet-338 145 13 median median NOUN admet-338 145 14 359 359 NUM admet-338 145 15 371 371 NUM admet-338 145 16 min min NOUN admet-338 145 17 . . PROPN admet-338 145 18 – – PUNCT admet-338 145 19 max max PROPN admet-338 145 20 . . PROPN admet-338 145 21 146 146 NUM admet-338 145 22 – – PUNCT admet-338 145 23 1069 1069 NUM admet-338 145 24 136 136 NUM admet-338 145 25 – – PUNCT admet-338 145 26 1344 1344 NUM admet-338 145 27 psa psa VERB admet-338 145 28 n n PROPN admet-338 145 29 56 56 NUM admet-338 145 30 111 111 NUM admet-338 145 31 median median NOUN admet-338 145 32 70 70 NUM admet-338 145 33 84 84 NUM admet-338 145 34 min min NOUN admet-338 145 35 . . PROPN admet-338 145 36 – – PUNCT admet-338 145 37 max max PROPN admet-338 145 38 . . PROPN admet-338 145 39 3 3 NUM admet-338 145 40 – – PUNCT admet-338 145 41 486 486 NUM admet-338 145 42 3 3 NUM admet-338 145 43 – – PUNCT admet-338 145 44 321 321 NUM admet-338 145 45 hbd hbd NOUN admet-338 145 46 n n CCONJ admet-338 145 47 56 56 NUM admet-338 145 48 111 111 NUM admet-338 145 49 median median NOUN admet-338 145 50 1 1 NUM admet-338 145 51 2 2 NUM admet-338 145 52 min min NOUN admet-338 145 53 . . PROPN admet-338 145 54 – – PUNCT admet-338 145 55 max max PROPN admet-338 145 56 . . PROPN admet-338 145 57 0 0 NUM admet-338 146 1 – – PUNCT admet-338 146 2 18 18 NUM admet-338 146 3 0 0 NUM admet-338 146 4 – – PUNCT admet-338 146 5 14 14 NUM admet-338 146 6 hba hba NOUN admet-338 146 7 n n CCONJ admet-338 146 8 56 56 NUM admet-338 146 9 111 111 NUM admet-338 146 10 median median NOUN admet-338 146 11 5 5 NUM admet-338 146 12 6 6 NUM admet-338 146 13 min min NOUN admet-338 146 14 . . PROPN admet-338 146 15 – – PUNCT admet-338 146 16 max max PROPN admet-338 146 17 . . PROPN admet-338 146 18 1 1 NUM admet-338 146 19 – – SYM admet-338 146 20 26 26 NUM admet-338 146 21 1 1 NUM admet-338 146 22 – – PUNCT admet-338 146 23 23 23 NUM admet-338 146 24 nc nc NOUN admet-338 146 25 a a DET admet-338 146 26 ph ph PROPN admet-338 146 27 7.4 7.4 NUM admet-338 146 28 n n DET admet-338 146 29 56 56 NUM admet-338 146 30 111 111 NUM admet-338 146 31 median median NOUN admet-338 146 32 0.2 0.2 NUM admet-338 146 33 0.0 0.0 NUM admet-338 146 34 min min NOUN admet-338 146 35 . . PROPN admet-338 146 36 – – PUNCT admet-338 146 37 max max PROPN admet-338 146 38 . . PUNCT admet-338 147 1 -2.0 -2.0 PROPN admet-338 147 2 – – PUNCT admet-338 147 3 1.0 1.0 NUM admet-338 147 4 -3.0 -3.0 NOUN admet-338 147 5 – – PUNCT admet-338 147 6 1.8 1.8 NUM admet-338 147 7 log log NOUN admet-338 147 8 d6.5 d6.5 PUNCT admet-338 147 9 n n CCONJ admet-338 147 10 56 56 NUM admet-338 147 11 111 111 NUM admet-338 147 12 median median NOUN admet-338 147 13 1.02 1.02 NUM admet-338 147 14 0.97 0.97 NUM admet-338 147 15 min min NOUN admet-338 147 16 . . PROPN admet-338 147 17 – – PUNCT admet-338 147 18 max max PROPN admet-338 147 19 . . PUNCT admet-338 148 1 -7.34 -7.34 ADJ admet-338 148 2 – – PUNCT admet-338 148 3 5.49 5.49 NUM admet-338 148 4 -8.44 -8.44 NOUN admet-338 148 5 – – PUNCT admet-338 148 6 11.14 11.14 NUM admet-338 148 7 the the DET admet-338 148 8 highest high ADJ admet-338 148 9 dose dose NOUN admet-338 148 10 strength strength NOUN admet-338 148 11 ( ( PUNCT admet-338 148 12 mg mg PROPN admet-338 148 13 ) ) PUNCT admet-338 148 14 n n PRON admet-338 148 15 57 57 NUM admet-338 148 16 113 113 NUM admet-338 148 17 median median NOUN admet-338 148 18 10 10 NUM admet-338 148 19 30 30 NUM admet-338 148 20 min min NOUN admet-338 148 21 . . PROPN admet-338 148 22 – – PUNCT admet-338 148 23 max max PROPN admet-338 148 24 . . PROPN admet-338 148 25 0.005 0.005 NUM admet-338 148 26 – – PUNCT admet-338 148 27 200 200 NUM admet-338 148 28 0.003 0.003 NUM admet-338 148 29 – – PUNCT admet-338 148 30 900 900 NUM admet-338 148 31 solubility solubility NOUN admet-338 148 32 in in ADP admet-338 148 33 water water NOUN admet-338 148 34 ( ( PUNCT admet-338 148 35 mg mg PROPN admet-338 148 36 / / SYM admet-338 148 37 ml ml NOUN admet-338 148 38 ) ) PUNCT admet-338 148 39 n n PRON admet-338 148 40 57 57 NUM admet-338 148 41 113 113 NUM admet-338 148 42 median median NOUN admet-338 148 43 1.43 1.43 NUM admet-338 148 44 3.33 3.33 NUM admet-338 148 45 min min NOUN admet-338 148 46 . . PROPN admet-338 148 47 – – PUNCT admet-338 148 48 max max PROPN admet-338 148 49 . . PROPN admet-338 148 50 0.003 0.003 NUM admet-338 148 51 – – PUNCT admet-338 148 52 1667 1667 NUM admet-338 148 53 0.0012 0.0012 NUM admet-338 148 54 – – PUNCT admet-338 148 55 1429 1429 NUM admet-338 148 56 do do AUX admet-338 148 57 n n PROPN admet-338 148 58 57 57 NUM admet-338 148 59 113 113 NUM admet-338 148 60 median median NOUN admet-338 148 61 0.1 0.1 NUM admet-338 148 62 0.04 0.04 NUM admet-338 148 63 min min NOUN admet-338 148 64 . . PROPN admet-338 148 65 – – PUNCT admet-338 148 66 max max PROPN admet-338 148 67 . . PROPN admet-338 149 1 3.48 3.48 NUM admet-338 149 2 Γ— Γ— NOUN admet-338 149 3 10 10 NUM admet-338 149 4 - - SYM admet-338 149 5 8 8 NUM admet-338 149 6 – – PUNCT admet-338 149 7 66.7 66.7 NUM admet-338 149 8 5.4 5.4 NUM admet-338 149 9 Γ— Γ— NOUN admet-338 149 10 10 10 NUM admet-338 149 11 - - SYM admet-338 149 12 8 8 NUM admet-338 149 13 – – PUNCT admet-338 149 14 375 375 NUM admet-338 149 15 elimination elimination NOUN admet-338 149 16 t1/2 t1/2 NOUN admet-338 149 17 ( ( PUNCT admet-338 149 18 h h NOUN admet-338 149 19 ) ) PUNCT admet-338 149 20 n n PRON admet-338 149 21 57 57 NUM admet-338 149 22 113 113 NUM admet-338 149 23 median median NOUN admet-338 149 24 6.7 6.7 NUM admet-338 149 25 3.3 3.3 NUM admet-338 149 26 min min NOUN admet-338 149 27 . . PROPN admet-338 149 28 – – PUNCT admet-338 149 29 max max PROPN admet-338 149 30 . . PROPN admet-338 149 31 0.9 0.9 NUM admet-338 149 32 – – PUNCT admet-338 149 33 128 128 NUM admet-338 149 34 0.2 0.2 NUM admet-338 149 35 – – PUNCT admet-338 149 36 70.7 70.7 NUM admet-338 149 37 a a DET admet-338 149 38 net net ADJ admet-338 149 39 charge charge NOUN admet-338 149 40 at at ADP admet-338 149 41 ph ph PROPN admet-338 149 42 7.4 7.4 NUM admet-338 149 43 calculated calculate VERB admet-338 149 44 by by ADP admet-338 149 45 eq eq PROPN admet-338 149 46 . . PROPN admet-338 149 47 1 1 X admet-338 149 48 . . X admet-338 149 49 figure figure NOUN admet-338 149 50 2 2 NUM admet-338 149 51 . . PUNCT admet-338 149 52 provisional provisional ADJ admet-338 149 53 bcs bcs NOUN admet-338 149 54 classification classification NOUN admet-338 149 55 of of ADP admet-338 149 56 drugs drug NOUN admet-338 149 57 in in ADP admet-338 149 58 odts odts NOUN admet-338 149 59 and and CCONJ admet-338 149 60 ir ir PROPN admet-338 149 61 formulations formulation NOUN admet-338 149 62 . . PUNCT admet-338 150 1 0 0 NUM admet-338 150 2 10 10 NUM admet-338 150 3 20 20 NUM admet-338 150 4 30 30 NUM admet-338 150 5 40 40 NUM admet-338 150 6 50 50 NUM admet-338 150 7 60 60 NUM admet-338 150 8 p p X admet-338 150 9 e e X admet-338 150 10 rc rc PROPN admet-338 150 11 e e PROPN admet-338 150 12 n n X admet-338 150 13 ta ta X admet-338 150 14 ge ge PROPN admet-338 151 1 o o X admet-338 151 2 f f PROPN admet-338 152 1 d d X admet-338 152 2 ru ru X admet-338 152 3 gs gs PROPN admet-338 153 1 w w NOUN admet-338 153 2 it it PRON admet-338 153 3 h h NOUN admet-338 153 4 in in ADP admet-338 153 5 b b PROPN admet-338 153 6 c c NOUN admet-338 153 7 s s X admet-338 153 8 cl cl NOUN admet-338 153 9 as as ADP admet-338 153 10 s s NOUN admet-338 153 11 odt odt X admet-338 153 12 ir ir PROPN admet-338 153 13 formulation formulation PROPN admet-338 153 14 admet admet PROPN admet-338 153 15 & & CCONJ admet-338 153 16 dmpk dmpk PROPN admet-338 153 17 4(4 4(4 NUM admet-338 153 18 ) ) PUNCT admet-338 153 19 ( ( PUNCT admet-338 153 20 2016 2016 NUM admet-338 153 21 ) ) PUNCT admet-338 153 22 335 335 NUM admet-338 153 23 - - SYM admet-338 153 24 360 360 NUM admet-338 153 25 biopharmaceutical biopharmaceutical NOUN admet-338 153 26 and and CCONJ admet-338 153 27 physchem physchem NOUN admet-338 153 28 properties property NOUN admet-338 153 29 for for ADP admet-338 153 30 odt odt ADJ admet-338 153 31 doi doi NOUN admet-338 153 32 : : PUNCT admet-338 153 33 10.5599 10.5599 NUM admet-338 153 34 / / SYM admet-338 153 35 admet.4.4.338 admet.4.4.338 VERB admet-338 153 36 347 347 NUM admet-338 153 37 discussion discussion NOUN admet-338 153 38 a a DET admet-338 153 39 significant significant ADJ admet-338 153 40 difference difference NOUN admet-338 153 41 was be AUX admet-338 153 42 seen see VERB admet-338 153 43 in in ADP admet-338 153 44 the the DET admet-338 153 45 highest high ADJ admet-338 153 46 dose dose NOUN admet-338 153 47 strength strength NOUN admet-338 153 48 between between ADP admet-338 153 49 the the DET admet-338 153 50 odt odt NOUN admet-338 153 51 and and CCONJ admet-338 153 52 ir ir PROPN admet-338 153 53 formulation formulation NOUN admet-338 153 54 . . PUNCT admet-338 154 1 the the DET admet-338 154 2 odt odt NOUN admet-338 154 3 would would AUX admet-338 154 4 have have VERB admet-338 154 5 to to PART admet-338 154 6 have have VERB admet-338 154 7 a a DET admet-338 154 8 feasible feasible ADJ admet-338 154 9 tablet tablet NOUN admet-338 154 10 size size NOUN admet-338 154 11 and and CCONJ admet-338 154 12 drug drug NOUN admet-338 154 13 loading loading NOUN admet-338 154 14 [ [ X admet-338 154 15 13,14 13,14 NUM admet-338 154 16 ] ] PUNCT admet-338 154 17 . . PUNCT admet-338 155 1 therefore therefore ADV admet-338 155 2 , , PUNCT admet-338 155 3 a a DET admet-338 155 4 drug drug NOUN admet-338 155 5 with with ADP admet-338 155 6 a a DET admet-338 155 7 high high ADJ admet-338 155 8 dose dose NOUN admet-338 155 9 strength strength NOUN admet-338 155 10 ( ( PUNCT admet-338 155 11 > > NOUN admet-338 155 12 200 200 NUM admet-338 155 13 mg mg NOUN admet-338 155 14 ) ) PUNCT admet-338 155 15 would would AUX admet-338 155 16 be be AUX admet-338 155 17 less less ADV admet-338 155 18 suitable suitable ADJ admet-338 155 19 an an DET admet-338 155 20 odt odt NOUN admet-338 155 21 . . PUNCT admet-338 156 1 there there PRON admet-338 156 2 was be VERB admet-338 156 3 no no DET admet-338 156 4 significant significant ADJ admet-338 156 5 difference difference NOUN admet-338 156 6 in in ADP admet-338 156 7 the the DET admet-338 156 8 solubility solubility NOUN admet-338 156 9 in in ADP admet-338 156 10 water water NOUN admet-338 156 11 and and CCONJ admet-338 156 12 do do VERB admet-338 156 13 between between ADP admet-338 156 14 the the DET admet-338 156 15 odt odt NOUN admet-338 156 16 and and CCONJ admet-338 156 17 ir ir PROPN admet-338 156 18 formulation formulation NOUN admet-338 156 19 . . PUNCT admet-338 157 1 this this DET admet-338 157 2 result result NOUN admet-338 157 3 suggests suggest VERB admet-338 157 4 that that SCONJ admet-338 157 5 many many ADJ admet-338 157 6 drugs drug NOUN admet-338 157 7 can can AUX admet-338 157 8 be be AUX admet-338 157 9 developed develop VERB admet-338 157 10 as as ADP admet-338 157 11 an an DET admet-338 157 12 odt odt NOUN admet-338 157 13 regardless regardless ADV admet-338 157 14 of of ADP admet-338 157 15 their their PRON admet-338 157 16 solubility solubility NOUN admet-338 157 17 and and CCONJ admet-338 157 18 do do VERB admet-338 157 19 ( ( PUNCT admet-338 157 20 e.g. e.g. ADV admet-338 157 21 , , PUNCT admet-338 157 22 bicalutamide bicalutamide VERB admet-338 157 23 : : PUNCT admet-338 157 24 s s PART admet-338 157 25 = = NOUN admet-338 157 26 0.01 0.01 NUM admet-338 157 27 mg mg PROPN admet-338 157 28 / / SYM admet-338 157 29 ml ml NOUN admet-338 157 30 , , PUNCT admet-338 157 31 do do VERB admet-338 157 32 = = SYM admet-338 157 33 32 32 NUM admet-338 157 34 , , PUNCT admet-338 157 35 cilostazole cilostazole NOUN admet-338 157 36 : : PUNCT admet-338 157 37 s s X admet-338 157 38 = = NOUN admet-338 157 39 0.01 0.01 NUM admet-338 157 40 mg mg PROPN admet-338 157 41 / / SYM admet-338 157 42 ml ml NOUN admet-338 157 43 , , PUNCT admet-338 157 44 do do VERB admet-338 157 45 = = NUM admet-338 157 46 40 40 NUM admet-338 157 47 ) ) PUNCT admet-338 157 48 . . PUNCT admet-338 158 1 furthermore furthermore ADV admet-338 158 2 , , PUNCT admet-338 158 3 an an DET admet-338 158 4 odt odt NOUN admet-338 158 5 shows show NOUN admet-338 158 6 be be VERB admet-338 158 7 with with ADP admet-338 158 8 a a DET admet-338 158 9 corresponding correspond VERB admet-338 158 10 ir ir NOUN admet-338 158 11 formulation formulation NOUN admet-338 158 12 with with ADP admet-338 158 13 and and CCONJ admet-338 158 14 without without ADP admet-338 158 15 water water NOUN admet-338 158 16 intake intake NOUN admet-338 158 17 . . PUNCT admet-338 159 1 therefore therefore ADV admet-338 159 2 , , PUNCT admet-338 159 3 even even ADV admet-338 159 4 though though SCONJ admet-338 159 5 it it PRON admet-338 159 6 is be AUX admet-338 159 7 counterintuitive counterintuitive ADJ admet-338 159 8 , , PUNCT admet-338 159 9 water water NOUN admet-338 159 10 intake intake NOUN admet-338 159 11 may may AUX admet-338 159 12 have have VERB admet-338 159 13 little little ADJ admet-338 159 14 effect effect NOUN admet-338 159 15 on on ADP admet-338 159 16 the the DET admet-338 159 17 dissolution dissolution NOUN admet-338 159 18 and and CCONJ admet-338 159 19 oral oral ADJ admet-338 159 20 absorption absorption NOUN admet-338 159 21 of of ADP admet-338 159 22 low low ADJ admet-338 159 23 solubility solubility NOUN admet-338 159 24 drugs drug NOUN admet-338 159 25 . . PUNCT admet-338 160 1 previously previously ADV admet-338 160 2 , , PUNCT admet-338 160 3 sumesen sumesen PROPN admet-338 160 4 et et PROPN admet-338 160 5 al al PROPN admet-338 160 6 . . PROPN admet-338 160 7 reported report VERB admet-338 160 8 that that SCONJ admet-338 160 9 the the DET admet-338 160 10 oral oral ADJ admet-338 160 11 absorption absorption NOUN admet-338 160 12 of of ADP admet-338 160 13 danazol danazol ADJ admet-338 160 14 was be AUX admet-338 160 15 not not PART admet-338 160 16 significantly significantly ADV admet-338 160 17 altered alter VERB admet-338 160 18 when when SCONJ admet-338 160 19 administered administer VERB admet-338 160 20 together together ADV admet-338 160 21 with with ADP admet-338 160 22 1000 1000 NUM admet-338 160 23 ml ml NOUN admet-338 160 24 of of ADP admet-338 160 25 water water NOUN admet-338 160 26 compared compare VERB admet-338 160 27 to to ADP admet-338 160 28 when when SCONJ admet-338 160 29 administered administer VERB admet-338 160 30 with with ADP admet-338 160 31 200 200 NUM admet-338 160 32 ml ml NOUN admet-338 160 33 [ [ X admet-338 160 34 15 15 NUM admet-338 160 35 ] ] PUNCT admet-338 160 36 . . PUNCT admet-338 161 1 danazol danazol PROPN admet-338 161 2 , , PUNCT admet-338 161 3 which which PRON admet-338 161 4 has have VERB admet-338 161 5 poor poor ADJ admet-338 161 6 water water NOUN admet-338 161 7 solubility solubility NOUN admet-338 161 8 ( ( PUNCT admet-338 161 9 0.2 0.2 NUM admet-338 161 10 g g PROPN admet-338 161 11 / / SYM admet-338 161 12 ml ml NOUN admet-338 161 13 ) ) PUNCT admet-338 161 14 and and CCONJ admet-338 161 15 high high ADJ admet-338 161 16 permeability permeability NOUN admet-338 161 17 ( ( PUNCT admet-338 161 18 log log PROPN admet-338 161 19 d6.5 d6.5 PROPN admet-338 161 20 = = SYM admet-338 161 21 4.5 4.5 NUM admet-338 161 22 ) ) PUNCT admet-338 161 23 , , PUNCT admet-338 161 24 is be AUX admet-338 161 25 a a DET admet-338 161 26 typical typical ADJ admet-338 161 27 bcs bcs NOUN admet-338 161 28 class class NOUN admet-338 161 29 ii ii PROPN admet-338 161 30 drug drug NOUN admet-338 161 31 [ [ X admet-338 161 32 16 16 NUM admet-338 161 33 ] ] PUNCT admet-338 161 34 . . PUNCT admet-338 162 1 the the DET admet-338 162 2 drugs drug NOUN admet-338 162 3 that that PRON admet-338 162 4 have have AUX admet-338 162 5 been be AUX admet-338 162 6 developed develop VERB admet-338 162 7 as as ADP admet-338 162 8 odts odts NOUN admet-338 162 9 tended tend VERB admet-338 162 10 to to PART admet-338 162 11 have have VERB admet-338 162 12 a a DET admet-338 162 13 longer long ADJ admet-338 162 14 elimination elimination NOUN admet-338 162 15 t1/2 t1/2 NOUN admet-338 162 16 . . PUNCT admet-338 163 1 previously previously ADV admet-338 163 2 , , PUNCT admet-338 163 3 we we PRON admet-338 163 4 reported report VERB admet-338 163 5 that that SCONJ admet-338 163 6 the the DET admet-338 163 7 elimination elimination NOUN admet-338 163 8 t1/2 t1/2 NOUN admet-338 163 9 of of ADP admet-338 163 10 drugs drug NOUN admet-338 163 11 influence influence VERB admet-338 163 12 the the DET admet-338 163 13 be be NOUN admet-338 163 14 of of ADP admet-338 163 15 cmax cmax NOUN admet-338 163 16 [ [ X admet-338 163 17 17 17 NUM admet-338 163 18 ] ] PUNCT admet-338 163 19 . . PUNCT admet-338 164 1 for for ADP admet-338 164 2 the the DET admet-338 164 3 drugs drug NOUN admet-338 164 4 with with ADP admet-338 164 5 high high ADJ admet-338 164 6 permeability permeability NOUN admet-338 164 7 and and CCONJ admet-338 164 8 short short ADJ admet-338 164 9 elimination elimination NOUN admet-338 164 10 t1/2 t1/2 NOUN admet-338 164 11 , , PUNCT admet-338 164 12 be be AUX admet-338 164 13 of of ADP admet-338 164 14 cmax cmax NOUN admet-338 164 15 between between ADP admet-338 164 16 two two NUM admet-338 164 17 formulations formulation NOUN admet-338 164 18 with with ADP admet-338 164 19 different different ADJ admet-338 164 20 dissolution dissolution NOUN admet-338 164 21 rates rate NOUN admet-338 164 22 would would AUX admet-338 164 23 become become VERB admet-338 164 24 more more ADV admet-338 164 25 difficult difficult ADJ admet-338 164 26 to to PART admet-338 164 27 prove prove VERB admet-338 164 28 . . PUNCT admet-338 165 1 this this DET admet-338 165 2 point point NOUN admet-338 165 3 has have AUX admet-338 165 4 been be AUX admet-338 165 5 suggested suggest VERB admet-338 165 6 by by ADP admet-338 165 7 several several ADJ admet-338 165 8 articles article NOUN admet-338 165 9 [ [ X admet-338 165 10 18 18 NUM admet-338 165 11 - - SYM admet-338 165 12 21 21 NUM admet-338 165 13 ] ] PUNCT admet-338 165 14 . . PUNCT admet-338 166 1 a a DET admet-338 166 2 drug drug NOUN admet-338 166 3 with with ADP admet-338 166 4 a a DET admet-338 166 5 long long ADJ admet-338 166 6 elimination elimination NOUN admet-338 166 7 t1/2 t1/2 NOUN admet-338 166 8 might might AUX admet-338 166 9 be be AUX admet-338 166 10 suitable suitable ADJ admet-338 166 11 for for ADP admet-338 166 12 an an DET admet-338 166 13 odt odt NOUN admet-338 166 14 . . PUNCT admet-338 167 1 the the DET admet-338 167 2 proportion proportion NOUN admet-338 167 3 of of ADP admet-338 167 4 bases basis NOUN admet-338 167 5 was be AUX admet-338 167 6 larger large ADJ admet-338 167 7 in in ADP admet-338 167 8 the the DET admet-338 167 9 odt odt NOUN admet-338 167 10 than than ADP admet-338 167 11 in in ADP admet-338 167 12 the the DET admet-338 167 13 ir ir PROPN admet-338 167 14 formulation formulation NOUN admet-338 167 15 . . PUNCT admet-338 168 1 it it PRON admet-338 168 2 is be AUX admet-338 168 3 well well ADV admet-338 168 4 known know VERB admet-338 168 5 that that SCONJ admet-338 168 6 the the DET admet-338 168 7 basic basic ADJ admet-338 168 8 lipophilic lipophilic ADJ admet-338 168 9 drugs drug NOUN admet-338 168 10 have have VERB admet-338 168 11 a a DET admet-338 168 12 large large ADJ admet-338 168 13 distribution distribution NOUN admet-338 168 14 volume volume NOUN admet-338 168 15 , , PUNCT admet-338 168 16 and and CCONJ admet-338 168 17 a a DET admet-338 168 18 long long ADJ admet-338 168 19 elimination elimination NOUN admet-338 168 20 t1/2 t1/2 NOUN admet-338 168 21 due due ADP admet-338 168 22 to to ADP admet-338 168 23 wide wide ADJ admet-338 168 24 tissue tissue NOUN admet-338 168 25 distribution distribution NOUN admet-338 168 26 [ [ X admet-338 168 27 22 22 NUM admet-338 168 28 ] ] PUNCT admet-338 168 29 . . PUNCT admet-338 169 1 a a DET admet-338 169 2 significant significant ADJ admet-338 169 3 difference difference NOUN admet-338 169 4 was be AUX admet-338 169 5 seen see VERB admet-338 169 6 in in ADP admet-338 169 7 elimination elimination NOUN admet-338 169 8 t1/2 t1/2 NOUN admet-338 169 9 between between ADP admet-338 169 10 acids acid NOUN admet-338 169 11 , , PUNCT admet-338 169 12 bases basis NOUN admet-338 169 13 , , PUNCT admet-338 169 14 and and CCONJ admet-338 169 15 undissociated undissociated ADJ admet-338 169 16 drugs drug NOUN admet-338 169 17 in in ADP admet-338 169 18 the the DET admet-338 169 19 ir ir PROPN admet-338 169 20 formulation formulation NOUN admet-338 169 21 ( ( PUNCT admet-338 169 22 p p X admet-338 169 23 = = NOUN admet-338 169 24 0.04 0.04 NUM admet-338 169 25 ) ) PUNCT admet-338 169 26 ( ( PUNCT admet-338 169 27 figure figure NOUN admet-338 169 28 3 3 NUM admet-338 169 29 ) ) PUNCT admet-338 169 30 . . PUNCT admet-338 170 1 figure figure VERB admet-338 170 2 3 3 NUM admet-338 170 3 . . PUNCT admet-338 170 4 box box NOUN admet-338 170 5 and and CCONJ admet-338 170 6 whisker whisker NOUN admet-338 170 7 plot plot NOUN admet-338 170 8 of of ADP admet-338 170 9 elimination elimination NOUN admet-338 170 10 t1/2 t1/2 NOUN admet-338 170 11 of of ADP admet-338 170 12 acid acid NOUN admet-338 170 13 , , PUNCT admet-338 170 14 base base NOUN admet-338 170 15 , , PUNCT admet-338 170 16 and and CCONJ admet-338 170 17 undissociated undissociated ADJ admet-338 170 18 drugs drug NOUN admet-338 170 19 the the DET admet-338 170 20 biowaiver biowaiver NOUN admet-338 170 21 schemes scheme NOUN admet-338 170 22 ( ( PUNCT admet-338 170 23 bws bws PROPN admet-338 170 24 ) ) PUNCT admet-338 170 25 has have AUX admet-338 170 26 been be AUX admet-338 170 27 discussed discuss VERB admet-338 170 28 based base VERB admet-338 170 29 on on ADP admet-338 170 30 bcs bc NOUN admet-338 170 31 proposed propose VERB admet-338 170 32 by by ADP admet-338 170 33 amidon amidon PROPN admet-338 170 34 et et PROPN admet-338 170 35 al al PROPN admet-338 170 36 . . PROPN admet-338 171 1 in in ADP admet-338 171 2 1995 1995 NUM admet-338 171 3 [ [ X admet-338 171 4 5 5 NUM admet-338 171 5 ] ] PUNCT admet-338 171 6 . . PUNCT admet-338 172 1 in in ADP admet-338 172 2 2000 2000 NUM admet-338 172 3 , , PUNCT admet-338 172 4 the the DET admet-338 172 5 us us PROPN admet-338 172 6 food food NOUN admet-338 172 7 and and CCONJ admet-338 172 8 drug drug PROPN admet-338 172 9 administration administration PROPN admet-338 172 10 ( ( PUNCT admet-338 172 11 fda fda PROPN admet-338 172 12 ) ) PUNCT admet-338 172 13 adopted adopt VERB admet-338 172 14 the the DET admet-338 172 15 bcs bc NOUN admet-338 172 16 - - PUNCT admet-338 172 17 bws bws PROPN admet-338 173 1 [ [ X admet-338 173 2 23 23 NUM admet-338 173 3 ] ] PUNCT admet-338 173 4 . . PUNCT admet-338 174 1 the the DET admet-338 174 2 guideline guideline NOUN admet-338 174 3 allows allow VERB admet-338 174 4 bcs bcs NOUN admet-338 174 5 class class NOUN admet-338 175 1 i i PRON admet-338 175 2 drugs drug NOUN admet-338 175 3 which which PRON admet-338 175 4 show show VERB admet-338 175 5 rapid rapid ADJ admet-338 175 6 dissolution dissolution NOUN admet-338 175 7 ( ( PUNCT admet-338 175 8 > > SYM admet-338 175 9 85 85 NUM admet-338 175 10 % % NOUN admet-338 175 11 dissolution dissolution NOUN admet-338 175 12 in in ADP admet-338 175 13 30 30 NUM admet-338 175 14 min min NOUN admet-338 175 15 ) ) PUNCT admet-338 175 16 to to PART admet-338 175 17 waive waive VERB admet-338 175 18 clinical clinical ADJ admet-338 175 19 be be AUX admet-338 175 20 studies study NOUN admet-338 175 21 . . PUNCT admet-338 176 1 the the DET admet-338 176 2 world world PROPN admet-338 176 3 health health PROPN admet-338 176 4 organization organization NOUN admet-338 176 5 ( ( PUNCT admet-338 176 6 who who PRON admet-338 176 7 ) ) PUNCT admet-338 176 8 and and CCONJ admet-338 176 9 other other ADJ admet-338 176 10 regulatory regulatory ADJ admet-338 176 11 agencies agency NOUN admet-338 176 12 followed follow VERB admet-338 176 13 the the DET admet-338 176 14 bcs bc NOUN admet-338 176 15 - - PUNCT admet-338 176 16 bws bws PROPN admet-338 177 1 [ [ X admet-338 177 2 24 24 NUM admet-338 177 3 - - SYM admet-338 177 4 27 27 NUM admet-338 177 5 ] ] PUNCT admet-338 177 6 . . PUNCT admet-338 178 1 however however ADV admet-338 178 2 , , PUNCT admet-338 178 3 odt odt PROPN admet-338 178 4 ir ir PROPN admet-338 178 5 formulation formulation NOUN admet-338 178 6 0 0 NUM admet-338 178 7 20 20 NUM admet-338 178 8 40 40 NUM admet-338 178 9 60 60 NUM admet-338 178 10 80 80 NUM admet-338 178 11 100 100 NUM admet-338 178 12 120 120 NUM admet-338 178 13 140 140 NUM admet-338 178 14 t t NOUN admet-338 178 15 1 1 NUM admet-338 178 16 /2 /2 NUM admet-338 178 17 ( ( PUNCT admet-338 178 18 h h NOUN admet-338 178 19 ) ) PUNCT admet-338 178 20 asami asami PROPN admet-338 178 21 ono ono PROPN admet-338 178 22 et et PROPN admet-338 178 23 al al PROPN admet-338 178 24 . . PROPN admet-338 178 25 admet admet PROPN admet-338 178 26 & & CCONJ admet-338 178 27 dmpk dmpk PROPN admet-338 178 28 4(4 4(4 NUM admet-338 178 29 ) ) PUNCT admet-338 178 30 ( ( PUNCT admet-338 178 31 2016 2016 NUM admet-338 178 32 ) ) PUNCT admet-338 178 33 335 335 NUM admet-338 178 34 - - SYM admet-338 178 35 360 360 NUM admet-338 178 36 348 348 NUM admet-338 178 37 there there PRON admet-338 178 38 are be VERB admet-338 178 39 some some DET admet-338 178 40 differences difference NOUN admet-338 178 41 among among ADP admet-338 178 42 these these DET admet-338 178 43 guidelines guideline NOUN admet-338 178 44 , , PUNCT admet-338 178 45 e.g. e.g. ADV admet-338 178 46 solubility solubility NOUN admet-338 178 47 ph ph ADJ admet-338 178 48 range range NOUN admet-338 178 49 , , PUNCT admet-338 178 50 criteria criterion NOUN admet-338 178 51 for for ADP admet-338 178 52 high high ADJ admet-338 178 53 permeability permeability NOUN admet-338 178 54 , , PUNCT admet-338 178 55 and and CCONJ admet-338 178 56 definition definition NOUN admet-338 178 57 of of ADP admet-338 178 58 the the DET admet-338 178 59 dose dose NOUN admet-338 178 60 used use VERB admet-338 178 61 for for ADP admet-338 178 62 the the DET admet-338 178 63 do do NOUN admet-338 178 64 calculation calculation NOUN admet-338 178 65 [ [ X admet-338 178 66 28 28 NUM admet-338 178 67 ] ] PUNCT admet-338 178 68 . . PUNCT admet-338 179 1 one one NUM admet-338 179 2 of of ADP admet-338 179 3 the the DET admet-338 179 4 most most ADV admet-338 179 5 significant significant ADJ admet-338 179 6 differences difference NOUN admet-338 179 7 is be AUX admet-338 179 8 about about ADP admet-338 179 9 the the DET admet-338 179 10 biowaiver biowaiver NOUN admet-338 179 11 for for ADP admet-338 179 12 bcs bcs NOUN admet-338 179 13 class class NOUN admet-338 179 14 iii iii NUM admet-338 179 15 drugs drug NOUN admet-338 179 16 . . PUNCT admet-338 180 1 who who PRON admet-338 180 2 , , PUNCT admet-338 180 3 european european PROPN admet-338 180 4 union union PROPN admet-338 180 5 , , PUNCT admet-338 180 6 and and CCONJ admet-338 180 7 canada canada PROPN admet-338 180 8 accept accept VERB admet-338 180 9 biowaiver biowaiver PROPN admet-338 180 10 for for ADP admet-338 180 11 bcs bcs NOUN admet-338 180 12 class class NOUN admet-338 180 13 iii iii NUM admet-338 180 14 drugs drug NOUN admet-338 180 15 which which PRON admet-338 180 16 show show VERB admet-338 180 17 very very ADV admet-338 180 18 rapid rapid ADJ admet-338 180 19 dissolution dissolution NOUN admet-338 180 20 ( ( PUNCT admet-338 180 21 > > SYM admet-338 180 22 85 85 NUM admet-338 180 23 % % NOUN admet-338 180 24 dissolution dissolution NOUN admet-338 180 25 in in ADP admet-338 180 26 15 15 NUM admet-338 180 27 min min NOUN admet-338 180 28 ) ) PUNCT admet-338 180 29 , , PUNCT admet-338 180 30 while while SCONJ admet-338 180 31 only only ADV admet-338 180 32 bcs bcs NOUN admet-338 180 33 class class NOUN admet-338 180 34 i i PRON admet-338 180 35 drugs drug NOUN admet-338 180 36 are be AUX admet-338 180 37 eligible eligible ADJ admet-338 180 38 for for ADP admet-338 180 39 biowaiver biowaiver PROPN admet-338 180 40 in in ADP admet-338 180 41 the the DET admet-338 180 42 us us PROPN admet-338 180 43 fda fda PROPN admet-338 180 44 and and CCONJ admet-338 180 45 korea korea PROPN admet-338 180 46 fda fda PROPN admet-338 180 47 guideline guideline PROPN admet-338 180 48 . . PUNCT admet-338 181 1 however however ADV admet-338 181 2 , , PUNCT admet-338 181 3 there there PRON admet-338 181 4 are be VERB admet-338 181 5 several several ADJ admet-338 181 6 computer computer NOUN admet-338 181 7 simulation simulation NOUN admet-338 181 8 and and CCONJ admet-338 181 9 experimental experimental ADJ admet-338 181 10 studies study NOUN admet-338 181 11 on on ADP admet-338 181 12 the the DET admet-338 181 13 biowaiver biowaiver NOUN admet-338 181 14 for for ADP admet-338 181 15 bcs bcs NOUN admet-338 181 16 class class NOUN admet-338 181 17 iii iii NUM admet-338 181 18 drugs drug NOUN admet-338 181 19 , , PUNCT admet-338 181 20 suggesting suggest VERB admet-338 181 21 that that SCONJ admet-338 181 22 bcs bcs NOUN admet-338 181 23 class class NOUN admet-338 181 24 iii iii NUM admet-338 181 25 drugs drug NOUN admet-338 181 26 are be AUX admet-338 181 27 suitable suitable ADJ admet-338 181 28 for for ADP admet-338 181 29 biowaiver biowaiver NOUN admet-338 182 1 [ [ X admet-338 182 2 20,21,29 20,21,29 NUM admet-338 182 3 - - SYM admet-338 182 4 33 33 NUM admet-338 182 5 ] ] PUNCT admet-338 182 6 . . PUNCT admet-338 183 1 in in ADP admet-338 183 2 addition addition NOUN admet-338 183 3 , , PUNCT admet-338 183 4 it it PRON admet-338 183 5 has have AUX admet-338 183 6 been be AUX admet-338 183 7 pointed point VERB admet-338 183 8 out out ADP admet-338 183 9 that that SCONJ admet-338 183 10 many many ADJ admet-338 183 11 bcs bcs NOUN admet-338 183 12 class class NOUN admet-338 183 13 iii iii NUM admet-338 183 14 drugs drug NOUN admet-338 183 15 show show NOUN admet-338 183 16 be be VERB admet-338 183 17 even even ADV admet-338 183 18 when when SCONJ admet-338 183 19 the the DET admet-338 183 20 dissolution dissolution NOUN admet-338 183 21 profiles profile NOUN admet-338 183 22 are be AUX admet-338 183 23 different different ADJ admet-338 183 24 between between ADP admet-338 183 25 the the DET admet-338 183 26 test test NOUN admet-338 183 27 and and CCONJ admet-338 183 28 reference reference NOUN admet-338 183 29 drugs drug NOUN admet-338 183 30 , , PUNCT admet-338 183 31 for for ADP admet-338 183 32 example example NOUN admet-338 183 33 famotidine famotidine NOUN admet-338 183 34 , , PUNCT admet-338 183 35 hydrochlorothiazide hydrochlorothiazide NOUN admet-338 183 36 , , PUNCT admet-338 183 37 and and CCONJ admet-338 183 38 cimetidine cimetidine NOUN admet-338 184 1 [ [ X admet-338 184 2 33,34 33,34 NOUN admet-338 184 3 ] ] PUNCT admet-338 184 4 . . PUNCT admet-338 185 1 moreover moreover ADV admet-338 185 2 , , PUNCT admet-338 185 3 who who PRON admet-338 185 4 adopts adopt VERB admet-338 185 5 the the DET admet-338 185 6 possibility possibility NOUN admet-338 185 7 of of ADP admet-338 185 8 biowaiver biowaiver NOUN admet-338 185 9 for for ADP admet-338 185 10 bcs bcs NOUN admet-338 185 11 class class NOUN admet-338 185 12 iia iia NOUN admet-338 185 13 drugs drug NOUN admet-338 185 14 with with ADP admet-338 185 15 low low ADJ admet-338 185 16 solubility solubility NOUN admet-338 185 17 at at ADP admet-338 185 18 acidic acidic ADJ admet-338 185 19 ph ph ADJ admet-338 185 20 and and CCONJ admet-338 185 21 high high ADJ admet-338 185 22 solubility solubility NOUN admet-338 185 23 at at ADP admet-338 185 24 neutral neutral ADJ admet-338 185 25 ph ph NOUN admet-338 185 26 that that PRON admet-338 185 27 are be AUX admet-338 185 28 absorbed absorb VERB admet-338 185 29 completely completely ADV admet-338 185 30 . . PUNCT admet-338 186 1 however however ADV admet-338 186 2 , , PUNCT admet-338 186 3 it it PRON admet-338 186 4 was be AUX admet-338 186 5 reported report VERB admet-338 186 6 that that SCONJ admet-338 186 7 , , PUNCT admet-338 186 8 in in ADP admet-338 186 9 the the DET admet-338 186 10 case case NOUN admet-338 186 11 of of ADP admet-338 186 12 ibuprofen ibuprofen NOUN admet-338 186 13 , , PUNCT admet-338 186 14 the the DET admet-338 186 15 typically typically ADV admet-338 186 16 bcs bcs NOUN admet-338 186 17 class class NOUN admet-338 186 18 iia iia NOUN admet-338 186 19 drug drug NOUN admet-338 186 20 , , PUNCT admet-338 186 21 the the DET admet-338 186 22 be be NOUN admet-338 186 23 of of ADP admet-338 186 24 cmax cmax NOUN admet-338 186 25 is be AUX admet-338 186 26 more more ADV admet-338 186 27 sensitive sensitive ADJ admet-338 186 28 to to ADP admet-338 186 29 the the DET admet-338 186 30 difference difference NOUN admet-338 186 31 of of ADP admet-338 186 32 dissolution dissolution NOUN admet-338 186 33 rates rate NOUN admet-338 186 34 [ [ X admet-338 186 35 35,36 35,36 NUM admet-338 186 36 ] ] PUNCT admet-338 186 37 . . PUNCT admet-338 187 1 the the DET admet-338 187 2 bcs bcs NOUN admet-338 187 3 class class NOUN admet-338 187 4 distribution distribution NOUN admet-338 187 5 of of ADP admet-338 187 6 odts odts NOUN admet-338 187 7 and and CCONJ admet-338 187 8 ir ir PROPN admet-338 187 9 formulations formulation NOUN admet-338 187 10 may may AUX admet-338 187 11 reflect reflect VERB admet-338 187 12 their their PRON admet-338 187 13 non non ADJ admet-338 187 14 - - ADJ admet-338 187 15 be be AUX admet-338 187 16 risk risk NOUN admet-338 187 17 due due ADP admet-338 187 18 to to ADP admet-338 187 19 the the DET admet-338 187 20 difference difference NOUN admet-338 187 21 of of ADP admet-338 187 22 the the DET admet-338 187 23 dissolution dissolution NOUN admet-338 187 24 rates rate NOUN admet-338 187 25 . . PUNCT admet-338 188 1 based base VERB admet-338 188 2 on on ADP admet-338 188 3 the the DET admet-338 188 4 bcs bcs NOUN admet-338 188 5 - - PUNCT admet-338 188 6 bws bws PROPN admet-338 188 7 , , PUNCT admet-338 188 8 be be AUX admet-338 188 9 is be AUX admet-338 188 10 most most ADV admet-338 188 11 easily easily ADV admet-338 188 12 established establish VERB admet-338 188 13 for for ADP admet-338 188 14 bcs bcs NOUN admet-338 188 15 class class NOUN admet-338 188 16 i i PRON admet-338 188 17 drugs drug VERB admet-338 188 18 . . PUNCT admet-338 189 1 however however ADV admet-338 189 2 , , PUNCT admet-338 189 3 no no DET admet-338 189 4 difference difference NOUN admet-338 189 5 in in ADP admet-338 189 6 the the DET admet-338 189 7 distribution distribution NOUN admet-338 189 8 of of ADP admet-338 189 9 the the DET admet-338 189 10 bcs bcs NOUN admet-338 189 11 classes class NOUN admet-338 189 12 , , PUNCT admet-338 189 13 including include VERB admet-338 189 14 subclasses subclass NOUN admet-338 189 15 , , PUNCT admet-338 189 16 between between ADP admet-338 189 17 the the DET admet-338 189 18 odts odts NOUN admet-338 189 19 and and CCONJ admet-338 189 20 ir ir PROPN admet-338 189 21 formulations formulation NOUN admet-338 189 22 was be AUX admet-338 189 23 observed observe VERB admet-338 189 24 in in ADP admet-338 189 25 this this DET admet-338 189 26 study study NOUN admet-338 189 27 . . PUNCT admet-338 190 1 this this DET admet-338 190 2 result result NOUN admet-338 190 3 may may AUX admet-338 190 4 suggest suggest VERB admet-338 190 5 that that SCONJ admet-338 190 6 a a DET admet-338 190 7 bcs bcs NOUN admet-338 190 8 class class NOUN admet-338 190 9 i i PRON admet-338 190 10 drug drug NOUN admet-338 190 11 would would AUX admet-338 190 12 not not PART admet-338 190 13 necessarily necessarily ADV admet-338 190 14 be be AUX admet-338 190 15 suitable suitable ADJ admet-338 190 16 to to PART admet-338 190 17 show show VERB admet-338 190 18 be be AUX admet-338 190 19 . . PUNCT admet-338 191 1 ramirez ramirez PROPN admet-338 191 2 et et PROPN admet-338 191 3 al al PROPN admet-338 191 4 . . PROPN admet-338 191 5 reported report VERB admet-338 191 6 that that SCONJ admet-338 191 7 in in ADP admet-338 191 8 the the DET admet-338 191 9 124 124 NUM admet-338 191 10 clinical clinical ADJ admet-338 191 11 be be VERB admet-338 191 12 studies study NOUN admet-338 191 13 there there PRON admet-338 191 14 is be VERB admet-338 191 15 no no DET admet-338 191 16 difference difference NOUN admet-338 191 17 in in ADP admet-338 191 18 the the DET admet-338 191 19 number number NOUN admet-338 191 20 of of ADP admet-338 191 21 subjects subject NOUN admet-338 191 22 in in ADP admet-338 191 23 the the DET admet-338 191 24 be be NOUN admet-338 191 25 study study NOUN admet-338 191 26 and and CCONJ admet-338 191 27 the the DET admet-338 191 28 interand interand NOUN admet-338 191 29 intra intra ADJ admet-338 191 30 - - ADJ admet-338 191 31 subject subject ADJ admet-338 191 32 variability variability NOUN admet-338 191 33 for for ADP admet-338 191 34 cmax cmax NOUN admet-338 191 35 or or CCONJ admet-338 191 36 auc auc VERB admet-338 191 37 between between ADP admet-338 191 38 four four NUM admet-338 191 39 bcs bcs NOUN admet-338 191 40 classes class NOUN admet-338 191 41 [ [ X admet-338 191 42 37 37 NUM admet-338 191 43 ] ] PUNCT admet-338 191 44 . . PUNCT admet-338 192 1 all all DET admet-338 192 2 the the DET admet-338 192 3 bcs bcs NOUN admet-338 192 4 classes class NOUN admet-338 192 5 drugs drug NOUN admet-338 192 6 have have VERB admet-338 192 7 the the DET admet-338 192 8 risk risk NOUN admet-338 192 9 of of ADP admet-338 192 10 non non ADJ admet-338 192 11 - - VERB admet-338 192 12 be be AUX admet-338 192 13 . . PUNCT admet-338 193 1 their their PRON admet-338 193 2 results result NOUN admet-338 193 3 also also ADV admet-338 193 4 showed show VERB admet-338 193 5 that that SCONJ admet-338 193 6 all all PRON admet-338 193 7 of of ADP admet-338 193 8 the the DET admet-338 193 9 bioinequivalent bioinequivalent NOUN admet-338 193 10 parameters parameter NOUN admet-338 193 11 in in ADP admet-338 193 12 bcs bcs NOUN admet-338 193 13 class class NOUN admet-338 193 14 i i PRON admet-338 193 15 drugs drug NOUN admet-338 193 16 was be AUX admet-338 193 17 cmax cmax NOUN admet-338 193 18 , , PUNCT admet-338 193 19 but but CCONJ admet-338 193 20 not not PART admet-338 193 21 auc auc NOUN admet-338 193 22 . . PUNCT admet-338 194 1 the the DET admet-338 194 2 results result NOUN admet-338 194 3 of of ADP admet-338 194 4 the the DET admet-338 194 5 present present ADJ admet-338 194 6 study study NOUN admet-338 194 7 suggest suggest VERB admet-338 194 8 that that SCONJ admet-338 194 9 the the DET admet-338 194 10 elimination elimination NOUN admet-338 194 11 t1/2 t1/2 PROPN admet-338 194 12 would would AUX admet-338 194 13 affect affect VERB admet-338 194 14 the the DET admet-338 194 15 success success NOUN admet-338 194 16 rate rate NOUN admet-338 194 17 of of ADP admet-338 194 18 a a DET admet-338 194 19 be be NOUN admet-338 194 20 study study NOUN admet-338 194 21 more more ADV admet-338 194 22 significantly significantly ADV admet-338 194 23 than than ADP admet-338 194 24 the the DET admet-338 194 25 bcs bcs NOUN admet-338 194 26 class class NOUN admet-338 194 27 of of ADP admet-338 194 28 a a DET admet-338 194 29 drug drug NOUN admet-338 194 30 ( ( PUNCT admet-338 194 31 e.g. e.g. ADV admet-338 194 32 ibuprofen ibuprofen NOUN admet-338 194 33 ) ) PUNCT admet-338 194 34 . . PUNCT admet-338 195 1 in in ADP admet-338 195 2 conclusion conclusion NOUN admet-338 195 3 , , PUNCT admet-338 195 4 drugs drug NOUN admet-338 195 5 with with ADP admet-338 195 6 a a DET admet-338 195 7 lower low ADJ admet-338 195 8 dose dose NOUN admet-338 195 9 strength strength NOUN admet-338 195 10 ( ( PUNCT admet-338 195 11 < < X admet-338 195 12 10 10 NUM admet-338 195 13 mg mg NUM admet-338 195 14 ) ) PUNCT admet-338 195 15 and and CCONJ admet-338 195 16 a a DET admet-338 195 17 longer long ADJ admet-338 195 18 elimination elimination NOUN admet-338 195 19 t1/2 t1/2 NOUN admet-338 195 20 ( ( PUNCT admet-338 195 21 > > SYM admet-338 195 22 6.5 6.5 NUM admet-338 195 23 h h NOUN admet-338 195 24 ) ) PUNCT admet-338 195 25 were be AUX admet-338 195 26 suggested suggest VERB admet-338 195 27 to to PART admet-338 195 28 be be AUX admet-338 195 29 more more ADV admet-338 195 30 suitable suitable ADJ admet-338 195 31 for for ADP admet-338 195 32 an an DET admet-338 195 33 odt odt NOUN admet-338 195 34 . . PUNCT admet-338 196 1 however however ADV admet-338 196 2 , , PUNCT admet-338 196 3 the the DET admet-338 196 4 distributions distribution NOUN admet-338 196 5 of of ADP admet-338 196 6 the the DET admet-338 196 7 odt odt NOUN admet-338 196 8 and and CCONJ admet-338 196 9 ir ir PROPN admet-338 196 10 formulation formulation NOUN admet-338 196 11 among among ADP admet-338 196 12 each each DET admet-338 196 13 bcs bcs NOUN admet-338 196 14 class class NOUN admet-338 196 15 were be AUX admet-338 196 16 similar similar ADJ admet-338 196 17 , , PUNCT admet-338 196 18 suggesting suggest VERB admet-338 196 19 that that SCONJ admet-338 196 20 the the DET admet-338 196 21 bcs bcs NOUN admet-338 196 22 classes class NOUN admet-338 196 23 are be AUX admet-338 196 24 irrelevant irrelevant ADJ admet-338 196 25 to to ADP admet-338 196 26 the the DET admet-338 196 27 development development NOUN admet-338 196 28 risk risk NOUN admet-338 196 29 of of ADP admet-338 196 30 odts odts NOUN admet-338 196 31 . . PUNCT admet-338 197 1 references reference NOUN admet-338 197 2 [ [ X admet-338 197 3 1 1 X admet-338 197 4 ] ] PUNCT admet-338 197 5 s. s. PROPN admet-338 197 6 v. v. PROPN admet-338 197 7 sastry sastry PROPN admet-338 197 8 , , PUNCT admet-338 197 9 j. j. PROPN admet-338 197 10 r. r. PROPN admet-338 197 11 nyshadham nyshadham PROPN admet-338 197 12 , , PUNCT admet-338 197 13 j. j. PROPN admet-338 197 14 a. a. PROPN admet-338 197 15 fix fix PROPN admet-338 197 16 . . PUNCT admet-338 198 1 recent recent ADJ admet-338 198 2 technological technological ADJ admet-338 198 3 advances advance NOUN admet-338 198 4 in in ADP admet-338 198 5 oral oral ADJ admet-338 198 6 drug drug NOUN admet-338 198 7 delivery delivery NOUN admet-338 198 8 – – PUNCT admet-338 198 9 a a DET admet-338 198 10 review review NOUN admet-338 198 11 . . PUNCT admet-338 199 1 pharm pharm NOUN admet-338 199 2 . . PUNCT admet-338 200 1 sci sci PROPN admet-338 200 2 . . PROPN admet-338 200 3 technolo technolo PROPN admet-338 200 4 . . PUNCT admet-338 201 1 today today NOUN admet-338 201 2 3 3 NUM admet-338 201 3 ( ( PUNCT admet-338 201 4 2000 2000 NUM admet-338 201 5 ) ) PUNCT admet-338 201 6 138 138 NUM admet-338 201 7 - - SYM admet-338 201 8 145 145 NUM admet-338 201 9 . . PUNCT admet-338 202 1 [ [ X admet-338 202 2 2 2 X admet-338 202 3 ] ] PUNCT admet-338 202 4 d. d. PROPN admet-338 202 5 hobbs hobbs PROPN admet-338 202 6 , , PUNCT admet-338 202 7 j. j. PROPN admet-338 202 8 karagianis karagianis PROPN admet-338 202 9 , , PUNCT admet-338 202 10 t. t. NOUN admet-338 202 11 treuer treuer NOUN admet-338 202 12 , , PUNCT admet-338 202 13 j. j. PROPN admet-338 202 14 raskin raskin PROPN admet-338 202 15 . . PUNCT admet-338 203 1 an an DET admet-338 203 2 in in ADP admet-338 203 3 vitro vitro X admet-338 203 4 analysis analysis NOUN admet-338 203 5 of of ADP admet-338 203 6 disintegration disintegration NOUN admet-338 203 7 times time NOUN admet-338 203 8 of of ADP admet-338 203 9 different different ADJ admet-338 203 10 formulations formulation NOUN admet-338 203 11 of of ADP admet-338 203 12 olanzapine olanzapine PROPN admet-338 203 13 orodispersible orodispersible ADJ admet-338 203 14 tablet tablet NOUN admet-338 203 15 : : PUNCT admet-338 203 16 a a DET admet-338 203 17 preliminary preliminary ADJ admet-338 203 18 report report NOUN admet-338 203 19 . . PUNCT admet-338 204 1 drugs drug NOUN admet-338 204 2 r r NOUN admet-338 204 3 d d NOUN admet-338 204 4 13 13 NUM admet-338 204 5 ( ( PUNCT admet-338 204 6 2013 2013 NUM admet-338 204 7 ) ) PUNCT admet-338 204 8 281 281 NUM admet-338 204 9 - - SYM admet-338 204 10 288 288 NUM admet-338 204 11 . . PUNCT admet-338 205 1 [ [ X admet-338 205 2 3 3 X admet-338 205 3 ] ] PUNCT admet-338 205 4 t. t. PROPN admet-338 205 5 takagi takagi PROPN admet-338 205 6 , , PUNCT admet-338 205 7 c. c. PROPN admet-338 205 8 ramachandran ramachandran PROPN admet-338 205 9 , , PUNCT admet-338 205 10 m. m. NOUN admet-338 205 11 bermejo bermejo PROPN admet-338 205 12 , , PUNCT admet-338 205 13 s. s. PROPN admet-338 205 14 yamashita yamashita PROPN admet-338 205 15 , , PUNCT admet-338 205 16 l. l. PROPN admet-338 205 17 x. x. PROPN admet-338 205 18 yu yu PROPN admet-338 205 19 , , PUNCT admet-338 205 20 g. g. PROPN admet-338 205 21 l. l. PROPN admet-338 205 22 amidon amidon PROPN admet-338 205 23 . . PUNCT admet-338 206 1 a a DET admet-338 206 2 provisional provisional ADJ admet-338 206 3 biopharmaceutical biopharmaceutical NOUN admet-338 206 4 classification classification NOUN admet-338 206 5 of of ADP admet-338 206 6 the the DET admet-338 206 7 top top ADJ admet-338 206 8 200 200 NUM admet-338 206 9 oral oral ADJ admet-338 206 10 drug drug NOUN admet-338 206 11 products product NOUN admet-338 206 12 in in ADP admet-338 206 13 the the DET admet-338 206 14 united united PROPN admet-338 206 15 states states PROPN admet-338 206 16 , , PUNCT admet-338 206 17 great great ADJ admet-338 206 18 britain britain PROPN admet-338 206 19 , , PUNCT admet-338 206 20 spain spain PROPN admet-338 206 21 , , PUNCT admet-338 206 22 and and CCONJ admet-338 206 23 japan japan PROPN admet-338 206 24 . . PUNCT admet-338 207 1 mol mol PROPN admet-338 207 2 . . PUNCT admet-338 207 3 pharm pharm PROPN admet-338 207 4 . . PUNCT admet-338 208 1 3 3 NUM admet-338 208 2 ( ( PUNCT admet-338 208 3 2006 2006 NUM admet-338 208 4 ) ) PUNCT admet-338 208 5 631 631 NUM admet-338 208 6 - - SYM admet-338 208 7 643 643 NUM admet-338 208 8 . . PUNCT admet-338 209 1 [ [ X admet-338 209 2 4 4 X admet-338 209 3 ] ] PUNCT admet-338 209 4 c. c. PROPN admet-338 209 5 a. a. PROPN admet-338 209 6 lipinski lipinski PROPN admet-338 209 7 , , PUNCT admet-338 209 8 f. f. PROPN admet-338 209 9 lombardo lombardo PROPN admet-338 209 10 , , PUNCT admet-338 209 11 b. b. PROPN admet-338 209 12 w. w. PROPN admet-338 209 13 dominy dominy PROPN admet-338 209 14 , , PUNCT admet-338 209 15 p. p. PROPN admet-338 209 16 j. j. PROPN admet-338 209 17 feeney feeney PROPN admet-338 209 18 . . PUNCT admet-338 210 1 experimental experimental ADJ admet-338 210 2 and and CCONJ admet-338 210 3 computational computational ADJ admet-338 210 4 approaches approach NOUN admet-338 210 5 to to PART admet-338 210 6 estimate estimate VERB admet-338 210 7 solubility solubility NOUN admet-338 210 8 and and CCONJ admet-338 210 9 permeability permeability NOUN admet-338 210 10 in in ADP admet-338 210 11 drug drug NOUN admet-338 210 12 discovery discovery NOUN admet-338 210 13 and and CCONJ admet-338 210 14 development development NOUN admet-338 210 15 settings setting NOUN admet-338 210 16 . . PUNCT admet-338 211 1 advanced advanced ADJ admet-338 211 2 drug drug NOUN admet-338 211 3 delivery delivery NOUN admet-338 211 4 reviews review VERB admet-338 211 5 64 64 NUM admet-338 211 6 ( ( PUNCT admet-338 211 7 2012 2012 NUM admet-338 211 8 ) ) PUNCT admet-338 211 9 4 4 NUM admet-338 211 10 - - SYM admet-338 211 11 17 17 NUM admet-338 211 12 . . PUNCT admet-338 212 1 [ [ X admet-338 212 2 5 5 X admet-338 212 3 ] ] PUNCT admet-338 212 4 g. g. PROPN admet-338 212 5 amidon amidon PROPN admet-338 212 6 , , PUNCT admet-338 212 7 h. h. PROPN admet-338 212 8 lennernΓ€s lennernΓ€s PROPN admet-338 212 9 , , PUNCT admet-338 212 10 v. v. CCONJ admet-338 212 11 shah shah PROPN admet-338 212 12 , , PUNCT admet-338 212 13 j. j. PROPN admet-338 212 14 crison crison PROPN admet-338 212 15 . . PUNCT admet-338 213 1 a a DET admet-338 213 2 theoretical theoretical ADJ admet-338 213 3 basis basis NOUN admet-338 213 4 for for ADP admet-338 213 5 a a DET admet-338 213 6 biopharmaceutic biopharmaceutic ADJ admet-338 213 7 drug drug NOUN admet-338 213 8 classification classification NOUN admet-338 213 9 : : PUNCT admet-338 213 10 the the DET admet-338 213 11 correlation correlation NOUN admet-338 213 12 of of ADP admet-338 213 13 in in ADP admet-338 213 14 vitro vitro X admet-338 213 15 drug drug NOUN admet-338 213 16 product product NOUN admet-338 213 17 dissolution dissolution NOUN admet-338 213 18 and and CCONJ admet-338 213 19 in in ADP admet-338 213 20 vivo vivo ADJ admet-338 213 21 bioavailability bioavailability NOUN admet-338 213 22 . . PUNCT admet-338 214 1 pharm pharm NOUN admet-338 214 2 . . PUNCT admet-338 215 1 res re NOUN admet-338 215 2 . . PROPN admet-338 216 1 12 12 NUM admet-338 216 2 ( ( PUNCT admet-338 216 3 1995 1995 NUM admet-338 216 4 ) ) PUNCT admet-338 216 5 413 413 NUM admet-338 216 6 - - SYM admet-338 216 7 420 420 NUM admet-338 216 8 . . PUNCT admet-338 217 1 [ [ X admet-338 217 2 6 6 NUM admet-338 217 3 ] ] PUNCT admet-338 217 4 s. s. PROPN admet-338 217 5 k. k. PROPN admet-338 217 6 poole poole PROPN admet-338 217 7 , , PUNCT admet-338 217 8 s. s. PROPN admet-338 217 9 patel patel PROPN admet-338 217 10 , , PUNCT admet-338 217 11 k. k. PROPN admet-338 217 12 dehring dehring PROPN admet-338 217 13 , , PUNCT admet-338 217 14 h. h. PROPN admet-338 217 15 workman workman PROPN admet-338 217 16 , , PUNCT admet-338 217 17 c. c. PROPN admet-338 217 18 f. f. PROPN admet-338 217 19 poole poole PROPN admet-338 217 20 . . PUNCT admet-338 218 1 determination determination NOUN admet-338 218 2 of of ADP admet-338 218 3 acid acid NOUN admet-338 218 4 dissociation dissociation NOUN admet-338 218 5 constants constant NOUN admet-338 218 6 by by ADP admet-338 218 7 capillary capillary ADJ admet-338 218 8 electrophoresis electrophoresis NOUN admet-338 218 9 . . PUNCT admet-338 219 1 j. j. PROPN admet-338 219 2 chromatogr chromatogr PROPN admet-338 219 3 . . PUNCT admet-338 220 1 a a DET admet-338 220 2 1037 1037 NUM admet-338 220 3 ( ( PUNCT admet-338 220 4 2004 2004 NUM admet-338 220 5 ) ) PUNCT admet-338 220 6 445 445 NUM admet-338 220 7 - - SYM admet-338 220 8 454 454 NUM admet-338 220 9 . . PUNCT admet-338 221 1 [ [ X admet-338 221 2 7 7 X admet-338 221 3 ] ] X admet-338 221 4 y. y. PROPN admet-338 221 5 tsume tsume PROPN admet-338 221 6 , , PUNCT admet-338 221 7 d. d. PROPN admet-338 221 8 m. m. PROPN admet-338 221 9 mudie mudie PROPN admet-338 221 10 , , PUNCT admet-338 221 11 p. p. PROPN admet-338 221 12 langguth langguth NOUN admet-338 221 13 , , PUNCT admet-338 221 14 g. g. PROPN admet-338 221 15 e. e. PROPN admet-338 221 16 amidon amidon PROPN admet-338 221 17 , , PUNCT admet-338 221 18 g. g. PROPN admet-338 221 19 l. l. PROPN admet-338 221 20 amidon amidon PROPN admet-338 221 21 . . PUNCT admet-338 222 1 the the DET admet-338 222 2 biopharmaceutics biopharmaceutics NOUN admet-338 222 3 classification classification NOUN admet-338 222 4 system system NOUN admet-338 222 5 : : PUNCT admet-338 222 6 subclasses subclass NOUN admet-338 222 7 for for ADP admet-338 222 8 in in ADP admet-338 222 9 vivo vivo ADJ admet-338 222 10 predictive predictive ADJ admet-338 222 11 dissolution dissolution NOUN admet-338 222 12 ( ( PUNCT admet-338 222 13 ipd ipd PROPN admet-338 222 14 ) ) PUNCT admet-338 222 15 methodology methodology NOUN admet-338 222 16 and and CCONJ admet-338 222 17 ivivc ivivc NOUN admet-338 222 18 . . PUNCT admet-338 223 1 eur eur PROPN admet-338 223 2 . . PUNCT admet-338 224 1 j. j. PROPN admet-338 224 2 pharm pharm PROPN admet-338 224 3 . . PUNCT admet-338 225 1 sci sci PROPN admet-338 225 2 . . PROPN admet-338 226 1 57 57 NUM admet-338 226 2 ( ( PUNCT admet-338 226 3 2014 2014 NUM admet-338 226 4 ) ) PUNCT admet-338 226 5 152 152 NUM admet-338 226 6 - - SYM admet-338 226 7 163 163 NUM admet-338 226 8 . . PUNCT admet-338 227 1 admet admet PROPN admet-338 227 2 & & CCONJ admet-338 227 3 dmpk dmpk PROPN admet-338 227 4 4(4 4(4 NUM admet-338 227 5 ) ) PUNCT admet-338 227 6 ( ( PUNCT admet-338 227 7 2016 2016 NUM admet-338 227 8 ) ) PUNCT admet-338 227 9 335 335 NUM admet-338 227 10 - - SYM admet-338 227 11 360 360 NUM admet-338 227 12 biopharmaceutical biopharmaceutical NOUN admet-338 227 13 and and CCONJ admet-338 227 14 physchem physchem NOUN admet-338 227 15 properties property NOUN admet-338 227 16 for for ADP admet-338 227 17 odt odt ADJ admet-338 227 18 doi doi NOUN admet-338 227 19 : : PUNCT admet-338 227 20 10.5599 10.5599 NUM admet-338 227 21 / / SYM admet-338 227 22 admet.4.4.338 admet.4.4.338 NUM admet-338 227 23 349 349 NUM admet-338 227 24 [ [ SYM admet-338 227 25 8 8 NUM admet-338 227 26 ] ] X admet-338 227 27 n. n. PROPN admet-338 227 28 a. a. PROPN admet-338 227 29 kasim kasim PROPN admet-338 227 30 , , PUNCT admet-338 227 31 m. m. NOUN admet-338 227 32 whitehouse whitehouse NOUN admet-338 227 33 , , PUNCT admet-338 227 34 c. c. PROPN admet-338 227 35 ramachandran ramachandran PROPN admet-338 227 36 , , PUNCT admet-338 227 37 m. m. NOUN admet-338 227 38 bermejo bermejo PROPN admet-338 227 39 , , PUNCT admet-338 227 40 h. h. PROPN admet-338 227 41 lennernΓ€s lennernΓ€s PROPN admet-338 227 42 , , PUNCT admet-338 227 43 a. a. PROPN admet-338 227 44 s. s. PROPN admet-338 227 45 hussain hussain PROPN admet-338 227 46 , , PUNCT admet-338 227 47 h. h. PROPN admet-338 227 48 e. e. PROPN admet-338 227 49 junginger junginger PROPN admet-338 227 50 , , PUNCT admet-338 227 51 s. s. PROPN admet-338 227 52 a. a. PROPN admet-338 227 53 stavchansky stavchansky PROPN admet-338 227 54 , , PUNCT admet-338 227 55 k. k. PROPN admet-338 227 56 k. k. PROPN admet-338 227 57 midha midha PROPN admet-338 227 58 , , PUNCT admet-338 227 59 v. v. ADP admet-338 227 60 p. p. NOUN admet-338 227 61 shah shah NOUN admet-338 227 62 , , PUNCT admet-338 227 63 g. g. PROPN admet-338 227 64 l. l. PROPN admet-338 227 65 amidon amidon PROPN admet-338 227 66 . . PUNCT admet-338 228 1 molecular molecular ADJ admet-338 228 2 properties property NOUN admet-338 228 3 of of ADP admet-338 228 4 who who PRON admet-338 228 5 essential essential ADJ admet-338 228 6 drugs drug NOUN admet-338 228 7 and and CCONJ admet-338 228 8 provisional provisional ADJ admet-338 228 9 biopharmaceutical biopharmaceutical NOUN admet-338 228 10 classification classification NOUN admet-338 228 11 . . PUNCT admet-338 229 1 mol mol PROPN admet-338 229 2 . . PUNCT admet-338 229 3 pharm pharm PROPN admet-338 229 4 . . PUNCT admet-338 230 1 1 1 NUM admet-338 230 2 ( ( PUNCT admet-338 230 3 2003 2003 NUM admet-338 230 4 ) ) PUNCT admet-338 230 5 85 85 NUM admet-338 230 6 - - SYM admet-338 230 7 96 96 NUM admet-338 230 8 . . PUNCT admet-338 231 1 [ [ X admet-338 231 2 9 9 NUM admet-338 231 3 ] ] PUNCT admet-338 231 4 h. h. PROPN admet-338 231 5 lennernΓ€s lennernΓ€s PROPN admet-338 231 6 . . PUNCT admet-338 232 1 intestinal intestinal ADJ admet-338 232 2 permeability permeability NOUN admet-338 232 3 and and CCONJ admet-338 232 4 its its PRON admet-338 232 5 relevance relevance NOUN admet-338 232 6 for for ADP admet-338 232 7 absorption absorption NOUN admet-338 232 8 and and CCONJ admet-338 232 9 elimination elimination NOUN admet-338 232 10 . . PUNCT admet-338 233 1 xenobiotica xenobiotica PROPN admet-338 233 2 37 37 NUM admet-338 233 3 ( ( PUNCT admet-338 233 4 2007 2007 NUM admet-338 233 5 ) ) PUNCT admet-338 233 6 1015 1015 NUM admet-338 233 7 - - SYM admet-338 233 8 1051 1051 NUM admet-338 233 9 . . PUNCT admet-338 234 1 [ [ X admet-338 234 2 10 10 NUM admet-338 234 3 ] ] PUNCT admet-338 234 4 a. a. NOUN admet-338 234 5 avdeef avdeef PROPN admet-338 234 6 . . PUNCT admet-338 235 1 absorption absorption NOUN admet-338 235 2 and and CCONJ admet-338 235 3 drug drug NOUN admet-338 235 4 development development NOUN admet-338 235 5 , , PUNCT admet-338 235 6 second second ADJ admet-338 235 7 edition edition NOUN admet-338 235 8 . . PUNCT admet-338 236 1 john john PROPN admet-338 236 2 wiley wiley PROPN admet-338 236 3 & & CCONJ admet-338 236 4 sons sons PROPN admet-338 236 5 , , PUNCT admet-338 236 6 inc inc PROPN admet-338 236 7 ( ( PUNCT admet-338 236 8 2012 2012 NUM admet-338 236 9 ) ) PUNCT admet-338 237 1 [ [ X admet-338 237 2 11 11 NUM admet-338 237 3 ] ] PUNCT admet-338 237 4 k. k. PROPN admet-338 237 5 sugano sugano PROPN admet-338 237 6 . . PUNCT admet-338 238 1 biopharmaceutics biopharmaceutics NOUN admet-338 238 2 modeling modeling NOUN admet-338 238 3 and and CCONJ admet-338 238 4 simulations simulation NOUN admet-338 238 5 . . PUNCT admet-338 239 1 wiley wiley PROPN admet-338 239 2 ( ( PUNCT admet-338 239 3 2012 2012 NUM admet-338 239 4 ) ) PUNCT admet-338 240 1 [ [ X admet-338 240 2 12 12 NUM admet-338 240 3 ] ] PUNCT admet-338 240 4 b. b. PROPN admet-338 240 5 reigner reigner PROPN admet-338 240 6 , , PUNCT admet-338 240 7 j. j. PROPN admet-338 240 8 verweij verweij PROPN admet-338 240 9 , , PUNCT admet-338 240 10 l. l. PROPN admet-338 240 11 dirix dirix PROPN admet-338 240 12 , , PUNCT admet-338 240 13 j. j. PROPN admet-338 240 14 cassidy cassidy PROPN admet-338 240 15 , , PUNCT admet-338 240 16 c. c. PROPN admet-338 240 17 twelves twelves PROPN admet-338 240 18 , , PUNCT admet-338 240 19 d. d. PROPN admet-338 240 20 allman allman PROPN admet-338 240 21 , , PUNCT admet-338 240 22 e. e. PROPN admet-338 240 23 weidekamm weidekamm PROPN admet-338 240 24 , , PUNCT admet-338 240 25 b. b. PROPN admet-338 240 26 roos roos PROPN admet-338 240 27 , , PUNCT admet-338 240 28 l. l. PROPN admet-338 240 29 banken banken PROPN admet-338 240 30 , , PUNCT admet-338 240 31 m. m. NOUN admet-338 240 32 utoh utoh PROPN admet-338 240 33 . . PUNCT admet-338 240 34 effect effect NOUN admet-338 240 35 of of ADP admet-338 240 36 food food NOUN admet-338 240 37 on on ADP admet-338 240 38 the the DET admet-338 240 39 pharmacokinetics pharmacokinetic NOUN admet-338 240 40 of of ADP admet-338 240 41 capecitabine capecitabine NOUN admet-338 240 42 and and CCONJ admet-338 240 43 its its PRON admet-338 240 44 metabolites metabolite NOUN admet-338 240 45 following follow VERB admet-338 240 46 oral oral ADJ admet-338 240 47 administration administration NOUN admet-338 240 48 in in ADP admet-338 240 49 cancer cancer NOUN admet-338 240 50 patients patient NOUN admet-338 240 51 . . PUNCT admet-338 241 1 clin clin PROPN admet-338 241 2 . . PUNCT admet-338 242 1 cancer cancer NOUN admet-338 242 2 res re NOUN admet-338 242 3 . . PROPN admet-338 242 4 4 4 NUM admet-338 242 5 ( ( PUNCT admet-338 242 6 1998 1998 NUM admet-338 242 7 ) ) PUNCT admet-338 242 8 941 941 NUM admet-338 242 9 - - SYM admet-338 242 10 948 948 NUM admet-338 242 11 . . PUNCT admet-338 243 1 [ [ X admet-338 243 2 13 13 NUM admet-338 243 3 ] ] PUNCT admet-338 243 4 j. j. PROPN admet-338 243 5 j. j. PROPN admet-338 243 6 hirani hirani PROPN admet-338 243 7 , , PUNCT admet-338 243 8 d. d. PROPN admet-338 243 9 a. a. PROPN admet-338 243 10 rathod rathod PROPN admet-338 243 11 , , PUNCT admet-338 243 12 k. k. PROPN admet-338 243 13 r. r. PROPN admet-338 243 14 vadalia vadalia PROPN admet-338 243 15 . . PUNCT admet-338 244 1 orally orally ADV admet-338 244 2 disintegrating disintegrate VERB admet-338 244 3 tablets tablet NOUN admet-338 244 4 : : PUNCT admet-338 244 5 a a DET admet-338 244 6 review review NOUN admet-338 244 7 . . PUNCT admet-338 245 1 trop trop X admet-338 245 2 . . PUNCT admet-338 246 1 j. j. PROPN admet-338 246 2 pharm pharm PROPN admet-338 246 3 . . PUNCT admet-338 247 1 res re NOUN admet-338 247 2 . . PROPN admet-338 247 3 8 8 NUM admet-338 247 4 ( ( PUNCT admet-338 247 5 2009 2009 NUM admet-338 247 6 ) ) PUNCT admet-338 247 7 161 161 NUM admet-338 247 8 - - SYM admet-338 247 9 172 172 NUM admet-338 247 10 . . PUNCT admet-338 248 1 [ [ X admet-338 248 2 14 14 NUM admet-338 248 3 ] ] PUNCT admet-338 248 4 t. t. PROPN admet-338 248 5 k. k. PROPN admet-338 248 6 ghosh ghosh PROPN admet-338 248 7 , , PUNCT admet-338 248 8 w. w. PROPN admet-338 248 9 r. r. PROPN admet-338 248 10 pfiste pfiste PROPN admet-338 248 11 . . PUNCT admet-338 249 1 drug drug NOUN admet-338 249 2 delivery delivery NOUN admet-338 249 3 to to ADP admet-338 249 4 the the DET admet-338 249 5 oral oral ADJ admet-338 249 6 cavity cavity NOUN admet-338 249 7 ; ; PUNCT admet-338 249 8 chapter chapter NOUN admet-338 249 9 14 14 NUM admet-338 249 10 . . PUNCT admet-338 250 1 quick quick ADV admet-338 250 2 - - PUNCT admet-338 250 3 dissolving dissolve VERB admet-338 250 4 oral oral ADJ admet-338 250 5 dosage dosage NOUN admet-338 250 6 forms form NOUN admet-338 250 7 taylor taylor PROPN admet-338 250 8 & & CCONJ admet-338 250 9 francis francis PROPN admet-338 250 10 group group PROPN admet-338 250 11 , , PUNCT admet-338 250 12 llc llc PROPN admet-338 250 13 ( ( PUNCT admet-338 250 14 2005 2005 NUM admet-338 250 15 ) ) PUNCT admet-338 250 16 337 337 NUM admet-338 250 17 - - SYM admet-338 250 18 356 356 NUM admet-338 250 19 . . PUNCT admet-338 251 1 [ [ X admet-338 251 2 15 15 NUM admet-338 251 3 ] ] X admet-338 251 4 v. v. ADP admet-338 251 5 h. h. PROPN admet-338 251 6 sunesen sunesen PROPN admet-338 251 7 , , PUNCT admet-338 251 8 r. r. PROPN admet-338 251 9 vedelsdal vedelsdal PROPN admet-338 251 10 , , PUNCT admet-338 251 11 h. h. PROPN admet-338 251 12 g. g. PROPN admet-338 251 13 kristensen kristensen PROPN admet-338 251 14 , , PUNCT admet-338 251 15 l. l. PROPN admet-338 251 16 christrup christrup PROPN admet-338 251 17 , , PUNCT admet-338 251 18 a. a. NOUN admet-338 251 19 mullertz mullertz NOUN admet-338 251 20 . . PUNCT admet-338 252 1 effect effect NOUN admet-338 252 2 of of ADP admet-338 252 3 liquid liquid ADJ admet-338 252 4 volume volume NOUN admet-338 252 5 and and CCONJ admet-338 252 6 food food NOUN admet-338 252 7 intake intake NOUN admet-338 252 8 on on ADP admet-338 252 9 the the DET admet-338 252 10 absolute absolute ADJ admet-338 252 11 bioavailability bioavailability NOUN admet-338 252 12 of of ADP admet-338 252 13 danazol danazol ADJ admet-338 252 14 , , PUNCT admet-338 252 15 a a DET admet-338 252 16 poorly poorly ADV admet-338 252 17 soluble soluble ADJ admet-338 252 18 drug drug NOUN admet-338 252 19 . . PUNCT admet-338 253 1 eur eur PROPN admet-338 253 2 . . PUNCT admet-338 254 1 j. j. PROPN admet-338 254 2 pharm pharm PROPN admet-338 254 3 . . PUNCT admet-338 255 1 sci sci PROPN admet-338 255 2 . . PROPN admet-338 256 1 24 24 NUM admet-338 256 2 ( ( PUNCT admet-338 256 3 2005 2005 NUM admet-338 256 4 ) ) PUNCT admet-338 256 5 297 297 NUM admet-338 256 6 - - SYM admet-338 256 7 303 303 NUM admet-338 256 8 . . PUNCT admet-338 257 1 [ [ X admet-338 257 2 16 16 NUM admet-338 257 3 ] ] PUNCT admet-338 257 4 k. k. PROPN admet-338 257 5 sugano sugano PROPN admet-338 257 6 . . PUNCT admet-338 258 1 fraction fraction NOUN admet-338 258 2 of of ADP admet-338 258 3 a a DET admet-338 258 4 dose dose NOUN admet-338 258 5 absorbed absorb VERB admet-338 258 6 estimation estimation NOUN admet-338 258 7 for for ADP admet-338 258 8 structurally structurally ADV admet-338 258 9 diverse diverse ADJ admet-338 258 10 low low ADJ admet-338 258 11 solubility solubility NOUN admet-338 258 12 compounds compound NOUN admet-338 258 13 . . PUNCT admet-338 259 1 int int NOUN admet-338 259 2 . . PUNCT admet-338 260 1 j. j. PROPN admet-338 260 2 pharm pharm PROPN admet-338 260 3 . . PUNCT admet-338 261 1 405 405 NUM admet-338 261 2 ( ( PUNCT admet-338 261 3 2011 2011 NUM admet-338 261 4 ) ) PUNCT admet-338 261 5 79 79 NUM admet-338 261 6 - - SYM admet-338 261 7 89 89 NUM admet-338 261 8 . . PUNCT admet-338 262 1 [ [ X admet-338 262 2 17 17 NUM admet-338 262 3 ] ] PUNCT admet-338 262 4 k. k. PROPN admet-338 262 5 sugano sugano PROPN admet-338 262 6 , , PUNCT admet-338 262 7 k. k. PROPN admet-338 262 8 terada terada PROPN admet-338 262 9 . . PUNCT admet-338 263 1 rateand rateand NOUN admet-338 263 2 extent extent NOUN admet-338 263 3 - - PUNCT admet-338 263 4 limiting limit VERB admet-338 263 5 factors factor NOUN admet-338 263 6 of of ADP admet-338 263 7 oral oral ADJ admet-338 263 8 drug drug NOUN admet-338 263 9 absorption absorption NOUN admet-338 263 10 : : PUNCT admet-338 263 11 theory theory NOUN admet-338 263 12 and and CCONJ admet-338 263 13 applications application NOUN admet-338 263 14 . . PUNCT admet-338 264 1 j. j. PROPN admet-338 264 2 pharm pharm PROPN admet-338 264 3 . . PUNCT admet-338 265 1 sci sci PROPN admet-338 265 2 . . PROPN admet-338 266 1 104 104 NUM admet-338 266 2 ( ( PUNCT admet-338 266 3 2015 2015 NUM admet-338 266 4 ) ) PUNCT admet-338 266 5 2777 2777 NUM admet-338 266 6 - - SYM admet-338 266 7 2788 2788 NUM admet-338 266 8 . . PUNCT admet-338 267 1 [ [ X admet-338 267 2 18 18 NUM admet-338 267 3 ] ] X admet-338 267 4 s. s. PROPN admet-338 267 5 colon colon PROPN admet-338 267 6 - - PUNCT admet-338 267 7 useche useche PROPN admet-338 267 8 , , PUNCT admet-338 267 9 i. i. PROPN admet-338 267 10 gonzalez gonzalez PROPN admet-338 267 11 - - PUNCT admet-338 267 12 alvarez alvarez PROPN admet-338 267 13 , , PUNCT admet-338 267 14 v. v. ADP admet-338 267 15 mangas mangas PROPN admet-338 267 16 - - PUNCT admet-338 267 17 sanjuan sanjuan PROPN admet-338 267 18 , , PUNCT admet-338 267 19 m. m. PROPN admet-338 267 20 gonzalez gonzalez PROPN admet-338 267 21 - - PUNCT admet-338 267 22 alvarez alvarez PROPN admet-338 267 23 , , PUNCT admet-338 267 24 p. p. PROPN admet-338 267 25 pastoriza pastoriza PROPN admet-338 267 26 , , PUNCT admet-338 267 27 i. i. PROPN admet-338 267 28 molina molina PROPN admet-338 267 29 - - PUNCT admet-338 267 30 martinez martinez PROPN admet-338 267 31 , , PUNCT admet-338 267 32 m. m. NOUN admet-338 267 33 bermejo bermejo PROPN admet-338 267 34 , , PUNCT admet-338 267 35 a. a. PROPN admet-338 267 36 garcia garcia PROPN admet-338 267 37 - - PUNCT admet-338 267 38 arieta arieta PROPN admet-338 267 39 . . PUNCT admet-338 267 40 investigating investigate VERB admet-338 267 41 the the DET admet-338 267 42 discriminatory discriminatory ADJ admet-338 267 43 power power NOUN admet-338 267 44 of of ADP admet-338 267 45 bcsbiowaiver bcsbiowaiver NOUN admet-338 267 46 in in ADP admet-338 267 47 vitro vitro X admet-338 267 48 methodology methodology NOUN admet-338 267 49 to to PART admet-338 267 50 detect detect VERB admet-338 267 51 bioavailability bioavailability NOUN admet-338 267 52 differences difference NOUN admet-338 267 53 between between ADP admet-338 267 54 immediate immediate ADJ admet-338 267 55 release release NOUN admet-338 267 56 products product NOUN admet-338 267 57 containing contain VERB admet-338 267 58 a a DET admet-338 267 59 class class NOUN admet-338 267 60 i i PRON admet-338 267 61 drug drug NOUN admet-338 267 62 . . PUNCT admet-338 268 1 mol mol PROPN admet-338 268 2 . . PUNCT admet-338 268 3 pharm pharm PROPN admet-338 268 4 . . PUNCT admet-338 269 1 12 12 NUM admet-338 269 2 ( ( PUNCT admet-338 269 3 2015 2015 NUM admet-338 269 4 ) ) PUNCT admet-338 269 5 3167 3167 NUM admet-338 269 6 - - SYM admet-338 269 7 3174 3174 NUM admet-338 269 8 . . PUNCT admet-338 270 1 [ [ X admet-338 270 2 19 19 NUM admet-338 270 3 ] ] PUNCT admet-338 270 4 a. a. NOUN admet-338 270 5 garcia garcia PROPN admet-338 270 6 - - PUNCT admet-338 270 7 arieta arieta PROPN admet-338 270 8 , , PUNCT admet-338 270 9 j. j. PROPN admet-338 270 10 gordon gordon PROPN admet-338 270 11 , , PUNCT admet-338 270 12 l. l. PROPN admet-338 270 13 gwaza gwaza PROPN admet-338 270 14 , , PUNCT admet-338 270 15 v. v. ADP admet-338 270 16 mangas mangas PROPN admet-338 270 17 - - PUNCT admet-338 270 18 sanjuan sanjuan PROPN admet-338 270 19 , , PUNCT admet-338 270 20 c. c. PROPN admet-338 270 21 alvarez alvarez PROPN admet-338 270 22 , , PUNCT admet-338 270 23 j. j. PROPN admet-338 270 24 j. j. PROPN admet-338 270 25 torrado torrado PROPN admet-338 270 26 . . PUNCT admet-338 271 1 agitation agitation NOUN admet-338 271 2 rate rate NOUN admet-338 271 3 and and CCONJ admet-338 271 4 time time NOUN admet-338 271 5 for for ADP admet-338 271 6 complete complete ADJ admet-338 271 7 dissolution dissolution NOUN admet-338 271 8 in in ADP admet-338 271 9 bcs bcs NOUN admet-338 271 10 biowaivers biowaiver NOUN admet-338 271 11 based base VERB admet-338 271 12 on on ADP admet-338 271 13 investigation investigation NOUN admet-338 271 14 of of ADP admet-338 271 15 a a DET admet-338 271 16 bcs bcs NOUN admet-338 271 17 biowaiver biowaiver NOUN admet-338 271 18 for for ADP admet-338 271 19 dexketoprofen dexketoprofen NOUN admet-338 271 20 tablets tablet NOUN admet-338 271 21 . . PUNCT admet-338 272 1 mol mol PROPN admet-338 272 2 . . PUNCT admet-338 272 3 pharm pharm PROPN admet-338 272 4 . . PUNCT admet-338 273 1 12 12 NUM admet-338 273 2 ( ( PUNCT admet-338 273 3 2015 2015 NUM admet-338 273 4 ) ) PUNCT admet-338 273 5 3194 3194 NUM admet-338 273 6 - - SYM admet-338 273 7 3201 3201 NUM admet-338 273 8 . . PUNCT admet-338 274 1 [ [ X admet-338 274 2 20 20 NUM admet-338 274 3 ] ] X admet-338 274 4 u. u. PROPN admet-338 274 5 fagerholm fagerholm PROPN admet-338 274 6 . . PUNCT admet-338 275 1 evaluation evaluation NOUN admet-338 275 2 and and CCONJ admet-338 275 3 suggested suggest VERB admet-338 275 4 improvements improvement NOUN admet-338 275 5 of of ADP admet-338 275 6 the the DET admet-338 275 7 biopharmaceutics biopharmaceutics NOUN admet-338 275 8 classification classification NOUN admet-338 275 9 system system NOUN admet-338 275 10 ( ( PUNCT admet-338 275 11 bcs bcs NOUN admet-338 275 12 ) ) PUNCT admet-338 275 13 . . PUNCT admet-338 276 1 j. j. PROPN admet-338 276 2 pharm pharm PROPN admet-338 276 3 . . PUNCT admet-338 277 1 pharmacol pharmacol PROPN admet-338 277 2 . . PUNCT admet-338 278 1 59 59 NUM admet-338 278 2 ( ( PUNCT admet-338 278 3 2007 2007 NUM admet-338 278 4 ) ) PUNCT admet-338 278 5 751 751 NUM admet-338 278 6 - - SYM admet-338 278 7 757 757 NOUN admet-338 278 8 . . PUNCT admet-338 279 1 [ [ X admet-338 279 2 21 21 NUM admet-338 279 3 ] ] X admet-338 279 4 h. h. PROPN admet-338 279 5 kortejarvi kortejarvi PROPN admet-338 279 6 , , PUNCT admet-338 279 7 a. a. NOUN admet-338 279 8 urtti urtti PROPN admet-338 279 9 , , PUNCT admet-338 279 10 m. m. NOUN admet-338 279 11 yliperttula yliperttula PROPN admet-338 279 12 . . PUNCT admet-338 280 1 pharmacokinetic pharmacokinetic ADJ admet-338 280 2 simulation simulation NOUN admet-338 280 3 of of ADP admet-338 280 4 biowaiver biowaiver PROPN admet-338 280 5 criteria criterion NOUN admet-338 280 6 : : PUNCT admet-338 280 7 the the DET admet-338 280 8 effects effect NOUN admet-338 280 9 of of ADP admet-338 280 10 gastric gastric ADJ admet-338 280 11 emptying emptying NOUN admet-338 280 12 , , PUNCT admet-338 280 13 dissolution dissolution NOUN admet-338 280 14 , , PUNCT admet-338 280 15 absorption absorption NOUN admet-338 280 16 and and CCONJ admet-338 280 17 elimination elimination NOUN admet-338 280 18 rates rate NOUN admet-338 280 19 . . PUNCT admet-338 281 1 eur eur PROPN admet-338 281 2 . . PUNCT admet-338 282 1 j. j. PROPN admet-338 282 2 pharm pharm PROPN admet-338 282 3 . . PUNCT admet-338 283 1 sci sci PROPN admet-338 283 2 . . PROPN admet-338 283 3 30 30 NUM admet-338 283 4 ( ( PUNCT admet-338 283 5 2007 2007 NUM admet-338 283 6 ) ) PUNCT admet-338 283 7 155 155 NUM admet-338 283 8 - - SYM admet-338 283 9 166 166 NUM admet-338 283 10 . . PUNCT admet-338 284 1 [ [ X admet-338 284 2 22 22 NUM admet-338 284 3 ] ] X admet-338 284 4 g. g. PROPN admet-338 284 5 a. a. PROPN admet-338 284 6 siebert siebert PROPN admet-338 284 7 , , PUNCT admet-338 284 8 d. d. PROPN admet-338 284 9 y. y. PROPN admet-338 284 10 hung hung PROPN admet-338 284 11 , , PUNCT admet-338 284 12 p. p. PROPN admet-338 284 13 chang chang PROPN admet-338 284 14 , , PUNCT admet-338 284 15 m. m. PROPN admet-338 284 16 s. s. PROPN admet-338 284 17 roberts roberts PROPN admet-338 284 18 . . PUNCT admet-338 284 19 ion ion NOUN admet-338 284 20 - - PUNCT admet-338 284 21 trapping trap VERB admet-338 284 22 , , PUNCT admet-338 284 23 microsomal microsomal ADJ admet-338 284 24 binding binding NOUN admet-338 284 25 , , PUNCT admet-338 284 26 and and CCONJ admet-338 284 27 unbound unbound NOUN admet-338 284 28 drug drug NOUN admet-338 284 29 distribution distribution NOUN admet-338 284 30 in in ADP admet-338 284 31 the the DET admet-338 284 32 hepatic hepatic ADJ admet-338 284 33 retention retention NOUN admet-338 284 34 of of ADP admet-338 284 35 basic basic ADJ admet-338 284 36 drugs drug NOUN admet-338 284 37 . . PUNCT admet-338 285 1 j. j. PROPN admet-338 285 2 pharmacol pharmacol PROPN admet-338 285 3 . . PUNCT admet-338 286 1 exp exp PROPN admet-338 286 2 . . PUNCT admet-338 287 1 ther ther PROPN admet-338 287 2 . . PUNCT admet-338 288 1 308 308 NUM admet-338 288 2 ( ( PUNCT admet-338 288 3 2004 2004 NUM admet-338 288 4 ) ) PUNCT admet-338 288 5 228 228 NUM admet-338 288 6 - - SYM admet-338 288 7 235 235 NUM admet-338 288 8 . . PUNCT admet-338 289 1 [ [ X admet-338 289 2 23 23 NUM admet-338 289 3 ] ] X admet-338 289 4 fda fda PROPN admet-338 289 5 . . PROPN admet-338 289 6 waiver waiver NOUN admet-338 289 7 of of ADP admet-338 289 8 in in ADP admet-338 289 9 vivo vivo ADJ admet-338 289 10 bioavailability bioavailability NOUN admet-338 289 11 and and CCONJ admet-338 289 12 bioequivalence bioequivalence NOUN admet-338 289 13 studies study NOUN admet-338 289 14 for for ADP admet-338 289 15 immediate immediate ADJ admet-338 289 16 - - PUNCT admet-338 289 17 release release NOUN admet-338 289 18 solid solid ADJ admet-338 289 19 oral oral ADJ admet-338 289 20 dosage dosage NOUN admet-338 289 21 forms form NOUN admet-338 289 22 based base VERB admet-338 289 23 on on ADP admet-338 289 24 a a DET admet-338 289 25 biopharmaceutics biopharmaceutics NOUN admet-338 289 26 classification classification NOUN admet-338 289 27 system system NOUN admet-338 289 28 . . PUNCT admet-338 290 1 fda fda PROPN admet-338 290 2 guidance guidance NOUN admet-338 290 3 for for ADP admet-338 290 4 industry industry NOUN admet-338 290 5 ( ( PUNCT admet-338 290 6 2000 2000 NUM admet-338 290 7 ) ) PUNCT admet-338 291 1 [ [ X admet-338 291 2 24 24 NUM admet-338 291 3 ] ] PUNCT admet-338 291 4 who who PRON admet-338 291 5 . . PUNCT admet-338 292 1 proposal proposal NOUN admet-338 292 2 to to PART admet-338 292 3 waive waive VERB admet-338 292 4 in in ADP admet-338 292 5 vivo vivo ADJ admet-338 292 6 bioequivalence bioequivalence NOUN admet-338 292 7 requirements requirement NOUN admet-338 292 8 for for ADP admet-338 292 9 who who PRON admet-338 292 10 model model NOUN admet-338 292 11 list list NOUN admet-338 292 12 of of ADP admet-338 292 13 essential essential ADJ admet-338 292 14 medicines medicine NOUN admet-338 292 15 immediate immediate ADJ admet-338 292 16 - - PUNCT admet-338 292 17 release release NOUN admet-338 292 18 , , PUNCT admet-338 292 19 solid solid ADJ admet-338 292 20 oral oral ADJ admet-338 292 21 dosage dosage NOUN admet-338 292 22 forms form NOUN admet-338 292 23 . . PUNCT admet-338 293 1 who who PRON admet-338 293 2 technical technical ADJ admet-338 293 3 report report NOUN admet-338 293 4 series series NOUN admet-338 293 5 , , PUNCT admet-338 293 6 no no INTJ admet-338 293 7 . . PROPN admet-338 293 8 937 937 NUM admet-338 293 9 , , PUNCT admet-338 293 10 annex annex VERB admet-338 293 11 8 8 NUM admet-338 293 12 ( ( PUNCT admet-338 293 13 2006 2006 NUM admet-338 293 14 ) ) PUNCT admet-338 294 1 [ [ X admet-338 294 2 25 25 NUM admet-338 294 3 ] ] PUNCT admet-338 294 4 ema ema PROPN admet-338 294 5 . . PUNCT admet-338 295 1 guideline guideline NOUN admet-338 295 2 on on ADP admet-338 295 3 the the DET admet-338 295 4 investigation investigation NOUN admet-338 295 5 of of ADP admet-338 295 6 bioequivalence bioequivalence NOUN admet-338 295 7 . . PUNCT admet-338 296 1 cpmp cpmp PROPN admet-338 296 2 / / SYM admet-338 296 3 ewp ewp PROPN admet-338 296 4 / / SYM admet-338 296 5 qwp/1401/98 qwp/1401/98 PROPN admet-338 296 6 ( ( PUNCT admet-338 296 7 2010 2010 NUM admet-338 296 8 ) ) PUNCT admet-338 297 1 [ [ X admet-338 297 2 26 26 NUM admet-338 297 3 ] ] X admet-338 297 4 h. h. PROPN admet-338 297 5 canada canada PROPN admet-338 297 6 . . PUNCT admet-338 298 1 biopharmaceutics biopharmaceutics NOUN admet-338 298 2 classification classification NOUN admet-338 298 3 system system NOUN admet-338 298 4 based base VERB admet-338 298 5 biowaiver biowaiver NOUN admet-338 298 6 . . PUNCT admet-338 299 1 guidance guidance NOUN admet-338 299 2 document document NOUN admet-338 299 3 ( ( PUNCT admet-338 299 4 2013 2013 NUM admet-338 299 5 ) ) PUNCT admet-338 300 1 [ [ X admet-338 300 2 27 27 NUM admet-338 300 3 ] ] PUNCT admet-338 300 4 k. k. PROPN admet-338 300 5 fda fda PROPN admet-338 300 6 . . PUNCT admet-338 301 1 bioequivalence bioequivalence NOUN admet-338 301 2 study study NOUN admet-338 301 3 . . PUNCT admet-338 302 1 guidance guidance NOUN admet-338 302 2 document document NOUN admet-338 302 3 ( ( PUNCT admet-338 302 4 2008 2008 NUM admet-338 302 5 ) ) PUNCT admet-338 303 1 [ [ X admet-338 303 2 28 28 NUM admet-338 303 3 ] ] X admet-338 303 4 b. b. PROPN admet-338 303 5 davit davit PROPN admet-338 303 6 , , PUNCT admet-338 303 7 a. a. PROPN admet-338 303 8 c. c. PROPN admet-338 303 9 braddy braddy PROPN admet-338 303 10 , , PUNCT admet-338 303 11 d. d. PROPN admet-338 303 12 p. p. PROPN admet-338 303 13 conner conner PROPN admet-338 303 14 , , PUNCT admet-338 303 15 l. l. PROPN admet-338 303 16 x. x. PROPN admet-338 303 17 yu yu PROPN admet-338 303 18 . . PUNCT admet-338 304 1 international international ADJ admet-338 304 2 guidelines guideline NOUN admet-338 304 3 for for ADP admet-338 304 4 bioequivalence bioequivalence NOUN admet-338 304 5 of of ADP admet-338 304 6 systemically systemically ADV admet-338 304 7 available available ADJ admet-338 304 8 orally orally ADV admet-338 304 9 administered administer VERB admet-338 304 10 generic generic ADJ admet-338 304 11 drug drug NOUN admet-338 304 12 products product NOUN admet-338 304 13 : : PUNCT admet-338 304 14 a a DET admet-338 304 15 survey survey NOUN admet-338 304 16 of of ADP admet-338 304 17 similarities similarity NOUN admet-338 304 18 and and CCONJ admet-338 304 19 differences difference NOUN admet-338 304 20 . . PUNCT admet-338 305 1 aaps aaps PROPN admet-338 305 2 j j PROPN admet-338 305 3 15 15 NUM admet-338 305 4 ( ( PUNCT admet-338 305 5 2013 2013 NUM admet-338 305 6 ) ) PUNCT admet-338 305 7 974 974 NUM admet-338 305 8 - - SYM admet-338 305 9 990 990 NUM admet-338 305 10 . . PUNCT admet-338 306 1 [ [ X admet-338 306 2 29 29 NUM admet-338 306 3 ] ] PUNCT admet-338 306 4 l. l. PROPN admet-338 306 5 yu yu PROPN admet-338 306 6 , , PUNCT admet-338 306 7 g. g. PROPN admet-338 306 8 amidon amidon PROPN admet-338 306 9 , , PUNCT admet-338 306 10 j. j. PROPN admet-338 306 11 polli polli PROPN admet-338 306 12 , , PUNCT admet-338 306 13 h. h. PROPN admet-338 306 14 zhao zhao PROPN admet-338 306 15 , , PUNCT admet-338 306 16 m. m. NOUN admet-338 306 17 mehta mehta PROPN admet-338 306 18 , , PUNCT admet-338 306 19 d. d. PROPN admet-338 306 20 conner conner PROPN admet-338 306 21 , , PUNCT admet-338 306 22 v. v. ADP admet-338 306 23 shah shah PROPN admet-338 306 24 , , PUNCT admet-338 306 25 l. l. PROPN admet-338 306 26 lesko lesko PROPN admet-338 306 27 , , PUNCT admet-338 306 28 m.-l m.-l PROPN admet-338 306 29 . . PUNCT admet-338 307 1 chen chen PROPN admet-338 307 2 , , PUNCT admet-338 307 3 v. v. PROPN admet-338 307 4 l. l. PROPN admet-338 307 5 lee lee PROPN admet-338 307 6 , , PUNCT admet-338 307 7 a. a. PROPN admet-338 307 8 hussain hussain PROPN admet-338 307 9 . . PUNCT admet-338 308 1 biopharmaceutics biopharmaceutics NOUN admet-338 308 2 classification classification NOUN admet-338 308 3 system system NOUN admet-338 308 4 : : PUNCT admet-338 308 5 the the DET admet-338 308 6 scientific scientific ADJ admet-338 308 7 basis basis NOUN admet-338 308 8 for for ADP admet-338 308 9 biowaiver biowaiver NOUN admet-338 308 10 extensions extension NOUN admet-338 308 11 . . PUNCT admet-338 309 1 pharm pharm NOUN admet-338 309 2 . . PUNCT admet-338 310 1 res re NOUN admet-338 310 2 . . PROPN admet-338 311 1 19 19 NUM admet-338 311 2 ( ( PUNCT admet-338 311 3 2002 2002 NUM admet-338 311 4 ) ) PUNCT admet-338 311 5 921 921 NUM admet-338 311 6 - - SYM admet-338 311 7 925 925 NUM admet-338 311 8 . . PUNCT admet-338 312 1 asami asami PROPN admet-338 312 2 ono ono PROPN admet-338 312 3 et et PROPN admet-338 312 4 al al PROPN admet-338 312 5 . . PROPN admet-338 312 6 admet admet PROPN admet-338 312 7 & & CCONJ admet-338 312 8 dmpk dmpk PROPN admet-338 312 9 4(4 4(4 NUM admet-338 312 10 ) ) PUNCT admet-338 312 11 ( ( PUNCT admet-338 312 12 2016 2016 NUM admet-338 312 13 ) ) PUNCT admet-338 312 14 335 335 NUM admet-338 312 15 - - SYM admet-338 312 16 360 360 NUM admet-338 312 17 350 350 NUM admet-338 312 18 [ [ SYM admet-338 312 19 30 30 NUM admet-338 312 20 ] ] X admet-338 312 21 c. c. PROPN admet-338 312 22 l. l. PROPN admet-338 312 23 cheng cheng PROPN admet-338 312 24 , , PUNCT admet-338 312 25 l. l. PROPN admet-338 312 26 x. x. PROPN admet-338 312 27 yu yu PROPN admet-338 312 28 , , PUNCT admet-338 312 29 h. h. PROPN admet-338 312 30 l. l. PROPN admet-338 312 31 lee lee PROPN admet-338 312 32 , , PUNCT admet-338 312 33 c. c. PROPN admet-338 312 34 y. y. PROPN admet-338 312 35 yang yang PROPN admet-338 312 36 , , PUNCT admet-338 312 37 c. c. PROPN admet-338 312 38 s. s. PROPN admet-338 312 39 lue lue PROPN admet-338 312 40 , , PUNCT admet-338 312 41 c. c. PROPN admet-338 312 42 h. h. PROPN admet-338 312 43 chou chou PROPN admet-338 312 44 . . PUNCT admet-338 313 1 biowaiver biowaiver PROPN admet-338 313 2 extension extension NOUN admet-338 313 3 potential potential NOUN admet-338 313 4 to to ADP admet-338 313 5 bcs bcs NOUN admet-338 313 6 class class NOUN admet-338 313 7 iii iii NUM admet-338 313 8 high high ADJ admet-338 313 9 solubility solubility NOUN admet-338 313 10 - - PUNCT admet-338 313 11 low low ADJ admet-338 313 12 permeability permeability NOUN admet-338 313 13 drugs drug NOUN admet-338 313 14 : : PUNCT admet-338 313 15 bridging bridge VERB admet-338 313 16 evidence evidence NOUN admet-338 313 17 for for ADP admet-338 313 18 metformin metformin NOUN admet-338 313 19 immediate immediate ADJ admet-338 313 20 - - PUNCT admet-338 313 21 release release NOUN admet-338 313 22 tablet tablet NOUN admet-338 313 23 . . PUNCT admet-338 314 1 eur eur PROPN admet-338 314 2 . . PUNCT admet-338 315 1 j. j. PROPN admet-338 315 2 pharm pharm PROPN admet-338 315 3 . . PUNCT admet-338 316 1 sci sci PROPN admet-338 316 2 . . PROPN admet-338 317 1 22 22 NUM admet-338 317 2 ( ( PUNCT admet-338 317 3 2004 2004 NUM admet-338 317 4 ) ) PUNCT admet-338 317 5 297 297 NUM admet-338 317 6 - - SYM admet-338 317 7 304 304 NUM admet-338 317 8 . . PUNCT admet-338 318 1 [ [ X admet-338 318 2 31 31 NUM admet-338 318 3 ] ] PUNCT admet-338 318 4 e. e. PROPN admet-338 318 5 jantratid jantratid PROPN admet-338 318 6 , , PUNCT admet-338 318 7 s. s. PROPN admet-338 318 8 prakongpan prakongpan PROPN admet-338 318 9 , , PUNCT admet-338 318 10 g. g. PROPN admet-338 318 11 l. l. PROPN admet-338 318 12 amidon amidon PROPN admet-338 318 13 , , PUNCT admet-338 318 14 j. j. PROPN admet-338 318 15 b. b. PROPN admet-338 318 16 dressman dressman PROPN admet-338 318 17 . . PUNCT admet-338 319 1 feasibility feasibility NOUN admet-338 319 2 of of ADP admet-338 319 3 biowaiver biowaiver ADJ admet-338 319 4 extension extension NOUN admet-338 319 5 to to ADP admet-338 319 6 biopharmaceutics biopharmaceutics NOUN admet-338 319 7 classification classification NOUN admet-338 319 8 system system NOUN admet-338 319 9 class class NOUN admet-338 319 10 iii iii NOUN admet-338 319 11 drug drug NOUN admet-338 319 12 products product NOUN admet-338 319 13 . . PUNCT admet-338 320 1 clin clin PROPN admet-338 320 2 . . PUNCT admet-338 320 3 pharmacokinet pharmacokinet PROPN admet-338 320 4 . . PUNCT admet-338 321 1 45 45 NUM admet-338 321 2 ( ( PUNCT admet-338 321 3 2006 2006 NUM admet-338 321 4 ) ) PUNCT admet-338 321 5 385399 385399 NUM admet-338 321 6 . . PUNCT admet-338 322 1 [ [ X admet-338 322 2 32 32 NUM admet-338 322 3 ] ] X admet-338 322 4 y. y. PROPN admet-338 322 5 tsume tsume PROPN admet-338 322 6 , , PUNCT admet-338 322 7 g. g. PROPN admet-338 322 8 l. l. PROPN admet-338 322 9 amidon amidon PROPN admet-338 322 10 . . PUNCT admet-338 323 1 the the DET admet-338 323 2 biowaiver biowaiver NOUN admet-338 323 3 extension extension NOUN admet-338 323 4 for for ADP admet-338 323 5 bcs bcs NOUN admet-338 323 6 class class NOUN admet-338 323 7 iii iii NUM admet-338 323 8 drugs drug NOUN admet-338 323 9 : : PUNCT admet-338 323 10 the the DET admet-338 323 11 effect effect NOUN admet-338 323 12 of of ADP admet-338 323 13 dissolution dissolution ADJ admet-338 323 14 rate rate NOUN admet-338 323 15 on on ADP admet-338 323 16 the the DET admet-338 323 17 bioequivalence bioequivalence NOUN admet-338 323 18 of of ADP admet-338 323 19 bcs bcs NOUN admet-338 323 20 class class NOUN admet-338 323 21 iii iii NUM admet-338 323 22 immediate immediate ADJ admet-338 323 23 - - PUNCT admet-338 323 24 release release NOUN admet-338 323 25 drugs drug NOUN admet-338 323 26 predicted predict VERB admet-338 323 27 by by ADP admet-338 323 28 computer computer NOUN admet-338 323 29 simulation simulation PROPN admet-338 323 30 . . PUNCT admet-338 324 1 mol mol PROPN admet-338 324 2 . . PUNCT admet-338 324 3 pharm pharm PROPN admet-338 324 4 . . PUNCT admet-338 325 1 7 7 NUM admet-338 325 2 ( ( PUNCT admet-338 325 3 2010 2010 NUM admet-338 325 4 ) ) PUNCT admet-338 325 5 1235 1235 NUM admet-338 325 6 - - SYM admet-338 325 7 1243 1243 NUM admet-338 325 8 . . PUNCT admet-338 326 1 [ [ X admet-338 326 2 33 33 NUM admet-338 326 3 ] ] PUNCT admet-338 326 4 a. a. NOUN admet-338 326 5 ono ono PROPN admet-338 326 6 , , PUNCT admet-338 326 7 k. k. PROPN admet-338 326 8 sugano sugano PROPN admet-338 326 9 . . PUNCT admet-338 327 1 application application NOUN admet-338 327 2 of of ADP admet-338 327 3 the the DET admet-338 327 4 bcs bcs NOUN admet-338 327 5 biowaiver biowaiver NOUN admet-338 327 6 approach approach NOUN admet-338 327 7 to to ADP admet-338 327 8 assessing assess VERB admet-338 327 9 bioequivalence bioequivalence NOUN admet-338 327 10 of of ADP admet-338 327 11 orally orally ADV admet-338 327 12 disintegrating disintegrate VERB admet-338 327 13 tablets tablet NOUN admet-338 327 14 with with ADP admet-338 327 15 immediate immediate ADJ admet-338 327 16 release release NOUN admet-338 327 17 formulations formulation NOUN admet-338 327 18 . . PUNCT admet-338 328 1 eur eur PROPN admet-338 328 2 . . PUNCT admet-338 329 1 j. j. PROPN admet-338 329 2 pharm pharm PROPN admet-338 329 3 . . PUNCT admet-338 330 1 sci sci PROPN admet-338 330 2 . . PROPN admet-338 331 1 64 64 NUM admet-338 331 2 ( ( PUNCT admet-338 331 3 2014 2014 NUM admet-338 331 4 ) ) PUNCT admet-338 331 5 37 37 NUM admet-338 331 6 - - SYM admet-338 331 7 43 43 NUM admet-338 331 8 . . PUNCT admet-338 332 1 [ [ X admet-338 332 2 34 34 NUM admet-338 332 3 ] ] X admet-338 332 4 e. e. PROPN admet-338 332 5 jantratid jantratid PROPN admet-338 332 6 , , PUNCT admet-338 332 7 s. s. PROPN admet-338 332 8 prakongpan prakongpan PROPN admet-338 332 9 , , PUNCT admet-338 332 10 j. j. PROPN admet-338 332 11 b. b. PROPN admet-338 332 12 dressman dressman PROPN admet-338 332 13 , , PUNCT admet-338 332 14 g. g. PROPN admet-338 332 15 l. l. PROPN admet-338 332 16 amidon amidon PROPN admet-338 332 17 , , PUNCT admet-338 332 18 h. h. PROPN admet-338 332 19 e. e. PROPN admet-338 332 20 junginger junginger PROPN admet-338 332 21 , , PUNCT admet-338 332 22 k. k. PROPN admet-338 332 23 k. k. PROPN admet-338 332 24 midha midha PROPN admet-338 332 25 , , PUNCT admet-338 332 26 d. d. PROPN admet-338 332 27 m. m. PROPN admet-338 332 28 barends barend VERB admet-338 332 29 . . PUNCT admet-338 333 1 biowaiver biowaiver PROPN admet-338 333 2 monographs monograph NOUN admet-338 333 3 for for ADP admet-338 333 4 immediate immediate ADJ admet-338 333 5 release release NOUN admet-338 333 6 solid solid ADJ admet-338 333 7 oral oral ADJ admet-338 333 8 dosage dosage NOUN admet-338 333 9 forms form NOUN admet-338 333 10 : : PUNCT admet-338 333 11 cimetidine cimetidine NOUN admet-338 333 12 . . PUNCT admet-338 334 1 j. j. PROPN admet-338 334 2 pharm pharm PROPN admet-338 334 3 . . PUNCT admet-338 335 1 sci sci PROPN admet-338 335 2 . . PROPN admet-338 336 1 95 95 NUM admet-338 336 2 ( ( PUNCT admet-338 336 3 2006 2006 NUM admet-338 336 4 ) ) PUNCT admet-338 336 5 974 974 NUM admet-338 336 6 - - SYM admet-338 336 7 984 984 NUM admet-338 336 8 . . PUNCT admet-338 337 1 [ [ X admet-338 337 2 35 35 NUM admet-338 337 3 ] ] X admet-338 337 4 c. c. PROPN admet-338 337 5 alvarez alvarez PROPN admet-338 337 6 , , PUNCT admet-338 337 7 i. i. PROPN admet-338 337 8 nunez nunez PROPN admet-338 337 9 , , PUNCT admet-338 337 10 j. j. PROPN admet-338 337 11 j. j. PROPN admet-338 337 12 torrado torrado PROPN admet-338 337 13 , , PUNCT admet-338 337 14 j. j. PROPN admet-338 337 15 gordon gordon PROPN admet-338 337 16 , , PUNCT admet-338 337 17 h. h. PROPN admet-338 337 18 potthast potthast PROPN admet-338 337 19 , , PUNCT admet-338 337 20 a. a. PROPN admet-338 337 21 garcia garcia PROPN admet-338 337 22 - - PUNCT admet-338 337 23 arieta arieta PROPN admet-338 337 24 . . PUNCT admet-338 338 1 investigation investigation NOUN admet-338 338 2 on on ADP admet-338 338 3 the the DET admet-338 338 4 possibility possibility NOUN admet-338 338 5 of of ADP admet-338 338 6 biowaivers biowaiver NOUN admet-338 338 7 for for ADP admet-338 338 8 ibuprofen ibuprofen NOUN admet-338 338 9 . . PUNCT admet-338 339 1 j. j. PROPN admet-338 339 2 pharm pharm PROPN admet-338 339 3 . . PUNCT admet-338 340 1 sci sci PROPN admet-338 340 2 . . PROPN admet-338 340 3 100 100 NUM admet-338 340 4 ( ( PUNCT admet-338 340 5 2011 2011 NUM admet-338 340 6 ) ) PUNCT admet-338 340 7 2343 2343 NUM admet-338 340 8 - - SYM admet-338 340 9 2349 2349 NUM admet-338 340 10 . . PUNCT admet-338 341 1 [ [ X admet-338 341 2 36 36 NUM admet-338 341 3 ] ] PUNCT admet-338 341 4 a. a. PROPN admet-338 341 5 garcia garcia PROPN admet-338 341 6 - - PUNCT admet-338 341 7 arieta arieta PROPN admet-338 341 8 , , PUNCT admet-338 341 9 j. j. PROPN admet-338 341 10 gordon gordon PROPN admet-338 341 11 , , PUNCT admet-338 341 12 h. h. PROPN admet-338 341 13 potthast potthast PROPN admet-338 341 14 . . PUNCT admet-338 342 1 on on ADP admet-338 342 2 the the DET admet-338 342 3 biopharmaceutics biopharmaceutics NOUN admet-338 342 4 classification classification NOUN admet-338 342 5 system system NOUN admet-338 342 6 biowaiver biowaiver NOUN admet-338 342 7 of of ADP admet-338 342 8 ibuprofen ibuprofen PROPN admet-338 342 9 . . PUNCT admet-338 343 1 j. j. PROPN admet-338 343 2 pharm pharm PROPN admet-338 343 3 . . PUNCT admet-338 344 1 sci sci PROPN admet-338 344 2 . . PROPN admet-338 345 1 104 104 NUM admet-338 345 2 ( ( PUNCT admet-338 345 3 2015 2015 NUM admet-338 345 4 ) ) PUNCT admet-338 345 5 2429 2429 NUM admet-338 345 6 - - SYM admet-338 345 7 2432 2432 NUM admet-338 345 8 . . PUNCT admet-338 346 1 [ [ X admet-338 346 2 37 37 NUM admet-338 346 3 ] ] PUNCT admet-338 346 4 e. e. PROPN admet-338 346 5 ramirez ramirez PROPN admet-338 346 6 , , PUNCT admet-338 346 7 o. o. PROPN admet-338 346 8 laosa laosa PROPN admet-338 346 9 , , PUNCT admet-338 346 10 p. p. NOUN admet-338 346 11 guerra guerra PROPN admet-338 346 12 , , PUNCT admet-338 346 13 b. b. PROPN admet-338 346 14 duque duque PROPN admet-338 346 15 , , PUNCT admet-338 346 16 b. b. PROPN admet-338 346 17 mosquera mosquera PROPN admet-338 346 18 , , PUNCT admet-338 346 19 a. a. NOUN admet-338 346 20 m. m. PROPN admet-338 346 21 borobia borobia PROPN admet-338 346 22 , , PUNCT admet-338 346 23 s. s. PROPN admet-338 346 24 h. h. PROPN admet-338 346 25 lei lei PROPN admet-338 346 26 , , PUNCT admet-338 346 27 a. a. NOUN admet-338 346 28 j. j. PROPN admet-338 346 29 carcas carcas PROPN admet-338 346 30 , , PUNCT admet-338 346 31 j. j. PROPN admet-338 346 32 frias frias PROPN admet-338 346 33 . . PUNCT admet-338 346 34 acceptability acceptability NOUN admet-338 346 35 and and CCONJ admet-338 346 36 characteristics characteristic NOUN admet-338 346 37 of of ADP admet-338 346 38 124 124 NUM admet-338 346 39 human human ADJ admet-338 346 40 bioequivalence bioequivalence NOUN admet-338 346 41 studies study NOUN admet-338 346 42 with with ADP admet-338 346 43 active active ADJ admet-338 346 44 substances substance NOUN admet-338 346 45 classified classify VERB admet-338 346 46 according accord VERB admet-338 346 47 to to ADP admet-338 346 48 the the DET admet-338 346 49 biopharmaceutic biopharmaceutic ADJ admet-338 346 50 classification classification NOUN admet-338 346 51 system system NOUN admet-338 346 52 . . PUNCT admet-338 347 1 br br PROPN admet-338 347 2 . . PUNCT admet-338 348 1 j. j. PROPN admet-338 348 2 clin clin PROPN admet-338 348 3 . . PUNCT admet-338 349 1 pharmacol pharmacol PROPN admet-338 349 2 . . PUNCT admet-338 350 1 70 70 NUM admet-338 350 2 ( ( PUNCT admet-338 350 3 2010 2010 NUM admet-338 350 4 ) ) PUNCT admet-338 350 5 694 694 NUM admet-338 350 6 - - SYM admet-338 350 7 702 702 NUM admet-338 350 8 . . PUNCT admet-338 351 1 Β© Β© PROPN admet-338 351 2 2016 2016 NUM admet-338 351 3 by by ADP admet-338 351 4 the the DET admet-338 351 5 authors author NOUN admet-338 351 6 ; ; PUNCT admet-338 351 7 licensee licensee PROPN admet-338 351 8 iapc iapc PROPN admet-338 351 9 , , PUNCT admet-338 351 10 zagreb zagreb PROPN admet-338 351 11 , , PUNCT admet-338 351 12 croatia croatia PROPN admet-338 351 13 . . PUNCT admet-338 352 1 this this DET admet-338 352 2 article article NOUN admet-338 352 3 is be AUX admet-338 352 4 an an DET admet-338 352 5 open open ADJ admet-338 352 6 - - PUNCT admet-338 352 7 access access NOUN admet-338 352 8 article article NOUN admet-338 352 9 distributed distribute VERB admet-338 352 10 under under ADP admet-338 352 11 the the DET admet-338 352 12 terms term NOUN admet-338 352 13 and and CCONJ admet-338 352 14 conditions condition NOUN admet-338 352 15 of of ADP admet-338 352 16 the the DET admet-338 352 17 creative creative ADJ admet-338 352 18 commons common NOUN admet-338 352 19 attribution attribution NOUN admet-338 352 20 license license NOUN admet-338 352 21 ( ( PUNCT admet-338 352 22 http://creativecommons.org/licenses/by/3.0/ http://creativecommons.org/licenses/by/3.0/ PROPN admet-338 352 23 ) ) PUNCT admet-338 352 24 http://creativecommons.org/licenses/by/3.0/ http://creativecommons.org/licenses/by/3.0/ PROPN admet-338 352 25 admet admet PROPN admet-338 352 26 & & CCONJ admet-338 352 27 dmpk dmpk PROPN admet-338 352 28 4(4 4(4 NUM admet-338 352 29 ) ) PUNCT admet-338 352 30 ( ( PUNCT admet-338 352 31 2016 2016 NUM admet-338 352 32 ) ) PUNCT admet-338 352 33 335 335 NUM admet-338 352 34 - - SYM admet-338 352 35 360 360 NUM admet-338 352 36 biopharmaceutical biopharmaceutical NOUN admet-338 352 37 and and CCONJ admet-338 352 38 physchem physchem NOUN admet-338 352 39 properties property NOUN admet-338 352 40 for for ADP admet-338 352 41 odt odt ADJ admet-338 352 42 doi doi NOUN admet-338 352 43 : : PUNCT admet-338 352 44 10.5599 10.5599 NUM admet-338 352 45 / / SYM admet-338 352 46 admet.4.4.338 admet.4.4.338 VERB admet-338 352 47 351 351 NUM admet-338 352 48 supplement supplement NOUN admet-338 352 49 table table NOUN admet-338 352 50 1 1 NUM admet-338 352 51 . . PUNCT admet-338 352 52 odt odt PROPN admet-338 352 53 drug drug NOUN admet-338 352 54 list list NOUN admet-338 352 55 used use VERB admet-338 352 56 in in ADP admet-338 352 57 this this DET admet-338 352 58 study study NOUN admet-338 352 59 drug drug NOUN admet-338 352 60 prescription prescription NOUN admet-338 352 61 information information NOUN admet-338 352 62 acarbose acarbose NOUN admet-338 352 63 http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f NOUN admet-338 352 64 ambroxol ambroxol NOUN admet-338 352 65 hydrochloride hydrochloride NOUN admet-338 352 66 http://www.info.pmda.go.jp/go/interview/1/300119_2239001g1039_1_061_1f http://www.info.pmda.go.jp/go/interview/1/300119_2239001g1039_1_061_1f NOUN admet-338 352 67 amlodipine amlodipine NOUN admet-338 352 68 besylate besylate VERB admet-338 352 69 http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f NOUN admet-338 352 70 http://www.info.pmda.go.jp/go/interview/3/400093_2171022f1045_3_017_1f http://www.info.pmda.go.jp/go/interview/3/400093_2171022f1045_3_017_1f NOUN admet-338 352 71 aripiprazole aripiprazole PROPN admet-338 352 72 http://www.info.pmda.go.jp/go/interview/1/180078_1179045f4022_1_012_1f http://www.info.pmda.go.jp/go/interview/1/180078_1179045f4022_1_012_1f NOUN admet-338 352 73 bepotastine bepotastine ADJ admet-338 352 74 besylate besylate ADJ admet-338 352 75 http://www.info.pmda.go.jp/go/interview/1/400315_4490022f3022_1_090_1f http://www.info.pmda.go.jp/go/interview/1/400315_4490022f3022_1_090_1f NOUN admet-338 352 76 bicalutamide bicalutamide VERB admet-338 352 77 http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f PROPN admet-338 352 78 brotizolam brotizolam PROPN admet-338 352 79 http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f PART admet-338 352 80 cetirizine cetirizine ADJ admet-338 352 81 hydrochloride hydrochloride NOUN admet-338 352 82 http://www.info.pmda.go.jp/go/interview/1/300119_4490020f1225_1_051_1f http://www.info.pmda.go.jp/go/interview/1/300119_4490020f1225_1_051_1f NOUN admet-338 352 83 cilostazol cilostazol ADJ admet-338 352 84 http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f NOUN admet-338 352 85 desmopressin desmopressin NOUN admet-338 352 86 acetate acetate NOUN admet-338 352 87 hydrate hydrate NOUN admet-338 352 88 http://www.info.pmda.go.jp/go/interview/1/670666_2419001f1023_2_1f http://www.info.pmda.go.jp/go/interview/1/670666_2419001f1023_2_1f NOUN admet-338 352 89 dienogest dienog ADJ admet-338 352 90 http://www.info.pmda.go.jp/go/interview/1/790005_2499010f1023_1_m02_1f http://www.info.pmda.go.jp/go/interview/1/790005_2499010f1023_1_m02_1f NOUN admet-338 352 91 domperidone domperidone NOUN admet-338 352 92 http://www.info.pmda.go.jp/go/interview/1/230124_2399005f3020_1_004_1f http://www.info.pmda.go.jp/go/interview/1/230124_2399005f3020_1_004_1f NOUN admet-338 352 93 donepezil donepezil VERB admet-338 352 94 hydrochloride hydrochloride NOUN admet-338 352 95 http://www.info.pmda.go.jp/go/interview/1/170033_1190012f3029_1_028_1f http://www.info.pmda.go.jp/go/interview/1/170033_1190012f3029_1_028_1f NOUN admet-338 352 96 doxazosin doxazosin VERB admet-338 352 97 mesylate mesylate NOUN admet-338 352 98 http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f NOUN admet-338 352 99 droxidopa droxidopa ADJ admet-338 352 100 http://www.info.pmda.go.jp/go/interview/2/400093_1169006c1039_2_009_1f http://www.info.pmda.go.jp/go/interview/2/400093_1169006c1039_2_009_1f PROPN admet-338 352 101 ebastine ebastine PROPN admet-338 352 102 http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f NOUN admet-338 352 103 famotidine famotidine NOUN admet-338 352 104 http://www.info.pmda.go.jp/go/interview/1/800126_2325003f1024_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2325003f1024_1_1f NOUN admet-338 352 105 fexofenadine fexofenadine PROPN admet-338 352 106 hydrochloride hydrochloride NOUN admet-338 352 107 http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f NOUN admet-338 352 108 galantamine galantamine VERB admet-338 352 109 hydrobromide hydrobromide NOUN admet-338 352 110 http://www.info.pmda.go.jp/go/interview/1/800155_1190019f1028_1_005_1f http://www.info.pmda.go.jp/go/interview/1/800155_1190019f1028_1_005_1f NOUN admet-338 352 111 gimeracil gimeracil PROPN admet-338 352 112 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f PUNCT admet-338 352 113 glimepiride glimepiride NOUN admet-338 352 114 http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f NOUN admet-338 352 115 hydrochlorothiazide hydrochlorothiazide VERB admet-338 352 116 http://www.info.pmda.go.jp/go/interview/1/480235_2132004f1103_1_002_1f http://www.info.pmda.go.jp/go/interview/1/480235_2132004f1103_1_002_1f NOUN admet-338 352 117 imidafenacin imidafenacin NOUN admet-338 352 118 http://www.info.pmda.go.jp/go/interview/1/230109_2590013f1027_1_a13_1f http://www.info.pmda.go.jp/go/interview/1/230109_2590013f1027_1_a13_1f VERB admet-338 352 119 http://www.info.pmda.go.jp/go/interview/1/180188_2590013f1035_1_009_1f http://www.info.pmda.go.jp/go/interview/1/180188_2590013f1035_1_009_1f NOUN admet-338 352 120 irsogladine irsogladine NOUN admet-338 352 121 maleate maleate NOUN admet-338 352 122 http://www.info.pmda.go.jp/go/interview/1/530263_2329020f3020_1_05f_1f http://www.info.pmda.go.jp/go/interview/1/530263_2329020f3020_1_05f_1f NOUN admet-338 352 123 http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f NOUN admet-338 352 124 http://www.info.pmda.go.jp/go/interview/1/300119_2239001g1039_1_061_1f http://www.info.pmda.go.jp/go/interview/1/300119_2239001g1039_1_061_1f NOUN admet-338 352 125 http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f NOUN admet-338 352 126 http://www.info.pmda.go.jp/go/interview/1/180078_1179045f4022_1_012_1f http://www.info.pmda.go.jp/go/interview/1/180078_1179045f4022_1_012_1f NOUN admet-338 352 127 http://www.info.pmda.go.jp/go/interview/1/400315_4490022f3022_1_090_1f http://www.info.pmda.go.jp/go/interview/1/400315_4490022f3022_1_090_1f NOUN admet-338 352 128 http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f NOUN admet-338 352 129 http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f PART admet-338 352 130 http://www.info.pmda.go.jp/go/interview/1/300119_4490020f1225_1_051_1f http://www.info.pmda.go.jp/go/interview/1/300119_4490020f1225_1_051_1f NOUN admet-338 352 131 http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f NOUN admet-338 352 132 http://www.info.pmda.go.jp/go/interview/1/670666_2419001f1023_2_1f http://www.info.pmda.go.jp/go/interview/1/670666_2419001f1023_2_1f NOUN admet-338 352 133 http://www.info.pmda.go.jp/go/interview/1/790005_2499010f1023_1_m02_1f http://www.info.pmda.go.jp/go/interview/1/790005_2499010f1023_1_m02_1f NOUN admet-338 352 134 http://www.info.pmda.go.jp/go/interview/1/230124_2399005f3020_1_004_1f http://www.info.pmda.go.jp/go/interview/1/230124_2399005f3020_1_004_1f NOUN admet-338 352 135 http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f VERB admet-338 352 136 http://www.info.pmda.go.jp/go/interview/2/400093_1169006c1039_2_009_1f http://www.info.pmda.go.jp/go/interview/2/400093_1169006c1039_2_009_1f NOUN admet-338 352 137 http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f NOUN admet-338 352 138 http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f NOUN admet-338 352 139 http://www.info.pmda.go.jp/go/interview/1/800155_1190019f1028_1_005_1f http://www.info.pmda.go.jp/go/interview/1/800155_1190019f1028_1_005_1f NOUN admet-338 352 140 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f PART admet-338 352 141 http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f NOUN admet-338 352 142 http://www.info.pmda.go.jp/go/interview/1/480235_2132004f1103_1_002_1f http://www.info.pmda.go.jp/go/interview/1/480235_2132004f1103_1_002_1f NOUN admet-338 352 143 http://www.info.pmda.go.jp/go/interview/1/230109_2590013f1027_1_a13_1f http://www.info.pmda.go.jp/go/interview/1/230109_2590013f1027_1_a13_1f VERB admet-338 352 144 http://www.info.pmda.go.jp/go/interview/1/180188_2590013f1035_1_009_1f http://www.info.pmda.go.jp/go/interview/1/180188_2590013f1035_1_009_1f NOUN admet-338 352 145 http://www.info.pmda.go.jp/go/interview/1/530263_2329020f3020_1_05f_1f http://www.info.pmda.go.jp/go/interview/1/530263_2329020f3020_1_05f_1f X admet-338 353 1 asami asami PROPN admet-338 353 2 ono ono PROPN admet-338 353 3 et et PROPN admet-338 353 4 al al PROPN admet-338 353 5 . . PROPN admet-338 353 6 admet admet PROPN admet-338 353 7 & & CCONJ admet-338 353 8 dmpk dmpk PROPN admet-338 353 9 4(4 4(4 NUM admet-338 353 10 ) ) PUNCT admet-338 353 11 ( ( PUNCT admet-338 353 12 2016 2016 NUM admet-338 353 13 ) ) PUNCT admet-338 353 14 335 335 NUM admet-338 353 15 - - SYM admet-338 353 16 360 360 NUM admet-338 353 17 352 352 NUM admet-338 353 18 lafutidine lafutidine ADJ admet-338 353 19 http://www.info.pmda.go.jp/go/interview/1/400107_2325006f3020_1_04e_1f http://www.info.pmda.go.jp/go/interview/1/400107_2325006f3020_1_04e_1f NOUN admet-338 353 20 lansoprazole lansoprazole NOUN admet-338 353 21 http://www.info.pmda.go.jp/go/interview/1/400256_2329023f1020_1_006_1f http://www.info.pmda.go.jp/go/interview/1/400256_2329023f1020_1_006_1f NOUN admet-338 353 22 loratadine loratadine NOUN admet-338 353 23 http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f NOUN admet-338 353 24 memantine memantine ADJ admet-338 353 25 hydrochloride hydrochloride NOUN admet-338 353 26 http://www.info.pmda.go.jp/go/interview/1/430574_1190018f1023_1_m09_1f http://www.info.pmda.go.jp/go/interview/1/430574_1190018f1023_1_m09_1f X admet-338 353 27 midodrine midodrine ADJ admet-338 353 28 hydrochloride hydrochloride NOUN admet-338 353 29 http://www.info.pmda.go.jp/go/interview/1/400059_2160002f2024_1_004_1f http://www.info.pmda.go.jp/go/interview/1/400059_2160002f2024_1_004_1f NOUN admet-338 353 30 miglitol miglitol PROPN admet-338 353 31 http://www.info.pmda.go.jp/go/interview/1/300297_39690a0f1026_1_001_1f http://www.info.pmda.go.jp/go/interview/1/300297_39690a0f1026_1_001_1f X admet-338 353 32 naftopizil naftopizil NOUN admet-338 353 33 http://www.info.pmda.go.jp/go/interview/1/100898_2590009f4020_1_1f http://www.info.pmda.go.jp/go/interview/1/100898_2590009f4020_1_1f PART admet-338 353 34 olanzapine olanzapine NOUN admet-338 353 35 http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f X admet-338 353 36 olopatadine olopatadine ADJ admet-338 353 37 hydrochloride hydrochloride NOUN admet-338 353 38 http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f NOUN admet-338 353 39 ondansetron ondansetron NOUN admet-338 353 40 hydrochloride hydrochloride NOUN admet-338 353 41 http://www.info.pmda.go.jp/go/interview/1/340278_2391006f1023_1_1f http://www.info.pmda.go.jp/go/interview/1/340278_2391006f1023_1_1f NOUN admet-338 353 42 oteracil oteracil NOUN admet-338 353 43 potassium potassium NOUN admet-338 353 44 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f PART admet-338 353 45 paroxetine paroxetine NOUN admet-338 353 46 hydrochloride hydrochloride NOUN admet-338 353 47 hydrate hydrate NOUN admet-338 353 48 http://www.info.pmda.go.jp/go/interview/1/480235_1179041f1254_1_005_1f http://www.info.pmda.go.jp/go/interview/1/480235_1179041f1254_1_005_1f NOUN admet-338 353 49 pioglitazone pioglitazone NOUN admet-338 353 50 hydrochloride hydrochloride NOUN admet-338 353 51 http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f NOUN admet-338 353 52 pitavastatin pitavastatin NOUN admet-338 353 53 calcium calcium NOUN admet-338 353 54 http://www.info.pmda.go.jp/go/interview/1/270072_2189016f4027_1_005_1f http://www.info.pmda.go.jp/go/interview/1/270072_2189016f4027_1_005_1f NOUN admet-338 353 55 polaprezinc polaprezinc PROPN admet-338 353 56 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2329027f1029_1_04 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2329027f1029_1_04 PRON admet-338 353 57 pramipexole pramipexole ADJ admet-338 353 58 hydrochloride hydrochloride NOUN admet-338 353 59 hydrate hydrate NOUN admet-338 353 60 http://www.info.pmda.go.jp/go/interview/1/480235_1169012f3025_1_004_1f http://www.info.pmda.go.jp/go/interview/1/480235_1169012f3025_1_004_1f NOUN admet-338 353 61 ramosetron ramosetron NOUN admet-338 353 62 hydrochloride hydrochloride NOUN admet-338 353 63 http://www.info.pmda.go.jp/go/interview/1/800126_2399014f3029_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2399014f3029_1_1f VERB admet-338 353 64 http://www.info.pmda.go.jp/go/interview/1/800126_2391004f1024_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2391004f1024_1_1f NOUN admet-338 353 65 rebamipide rebamipide ADJ admet-338 353 66 http://www.info.pmda.go.jp/go/interview/1/530113_2329021f2028_1_002_1f http://www.info.pmda.go.jp/go/interview/1/530113_2329021f2028_1_002_1f NOUN admet-338 353 67 risperidone risperidone NOUN admet-338 353 68 http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f PROPN admet-338 353 69 rizatriptan rizatriptan ADJ admet-338 353 70 benzoate benzoate NOUN admet-338 353 71 http://www.info.pmda.go.jp/go/interview/2/230109_2160006f1026_2_011_1f http://www.info.pmda.go.jp/go/interview/2/230109_2160006f1026_2_011_1f NOUN admet-338 353 72 selegiline selegiline VERB admet-338 353 73 hydrochloride hydrochloride NOUN admet-338 353 74 http://www.info.pmda.go.jp/go/interview/1/170654_1169010f2020_1_s03_1f http://www.info.pmda.go.jp/go/interview/1/170654_1169010f2020_1_s03_1f X admet-338 353 75 sertraline sertraline VERB admet-338 353 76 hydrochloride hydrochloride NOUN admet-338 353 77 http://www.info.pmda.go.jp/go/interview/2/671450_1179046f1028_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_1179046f1028_2_1f NOUN admet-338 353 78 sildenafil sildenafil PROPN admet-338 353 79 citrate citrate PROPN admet-338 353 80 http://www.info.pmda.go.jp/go/interview/1/480235_259000af3027_1_002_1f http://www.info.pmda.go.jp/go/interview/1/480235_259000af3027_1_002_1f PROPN admet-338 353 81 solifenacin solifenacin PROPN admet-338 353 82 succinate succinate PROPN admet-338 353 83 http://www.info.pmda.go.jp/go/interview/1/800126_2590011f3020_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2590011f3020_1_1f VERB admet-338 353 84 taltirelin taltirelin NOUN admet-338 353 85 hydrate hydrate NOUN admet-338 353 86 http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f NOUN admet-338 353 87 tamsulosin tamsulosin VERB admet-338 353 88 hydrochloride hydrochloride NOUN admet-338 353 89 http://www.info.pmda.go.jp/go/interview/1/800126_2590008f1026_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2590008f1026_1_1f NOUN admet-338 353 90 tegafur tegafur NOUN admet-338 353 91 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f NOUN admet-338 353 92 http://www.info.pmda.go.jp/go/interview/1/400107_2325006f3020_1_04e_1f http://www.info.pmda.go.jp/go/interview/1/400107_2325006f3020_1_04e_1f NOUN admet-338 353 93 http://www.info.pmda.go.jp/go/interview/1/400256_2329023f1020_1_006_1f http://www.info.pmda.go.jp/go/interview/1/400256_2329023f1020_1_006_1f NOUN admet-338 353 94 http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f NOUN admet-338 353 95 http://www.info.pmda.go.jp/go/interview/1/430574_1190018f1023_1_m09_1f http://www.info.pmda.go.jp/go/interview/1/430574_1190018f1023_1_m09_1f NOUN admet-338 353 96 http://www.info.pmda.go.jp/go/interview/1/400059_2160002f2024_1_004_1f http://www.info.pmda.go.jp/go/interview/1/400059_2160002f2024_1_004_1f NOUN admet-338 353 97 http://www.info.pmda.go.jp/go/interview/1/300297_39690a0f1026_1_001_1f http://www.info.pmda.go.jp/go/interview/1/300297_39690a0f1026_1_001_1f NOUN admet-338 353 98 http://www.info.pmda.go.jp/go/interview/1/100898_2590009f4020_1_1f http://www.info.pmda.go.jp/go/interview/1/100898_2590009f4020_1_1f NOUN admet-338 353 99 http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f PART admet-338 353 100 http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f NOUN admet-338 353 101 http://www.info.pmda.go.jp/go/interview/1/340278_2391006f1023_1_1f http://www.info.pmda.go.jp/go/interview/1/340278_2391006f1023_1_1f NOUN admet-338 353 102 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f NOUN admet-338 353 103 http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f NOUN admet-338 353 104 http://www.info.pmda.go.jp/go/interview/1/270072_2189016f4027_1_005_1f http://www.info.pmda.go.jp/go/interview/1/270072_2189016f4027_1_005_1f NOUN admet-338 353 105 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2329027f1029_1_04 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2329027f1029_1_04 PRON admet-338 353 106 http://www.info.pmda.go.jp/go/interview/1/800126_2399014f3029_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2399014f3029_1_1f VERB admet-338 353 107 http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f NOUN admet-338 353 108 http://www.info.pmda.go.jp/go/interview/2/230109_2160006f1026_2_011_1f http://www.info.pmda.go.jp/go/interview/2/230109_2160006f1026_2_011_1f NOUN admet-338 353 109 http://www.info.pmda.go.jp/go/interview/1/170654_1169010f2020_1_s03_1f http://www.info.pmda.go.jp/go/interview/1/170654_1169010f2020_1_s03_1f NOUN admet-338 353 110 http://www.info.pmda.go.jp/go/interview/2/671450_1179046f1028_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_1179046f1028_2_1f NOUN admet-338 353 111 http://www.info.pmda.go.jp/go/interview/1/800126_2590011f3020_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2590011f3020_1_1f VERB admet-338 353 112 http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f NOUN admet-338 353 113 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f NUM admet-338 353 114 admet admet PROPN admet-338 353 115 & & CCONJ admet-338 353 116 dmpk dmpk PROPN admet-338 353 117 4(4 4(4 NUM admet-338 353 118 ) ) PUNCT admet-338 353 119 ( ( PUNCT admet-338 353 120 2016 2016 NUM admet-338 353 121 ) ) PUNCT admet-338 353 122 335 335 NUM admet-338 353 123 - - SYM admet-338 353 124 360 360 NUM admet-338 353 125 biopharmaceutical biopharmaceutical NOUN admet-338 353 126 and and CCONJ admet-338 353 127 physchem physchem NOUN admet-338 353 128 properties property NOUN admet-338 353 129 for for ADP admet-338 353 130 odt odt ADJ admet-338 353 131 doi doi NOUN admet-338 353 132 : : PUNCT admet-338 353 133 10.5599 10.5599 NUM admet-338 353 134 / / SYM admet-338 353 135 admet.4.4.338 admet.4.4.338 VERB admet-338 353 136 353 353 NUM admet-338 353 137 tramadol tramadol NOUN admet-338 353 138 hydrochloride hydrochloride NOUN admet-338 353 139 http://www.info.pmda.go.jp/go/interview/1/530263_1149038f1024_1_01f_1f http://www.info.pmda.go.jp/go/interview/1/530263_1149038f1024_1_01f_1f PUNCT admet-338 353 140 valsartan valsartan VERB admet-338 353 141 http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f PROPN admet-338 353 142 voglibose voglibose NOUN admet-338 353 143 http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f PROPN admet-338 353 144 zolmitriptan zolmitriptan PROPN admet-338 353 145 http://www.info.pmda.go.jp/go/interview/1/670227_2160004f2023_1_101_1f http://www.info.pmda.go.jp/go/interview/1/670227_2160004f2023_1_101_1f PROPN admet-338 353 146 zolpidem zolpidem PROPN admet-338 353 147 tartrate tartrate NOUN admet-338 353 148 http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f NOUN admet-338 353 149 zonizamide zonizamide NOUN admet-338 353 150 http://www.info.pmda.go.jp/go/interview/1/400093_1169015f2022_1_004_1f http://www.info.pmda.go.jp/go/interview/1/400093_1169015f2022_1_004_1f NOUN admet-338 353 151 http://www.info.pmda.go.jp/go/interview/1/530263_1149038f1024_1_01f_1f http://www.info.pmda.go.jp/go/interview/1/530263_1149038f1024_1_01f_1f PART admet-338 353 152 http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f PROPN admet-338 353 153 http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f NOUN admet-338 353 154 http://www.info.pmda.go.jp/go/interview/1/670227_2160004f2023_1_101_1f http://www.info.pmda.go.jp/go/interview/1/670227_2160004f2023_1_101_1f NOUN admet-338 353 155 http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f NOUN admet-338 353 156 http://www.info.pmda.go.jp/go/interview/1/400093_1169015f2022_1_004_1f http://www.info.pmda.go.jp/go/interview/1/400093_1169015f2022_1_004_1f NOUN admet-338 353 157 asami asami PROPN admet-338 353 158 ono ono PROPN admet-338 353 159 et et PROPN admet-338 353 160 al al PROPN admet-338 353 161 . . PROPN admet-338 353 162 admet admet PROPN admet-338 353 163 & & CCONJ admet-338 353 164 dmpk dmpk PROPN admet-338 353 165 4(4 4(4 NUM admet-338 353 166 ) ) PUNCT admet-338 353 167 ( ( PUNCT admet-338 353 168 2016 2016 NUM admet-338 353 169 ) ) PUNCT admet-338 353 170 335 335 NUM admet-338 353 171 - - SYM admet-338 353 172 360 360 NUM admet-338 353 173 354 354 NUM admet-338 353 174 supplement supplement NOUN admet-338 353 175 table table NOUN admet-338 353 176 2 2 NUM admet-338 353 177 . . X admet-338 353 178 ir ir PROPN admet-338 353 179 formulation formulation NOUN admet-338 353 180 drug drug NOUN admet-338 353 181 list list NOUN admet-338 353 182 used use VERB admet-338 353 183 in in ADP admet-338 353 184 this this DET admet-338 353 185 study study NOUN admet-338 353 186 drug drug NOUN admet-338 353 187 prescription prescription NOUN admet-338 353 188 information information NOUN admet-338 353 189 acarbose acarbose NOUN admet-338 353 190 http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f NOUN admet-338 353 191 acetaminophen acetaminophen NOUN admet-338 353 192 http://www.info.pmda.go.jp/go/interview/3/671610_1141007f1063_3_15l_1f http://www.info.pmda.go.jp/go/interview/3/671610_1141007f1063_3_15l_1f PUNCT admet-338 353 193 acetylsalicylic acetylsalicylic ADJ admet-338 353 194 acid acid NOUN admet-338 353 195 http://www.info.pmda.go.jp/go/interview/1/630004_3399007h1021_1_002_1f http://www.info.pmda.go.jp/go/interview/1/630004_3399007h1021_1_002_1f NOUN admet-338 353 196 acyclovir acyclovir PROPN admet-338 353 197 http://www.info.pmda.go.jp/go/interview/w/340278_6250002f1025_1_001_1f http://www.info.pmda.go.jp/go/interview/w/340278_6250002f1025_1_001_1f PROPN admet-338 353 198 alendronate alendronate PROPN admet-338 353 199 sodium sodium NOUN admet-338 353 200 hydrate hydrate NOUN admet-338 353 201 http://www.info.pmda.go.jp/go/interview/2/170050_3999018f1021_2_018_1f http://www.info.pmda.go.jp/go/interview/2/170050_3999018f1021_2_018_1f NOUN admet-338 353 202 alfacalcidol alfacalcidol NOUN admet-338 353 203 http://www.info.pmda.go.jp/go/interview/1/450045_3112001m1046_1_007_1f http://www.info.pmda.go.jp/go/interview/1/450045_3112001m1046_1_007_1f PROPN admet-338 353 204 allopurinol allopurinol VERB admet-338 353 205 http://www.info.pmda.go.jp/go/interview/w/340278_3943001f1314_1_1f http://www.info.pmda.go.jp/go/interview/w/340278_3943001f1314_1_1f PART admet-338 353 206 ambroxol ambroxol NOUN admet-338 353 207 hydrochloride hydrochloride NOUN admet-338 353 208 http://www.info.pmda.go.jp/go/interview/1/650168_2239001n1135_1_148_1f http://www.info.pmda.go.jp/go/interview/1/650168_2239001n1135_1_148_1f NOUN admet-338 353 209 amlodipine amlodipine NOUN admet-338 353 210 besylate besylate VERB admet-338 353 211 http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f NOUN admet-338 353 212 atenolol atenolol PROPN admet-338 353 213 http://www.info.pmda.go.jp/go/interview/3/670227_2123011f1155_1_131_1f http://www.info.pmda.go.jp/go/interview/3/670227_2123011f1155_1_131_1f PROPN admet-338 353 214 atorvastatin atorvastatin PROPN admet-338 353 215 calcium calcium NOUN admet-338 353 216 http://www.info.pmda.go.jp/go/interview/1/800126_2189015f1023_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2189015f1023_1_1f NOUN admet-338 353 217 azithromycin azithromycin NOUN admet-338 353 218 hydrate hydrate NOUN admet-338 353 219 http://www.info.pmda.go.jp/go/interview/2/671450_6149004f1028_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_6149004f1028_2_1f NOUN admet-338 353 220 azulene azulene NOUN admet-338 353 221 sulfonate sulfonate NOUN admet-338 353 222 http://www.info.pmda.go.jp/go/interview/1/530263_2323001f1225_1_04f_1f http://www.info.pmda.go.jp/go/interview/1/530263_2323001f1225_1_04f_1f SYM admet-338 353 223 benidipine benidipine VERB admet-338 353 224 hydrochloride hydrochloride NOUN admet-338 353 225 http://www.info.pmda.go.jp/go/interview/1/230124_2171021f1024_1_001_1f http://www.info.pmda.go.jp/go/interview/1/230124_2171021f1024_1_001_1f NOUN admet-338 353 226 beraprost beraprost PROPN admet-338 353 227 sodium sodium NOUN admet-338 353 228 http://www.info.pmda.go.jp/go/interview/1/480220_3399005f1021_1_a06_1f http://www.info.pmda.go.jp/go/interview/1/480220_3399005f1021_1_a06_1f NOUN admet-338 353 229 bicalutamide bicalutamide VERB admet-338 353 230 http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f PROPN admet-338 353 231 bisoprolol bisoprolol VERB admet-338 353 232 fumarate fumarate ADJ admet-338 353 233 http://www.info.pmda.go.jp/go/interview/1/400315_2123016f1107_1_120_1f http://www.info.pmda.go.jp/go/interview/1/400315_2123016f1107_1_120_1f NOUN admet-338 353 234 brotizolam brotizolam PROPN admet-338 353 235 http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f PART admet-338 353 236 cabergoline cabergoline NOUN admet-338 353 237 http://www.info.pmda.go.jp/go/interview/4/671450_1169011f1028_4_1f http://www.info.pmda.go.jp/go/interview/4/671450_1169011f1028_4_1f NOUN admet-338 353 238 camostat camostat PROPN admet-338 353 239 mesylate mesylate NOUN admet-338 353 240 http://www.info.pmda.go.jp/go/interview/1/180188_3999003f1297_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180188_3999003f1297_1_005_1f NOUN admet-338 353 241 candesartan candesartan VERB admet-338 353 242 cilexetil cilexetil PROPN admet-338 353 243 http://www.info.pmda.go.jp/go/interview/1/400256_2149040f1026_1_004_1f http://www.info.pmda.go.jp/go/interview/1/400256_2149040f1026_1_004_1f PROPN admet-338 353 244 carvedilol carvedilol PROPN admet-338 353 245 http://www.info.pmda.go.jp/go/interview/2/430574_2149032f1021_2_a13_1f http://www.info.pmda.go.jp/go/interview/2/430574_2149032f1021_2_a13_1f NOUN admet-338 353 246 cefcapene cefcapene ADJ admet-338 353 247 pivoxil pivoxil NOUN admet-338 353 248 hydrochloride hydrochloride NOUN admet-338 353 249 http://www.info.pmda.go.jp/go/interview/1/340018_6132016f1023_1_011_1f http://www.info.pmda.go.jp/go/interview/1/340018_6132016f1023_1_011_1f NOUN admet-338 353 250 cefdinir cefdinir NOUN admet-338 353 251 http://www.info.pmda.go.jp/go/interview/3/800126_6132013m1029_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_6132013m1029_3_1f NOUN admet-338 353 252 cefditoren cefditoren NOUN admet-338 353 253 pivoxil pivoxil NOUN admet-338 353 254 http://www.info.pmda.go.jp/go/interview/1/780009_6132015f1037_1_01a_1f http://www.info.pmda.go.jp/go/interview/1/780009_6132015f1037_1_01a_1f PUNCT admet-338 353 255 cefotiam cefotiam PROPN admet-338 353 256 hexetil hexetil PROPN admet-338 353 257 hydrochloride hydrochloride NOUN admet-338 353 258 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_6132012f1025_1_12 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_6132012f1025_1_12 PROPN admet-338 353 259 http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f http://www.info.pmda.go.jp/go/interview/1/630004_3969003f3037_1_005_1f NOUN admet-338 353 260 http://www.info.pmda.go.jp/go/interview/3/671610_1141007f1063_3_15l_1f http://www.info.pmda.go.jp/go/interview/3/671610_1141007f1063_3_15l_1f PART admet-338 353 261 http://www.info.pmda.go.jp/go/interview/1/630004_3399007h1021_1_002_1f http://www.info.pmda.go.jp/go/interview/1/630004_3399007h1021_1_002_1f NOUN admet-338 353 262 http://www.info.pmda.go.jp/go/interview/w/340278_6250002f1025_1_001_1f http://www.info.pmda.go.jp/go/interview/w/340278_6250002f1025_1_001_1f NOUN admet-338 353 263 http://www.info.pmda.go.jp/go/interview/2/170050_3999018f1021_2_018_1f http://www.info.pmda.go.jp/go/interview/2/170050_3999018f1021_2_018_1f NOUN admet-338 353 264 http://www.info.pmda.go.jp/go/interview/1/450045_3112001m1046_1_007_1f http://www.info.pmda.go.jp/go/interview/1/450045_3112001m1046_1_007_1f NOUN admet-338 353 265 http://www.info.pmda.go.jp/go/interview/w/340278_3943001f1314_1_1f http://www.info.pmda.go.jp/go/interview/w/340278_3943001f1314_1_1f PART admet-338 353 266 http://www.info.pmda.go.jp/go/interview/1/650168_2239001n1135_1_148_1f http://www.info.pmda.go.jp/go/interview/1/650168_2239001n1135_1_148_1f NOUN admet-338 353 267 http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2171022f1029_2_1f NOUN admet-338 353 268 http://www.info.pmda.go.jp/go/interview/3/670227_2123011f1155_1_131_1f http://www.info.pmda.go.jp/go/interview/3/670227_2123011f1155_1_131_1f NOUN admet-338 353 269 http://www.info.pmda.go.jp/go/interview/1/800126_2189015f1023_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2189015f1023_1_1f NOUN admet-338 353 270 http://www.info.pmda.go.jp/go/interview/2/671450_6149004f1028_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_6149004f1028_2_1f NOUN admet-338 353 271 http://www.info.pmda.go.jp/go/interview/1/530263_2323001f1225_1_04f_1f http://www.info.pmda.go.jp/go/interview/1/530263_2323001f1225_1_04f_1f NOUN admet-338 353 272 http://www.info.pmda.go.jp/go/interview/1/230124_2171021f1024_1_001_1f http://www.info.pmda.go.jp/go/interview/1/230124_2171021f1024_1_001_1f NOUN admet-338 353 273 http://www.info.pmda.go.jp/go/interview/1/480220_3399005f1021_1_a06_1f http://www.info.pmda.go.jp/go/interview/1/480220_3399005f1021_1_a06_1f NOUN admet-338 353 274 http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291009f1039_1_171_1f NOUN admet-338 353 275 http://www.info.pmda.go.jp/go/interview/1/400315_2123016f1107_1_120_1f http://www.info.pmda.go.jp/go/interview/1/400315_2123016f1107_1_120_1f NOUN admet-338 353 276 http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f http://www.info.pmda.go.jp/go/interview/1/650168_1124009f2025_1_14x_1f PUNCT admet-338 353 277 http://www.info.pmda.go.jp/go/interview/4/671450_1169011f1028_4_1f http://www.info.pmda.go.jp/go/interview/4/671450_1169011f1028_4_1f VERB admet-338 353 278 http://www.info.pmda.go.jp/go/interview/1/180188_3999003f1297_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180188_3999003f1297_1_005_1f NOUN admet-338 353 279 http://www.info.pmda.go.jp/go/interview/1/400256_2149040f1026_1_004_1f http://www.info.pmda.go.jp/go/interview/1/400256_2149040f1026_1_004_1f NOUN admet-338 353 280 http://www.info.pmda.go.jp/go/interview/2/430574_2149032f1021_2_a13_1f http://www.info.pmda.go.jp/go/interview/2/430574_2149032f1021_2_a13_1f PART admet-338 353 281 http://www.info.pmda.go.jp/go/interview/1/340018_6132016f1023_1_011_1f http://www.info.pmda.go.jp/go/interview/1/340018_6132016f1023_1_011_1f NOUN admet-338 353 282 http://www.info.pmda.go.jp/go/interview/3/800126_6132013m1029_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_6132013m1029_3_1f NOUN admet-338 353 283 http://www.info.pmda.go.jp/go/interview/1/780009_6132015f1037_1_01a_1f http://www.info.pmda.go.jp/go/interview/1/780009_6132015f1037_1_01a_1f X admet-338 353 284 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_6132012f1025_1_12 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_6132012f1025_1_12 PROPN admet-338 353 285 admet admet PROPN admet-338 353 286 & & CCONJ admet-338 353 287 dmpk dmpk PROPN admet-338 353 288 4(4 4(4 NUM admet-338 353 289 ) ) PUNCT admet-338 353 290 ( ( PUNCT admet-338 353 291 2016 2016 NUM admet-338 353 292 ) ) PUNCT admet-338 353 293 335 335 NUM admet-338 353 294 - - SYM admet-338 353 295 360 360 NUM admet-338 353 296 biopharmaceutical biopharmaceutical NOUN admet-338 353 297 and and CCONJ admet-338 353 298 physchem physchem NOUN admet-338 353 299 properties property NOUN admet-338 353 300 for for ADP admet-338 353 301 odt odt ADJ admet-338 353 302 doi doi NOUN admet-338 353 303 : : PUNCT admet-338 353 304 10.5599 10.5599 NUM admet-338 353 305 / / SYM admet-338 353 306 admet.4.4.338 admet.4.4.338 NUM admet-338 353 307 355 355 NUM admet-338 353 308 cetirizine cetirizine NOUN admet-338 353 309 hydrochloride hydrochloride NOUN admet-338 353 310 http://www.info.pmda.go.jp/go/interview/2/820110_4490020f1020_2_013_1f http://www.info.pmda.go.jp/go/interview/2/820110_4490020f1020_2_013_1f VERB admet-338 353 311 cilostazol cilostazol ADJ admet-338 353 312 http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f NOUN admet-338 353 313 clarithromycin clarithromycin NOUN admet-338 353 314 http://www.info.pmda.go.jp/go/interview/1/400059_6149003f2038_1_028_1f http://www.info.pmda.go.jp/go/interview/1/400059_6149003f2038_1_028_1f NOUN admet-338 353 315 cyclosporin cyclosporin NOUN admet-338 353 316 a a DET admet-338 353 317 http://www.info.pmda.go.jp/go/interview/2/300242_3999004m3021_2_neo_1f http://www.info.pmda.go.jp/go/interview/2/300242_3999004m3021_2_neo_1f NOUN admet-338 353 318 diclofenac diclofenac NOUN admet-338 353 319 sodium sodium NOUN admet-338 353 320 http://www.info.pmda.go.jp/go/interview/1/300242_1147002f1560_1_vol_1f http://www.info.pmda.go.jp/go/interview/1/300242_1147002f1560_1_vol_1f NOUN admet-338 353 321 donepezil donepezil NOUN admet-338 353 322 hydrochloride hydrochloride NOUN admet-338 353 323 http://www.info.pmda.go.jp/go/interview/1/170033_1190012f3029_1_028_1f http://www.info.pmda.go.jp/go/interview/1/170033_1190012f3029_1_028_1f NOUN admet-338 353 324 doxazosin doxazosin VERB admet-338 353 325 mesylate mesylate NOUN admet-338 353 326 http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f NOUN admet-338 353 327 doxifluridine doxifluridine NOUN admet-338 353 328 http://www.info.pmda.go.jp/go/interview/2/450045_4223004m1027_2_004_1f http://www.info.pmda.go.jp/go/interview/2/450045_4223004m1027_2_004_1f PROPN admet-338 353 329 ebastine ebastine PROPN admet-338 353 330 http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f NOUN admet-338 353 331 enalapril enalapril NOUN admet-338 353 332 maleate maleate NOUN admet-338 353 333 http://www.info.pmda.go.jp/go/interview/2/170050_2144002f1024_2_016_1f http://www.info.pmda.go.jp/go/interview/2/170050_2144002f1024_2_016_1f NOUN admet-338 353 334 epalrestat epalrestat NOUN admet-338 353 335 http://www.info.pmda.go.jp/go/interview/1/180188_3999013f1231_1_004_1f http://www.info.pmda.go.jp/go/interview/1/180188_3999013f1231_1_004_1f NOUN admet-338 353 336 eperisone eperisone NOUN admet-338 353 337 hydrochloride hydrochloride NOUN admet-338 353 338 http://www.info.pmda.go.jp/go/interview/1/170033_1249009d1030_1_007_1f http://www.info.pmda.go.jp/go/interview/1/170033_1249009d1030_1_007_1f NOUN admet-338 353 339 epinastine epinastine VERB admet-338 353 340 hydrochloride hydrochloride NOUN admet-338 353 341 http://www.info.pmda.go.jp/go/interview/1/650168_4490014f1025_1_119_1f http://www.info.pmda.go.jp/go/interview/1/650168_4490014f1025_1_119_1f NOUN admet-338 353 342 ethyl ethyl PROPN admet-338 353 343 icosapentate icosapentate ADJ admet-338 353 344 http://www.info.pmda.go.jp/go/interview/1/790005_3399004m2022_1_m03_1f http://www.info.pmda.go.jp/go/interview/1/790005_3399004m2022_1_m03_1f PUNCT admet-338 353 345 etizolam etizolam PROPN admet-338 353 346 http://www.info.pmda.go.jp/go/interview/2/400315_1179025c1054_2_150_1f http://www.info.pmda.go.jp/go/interview/2/400315_1179025c1054_2_150_1f PROPN admet-338 353 347 famotidine famotidine PROPN admet-338 353 348 http://www.info.pmda.go.jp/go/interview/1/800126_2325003f1024_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2325003f1024_1_1f NOUN admet-338 353 349 fexofenadine fexofenadine PROPN admet-338 353 350 hydrochloride hydrochloride NOUN admet-338 353 351 http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f NOUN admet-338 353 352 fluconazole fluconazole NOUN admet-338 353 353 http://www.info.pmda.go.jp/go/interview/2/671450_6290002m1020_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_6290002m1020_2_1f NOUN admet-338 353 354 flurbiprofen flurbiprofen NOUN admet-338 353 355 http://www.info.pmda.go.jp/go/interview/1/200022_1149011d1032_1_080_1f http://www.info.pmda.go.jp/go/interview/1/200022_1149011d1032_1_080_1f NOUN admet-338 353 356 fluvastatin fluvastatin NOUN admet-338 353 357 sodium sodium PROPN admet-338 353 358 http://www.info.pmda.go.jp/go/interview/3/300242_2189012f1020_3_loc_1f http://www.info.pmda.go.jp/go/interview/3/300242_2189012f1020_3_loc_1f PROPN admet-338 353 359 fluvoxamine fluvoxamine PROPN admet-338 353 360 maleate maleate PROPN admet-338 353 361 http://www.info.pmda.go.jp/go/interview/1/780009_1179039f1028_1_1f http://www.info.pmda.go.jp/go/interview/1/780009_1179039f1028_1_1f NOUN admet-338 353 362 fursultiamine fursultiamine VERB admet-338 353 363 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_3122007f2039_1_10 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_3122007f2039_1_10 NUM admet-338 353 364 gefitinib gefitinib NOUN admet-338 353 365 http://www.info.pmda.go.jp/go/interview/1/670227_4291013f1027_1_192_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291013f1027_1_192_1f NOUN admet-338 353 366 glimepiride glimepiride PROPN admet-338 353 367 http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f AUX admet-338 353 368 granisetron granisetron ADJ admet-338 353 369 hydrochloride hydrochloride NOUN admet-338 353 370 http://www.info.pmda.go.jp/go/interview/1/450045_2391002c1037_1_010_1f http://www.info.pmda.go.jp/go/interview/1/450045_2391002c1037_1_010_1f NOUN admet-338 353 371 imatinib imatinib NOUN admet-338 353 372 mesylate mesylate VERB admet-338 353 373 http://www.info.pmda.go.jp/go/interview/1/300242_4291011f1028_1_gli_1f http://www.info.pmda.go.jp/go/interview/1/300242_4291011f1028_1_gli_1f NOUN admet-338 353 374 imidapril imidapril VERB admet-338 353 375 hydrochloride hydrochloride NOUN admet-338 353 376 http://www.info.pmda.go.jp/go/interview/1/400315_2144008f1021_1_090_1f http://www.info.pmda.go.jp/go/interview/1/400315_2144008f1021_1_090_1f NOUN admet-338 353 377 itraconazole itraconazole NOUN admet-338 353 378 http://www.info.pmda.go.jp/go/interview/1/800155_6290004m1029_2_008_1f http://www.info.pmda.go.jp/go/interview/1/800155_6290004m1029_2_008_1f NOUN admet-338 353 379 http://www.info.pmda.go.jp/go/interview/2/820110_4490020f1020_2_013_1f http://www.info.pmda.go.jp/go/interview/2/820110_4490020f1020_2_013_1f VERB admet-338 353 380 http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180078_3399002f3020_1_005_1f NOUN admet-338 353 381 http://www.info.pmda.go.jp/go/interview/1/400059_6149003f2038_1_028_1f http://www.info.pmda.go.jp/go/interview/1/400059_6149003f2038_1_028_1f NOUN admet-338 353 382 http://www.info.pmda.go.jp/go/interview/2/300242_3999004m3021_2_neo_1f http://www.info.pmda.go.jp/go/interview/2/300242_3999004m3021_2_neo_1f NOUN admet-338 353 383 http://www.info.pmda.go.jp/go/interview/1/300242_1147002f1560_1_vol_1f http://www.info.pmda.go.jp/go/interview/1/300242_1147002f1560_1_vol_1f NOUN admet-338 353 384 http://www.info.pmda.go.jp/go/interview/1/170033_1190012f3029_1_028_1f http://www.info.pmda.go.jp/go/interview/1/170033_1190012f3029_1_028_1f NOUN admet-338 353 385 http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_2149026f1026_2_1f VERB admet-338 353 386 http://www.info.pmda.go.jp/go/interview/2/450045_4223004m1027_2_004_1f http://www.info.pmda.go.jp/go/interview/2/450045_4223004m1027_2_004_1f NOUN admet-338 353 387 http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f http://www.info.pmda.go.jp/go/interview/1/400093_4490019f1028_1_018_1f NOUN admet-338 353 388 http://www.info.pmda.go.jp/go/interview/2/170050_2144002f1024_2_016_1f http://www.info.pmda.go.jp/go/interview/2/170050_2144002f1024_2_016_1f NOUN admet-338 353 389 http://www.info.pmda.go.jp/go/interview/1/180188_3999013f1231_1_004_1f http://www.info.pmda.go.jp/go/interview/1/180188_3999013f1231_1_004_1f NOUN admet-338 353 390 http://www.info.pmda.go.jp/go/interview/1/170033_1249009d1030_1_007_1f http://www.info.pmda.go.jp/go/interview/1/170033_1249009d1030_1_007_1f NOUN admet-338 353 391 http://www.info.pmda.go.jp/go/interview/1/650168_4490014f1025_1_119_1f http://www.info.pmda.go.jp/go/interview/1/650168_4490014f1025_1_119_1f NOUN admet-338 353 392 http://www.info.pmda.go.jp/go/interview/1/790005_3399004m2022_1_m03_1f http://www.info.pmda.go.jp/go/interview/1/790005_3399004m2022_1_m03_1f VERB admet-338 354 1 http://www.info.pmda.go.jp/go/interview/2/400315_1179025c1054_2_150_1f http://www.info.pmda.go.jp/go/interview/2/400315_1179025c1054_2_150_1f NOUN admet-338 354 2 http://www.info.pmda.go.jp/go/interview/1/800126_2325003f1024_1_1f http://www.info.pmda.go.jp/go/interview/1/800126_2325003f1024_1_1f NOUN admet-338 354 3 http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f http://www.info.pmda.go.jp/go/interview/1/780069_4490023f1024_1_021_1f NOUN admet-338 354 4 http://www.info.pmda.go.jp/go/interview/2/671450_6290002m1020_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_6290002m1020_2_1f NOUN admet-338 354 5 http://www.info.pmda.go.jp/go/interview/1/200022_1149011d1032_1_080_1f http://www.info.pmda.go.jp/go/interview/1/200022_1149011d1032_1_080_1f VERB admet-338 354 6 http://www.info.pmda.go.jp/go/interview/3/300242_2189012f1020_3_loc_1f http://www.info.pmda.go.jp/go/interview/3/300242_2189012f1020_3_loc_1f PART admet-338 354 7 http://www.info.pmda.go.jp/go/interview/1/780009_1179039f1028_1_1f http://www.info.pmda.go.jp/go/interview/1/780009_1179039f1028_1_1f NOUN admet-338 354 8 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_3122007f2039_1_10 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_3122007f2039_1_10 NUM admet-338 354 9 http://www.info.pmda.go.jp/go/interview/1/670227_4291013f1027_1_192_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291013f1027_1_192_1f NOUN admet-338 354 10 http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f http://www.info.pmda.go.jp/go/interview/1/780069_3961008f4070_1_020_1f VERB admet-338 354 11 http://www.info.pmda.go.jp/go/interview/1/450045_2391002c1037_1_010_1f http://www.info.pmda.go.jp/go/interview/1/450045_2391002c1037_1_010_1f NOUN admet-338 354 12 http://www.info.pmda.go.jp/go/interview/1/300242_4291011f1028_1_gli_1f http://www.info.pmda.go.jp/go/interview/1/300242_4291011f1028_1_gli_1f NOUN admet-338 354 13 http://www.info.pmda.go.jp/go/interview/1/400315_2144008f1021_1_090_1f http://www.info.pmda.go.jp/go/interview/1/400315_2144008f1021_1_090_1f NOUN admet-338 354 14 http://www.info.pmda.go.jp/go/interview/1/800155_6290004m1029_2_008_1f http://www.info.pmda.go.jp/go/interview/1/800155_6290004m1029_2_008_1f NOUN admet-338 354 15 asami asami PROPN admet-338 354 16 ono ono PROPN admet-338 354 17 et et PROPN admet-338 354 18 al al PROPN admet-338 354 19 . . PROPN admet-338 354 20 admet admet PROPN admet-338 354 21 & & CCONJ admet-338 354 22 dmpk dmpk PROPN admet-338 354 23 4(4 4(4 NUM admet-338 354 24 ) ) PUNCT admet-338 354 25 ( ( PUNCT admet-338 354 26 2016 2016 NUM admet-338 354 27 ) ) PUNCT admet-338 354 28 335 335 NUM admet-338 354 29 - - SYM admet-338 354 30 360 360 NUM admet-338 354 31 356 356 NUM admet-338 354 32 ketoprofen ketoprofen VERB admet-338 354 33 a a DET admet-338 354 34 http://www.info.pmda.go.jp/go/interview/2/650208_1149700j1035_2_1f http://www.info.pmda.go.jp/go/interview/2/650208_1149700j1035_2_1f NOUN admet-338 354 35 ketotifen ketotifen VERB admet-338 354 36 fumarate fumarate ADJ admet-338 355 1 http://www.info.pmda.go.jp/go/interview/1/300242_4490003m1263_1_z-c_1f http://www.info.pmda.go.jp/go/interview/1/300242_4490003m1263_1_z-c_1f PROPN admet-338 355 2 l l NOUN admet-338 355 3 - - PUNCT admet-338 355 4 carbocysteine carbocysteine NOUN admet-338 355 5 http://www.info.pmda.go.jp/go/interview/1/230109_2233002f1174_1_001_1f http://www.info.pmda.go.jp/go/interview/1/230109_2233002f1174_1_001_1f NOUN admet-338 355 6 levofloxacin levofloxacin PROPN admet-338 355 7 http://www.info.pmda.go.jp/go/interview/1/430574_6241013c2024_1_c11_1f http://www.info.pmda.go.jp/go/interview/1/430574_6241013c2024_1_c11_1f NOUN admet-338 355 8 limaprost limaprost PROPN admet-338 355 9 alfadex alfadex PROPN admet-338 355 10 http://www.info.pmda.go.jp/go/interview/1/180188_3399003f1073_1_010_1f http://www.info.pmda.go.jp/go/interview/1/180188_3399003f1073_1_010_1f PROPN admet-338 355 11 loratadine loratadine PROPN admet-338 355 12 http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f NOUN admet-338 355 13 losartan losartan ADJ admet-338 355 14 potassium potassium NOUN admet-338 355 15 http://www.info.pmda.go.jp/go/interview/2/170050_2149039f1031_2_018_1f http://www.info.pmda.go.jp/go/interview/2/170050_2149039f1031_2_018_1f NOUN admet-338 355 16 loxoprofen loxoprofen VERB admet-338 355 17 sodium sodium NOUN admet-338 355 18 hydrate hydrate NOUN admet-338 355 19 http://www.info.pmda.go.jp/go/interview/1/430574_1149019c1149_1_lo8_1f http://www.info.pmda.go.jp/go/interview/1/430574_1149019c1149_1_lo8_1f NOUN admet-338 355 20 manidipine manidipine NOUN admet-338 355 21 hydrochloride hydrochloride NOUN admet-338 355 22 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_2149027f1020_1_09 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_2149027f1020_1_09 NOUN admet-338 355 23 mecobalamin mecobalamin NOUN admet-338 355 24 http://www.info.pmda.go.jp/go/interview/1/170033_3136004c1038_1_006_1f http://www.info.pmda.go.jp/go/interview/1/170033_3136004c1038_1_006_1f NOUN admet-338 355 25 meloxicam meloxicam NOUN admet-338 355 26 http://www.info.pmda.go.jp/go/interview/1/650168_1149035f1020_1_156_1f http://www.info.pmda.go.jp/go/interview/1/650168_1149035f1020_1_156_1f NOUN admet-338 355 27 menatetrenone menatetrenone PROPN admet-338 355 28 http://www.info.pmda.go.jp/go/interview/1/170033_3160002m2028_1_008_1f http://www.info.pmda.go.jp/go/interview/1/170033_3160002m2028_1_008_1f PROPN admet-338 355 29 mesalazine mesalazine PROPN admet-338 355 30 http://www.info.pmda.go.jp/go/interview/1/230109_2399009f1149_1_015_1f http://www.info.pmda.go.jp/go/interview/1/230109_2399009f1149_1_015_1f PROPN admet-338 355 31 methylmethionine methylmethionine PROPN admet-338 355 32 sulfonium sulfonium PROPN admet-338 355 33 chloride chloride NOUN admet-338 355 34 http://www.info.pmda.go.jp/go/interview/1/270072_2321001f1042_1_002_1f http://www.info.pmda.go.jp/go/interview/1/270072_2321001f1042_1_002_1f NOUN admet-338 355 35 mexiletine mexiletine NOUN admet-338 355 36 hydrochloride hydrochloride NOUN admet-338 355 37 http://www.info.pmda.go.jp/go/interview/1/650168_2129003m1021_1_14y_1f http://www.info.pmda.go.jp/go/interview/1/650168_2129003m1021_1_14y_1f PART admet-338 355 38 montelukast montelukast NOUN admet-338 355 39 sodium sodium NOUN admet-338 355 40 http://www.info.pmda.go.jp/go/interview/1/230109_4490026f2040_1_035_1f http://www.info.pmda.go.jp/go/interview/1/230109_4490026f2040_1_035_1f NOUN admet-338 355 41 . . PUNCT admet-338 356 1 mosapride mosapride ADJ admet-338 356 2 citrate citrate NOUN admet-338 356 3 hydrate hydrate NOUN admet-338 356 4 http://www.info.pmda.go.jp/go/interview/1/400093_2399010b1034_1_020_1f http://www.info.pmda.go.jp/go/interview/1/400093_2399010b1034_1_020_1f NOUN admet-338 356 5 nicardipine nicardipine PROPN admet-338 356 6 hydrochloride hydrochloride NOUN admet-338 356 7 http://www.info.pmda.go.jp/go/interview/1/300119_2149019f1085_1_041_1f http://www.info.pmda.go.jp/go/interview/1/300119_2149019f1085_1_041_1f NOUN admet-338 356 8 nicergoline nicergoline PROPN admet-338 356 9 http://www.info.pmda.go.jp/go/interview/1/400315_2190021b1095_1_100_1f http://www.info.pmda.go.jp/go/interview/1/400315_2190021b1095_1_100_1f PROPN admet-338 356 10 nicorandil nicorandil PROPN admet-338 356 11 http://www.info.pmda.go.jp/go/interview/1/450045_2171017f1028_1_009_1f http://www.info.pmda.go.jp/go/interview/1/450045_2171017f1028_1_009_1f PROPN admet-338 356 12 nifedipine nifedipine PROPN admet-338 356 13 http://www.info.pmda.go.jp/go/interview/1/630004_2171014m1104_1_001_1f http://www.info.pmda.go.jp/go/interview/1/630004_2171014m1104_1_001_1f PROPN admet-338 356 14 nilvadipine nilvadipine NOUN admet-338 356 15 http://www.info.pmda.go.jp/go/interview/3/800126_2149022f1028_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_2149022f1028_3_1f PROPN admet-338 356 16 nizatidine nizatidine PROPN admet-338 356 17 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2325005f1031_1_06 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2325005f1031_1_06 NUM admet-338 356 18 olanzapine olanzapine NOUN admet-338 356 19 http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f X admet-338 356 20 olopatadine olopatadine ADJ admet-338 356 21 hydrochloride hydrochloride NOUN admet-338 356 22 http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f NOUN admet-338 356 23 oseltamivir oseltamivir PROPN admet-338 356 24 phosphate phosphate PROPN admet-338 356 25 http://www.info.pmda.go.jp/go/interview/1/450045_6250021m1027_1_026_1f http://www.info.pmda.go.jp/go/interview/1/450045_6250021m1027_1_026_1f PROPN admet-338 356 26 paroxetine paroxetine NOUN admet-338 356 27 hydrochloride hydrochloride NOUN admet-338 356 28 hydrate hydrate NOUN admet-338 356 29 http://www.info.pmda.go.jp/go/interview/2/340278_1179041f1025_1_018_1f http://www.info.pmda.go.jp/go/interview/2/340278_1179041f1025_1_018_1f NOUN admet-338 356 30 http://www.info.pmda.go.jp/go/interview/2/650208_1149700j1035_2_1f http://www.info.pmda.go.jp/go/interview/2/650208_1149700j1035_2_1f NOUN admet-338 356 31 http://www.info.pmda.go.jp/go/interview/1/300242_4490003m1263_1_z-c_1f http://www.info.pmda.go.jp/go/interview/1/300242_4490003m1263_1_z-c_1f VERB admet-338 356 32 http://www.info.pmda.go.jp/go/interview/1/230109_2233002f1174_1_001_1f http://www.info.pmda.go.jp/go/interview/1/230109_2233002f1174_1_001_1f NOUN admet-338 356 33 http://www.info.pmda.go.jp/go/interview/1/430574_6241013c2024_1_c11_1f http://www.info.pmda.go.jp/go/interview/1/430574_6241013c2024_1_c11_1f NOUN admet-338 356 34 http://www.info.pmda.go.jp/go/interview/1/180188_3399003f1073_1_010_1f http://www.info.pmda.go.jp/go/interview/1/180188_3399003f1073_1_010_1f NOUN admet-338 356 35 http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f http://www.info.pmda.go.jp/go/interview/1/170050_4490027f1022_1_015_1f NOUN admet-338 356 36 http://www.info.pmda.go.jp/go/interview/2/170050_2149039f1031_2_018_1f http://www.info.pmda.go.jp/go/interview/2/170050_2149039f1031_2_018_1f NOUN admet-338 356 37 http://www.info.pmda.go.jp/go/interview/1/430574_1149019c1149_1_lo8_1f http://www.info.pmda.go.jp/go/interview/1/430574_1149019c1149_1_lo8_1f NOUN admet-338 356 38 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_2149027f1020_1_09 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/400256_2149027f1020_1_09 NOUN admet-338 356 39 http://www.info.pmda.go.jp/go/interview/1/170033_3136004c1038_1_006_1f http://www.info.pmda.go.jp/go/interview/1/170033_3136004c1038_1_006_1f NOUN admet-338 356 40 http://www.info.pmda.go.jp/go/interview/1/650168_1149035f1020_1_156_1f http://www.info.pmda.go.jp/go/interview/1/650168_1149035f1020_1_156_1f VERB admet-338 356 41 http://www.info.pmda.go.jp/go/interview/1/170033_3160002m2028_1_008_1f http://www.info.pmda.go.jp/go/interview/1/170033_3160002m2028_1_008_1f PRON admet-338 356 42 http://www.info.pmda.go.jp/go/interview/1/230109_2399009f1149_1_015_1f http://www.info.pmda.go.jp/go/interview/1/230109_2399009f1149_1_015_1f NOUN admet-338 356 43 http://www.info.pmda.go.jp/go/interview/1/270072_2321001f1042_1_002_1f http://www.info.pmda.go.jp/go/interview/1/270072_2321001f1042_1_002_1f NOUN admet-338 356 44 http://www.info.pmda.go.jp/go/interview/1/650168_2129003m1021_1_14y_1f http://www.info.pmda.go.jp/go/interview/1/650168_2129003m1021_1_14y_1f PART admet-338 356 45 http://www.info.pmda.go.jp/go/interview/1/230109_4490026f2040_1_035_1f http://www.info.pmda.go.jp/go/interview/1/230109_4490026f2040_1_035_1f NOUN admet-338 356 46 . . PUNCT admet-338 357 1 http://www.info.pmda.go.jp/go/interview/1/400093_2399010b1034_1_020_1f http://www.info.pmda.go.jp/go/interview/1/400093_2399010b1034_1_020_1f NOUN admet-338 357 2 http://www.info.pmda.go.jp/go/interview/1/300119_2149019f1085_1_041_1f http://www.info.pmda.go.jp/go/interview/1/300119_2149019f1085_1_041_1f PROPN admet-338 357 3 http://www.info.pmda.go.jp/go/interview/1/400315_2190021b1095_1_100_1f http://www.info.pmda.go.jp/go/interview/1/400315_2190021b1095_1_100_1f PROPN admet-338 357 4 http://www.info.pmda.go.jp/go/interview/1/450045_2171017f1028_1_009_1f http://www.info.pmda.go.jp/go/interview/1/450045_2171017f1028_1_009_1f VERB admet-338 357 5 http://www.info.pmda.go.jp/go/interview/1/630004_2171014m1104_1_001_1f http://www.info.pmda.go.jp/go/interview/1/630004_2171014m1104_1_001_1f NOUN admet-338 357 6 http://www.info.pmda.go.jp/go/interview/3/800126_2149022f1028_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_2149022f1028_3_1f NOUN admet-338 357 7 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2325005f1031_1_06 http://www.pmda.go.jp/pmdasearch/iyakudetail/resultdatasetpdf/380077_2325005f1031_1_06 PUNCT admet-338 357 8 http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f http://www.info.pmda.go.jp/go/interview/1/530471_1179044f4028_1_18f_1f NOUN admet-338 357 9 http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f http://www.info.pmda.go.jp/go/interview/1/230124_4490025f3026_1_006_1f NOUN admet-338 357 10 http://www.info.pmda.go.jp/go/interview/1/450045_6250021m1027_1_026_1f http://www.info.pmda.go.jp/go/interview/1/450045_6250021m1027_1_026_1f PROPN admet-338 357 11 http://www.info.pmda.go.jp/go/interview/2/340278_1179041f1025_1_018_1f http://www.info.pmda.go.jp/go/interview/2/340278_1179041f1025_1_018_1f PROPN admet-338 357 12 admet admet PROPN admet-338 357 13 & & CCONJ admet-338 357 14 dmpk dmpk PROPN admet-338 357 15 4(4 4(4 NUM admet-338 357 16 ) ) PUNCT admet-338 357 17 ( ( PUNCT admet-338 357 18 2016 2016 NUM admet-338 357 19 ) ) PUNCT admet-338 357 20 335 335 NUM admet-338 357 21 - - SYM admet-338 357 22 360 360 NUM admet-338 357 23 biopharmaceutical biopharmaceutical NOUN admet-338 357 24 and and CCONJ admet-338 357 25 physchem physchem NOUN admet-338 357 26 properties property NOUN admet-338 357 27 for for ADP admet-338 357 28 odt odt ADJ admet-338 357 29 doi doi NOUN admet-338 357 30 : : PUNCT admet-338 357 31 10.5599 10.5599 NUM admet-338 357 32 / / SYM admet-338 357 33 admet.4.4.338 admet.4.4.338 VERB admet-338 357 34 357 357 NUM admet-338 357 35 pergolide pergolide NOUN admet-338 357 36 mesylate mesylate NOUN admet-338 357 37 http://www.info.pmda.go.jp/go/interview/2/230124_1169008f1026_2_004_1f http://www.info.pmda.go.jp/go/interview/2/230124_1169008f1026_2_004_1f PROPN admet-338 357 38 perindopril perindopril PROPN admet-338 357 39 erbumine erbumine PROPN admet-338 357 40 http://www.info.pmda.go.jp/go/interview/3/230124_2144012f1028_3_001_1f http://www.info.pmda.go.jp/go/interview/3/230124_2144012f1028_3_001_1f PROPN admet-338 357 41 pilsicainide pilsicainide VERB admet-338 357 42 hydrochloride hydrochloride NOUN admet-338 357 43 hydrate hydrate NOUN admet-338 357 44 http://www.info.pmda.go.jp/go/interview/3/430574_2129008m1024_3_s10_1f http://www.info.pmda.go.jp/go/interview/3/430574_2129008m1024_3_s10_1f NOUN admet-338 357 45 pioglitazone pioglitazone NOUN admet-338 357 46 hydrochloride hydrochloride NOUN admet-338 357 47 http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f NOUN admet-338 357 48 pranlukast pranlukast VERB admet-338 357 49 hydrate hydrate ADJ admet-338 357 50 http://www.info.pmda.go.jp/go/interview/1/180188_4490017m1036_1_009_1f http://www.info.pmda.go.jp/go/interview/1/180188_4490017m1036_1_009_1f NOUN admet-338 357 51 pravastatin pravastatin NOUN admet-338 357 52 sodium sodium NOUN admet-338 357 53 http://www.info.pmda.go.jp/go/interview/2/430574_2189010c1032_2_m10_1f http://www.info.pmda.go.jp/go/interview/2/430574_2189010c1032_2_m10_1f NOUN admet-338 357 54 procaterol procaterol VERB admet-338 357 55 hydrochloride hydrochloride NOUN admet-338 357 56 hydrate hydrate NOUN admet-338 357 57 http://www.info.pmda.go.jp/go/interview/1/180078_2259004f2168_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180078_2259004f2168_1_005_1f NOUN admet-338 357 58 propiverine propiverine ADJ admet-338 357 59 hydrochloride hydrochloride NOUN admet-338 357 60 http://www.info.pmda.go.jp/go/interview/1/400107_2590007c1025_1_04l_1f http://www.info.pmda.go.jp/go/interview/1/400107_2590007c1025_1_04l_1f NOUN admet-338 357 61 quetiapine quetiapine NOUN admet-338 357 62 fumarate fumarate ADJ admet-338 357 63 http://www.info.pmda.go.jp/go/interview/2/800126_1179042c1023_2_1f http://www.info.pmda.go.jp/go/interview/2/800126_1179042c1023_2_1f NOUN admet-338 357 64 ranitidine ranitidine NOUN admet-338 357 65 hydrochloride hydrochloride NOUN admet-338 357 66 http://www.info.pmda.go.jp/go/interview/1/340278_2325002f1194_1_009_1f http://www.info.pmda.go.jp/go/interview/1/340278_2325002f1194_1_009_1f NOUN admet-338 357 67 rebamipide rebamipide ADJ admet-338 357 68 http://www.info.pmda.go.jp/go/interview/1/180078_2329021d1020_1_013_1f http://www.info.pmda.go.jp/go/interview/1/180078_2329021d1020_1_013_1f NOUN admet-338 357 69 risedronate risedronate VERB admet-338 357 70 sodium sodium NOUN admet-338 357 71 hydrate hydrate NOUN admet-338 357 72 http://www.info.pmda.go.jp/go/interview/2/111890_3999019f1026_2_016_1f http://www.info.pmda.go.jp/go/interview/2/111890_3999019f1026_2_016_1f NOUN admet-338 357 73 risperidone risperidone NOUN admet-338 357 74 http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f NOUN admet-338 357 75 sarpogrelate sarpogrelate NOUN admet-338 357 76 hydrochloride hydrochloride NOUN admet-338 357 77 http://www.info.pmda.go.jp/go/interview/3/400315_3399006c1020_3_15a_1f http://www.info.pmda.go.jp/go/interview/3/400315_3399006c1020_3_15a_1f PART admet-338 357 78 simvastatin simvastatin NOUN admet-338 357 79 http://www.info.pmda.go.jp/go/interview/2/170050_2189011f1025_2_022_1f http://www.info.pmda.go.jp/go/interview/2/170050_2189011f1025_2_022_1f NOUN admet-338 357 80 sultamicillin sultamicillin NOUN admet-338 357 81 tosilate tosilate NOUN admet-338 357 82 hydrate hydrate NOUN admet-338 357 83 http://www.info.pmda.go.jp/go/interview/2/671450_6131008f1030_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_6131008f1030_2_1f NOUN admet-338 357 84 tacrolimus tacrolimus NOUN admet-338 357 85 hydrate hydrate NOUN admet-338 357 86 http://www.info.pmda.go.jp/go/interview/3/800126_3999014d1022_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_3999014d1022_3_1f NOUN admet-338 357 87 taltirelin taltirelin NOUN admet-338 357 88 hydrate hydrate NOUN admet-338 357 89 http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f NOUN admet-338 357 90 tamoxifen tamoxifen NOUN admet-338 357 91 citrate citrate NOUN admet-338 357 92 http://www.info.pmda.go.jp/go/interview/1/670227_4291003f1163_1_012_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291003f1163_1_012_1f NOUN admet-338 357 93 tegafur tegafur PROPN admet-338 357 94 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f X admet-338 357 95 temocapril temocapril ADJ admet-338 357 96 hydrochloride hydrochloride NOUN admet-338 357 97 http://www.info.pmda.go.jp/go/interview/3/430574_2144009f1026_3_c10_1f http://www.info.pmda.go.jp/go/interview/3/430574_2144009f1026_3_c10_1f NOUN admet-338 357 98 teprenone teprenone NOUN admet-338 357 99 http://www.info.pmda.go.jp/go/interview/1/170033_2329012c1026_1_009_1f http://www.info.pmda.go.jp/go/interview/1/170033_2329012c1026_1_009_1f NOUN admet-338 357 100 terbinafine terbinafine NOUN admet-338 357 101 hydrochloride hydrochloride NOUN admet-338 357 102 http://www.info.pmda.go.jp/go/interview/1/730012_6290005f1032_1_006_1f http://www.info.pmda.go.jp/go/interview/1/730012_6290005f1032_1_006_1f NOUN admet-338 357 103 ticlopidine ticlopidine NOUN admet-338 357 104 hydrochloride hydrochloride NOUN admet-338 357 105 http://www.info.pmda.go.jp/go/interview/4/780069_3399001c1027_4_011_1f http://www.info.pmda.go.jp/go/interview/4/780069_3399001c1027_4_011_1f NOUN admet-338 357 106 tocopherol tocopherol VERB admet-338 357 107 nicotinate nicotinate ADJ admet-338 357 108 http://www.info.pmda.go.jp/go/interview/1/170033_2190006c1037_1_008_1f http://www.info.pmda.go.jp/go/interview/1/170033_2190006c1037_1_008_1f NOUN admet-338 357 109 tulobuterol tulobuterol ADJ admet-338 357 110 hydrochloride hydrochloride NOUN admet-338 357 111 http://www.info.pmda.go.jp/go/interview/3/100159_2259002f1065_3_004_1f http://www.info.pmda.go.jp/go/interview/3/100159_2259002f1065_3_004_1f NOUN admet-338 357 112 ursodeoxycholic ursodeoxycholic PROPN admet-338 357 113 acid acid PROPN admet-338 357 114 http://www.info.pmda.go.jp/go/interview/2/400315_2362001f1088_2_11a_1f http://www.info.pmda.go.jp/go/interview/2/400315_2362001f1088_2_11a_1f PART admet-338 357 115 valacyclovir valacyclovir PROPN admet-338 357 116 hydrochloride hydrochloride VERB admet-338 357 117 http://www.info.pmda.go.jp/go/interview/1/340278_6250019f1020_1_013_1f http://www.info.pmda.go.jp/go/interview/1/340278_6250019f1020_1_013_1f NOUN admet-338 357 118 http://www.info.pmda.go.jp/go/interview/2/230124_1169008f1026_2_004_1f http://www.info.pmda.go.jp/go/interview/2/230124_1169008f1026_2_004_1f PART admet-338 357 119 http://www.info.pmda.go.jp/go/interview/3/230124_2144012f1028_3_001_1f http://www.info.pmda.go.jp/go/interview/3/230124_2144012f1028_3_001_1f NOUN admet-338 357 120 http://www.info.pmda.go.jp/go/interview/3/430574_2129008m1024_3_s10_1f http://www.info.pmda.go.jp/go/interview/3/430574_2129008m1024_3_s10_1f NOUN admet-338 357 121 http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969007f3027_1_007_1f NOUN admet-338 357 122 http://www.info.pmda.go.jp/go/interview/1/180188_4490017m1036_1_009_1f http://www.info.pmda.go.jp/go/interview/1/180188_4490017m1036_1_009_1f NOUN admet-338 357 123 http://www.info.pmda.go.jp/go/interview/2/430574_2189010c1032_2_m10_1f http://www.info.pmda.go.jp/go/interview/2/430574_2189010c1032_2_m10_1f PART admet-338 357 124 http://www.info.pmda.go.jp/go/interview/1/180078_2259004f2168_1_005_1f http://www.info.pmda.go.jp/go/interview/1/180078_2259004f2168_1_005_1f NOUN admet-338 357 125 http://www.info.pmda.go.jp/go/interview/1/400107_2590007c1025_1_04l_1f http://www.info.pmda.go.jp/go/interview/1/400107_2590007c1025_1_04l_1f NOUN admet-338 357 126 http://www.info.pmda.go.jp/go/interview/2/800126_1179042c1023_2_1f http://www.info.pmda.go.jp/go/interview/2/800126_1179042c1023_2_1f NOUN admet-338 357 127 http://www.info.pmda.go.jp/go/interview/1/340278_2325002f1194_1_009_1f http://www.info.pmda.go.jp/go/interview/1/340278_2325002f1194_1_009_1f NOUN admet-338 357 128 http://www.info.pmda.go.jp/go/interview/1/180078_2329021d1020_1_013_1f http://www.info.pmda.go.jp/go/interview/1/180078_2329021d1020_1_013_1f NOUN admet-338 357 129 http://www.info.pmda.go.jp/go/interview/2/111890_3999019f1026_2_016_1f http://www.info.pmda.go.jp/go/interview/2/111890_3999019f1026_2_016_1f NOUN admet-338 357 130 http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f http://www.info.pmda.go.jp/go/interview/1/800155_1179038f5029_1_005_1f NOUN admet-338 357 131 http://www.info.pmda.go.jp/go/interview/3/400315_3399006c1020_3_15a_1f http://www.info.pmda.go.jp/go/interview/3/400315_3399006c1020_3_15a_1f PART admet-338 357 132 http://www.info.pmda.go.jp/go/interview/2/170050_2189011f1025_2_022_1f http://www.info.pmda.go.jp/go/interview/2/170050_2189011f1025_2_022_1f NOUN admet-338 357 133 http://www.info.pmda.go.jp/go/interview/2/671450_6131008f1030_2_1f http://www.info.pmda.go.jp/go/interview/2/671450_6131008f1030_2_1f NOUN admet-338 357 134 http://www.info.pmda.go.jp/go/interview/3/800126_3999014d1022_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_3999014d1022_3_1f NOUN admet-338 357 135 http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f http://www.info.pmda.go.jp/go/interview/1/400315_1190014f2021_1_050_1f NOUN admet-338 357 136 http://www.info.pmda.go.jp/go/interview/1/670227_4291003f1163_1_012_1f http://www.info.pmda.go.jp/go/interview/1/670227_4291003f1163_1_012_1f VERB admet-338 357 137 http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f http://www.info.pmda.go.jp/go/interview/1/400107_4229101f1026_1_10e_1f NOUN admet-338 357 138 http://www.info.pmda.go.jp/go/interview/3/430574_2144009f1026_3_c10_1f http://www.info.pmda.go.jp/go/interview/3/430574_2144009f1026_3_c10_1f NOUN admet-338 357 139 http://www.info.pmda.go.jp/go/interview/1/170033_2329012c1026_1_009_1f http://www.info.pmda.go.jp/go/interview/1/170033_2329012c1026_1_009_1f NOUN admet-338 357 140 http://www.info.pmda.go.jp/go/interview/1/730012_6290005f1032_1_006_1f http://www.info.pmda.go.jp/go/interview/1/730012_6290005f1032_1_006_1f VERB admet-338 357 141 http://www.info.pmda.go.jp/go/interview/4/780069_3399001c1027_4_011_1f http://www.info.pmda.go.jp/go/interview/4/780069_3399001c1027_4_011_1f NOUN admet-338 357 142 http://www.info.pmda.go.jp/go/interview/1/170033_2190006c1037_1_008_1f http://www.info.pmda.go.jp/go/interview/1/170033_2190006c1037_1_008_1f NOUN admet-338 357 143 http://www.info.pmda.go.jp/go/interview/3/100159_2259002f1065_3_004_1f http://www.info.pmda.go.jp/go/interview/3/100159_2259002f1065_3_004_1f NOUN admet-338 357 144 http://www.info.pmda.go.jp/go/interview/2/400315_2362001f1088_2_11a_1f http://www.info.pmda.go.jp/go/interview/2/400315_2362001f1088_2_11a_1f PART admet-338 357 145 http://www.info.pmda.go.jp/go/interview/1/340278_6250019f1020_1_013_1f http://www.info.pmda.go.jp/go/interview/1/340278_6250019f1020_1_013_1f NOUN admet-338 357 146 asami asami PROPN admet-338 357 147 ono ono PROPN admet-338 357 148 et et PROPN admet-338 357 149 al al PROPN admet-338 357 150 . . PROPN admet-338 357 151 admet admet PROPN admet-338 357 152 & & CCONJ admet-338 357 153 dmpk dmpk PROPN admet-338 357 154 4(4 4(4 NUM admet-338 357 155 ) ) PUNCT admet-338 357 156 ( ( PUNCT admet-338 357 157 2016 2016 NUM admet-338 357 158 ) ) PUNCT admet-338 357 159 335 335 NUM admet-338 357 160 - - SYM admet-338 357 161 360 360 NUM admet-338 357 162 358 358 NUM admet-338 357 163 valproate valproate ADJ admet-338 357 164 sodium sodium NOUN admet-338 357 165 http://www.info.pmda.go.jp/go/interview/1/230124_1139004f1096_1_005_1f http://www.info.pmda.go.jp/go/interview/1/230124_1139004f1096_1_005_1f NOUN admet-338 357 166 valsartan valsartan VERB admet-338 357 167 http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f PROPN admet-338 357 168 voglibose voglibose NOUN admet-338 357 169 http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f PROPN admet-338 357 170 zolpidem zolpidem PROPN admet-338 357 171 tartrate tartrate NOUN admet-338 357 172 http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f NOUN admet-338 357 173 a a DET admet-338 357 174 ir ir PROPN admet-338 357 175 formulations formulation NOUN admet-338 357 176 of of ADP admet-338 357 177 ketoprofen ketoprofen NOUN admet-338 357 178 are be AUX admet-338 357 179 no no ADV admet-338 357 180 longer long ADV admet-338 357 181 in in ADP admet-338 357 182 production production NOUN admet-338 357 183 in in ADP admet-338 357 184 japan japan PROPN admet-338 357 185 . . PUNCT admet-338 358 1 the the DET admet-338 358 2 dose dose NOUN admet-338 358 3 strengths strength NOUN admet-338 358 4 of of ADP admet-338 358 5 the the DET admet-338 358 6 ir ir PROPN admet-338 358 7 formulations formulation NOUN admet-338 358 8 were be AUX admet-338 358 9 from from ADP admet-338 358 10 the the DET admet-338 358 11 fda fda PROPN admet-338 358 12 website website NOUN admet-338 358 13 ( ( PUNCT admet-338 358 14 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm PROPN admet-338 358 15 ) ) PUNCT admet-338 358 16 . . PUNCT admet-338 359 1 http://www.info.pmda.go.jp/go/interview/1/230124_1139004f1096_1_005_1f http://www.info.pmda.go.jp/go/interview/1/230124_1139004f1096_1_005_1f NOUN admet-338 359 2 http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f http://www.info.pmda.go.jp/go/interview/1/300242_2149041f5026_5_dio_1f PROPN admet-338 359 3 http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f http://www.info.pmda.go.jp/go/interview/1/400256_3969004f3023_1_006_1f VERB admet-338 359 4 http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f http://www.info.pmda.go.jp/go/interview/3/800126_1129009f1025_3_1f NOUN admet-338 359 5 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm PROPN admet-338 359 6 admet admet PROPN admet-338 359 7 & & CCONJ admet-338 359 8 dmpk dmpk PROPN admet-338 359 9 4(4 4(4 NUM admet-338 359 10 ) ) PUNCT admet-338 359 11 ( ( PUNCT admet-338 359 12 2016 2016 NUM admet-338 359 13 ) ) PUNCT admet-338 359 14 335 335 NUM admet-338 359 15 - - SYM admet-338 359 16 360 360 NUM admet-338 359 17 biopharmaceutical biopharmaceutical NOUN admet-338 359 18 and and CCONJ admet-338 359 19 physchem physchem NOUN admet-338 359 20 properties property NOUN admet-338 359 21 for for ADP admet-338 359 22 odt odt ADJ admet-338 359 23 doi doi NOUN admet-338 359 24 : : PUNCT admet-338 359 25 10.5599 10.5599 NUM admet-338 359 26 / / SYM admet-338 359 27 admet.4.4.338 admet.4.4.338 VERB admet-338 359 28 359 359 NUM admet-338 359 29 supplement supplement NOUN admet-338 359 30 table table NOUN admet-338 359 31 3 3 NUM admet-338 359 32 . . PUNCT admet-338 359 33 model model NOUN admet-338 359 34 equation equation NOUN admet-338 359 35 for for ADP admet-338 359 36 nc nc PROPN admet-338 359 37 calculation calculation NOUN admet-338 359 38 by by ADP admet-338 359 39 using use VERB admet-338 359 40 the the DET admet-338 359 41 henderson henderson PROPN admet-338 359 42 - - PUNCT admet-338 359 43 hasselbalch hasselbalch PROPN admet-338 359 44 equation equation NOUN admet-338 359 45 . . PUNCT admet-338 360 1 compound compound NOUN admet-338 360 2 type type NOUN admet-338 360 3 model model NOUN admet-338 360 4 equation equation NOUN admet-338 360 5 mono mono PROPN admet-338 360 6 acid acid PROPN admet-338 360 7 nc nc PROPN admet-338 360 8 = = PRON admet-338 360 9 ( ( PUNCT admet-338 360 10 βˆ’1 βˆ’1 NOUN admet-338 360 11 ) ) PUNCT admet-338 360 12 Γ— Γ— NOUN admet-338 360 13 10βˆ’π‘πΎπ‘Ž 10βˆ’π‘πΎπ‘Ž NUM admet-338 360 14 10βˆ’π‘πΎπ‘Ž 10βˆ’π‘πΎπ‘Ž NUM admet-338 360 15 + + CCONJ admet-338 360 16 10βˆ’π‘π» 10βˆ’π‘π» NUM admet-338 360 17 mono mono NOUN admet-338 360 18 base base NOUN admet-338 360 19 nc nc PROPN admet-338 361 1 = = PUNCT admet-338 361 2 10βˆ’π‘π» 10βˆ’π‘π» NUM admet-338 361 3 10βˆ’π‘πΎπ‘Ž 10βˆ’π‘πΎπ‘Ž NUM admet-338 361 4 + + CCONJ admet-338 361 5 10βˆ’π‘π» 10βˆ’π‘π» NUM admet-338 361 6 di di NOUN admet-338 361 7 acid acid PROPN admet-338 361 8 nc nc PROPN admet-338 362 1 = = PRON admet-338 362 2 ( ( PUNCT admet-338 362 3 βˆ’1 βˆ’1 NOUN admet-338 362 4 ) ) PUNCT admet-338 362 5 Γ— Γ— NOUN admet-338 362 6 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 362 7 Γ— Γ— NOUN admet-338 362 8 10βˆ’π‘π» 10βˆ’π‘π» NUM admet-338 362 9 + + CCONJ admet-338 362 10 ( ( PUNCT admet-338 362 11 βˆ’2 βˆ’2 NOUN admet-338 362 12 ) ) PUNCT admet-338 362 13 Γ— Γ— NOUN admet-338 362 14 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 362 15 Γ— Γ— NOUN admet-338 362 16 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 363 1 [ [ X admet-338 363 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 363 3 + + NUM admet-338 363 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 363 5 Γ— Γ— PROPN admet-338 363 6 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 NUM admet-338 363 7 Γ— Γ— NOUN admet-338 363 8 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 363 9 di di NOUN admet-338 363 10 base base NOUN admet-338 363 11 nc nc PROPN admet-338 364 1 = = NOUN admet-338 364 2 2 2 NUM admet-338 364 3 Γ— Γ— NOUN admet-338 364 4 [ [ X admet-338 364 5 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 364 6 + + NUM admet-338 364 7 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 364 8 Γ— Γ— NOUN admet-338 364 9 10βˆ’π‘π» 10βˆ’π‘π» NUM admet-338 365 1 [ [ X admet-338 365 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 365 3 + + NUM admet-338 365 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 365 5 Γ— Γ— PROPN admet-338 365 6 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 NUM admet-338 365 7 Γ— Γ— NOUN admet-338 365 8 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 365 9 mono mono NOUN admet-338 365 10 acid acid NOUN admet-338 365 11 / / SYM admet-338 365 12 mono mono NOUN admet-338 365 13 base base NOUN admet-338 365 14 nc nc PROPN admet-338 366 1 = = PUNCT admet-338 367 1 [ [ X admet-338 367 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 367 3 + + CCONJ admet-338 367 4 ( ( PUNCT admet-338 367 5 βˆ’1 βˆ’1 NOUN admet-338 367 6 ) ) PUNCT admet-338 367 7 Γ— Γ— NOUN admet-338 367 8 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 367 9 Γ— Γ— NOUN admet-338 367 10 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 368 1 [ [ X admet-338 368 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 368 3 + + NUM admet-338 368 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 368 5 Γ— Γ— PROPN admet-338 368 6 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 NUM admet-338 368 7 Γ— Γ— NOUN admet-338 368 8 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 368 9 tri tri PROPN admet-338 368 10 acid acid PROPN admet-338 368 11 nc nc PROPN admet-338 368 12 = = PRON admet-338 368 13 ( ( PUNCT admet-338 368 14 βˆ’1 βˆ’1 NOUN admet-338 368 15 ) ) PUNCT admet-338 368 16 Γ— Γ— NOUN admet-338 368 17 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 368 18 Γ— Γ— NOUN admet-338 369 1 [ [ X admet-338 369 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 369 3 + + CCONJ admet-338 369 4 ( ( PUNCT admet-338 369 5 βˆ’2 βˆ’2 NOUN admet-338 369 6 ) ) PUNCT admet-338 369 7 Γ— Γ— NOUN admet-338 369 8 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 369 9 Γ— Γ— NOUN admet-338 370 1 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 370 2 Γ— Γ— NOUN admet-338 370 3 10βˆ’π‘π» 10βˆ’π‘π» NUM admet-338 370 4 + + CCONJ admet-338 370 5 ( ( PUNCT admet-338 370 6 βˆ’3 βˆ’3 NOUN admet-338 370 7 ) ) PUNCT admet-338 370 8 Γ— Γ— NOUN admet-338 370 9 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 370 10 Γ— Γ— NOUN admet-338 371 1 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 371 2 Γ— Γ— NOUN admet-338 371 3 10βˆ’π‘πΎπ‘Ž3 10βˆ’π‘πΎπ‘Ž3 NUM admet-338 372 1 [ [ X admet-338 372 2 10βˆ’π‘π»]3 10βˆ’π‘π»]3 NOUN admet-338 372 3 + + NUM admet-338 372 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 372 5 Γ— Γ— NOUN admet-338 373 1 [ [ X admet-338 373 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 373 3 + + NOUN admet-338 373 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 373 5 Γ— Γ— NOUN admet-338 374 1 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 374 2 Γ— Γ— NOUN admet-338 374 3 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 NUM admet-338 374 4 Γ— Γ— NOUN admet-338 374 5 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 374 6 Γ— Γ— NOUN admet-338 374 7 10βˆ’π‘πΎπ‘Ž3 10βˆ’π‘πΎπ‘Ž3 NUM admet-338 374 8 tri tri PROPN admet-338 374 9 base base NOUN admet-338 374 10 nc nc PROPN admet-338 374 11 = = NOUN admet-338 374 12 3 3 NUM admet-338 374 13 Γ— Γ— NOUN admet-338 375 1 [ [ X admet-338 375 2 10βˆ’π‘π»]3 10βˆ’π‘π»]3 NOUN admet-338 375 3 + + NUM admet-338 375 4 2 2 NUM admet-338 375 5 Γ— Γ— NOUN admet-338 375 6 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 375 7 Γ— Γ— NOUN admet-338 376 1 [ [ X admet-338 376 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 376 3 + + NUM admet-338 376 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 376 5 Γ— Γ— NOUN admet-338 376 6 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 377 1 Γ— Γ— NOUN admet-338 377 2 10βˆ’π‘π» 10βˆ’π‘π» NUM admet-338 378 1 [ [ X admet-338 378 2 10βˆ’π‘π»]3 10βˆ’π‘π»]3 PROPN admet-338 378 3 + + NUM admet-338 378 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 378 5 Γ— Γ— NOUN admet-338 379 1 [ [ X admet-338 379 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 379 3 + + NOUN admet-338 379 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 379 5 Γ— Γ— NOUN admet-338 380 1 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 380 2 Γ— Γ— NOUN admet-338 380 3 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 NUM admet-338 380 4 Γ— Γ— NOUN admet-338 380 5 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 380 6 Γ— Γ— NOUN admet-338 380 7 10βˆ’π‘πΎπ‘Ž3 10βˆ’π‘πΎπ‘Ž3 NUM admet-338 380 8 di di NOUN admet-338 380 9 acid acid NOUN admet-338 380 10 / / SYM admet-338 380 11 mono mono PROPN admet-338 380 12 base base NOUN admet-338 380 13 nc nc PROPN admet-338 381 1 = = PUNCT admet-338 382 1 [ [ X admet-338 382 2 10βˆ’π‘π»]3 10βˆ’π‘π»]3 NOUN admet-338 382 3 + + CCONJ admet-338 382 4 ( ( PUNCT admet-338 382 5 βˆ’1 βˆ’1 NOUN admet-338 382 6 ) ) PUNCT admet-338 382 7 Γ— Γ— NOUN admet-338 382 8 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 382 9 Γ— Γ— NOUN admet-338 382 10 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 382 11 Γ— Γ— NOUN admet-338 382 12 10βˆ’π‘π»+(βˆ’2 10βˆ’π‘π»+(βˆ’2 NUM admet-338 382 13 ) ) PUNCT admet-338 382 14 Γ— Γ— NOUN admet-338 382 15 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 382 16 Γ— Γ— NOUN admet-338 383 1 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 383 2 Γ— Γ— NOUN admet-338 383 3 10βˆ’π‘πΎπ‘Ž3 10βˆ’π‘πΎπ‘Ž3 NUM admet-338 384 1 [ [ X admet-338 384 2 10βˆ’π‘π»]3 10βˆ’π‘π»]3 NOUN admet-338 384 3 + + NUM admet-338 384 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 384 5 Γ— Γ— NOUN admet-338 385 1 [ [ X admet-338 385 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 385 3 + + NOUN admet-338 385 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 385 5 Γ— Γ— NOUN admet-338 386 1 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 386 2 Γ— Γ— NOUN admet-338 386 3 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 NUM admet-338 386 4 Γ— Γ— NOUN admet-338 386 5 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 386 6 Γ— Γ— NOUN admet-338 386 7 10βˆ’π‘πΎπ‘Ž3 10βˆ’π‘πΎπ‘Ž3 NUM admet-338 386 8 mono mono NOUN admet-338 386 9 acid acid NOUN admet-338 386 10 / / SYM admet-338 386 11 di di NOUN admet-338 386 12 base base NOUN admet-338 386 13 nc nc PROPN admet-338 386 14 = = NOUN admet-338 386 15 2 2 NUM admet-338 386 16 Γ— Γ— NOUN admet-338 387 1 [ [ X admet-338 387 2 10βˆ’π‘π»]3 10βˆ’π‘π»]3 NOUN admet-338 387 3 + + NUM admet-338 387 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 387 5 Γ— Γ— NOUN admet-338 388 1 [ [ X admet-338 388 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 388 3 + + CCONJ admet-338 388 4 ( ( PUNCT admet-338 388 5 βˆ’1 βˆ’1 NOUN admet-338 388 6 ) ) PUNCT admet-338 388 7 Γ— Γ— NOUN admet-338 388 8 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 388 9 Γ— Γ— NOUN admet-338 388 10 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 388 11 Γ— Γ— NOUN admet-338 389 1 10βˆ’π‘πΎπ‘Ž3 10βˆ’π‘πΎπ‘Ž3 NUM admet-338 390 1 [ [ X admet-338 390 2 10βˆ’π‘π»]3 10βˆ’π‘π»]3 NOUN admet-338 390 3 + + NUM admet-338 390 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 390 5 Γ— Γ— NOUN admet-338 391 1 [ [ X admet-338 391 2 10βˆ’π‘π»]2 10βˆ’π‘π»]2 NUM admet-338 391 3 + + NOUN admet-338 391 4 10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘πΎπ‘Ž1 NUM admet-338 391 5 Γ— Γ— NOUN admet-338 392 1 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 392 2 Γ— Γ— NOUN admet-338 392 3 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 10βˆ’π‘π»+10βˆ’π‘πΎπ‘Ž1 NUM admet-338 392 4 Γ— Γ— NOUN admet-338 392 5 10βˆ’π‘πΎπ‘Ž2 10βˆ’π‘πΎπ‘Ž2 NUM admet-338 392 6 Γ— Γ— NOUN admet-338 392 7 10βˆ’π‘πΎπ‘Ž3 10βˆ’π‘πΎπ‘Ž3 NUM admet-338 392 8 doi doi NOUN admet-338 392 9 : : PUNCT admet-338 392 10 10.5599 10.5599 NUM admet-338 392 11 / / SYM admet-338 392 12 admet.4.4.338 admet.4.4.338 VERB admet-338 392 13 360 360 NUM admet-338 392 14 supplement supplement NOUN admet-338 392 15 table table NOUN admet-338 392 16 4 4 NUM admet-338 392 17 solubility solubility NOUN admet-338 392 18 definitions definition NOUN admet-338 392 19 solubility solubility NOUN admet-338 392 20 definition definition NOUN admet-338 392 21 parts part NOUN admet-338 392 22 of of ADP admet-338 392 23 solvent solvent NOUN admet-338 392 24 required require VERB admet-338 392 25 for for ADP admet-338 392 26 1 1 NUM admet-338 392 27 part part NOUN admet-338 392 28 of of ADP admet-338 392 29 solute solute NOUN admet-338 392 30 solubility solubility NOUN admet-338 392 31 range range NOUN admet-338 392 32 ( ( PUNCT admet-338 392 33 mg mg NOUN admet-338 392 34 / / SYM admet-338 392 35 ml ml NOUN admet-338 392 36 ) ) PUNCT admet-338 392 37 solubility solubility NOUN admet-338 392 38 assigned assign VERB admet-338 392 39 ( ( PUNCT admet-338 392 40 mg mg PROPN admet-338 392 41 / / SYM admet-338 392 42 ml ml NOUN admet-338 392 43 ) ) PUNCT admet-338 392 44 very very ADV admet-338 392 45 soluble soluble ADJ admet-338 392 46 < < X admet-338 392 47 1 1 NUM admet-338 392 48 β‰₯1000 β‰₯1000 NUM admet-338 392 49 1000 1000 NUM admet-338 392 50 freely freely ADV admet-338 392 51 soluble soluble ADJ admet-338 392 52 1‐10 1‐10 NUM admet-338 392 53 100‐1000 100‐1000 NUM admet-338 392 54 100 100 NUM admet-338 392 55 soluble soluble ADJ admet-338 392 56 10‐30 10‐30 NOUN admet-338 392 57 33‐100 33‐100 NUM admet-338 392 58 33 33 NUM admet-338 392 59 sparingly sparingly ADV admet-338 392 60 soluble soluble ADJ admet-338 392 61 30‐100 30‐100 NUM admet-338 392 62 10‐33 10‐33 NUM admet-338 392 63 10 10 NUM admet-338 392 64 slightly slightly ADV admet-338 392 65 soluble soluble ADJ admet-338 392 66 100‐1000 100‐1000 NUM admet-338 392 67 1‐10 1‐10 NUM admet-338 392 68 1 1 NUM admet-338 392 69 very very ADV admet-338 392 70 slightly slightly ADV admet-338 392 71 soluble soluble ADJ admet-338 392 72 1000‐10000 1000‐10000 NUM admet-338 392 73 0.1 0.1 NUM admet-338 392 74 - - SYM admet-338 392 75 1 1 NUM admet-338 392 76 0.1 0.1 NUM admet-338 392 77 practically practically ADV admet-338 392 78 insoluble insoluble ADJ admet-338 392 79 β‰₯10000 β‰₯10000 NOUN admet-338 392 80 < < X admet-338 392 81 0.1 0.1 NUM admet-338 392 82 0.01 0.01 NUM